<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005370.pub3" GROUP_ID="ANAESTH" ID="905304080717244766" MERGED_FROM="" MODIFIED="2016-01-11 12:34:59 +0000" MODIFIED_BY="Jane Cracknell" REVIEW_NO="100" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.3">
<COVER_SHEET MODIFIED="2016-01-11 12:34:59 +0000" MODIFIED_BY="Jane Cracknell">
<TITLE>Antithrombin III for critically ill patients</TITLE>
<CONTACT MODIFIED="2016-01-11 12:34:59 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="z1403241137508671148788714740679" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mikkel</FIRST_NAME><LAST_NAME>Allingstrup</LAST_NAME><EMAIL_1>mikkel.allingstrup@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesia</DEPARTMENT><ORGANISATION>Køge Sygehus, Copenhagen University Hospital</ORGANISATION><CITY>Copenhagen</CITY><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-01-11 12:34:59 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="z1403241137508671148788714740679" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mikkel</FIRST_NAME><LAST_NAME>Allingstrup</LAST_NAME><EMAIL_1>mikkel.allingstrup@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesia</DEPARTMENT><ORGANISATION>Køge Sygehus, Copenhagen University Hospital</ORGANISATION><CITY>Copenhagen</CITY><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON><PERSON ID="6564" ROLE="AUTHOR"><FIRST_NAME>Jørn</FIRST_NAME><LAST_NAME>Wetterslev</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Chief Physician</POSITION><EMAIL_1>wetterslev@ctu.dk</EMAIL_1><ADDRESS><DEPARTMENT>Copenhagen Trial Unit, Centre for Clinical Intervention Research</DEPARTMENT><ORGANISATION>Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION><ADDRESS_1>Blegdamsvej 9</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3545 7159</PHONE_1><FAX_1>+45 3545 7001</FAX_1></ADDRESS></PERSON><PERSON ID="z1409301447336207646717118234649" ROLE="AUTHOR"><FIRST_NAME>Frederikke</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Ravn</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>frederikkebravn@gmail.com</EMAIL_1><EMAIL_2>Zsk348@alumni.ku.dk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Paediatric and Obstetric Anaesthesia</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, Afsnit 3342, rum 52</ADDRESS_1><CITY>Copenhagen</CITY><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON><PERSON ID="EB70DC0182E26AA2017A33F280B4E311" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ann  Merete</FIRST_NAME><LAST_NAME>Møller</LAST_NAME><SUFFIX>MD, DMSc</SUFFIX><POSITION>Co-ordinating Editor</POSITION><EMAIL_1>ann.moeller@regionh.dk</EMAIL_1><EMAIL_2>docamm@yahoo.com</EMAIL_2><URL>http://ace.cochrane.org/</URL><MOBILE_PHONE>00 45 2613 7490</MOBILE_PHONE><ADDRESS><DEPARTMENT>The Cochrane Anaesthesia, Critical and Emergency Care Group</DEPARTMENT><ORGANISATION>University of Copenhagen Herlev Hospital</ORGANISATION><ADDRESS_1>Herlev Ringvej</ADDRESS_1><CITY>Herlev</CITY><ZIP>2730</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 38682  879</PHONE_1><PHONE_2>+45 26 13 74 90</PHONE_2></ADDRESS></PERSON><PERSON ID="18607" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arash</FIRST_NAME><LAST_NAME>Afshari</LAST_NAME><POSITION>Affiliated Researcher</POSITION><EMAIL_1>arriba.a@gmail.com</EMAIL_1><EMAIL_2>afshari@rocketmail.com</EMAIL_2><MOBILE_PHONE>004551948186</MOBILE_PHONE><ADDRESS><DEPARTMENT>The Cochrane Anaesthesia, Critical and Emergency Care Group &amp; Copenhagen Trial Unit and Department of Paediatric and Obstetric Anaesthesia</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9</ADDRESS_1><ADDRESS_2>Afsnit 3342, rum 52</ADDRESS_2><CITY>Copenhagen</CITY><ZIP>2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-01-11 12:34:59 +0000" MODIFIED_BY="Jane Cracknell">
<UP_TO_DATE>
<DATE DAY="27" MONTH="8" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="8" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-01-04 09:14:56 +0000" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-01-04 09:14:49 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="4" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>We searched the databases until 27 August 2015. We included 10 new antithrombin III (AT III) trials in this updated review. This review now has 30 included studies in total (3933 participants).</P>
<P>We have updated the Methods section, included full 'Risk of bias' tables and 'Summary of findings' tables. We applied trial sequential analysis (TSA).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-01-04 09:14:56 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="4" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>A new lead author (Allingstrup M) has updated this review in collaboration with the original authors.</P>
<P>In this updated review we chose to include trials which had only been published as abstracts (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>). These trials report mortality data from 236 participants. The trial abstracts do not provide us with much data to examine. However, we provide the limited mortality data that we were able to retrieve from these trials. We classify all of these trials as being at high risk of bias.</P>
<P>The conclusions have not changed in this updated review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-10-17 15:36:18 +0100" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-10-17 15:36:18 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="11" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>Contact details updated; order of tables corrected</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-02-11 14:20:12 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="12" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-12 13:55:07 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="11" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-05-11 16:07:49 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="7" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Minor edits to text</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-08-07 16:23:03 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="12" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>converted to new Review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<INTERNAL_SOURCES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<SOURCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<NAME>Cochrane Anaesthesia Critical and Emergency Care Group (ACE)</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-01-04 10:01:48 +0000" MODIFIED_BY="Mikkel Allingstrup">
<SUMMARY MODIFIED="2016-01-02 13:27:49 +0000" MODIFIED_BY="Mikkel Allingstrup">
<TITLE MODIFIED="2015-07-21 03:31:18 +0100" MODIFIED_BY="Jane Cracknell">Antithrombin III for critically ill patients</TITLE>
<SUMMARY_BODY MODIFIED="2016-01-02 13:27:49 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>
<B>Background</B>
</P>
<P>Antithrombin is a small particle produced by the liver. It deactivates several substances which affect the ability of the blood to form clots. Its activity is increased many-fold by the drug heparin, which enhances the binding of antithrombin to clotting factors so that the blood does not form clots. Antithrombin also reduces inflammation in the human body. Inflammation is the body's attempt at self protection to remove harmful stimuli and begin healing processes. Inflammation is thus not always a bad process.</P>
<P>This updated review assessed the effects of antithrombin in people recovering from critical illness. Our primary goal was to investigate whether the number of people who died changed by giving antithrombin. We also investigated whether there were more complications among people treated with this drug, the extent of bleeding and the amount of blood given to the critical ill people. Finally we examined the impact of antithrombin on the duration of respiratory therapy, length of stay in the intensive care units and in the hospital in general.</P>
<P>
<B>Study</B> <B>characteristics</B>
</P>
<P>We included 30 trials with 3933 participants (3882 in our data calculation) in this updated review. We found the overall quality of trials to be poor, with little information on how the experiments were carried out. The results were limited and the included trials were mostly small. In most trials, there was a high risk of misleading information. Thus, the results must be interpreted with caution. The evidence is up to date to 27 August 2015.</P>
<P>
<B>Study</B> <B>funding</B> <B>sources</B>
</P>
<P>Three of the 30 included trials reported receiving money from drug companies.</P>
<P>
<B>Key</B> <B>results</B>
</P>
<P>In our review we could not identify a clear advantage of antithrombin for the objectives we examined, overall or among various types of patients or subgroups. In our investigation of bleeding events, however, we found an increased risk of bleeding for patients treated with antithrombin.</P>
<P>
<B>Quality</B> <B>of</B> <B>the</B> <B>evidence</B>
</P>
<P>Overall, there was a low quality of information from the studies regarding all of the results. We conclude that there is a need for a large-scale clinical trial with low risk of misleading information to investigate the advantages and harms of this drug among critically ill patients.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-01-03 15:20:01 +0000" MODIFIED_BY="Mikkel Allingstrup">
<ABS_BACKGROUND MODIFIED="2015-10-22 15:02:56 +0100" MODIFIED_BY="Jane Cracknell">
<P>Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties but the efficacy and any harmful effects of AT III supplementation in critically ill patients are unknown. This review was published in 2008 and updated in 2015.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-01-03 15:20:01 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>To examine:</P>
<P>1. The effect of AT III on mortality in critically ill participants. </P>
<P>2. The benefits and harms of AT III.</P>
<P>We investigated complications specific and not specific to the trial intervention, bleeding events, the effect on sepsis and disseminated intravascular coagulation (DIC) and the length of stay in the intensive care unit (ICU) and in hospital in general.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-12-23 13:05:09 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We searched the following databases from inception to 27 August 2015: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid SP), EMBASE (Ovid SP,), CAB, BIOSIS and CINAHL. We contacted the main authors of trials to ask for any missed, unreported or ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-12-23 13:05:09 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published, or language. We contacted the investigators and the trial authors in order to retrieve missing data. In this updated review we include trials only published as abstracts.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Our primary outcome measure was mortality. Two authors each independently abstracted data and resolved any disagreements by discussion. We presented pooled estimates of the intervention effects on dichotomous outcomes as risk ratios (RR) with 95% confidence intervals (CI). We performed subgroup analyses to assess risk of bias, the effect of AT III in different populations (sepsis, trauma, obstetrics, and paediatrics), and the effect of AT III in patients with or without the use of concomitant heparin. We assessed the adequacy of the available number of participants and performed trial sequential analysis (TSA) to establish the implications for further research.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-01-02 13:27:49 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We included 30 RCTs with a total of 3933 participants (3882 in the primary outcome analyses).</P>
<P>Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality with a RR of 0.95 (95% CI 0.88 to 1.03), I² statistic = 0%, fixed-effect model, 29 trials, 3882 participants, <I>moderate</I> <I>quality</I> <I>of</I> <I>evidence</I>). For trials with low risk of bias the RR was 0.96 (95% Cl 0.88 to 1.04, I² statistic = 0%, fixed-effect model, 9 trials, 2915 participants) and for high risk of bias RR 0.94 (95% Cl 0.77 to 1.14, I² statistic = 0%, fixed-effect model, 20 trials, 967 participants).</P>
<P>For participants with severe sepsis and DIC the RR for mortality was non-significant, 0.95 (95% Cl 0.88 to 1.03, I² statistic = 0%, fixed-effect model, 12 trials, 2858 participants, <I>moderate</I> <I>quality</I> <I>of</I> <I>evidence</I>).</P>
<P>We conducted 14 subgroup and sensitivity analyses with respect to the different domains of risk of bias, but detected no statistically significant benefit in any subgroup analyses.</P>
<P>Our secondary objective was to assess the benefits and harms of AT III. For complications specific to the trial intervention the RR was 1.26 (95% Cl 0.83 to 1.92, I² statistic = 0%, random-effect model, 3 trials, 2454 participants, <I>very</I> <I>low</I> <I>quality</I> <I>of</I> <I>evidence</I>). For complications not specific to the trial intervention, the RR was 0.71 (95% Cl 0.08 to 6.11, I² statistic = 28%, random-effects model, 2 trials, 65 participants, <I>very</I> <I>low</I> <I>quality</I> <I>of</I> <I>evidence</I>). For complications other than bleeding, the RR was 0.72 ( 95% Cl 0.42 to 1.25, I² statistic = 0%, fixed-effect model, 3 trials, 187 participants, <I>very</I> <I>low</I> <I>quality</I> <I>of</I> <I>evidence</I>). Eleven trials investigated bleeding events and we found a statistically significant increase, RR 1.58 (95% CI 1.35 to 1.84, I² statistic = 0%, fixed-effect model, 11 trials, 3019 participants, <I>moderate</I> <I>quality</I> <I>of</I> <I>evidence</I>) in the AT III group. The amount of red blood cells administered had a mean difference (MD) of 138.49 (95% Cl -391.35 to 668.34, I² statistic = 84%, random-effect model, 4 trials, 137 participants, <I>very</I> <I>low</I> <I>quality</I> <I>of</I> <I>evidence</I>). The effect of AT III in patients with multiple organ failure (MOF) was a MD of -1.24 (95% Cl -2.18 to -0.29, I² statistic = 48%, random-effects model, 3 trials, 156 participants, <I>very</I> <I>low</I> <I>quality</I> <I>of</I> <I>evidence</I>) and for patients with an Acute Physiology and Chronic Health Evaluation score (APACHE) at II and III the MD was -2.18 (95% Cl -4.36 to -0.00, I² statistic = 0%, fixed-effect model, 3 trials, 102 participants, <I>very</I> <I>low</I> <I>quality</I> <I>of</I> <I>evidence</I>). The incidence of respiratory failure had a RR of 0.93 (95% Cl 0.76 to 1.14, I² statistic = 32%, random-effects model, 6 trials, 2591 participants, <I>moderate</I> <I>quality</I> <I>of</I> <I>evidence</I>). AT III had no statistically significant impact on the duration of mechanical ventilation (MD 2.20 days, 95% Cl -1.21 to 5.60, I² statistic = 0%, fixed-effect model, 3 trials, 190 participants, <I>very</I> <I>low</I> <I>quality</I> <I>of</I> <I>evidence</I>); on the length of stay in the ICU (MD 0.24, 95% Cl -1.34 to 1.83, I² statistic = 0%, fixed-effect model, 7 trials, 376 participants, <I>very</I> <I>low</I> <I>quality</I> <I>of</I> <I>evidence</I>) or on the length of stay in hospital in general (MD 1.10, 95% Cl -7.16 to 9.36), I² statistic = 74%, 4 trials, 202 participants, <I>very</I> <I>low</I> <I>quality</I> <I>of</I> <I>evidence</I>).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>There is insufficient evidence to support AT III substitution in any category of critically ill participants including the subset of patients with sepsis and DIC. We did not find a statistically significant effect of AT III on mortality, but AT III increased the risk of bleeding events. Subgroup analyses performed according to duration of intervention, length of follow-up, different patient groups, and use of adjuvant heparin did not show differences in the estimates of intervention effects. The majority of included trials were at high risk of bias (GRADE; very low quality of evidence for most of the analyses). Hence a large RCT of AT III is needed, without adjuvant heparin among critically ill patients such as those with severe sepsis and DIC, with prespecified inclusion criteria and good bias protection.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-01-04 10:01:48 +0000" MODIFIED_BY="Mikkel Allingstrup">
<BACKGROUND MODIFIED="2016-01-02 13:27:49 +0000" MODIFIED_BY="Mikkel Allingstrup">
<CONDITION MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Despite advances in the medical field, growing numbers of patients are becoming critically ill. Each year, 5,700,000 people in the USA are admitted to intensive care units (ICUs) (<LINK REF="REF-Wunsch-2008" TYPE="REFERENCE">Wunsch 2008</LINK>).</P>
<P>Critical illness is characterized by cellular immune dysfunction, vascular damage and uncontrolled hyperinflammation, even when the cause of illness is not infection. In critical illness, a systemic activation of coagulation may occur which, at its worst, results in a fulminant disseminated intravascular coagulation (DIC). DIC is characterized by simultaneous widespread microvascular thrombosis and profuse bleeding from various sites (<LINK REF="REF-Levi-2004" TYPE="REFERENCE">Levi 2004</LINK>). Sepsis resulting from a generalized inflammatory and procoagulant response to an infection is associated with a high risk of mortality. Twenty per cent of patients who develop severe sepsis will die during their hospitalization (<LINK REF="REF-Mayr-2014" TYPE="REFERENCE">Mayr 2014</LINK>). Septic shock is associated with the highest mortality, approaching 50% (<LINK REF="REF-Mayr-2014" TYPE="REFERENCE">Mayr 2014</LINK>). This rate increases in the presence of circulatory shock despite aggressive antimicrobial therapy, adequate fluid resuscitation, and optimal care (<LINK REF="REF-Periti-2000" TYPE="REFERENCE">Periti 2000</LINK>), and may reach as high as 70% in patients with multiple organ dysfunction (<LINK REF="REF-Polderman-2004" TYPE="REFERENCE">Polderman 2004</LINK>).</P>
<P>The inflammation associated with critical illness is characterized by an increase in the number and activity of numerous molecules, such as platelet activating factor, von Willebrand factor, and tumour necrosis factor. There is a simultaneous increase in the activity of pro-inflammatory and pro-coagulant processes, such as thrombin formation, fibrin deposition at the vascular wall, and the formation of aggregates containing platelets and leukocytes. Leukocyte rolling, adhesion, and transmigration are also important parts of the inflammatory reaction. These processes lead to capillary leakage, severe disturbance of the microcirculation, tissue damage, and eventually multiorgan failure and death (<LINK REF="REF-Becker-2000" TYPE="REFERENCE">Becker 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Any proposed treatment of critical illness should aim to eliminate the underlying disorder or condition and to restore microvascular function, hence reducing organ dysfunction (<LINK REF="REF-Levi-2004" TYPE="REFERENCE">Levi 2004</LINK>).</P>
<P>Antithrombin III (AT III) is primarily a potent anticoagulant with independent anti-inflammatory properties. AT III irreversibly inhibits serine proteases (for example, activated factor X and thrombin) in a one-to-one ratio, with the generation of protease-AT III complexes. Heparin prevents AT III from interacting with the endothelial cell surface by binding to sites on the AT III molecule, competing for the AT III binding site, and reducing AT III ability to interact with its cellular receptor. AT III's anticoagulant effect is thus greatly accelerated (by a factor of 1000) by heparin; heparin reduces AT III's anti-inflammatory properties, weakens vascular protection, and increases bleeding events (<LINK REF="REF-Diaz-2015" TYPE="REFERENCE">Diaz 2015</LINK>; <LINK REF="REF-Opal-2002" TYPE="REFERENCE">Opal 2002</LINK>; <LINK REF="REF-Rublee-2003" TYPE="REFERENCE">Rublee 2003</LINK>).</P>
<P>Heparin in patients with sepsis, septic shock, or DIC associated with infection may be associated with decreased mortality (<LINK REF="REF-Zarychanski-2015" TYPE="REFERENCE">Zarychanski 2015</LINK>). However, the overall effect is still not clear. Major bleeding events related to heparin administration cannot be excluded (<LINK REF="REF-Zarychanski-2015" TYPE="REFERENCE">Zarychanski 2015</LINK>) and safety outcomes have yet to be validated in a multicentre trial setting.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-01-02 13:27:49 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>The blood concentration of AT III falls by 20% to 40% in septic patients, and these levels correlate with disease severity and clinical outcome (<LINK REF="REF-Opal-2002" TYPE="REFERENCE">Opal 2002</LINK>; <LINK REF="REF-Wiedermann-2002" TYPE="REFERENCE">Wiedermann 2002</LINK>). This reduction in concentration is due to the combined effect of decreased production of AT III in the liver, inactivation by the enzyme elastase, which is increased during inflammation, and loss of AT III from the circulation into tissues through inflamed and leaking capillary blood vessels. These processes reduce the half-life of AT III from a mean of 55 hours to 20 hours (<LINK REF="REF-Fourrier-2000" TYPE="REFERENCE">Fourrier 2000</LINK>). The main mechanism of AT III depletion in severe sepsis is linked to consumption of the molecule.</P>
<P>It is this depletion of AT III that has prompted research into the potential benefits of replenishing AT III levels. Investigators have often tried to increase the antithrombin concentration to supranormal values because the activity of pro-inflammatory and pro-coagulant molecules are increased in critically ill patients. Thus artificially high levels of AT III may be required to overcome the inhibitory effect of thrombin and other such serine proteases. This is because the normal serum concentration of AT III does not necessarily reflect the amount bound to endothelial receptors and appears insufficient (<LINK REF="REF-Fourrier-2000" TYPE="REFERENCE">Fourrier 2000</LINK>). Finally, by blocking the actions of thrombin, AT III may have anti-angiogenic and antitumour properties (<LINK REF="REF-Larsson-2001" TYPE="REFERENCE">Larsson 2001</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Although critically ill patients are a heterogeneous population, they are characterized by having systemic inflammation, no matter what the cause of their illness. This inflammation causes further damage to tissues and organs and can result in multiple organ failure and death. The process of inflammation can be modified by AT III, whether or not clotting is abnormal, and it is possible that AT III can reduce the high death rate or permanent damage experienced by critically ill patients. The benefit of AT III supplementation in critically ill patients is still controversial and its efficacy is still debated (<LINK REF="REF-Tagami-2014" TYPE="REFERENCE">Tagami 2014</LINK>; <LINK REF="REF-Tagami-2015" TYPE="REFERENCE">Tagami 2015</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>To examine:</P>
<OL>
<LI>The effect of AT III on mortality in critically ill participants.</LI>
<LI>The benefits and harms of AT III.</LI>
</OL>
<P>We investigated complications specific and not specific to the trial intervention, bleeding events, the effect on sepsis and DIC and the length of stay in ICU and in hospital in general.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-01-02 13:27:50 +0000" MODIFIED_BY="Mikkel Allingstrup">
<SELECTION_CRITERIA MODIFIED="2016-01-02 13:27:49 +0000" MODIFIED_BY="Mikkel Allingstrup">
<CRIT_STUDIES MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published, or language. We contacted the investigators and the authors in order to retrieve relevant data. We included unpublished trials only if trial data and methodological descriptions were either provided in written form or could be retrieved from the trial authors. We excluded cross-over trials. We include In this updated review trials published as abstracts (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-01-02 13:27:49 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We included critically ill participants as variously defined by the trial authors. However, we excluded trials of adjuvant AT III administration for the reduction of cardiovascular events in the invasive treatment of acute myocardial infarction.</P>
<P>The terminology for sepsis, as originally proposed by the American College of Chest Physicians and the Society of Critical Care Medicine, is in many ways outdated (<LINK REF="REF-Opal-2003" TYPE="REFERENCE">Opal 2003</LINK>). A loose definition of sepsis can easily result in enrolment of a heterogeneous population and hence in exaggerated findings, in either direction, that are difficult to reproduce. However, we accepted the various definitions of sepsis, septic shock, DIC, and other critical illnesses as proposed by the authors; we did not exclude any trial based on their definitions. We chose to accept the term 'standard treatment of sepsis and DIC' as reported by many authors, despite the lack of a generally accepted treatment regimen.</P>
<P>We classified two trials as obstetric trials (<LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>); four trials as paediatric trials (<LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>); and a further two trials as trauma trials (<LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We included AT III versus no intervention or placebo. We included any dose of AT III, any duration of administration, and co-interventions, but excluded trials that compared different doses of AT III.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-07-21 03:31:18 +0100" MODIFIED_BY="Jane Cracknell">
<OL>
<LI>Overall mortality (longest follow-up, regardless of the period of follow-up)</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<OL>
<LI>Complications during the inpatient stay specific to the trial intervention, e.g. pneumonia, congestive cardiac failure, respiratory failure, myocardial infarction, renal failure, cerebrovascular accident</LI>
<LI>Complications during the inpatient stay not specific to the trial intervention, e.g. bleeding, limb venous thrombosis, line sepsis, local haematoma</LI>
<LI>Complications specific to the trial intervention other than bleeding</LI>
<LI>Bleeding events</LI>
<LI>Amount of red blood cells administered</LI>
<LI>Incidence of surgical intervention</LI>
<LI>Severity of sepsis (according to different organ dysfunction scores; sepsis versus septic shock if adequately defined by authors)</LI>
<LI>Incidence of respiratory failure not present at admission (mechanically-assisted ventilation)</LI>
<LI>Duration of mechanical ventilation</LI>
<LI>Length of stay in hospital</LI>
<LI>Mean length of stay in the intensive care unit (ICU)</LI>
<LI>Overall mortality among patients with severe sepsis and DIC</LI>
</OL>
<P>We defined bleeding events (4) as intracranial bleeding or bleeding requiring transfusion of at least three units of blood. We counted repeated transfusions in the same participant as a singular event.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-01-02 13:27:50 +0000" MODIFIED_BY="Mikkel Allingstrup">
<ELECTRONIC_SEARCHES MODIFIED="2016-01-02 13:27:50 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>In this updated review, we have further extended the original review's search from November 2006 (<LINK REF="REF-Afshari-2008" TYPE="REFERENCE">Afshari 2008</LINK>). Thus, we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 8). We updated our search of MEDLINE (Ovid SP, to 27 August 2015), EMBASE (Ovid SP, to 27 August 2015) and CINAHL (to 27 August 2015). The search is now from inception until 27 August 2015.</P>
<P>For specific information regarding our search strategies and results, please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-12-23 13:05:10 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We searched for ongoing clinical trials and unpublished trials on the following Internet sites:</P>
<OL>
<LI>
<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>
</LI>
<LI>
<A HREF="http://clinicaltrials.gov">clinicaltrials.gov</A>
</LI>
<LI>
<A HREF="http://www.centerwatch.com">www.centerwatch.com</A>
</LI>
</OL>
<P>We handsearched the reference lists of reviews, randomized and non-randomized trials, and editorials for additional trials. We contacted the main authors of trials and experts in this field to ask for any missed, unreported, or ongoing studies. We applied no language restrictions to eligible reports. We conducted the latest search on 27 August 2015.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-01-02 13:27:50 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Three review authors (FR, MA and AA) independently screened and classified all citations as potential primary studies, review articles or other. The three review authors also independently examined all potential primary studies and decided on their inclusion in the review. We evaluated all trials for major potential sources of bias (random sequence generation, allocation concealment, blinding, intention-to-treat analysis, funding and completeness of follow-up) (See Figure 2; Figure 3). We assessed each trial quality factor separately and defined the trials as having low risk of bias only if they adequately fulfilled all of the criteria. We independently abstracted and evaluated methodology and outcomes from each trial, in accordance with the <I>Cochrane</I> <I>Handbook</I> <I>for</I> <I>Systematic</I> <I>Reviews</I> <I>of</I> <I>Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved disagreements by consensus among the review authors.</P>
<STUDY_SELECTION MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We assessed the reports identified from the described searches and excluded obviously irrelevant reports. We screened all articles by title and abstract, and then as full-text articles for inclusion. We list all excluded studies with reasons for their exclusion in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>
</P>
<P>Two review authors (FR, MA) independently examined the retrieved reports for eligibility. We performed this process without blinding to study authors, institution, journal of publication or results. We resolved disagreements by consensus among the review authors. We provide a detailed description of the search and assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We used the above strategy to search for relevant trials. We then screened the titles and abstracts in order to identify studies for eligibility. We independently extracted and collected the data on a standardized paper form. We were not blinded to the study author, source institution, or the publication source of trials. We resolved disagreements by discussion and approached all first authors of the included trials for additional information on risks of bias. For more detailed information please see the section <LINK TAG="CONTRIBUTIONS" TYPE="SECTION">Contributions of authors</LINK>.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We evaluated the validity and design characteristics of each trial. We evaluated trials for major potential sources of bias (random sequence generation, allocation concealment, blinding, intention-to-treat analysis, funding and completeness of follow-up). We assessed each trial quality factor separately and defined the trials as having a low risk of bias only if they adequately fulfilled all of the criteria.</P>
<P>1. Random sequence generation</P>
<P>Assessment of randomization: sufficiency of the method in producing two comparable groups before intervention.</P>
<P>Grade: &#8217;low risk&#8217;: a truly random process (e.g. random computer number generator, coin tossing, throwing dice); &#8217;high risk&#8217;: any non-random process (e.g. date of birth, date of admission by hospital or clinic record number or by availability of the intervention); or &#8217;unclear risk&#8217;: insufficient information.</P>
<P>2. Allocation concealment</P>
<P>Allocation method prevented investigators or participants from foreseeing assignment.</P>
<P>Grade: &#8217;low risk&#8217;: central allocation or sealed opaque envelopes; &#8217;high risk&#8217;: using an open allocation schedule or other unconcealed procedure; or &#8217;unclear risk&#8217;: insufficient information.</P>
<P>3. Blinding</P>
<P>Assessment of appropriate blinding of the team of investigators and participants: person responsible for participant care, participants and outcome assessors.</P>
<P>Grade: &#8217;low risk&#8217;: blinding considered adequate if participants and personnel were kept unaware of intervention allocations after inclusion of participants into the study, and if the method of blinding involved a placebo indistinguishable from the intervention, as mortality is an objective outcome; &#8217;high risk&#8217;: not double-blinded, categorized as an open-label study, or without use of a placebo indistinguishable from the intervention; &#8217;unclear risk&#8217;: blinding not described.</P>
<P>4. Incomplete outcome data</P>
<P>Completeness of outcome data, including attritions and exclusions.</P>
<P>Grade: &#8217;low risk&#8217;: numbers and reasons for dropouts and withdrawals in the intervention groups described, or no dropouts or withdrawals were specified; &#8217;high risk&#8217;: no description of dropouts and withdrawals provided; &#8217;unclear risk&#8217;: report gave the impression of no dropouts or withdrawals, but this was not specifically stated.</P>
<P>5. Selective reporting</P>
<P>The possibility of selective outcome reporting.</P>
<P>Grade: &#8217;low risk&#8217;: reported outcomes prespecified in an available study protocol, or, if this is not available, published report includes all expected outcomes; &#8217;high risk&#8217;: not all prespecified outcomes reported, reported using non-prespecified subscales, reported incompletely or report fails to include a key outcome that would have been expected for such a study; &#8217;unclear risk&#8217;: insufficient information.</P>
<P>6. Funding bias</P>
<P>Assessment of any possible funding bias.</P>
<P>Grade: &#8217;low risk&#8217;: reported no funding, funding from universities or public institutions; &#8217;high risk&#8217;: funding from private investors, pharmaceutical companies or trial investigator employed by the pharmaceutical company; &#8217;unclear risk&#8217;: insufficient information.</P>
<P>7. Other bias</P>
<P>Assessment of any possible sources of bias not addressed in domains 1 to 6.</P>
<P>Grade: &#8217;low risk&#8217;: report appears to be free of such biases; &#8217;high risk&#8217;: at least one important bias is present that is related to study design, early stopping because of some data-dependent process, extreme baseline imbalance, academic bias, claimed fraudulence or other problems; or &#8217;unclear risk&#8217;: insufficient information or evidence that an identified problem will introduce bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data (binary outcomes). These included:</P>
<P>Primary outcomes:</P>
<OL>
<LI>Overall mortality (longest follow-up, regardless of the period of follow-up)</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>Complications during the inpatient stay specific to the trial intervention</LI>
<LI>Complications during the inpatient stay not specific to the trial intervention</LI>
<LI>Complications specific to the trial intervention other than bleeding</LI>
<LI>Bleeding events</LI>
<LI>Incidence of surgical intervention</LI>
<LI>Incidence of respiratory failure not present at admission</LI>
<LI>Overall mortality among patients with severe sepsis and DIC</LI>
</OL>
<P>We used the mean difference (MD) with a 95% confidence interval (CI), if data were continuous and measured in the same way between trials.</P>
<OL>
<LI>Amount of red blood cells administered</LI>
<LI>Severity of sepsis</LI>
<LI>Duration of mechanical ventilation</LI>
<LI>Length of stay in hospital</LI>
<LI>Mean length of stay in the ICU</LI>
</OL>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-01-02 13:27:50 +0000" MODIFIED_BY="Mikkel Allingstrup">
<SUBSECTION>
<HEADING LEVEL="5">Studies with multiple intervention groups</HEADING>
<P>In accordance with the <I>Cochrane</I> <I>Handbook</I> <I>for</I> <I>Systematic</I> <I>Reviews</I> <I>of</I> <I>Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), for trials with two or more groups receiving different doses, we combined data for the primary and secondary outcomes. We excluded trials that only compared different doses of AT III and did not have a control group, with or without placebo.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We contacted the authors of trials with missing data in order to retrieve the relevant information. For all included studies we noted levels of attrition and any exclusions. In case of missing data, we chose &#8217;complete-case analysis&#8217; for our primary outcomes, which excludes from the analysis all participants with the outcome missing.</P>
<P>Selective outcome reporting occurs when nonsignificant results are selectively withheld from publication (<LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>), and is defined as the selection, on the basis of the results, of a subset of the original variables recorded for inclusion in publication of trials (<LINK REF="REF-Hutton-2000" TYPE="REFERENCE">Hutton 2000</LINK>). The most important types of selective outcome reporting are: selective omission of outcomes from reports; selective choice of data for an outcome; selective reporting of different analyses using the same data; selective reporting of subsets of the data and selective underreporting of data (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We explored heterogeneity using the I² statistic and Chi² test. An I² statistic above 50% represents substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). In case of I² statistic &gt; 0, we tried to determine the cause of heterogeneity by performing relevant subgroup analyses. We used the Chi² test to provide an indication of heterogeneity between studies, with a P value &#8804; 0.1 considered significant.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-07-28 18:41:53 +0100" MODIFIED_BY="[Empty name]">
<P>Funding bias is related to the possible publication delay or discouragement of undesired results in trials sponsored by the industry (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-01-02 13:27:50 +0000" MODIFIED_BY="Mikkel Allingstrup">
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>We used Review Manager 5 software (<LINK REF="REF-RevMan--5.3" TYPE="REFERENCE">RevMan 5.3</LINK>). We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous variables and mean difference (MD) with CI for continuous outcomes. We used the Chi² test to provide an indication of heterogeneity between studies, with a P value &lt; 0.1 considered significant. The degree of heterogeneity observed in the results was quantified using the I² statistic, which can be interpreted as the proportion of the total variation observed between the studies that is attributable to differences between studies rather than to sampling error (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). An I² statistic &gt; 75% is considered as very heterogeneous. We used both a random-effects model and a fixed-effect model. If the I² statistic = 0% we only reported the results from the fixed-effect model, and in the case of I² statistic &gt; 0% we reported only the results from the random-effects model.</P>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Trial</I> <I>sequential</I> <I>analysis</I>
</HEADING>
<P>The risk of type 1 errors in meta-analyses due to sparse data and repeated significance testing following updates with new trials remains a serious concern (<LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). As a result, spurious P values due to systematic errors from trials with high risk of bias, outcome reporting bias, publication bias, early stopping for benefit and small trial bias may result in false conclusions. In a single trial, interim analysis increases the risk of type 1 errors. In order to avoid type 1 errors, group sequential monitoring boundaries (<LINK REF="REF-Lan-1983" TYPE="REFERENCE">Lan 1983</LINK>) are used to decide whether a trial could be terminated early because of a sufficiently small P value; thus, the cumulative Z-curve crosses the monitoring boundary.</P>
<P>Equally, sequential monitoring boundaries can be applied to meta-analyses and are labelled &#8217;trial sequential monitoring boundaries&#8217; (TSMBs). In &#8217;trial sequential analysis&#8217; (TSA), the addition of each new trial in a cumulative meta-analysis is viewed as an interim meta-analysis, which provides useful information on the need for additional trials (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>).</P>
<P>It is appropriate and wise to adjust new meta-analyses for multiple testing on accumulating data to control the overall type 1 error risk in cumulative meta-analysis (<LINK REF="REF-Pogue-1997" TYPE="REFERENCE">Pogue 1997</LINK>; <LINK REF="REF-Pogue-1998" TYPE="REFERENCE">Pogue 1998</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>).</P>
<P>When using TSA, if the cumulative Z-curve crosses the boundary, there is an indication of a sufficient level of evidence having been reached, and as a consequence one may conclude that no further trials may be needed. However, evidence is insufficient to allow a conclusion if the Z-curve does not cross the boundary or does not surpass the required information size.</P>
<P>In order to construct the TSMBs, one needs a required information size which is calculated as the least number of participants required in a well-powered single trial with low risk of bias (<LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Pogue-1998" TYPE="REFERENCE">Pogue 1998</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>).</P>
<P>In this updated review, we adjusted the required information size for heterogeneity with the diversity adjustment factor (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). We applied TSA, as it prevents an increase in the risk of type 1 errors (20%). If the actual accrued information size was too small, we provided the required information size given the actual diversity (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>)</P>
</SUBSECTION>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We conducted the following subgroup analyses:</P>
<OL>
<LI>The effect of AT III in participants given heparin (all types and doses) versus participants not given heparin</LI>
<LI>Comparing estimates of the pooled intervention effect in trials with low risk of bias to estimates from trials with high risk of bias (i.e. trials having at least one inadequate risk of bias component)</LI>
<LI>Duration of drug administration (up to one week, more than one week)</LI>
<LI>Completeness of follow-up</LI>
<LI>Comparing the pooled intervention effect in trials with a follow-up that was longer than the median follow-up with trials having a follow-up equal to or shorter than the median follow-up of trial participants. This was in order to detect a possible dependency of the estimate of intervention effect with length of follow-up</LI>
<LI>The effect of AT III in the trauma population</LI>
<LI>The effect of AT III in obstetrics (eclampsia, pre-eclampsia)</LI>
<LI>The effect of AT III in paediatrics (we defined an age below 18 years for our inclusion criteria)</LI>
<LI>The effect of AT III in sepsis and DIC</LI>
</OL>
<P>If analyses of various subgroups were significant, we performed a test of interaction (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>). We considered P values &lt; 0.05 as indicating significant interaction between the AT III effect and subgroup category.</P>
<P>We included entire trials for subgroup analysis of trauma, obstetric, and paediatric participants.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We decided to carry out a sensitivity analysis on the results by applying fixed-effect and random-effects models to assess the impact of heterogeneity on our results.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>We used the principles of the GRADE approach to provide an overall assessment of the evidence relating to all of our outcomes. We constructed a 'Summary of findings' table using the GRADEpro software. As outcomes of public interest, we chose to present: mortality, bleeding events, incidence of respiratory failure not present at admission, duration of mechanical ventilation, length of stay in hospital, mean length of stay in ICU and overall mortality among patients with severe sepsis and DIC (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-01-04 10:01:48 +0000" MODIFIED_BY="Mikkel Allingstrup">
<STUDY_DESCRIPTION MODIFIED="2016-01-04 10:01:48 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>
</P>
<SEARCH_RESULTS MODIFIED="2016-01-04 10:01:48 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Through electronic searches and from reading the references of potentially relevant articles, we identified 11287 publications on AT III (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After reading the abstracts, we could directly exclude 11,173 publications. We retrieved 65 relevant publications for further assessment. From these 65 publications, we included 30 (<LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>), which randomized a total of 3933 participants. One trial (<LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>) was only published as an abstract and the data were so inadequate that they could not be used for further processing. Our analyses include a total of 3882 participants. The sample size varied from 16 to 2314 participants. We excluded 24 publications for the reasons detailed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. We found one ongoing trial (<LINK REF="STD-D_x0027_angelo-2005" TYPE="STUDY">D'angelo 2005</LINK>) but no data were provided for this trial (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).</P>
<P>One trial was published in Russian only (<LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>), and one excluded trial was in German (Angstwurm 2009, a secondary publication of <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>). We had these studies translated into English. Five trials had multiple full-text publications or published post hoc subgroup analyses (<LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>).</P>
<P>In this updated review, we also included trials that were only published as abstracts in order to avoid publication bias (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Types of participants</HEADING>
<P>We classified two trials as obstetric studies (<LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>); four trials as paediatric trials (<LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>); and a further two trials as trauma studies (<LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>). The remaining trials consisted of mixed populations of critically ill participants, mainly with sepsis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of interventions</HEADING>
<P>The duration of the intervention varied from less than 24 hours to four weeks. Three trials had a median duration of AT III intervention that was longer than one week (<LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>). Follow-up ranged from seven to 90 days.</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-01-02 13:27:50 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>The 30 included trials were all published between 1985 and 2013. Five trials of AT III were multicentre trials (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>). Five trials of AT III were multinational trials including Germany, Belgium, the Netherlands, Canada and the USA (<LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>). One trial was carried out in 19 countries (<LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>). Two trials did not state the location (<LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>).</P>
<P>The 30 included trials involved a total of 3933 participants. The details of the included studies are provided in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Fourteen trials recruited more male than female participants (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>). One trial recruited only men (<LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>), two trials recruited only women (<LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>), six did not report the gender of the participants (<LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>) and two studies had more female than male participants (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>). The age of the participants included extends from the premature infant to the elderly intensive-care participant. It therefore makes little sense to calculate the average age of the participants included. One trial however, excluded participants older than 75 (<LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>).</P>
<P>Eighteen trials used an initial loading dose either based on weight (u/kg) or as a fixed dose (<LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>). All trials except two (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>) stated the use of a maintenance dose. Nine trials used albumin as the control intervention (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>); two trials used fresh frozen plasma as the control intervention (<LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>); three trials only stated the use of an unknown placebo (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>). Nine trials used no placebo (<LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>). Four trials did not state which control they applied (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-12-26 09:25:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We excluded 24 randomized trials (<LINK REF="STD-Aibiki-2006" TYPE="STUDY">Aibiki 2006</LINK>; <LINK REF="STD-Dietrich-2013" TYPE="STUDY">Dietrich 2013</LINK>; <LINK REF="STD-Doi-2012" TYPE="STUDY">Doi 2012</LINK>; <LINK REF="STD-Hoffmann-2010" TYPE="STUDY">Hoffmann 2010</LINK>; <LINK REF="STD-Ilias-2000" TYPE="STUDY">Ilias 2000</LINK>; <LINK REF="STD-Jochum-1995" TYPE="STUDY">Jochum 1995</LINK>; <LINK REF="STD-Kanbak-2011" TYPE="STUDY">Kanbak 2011</LINK>; <LINK REF="STD-Kim-2013" TYPE="STUDY">Kim 2013</LINK>; <LINK REF="STD-Korninger-1987" TYPE="STUDY">Korninger 1987</LINK>; <LINK REF="STD-Leitner-2006" TYPE="STUDY">Leitner 2006</LINK>; <LINK REF="STD-Maki-1987" TYPE="STUDY">Maki 1987</LINK>; <LINK REF="STD-Mayumi-2011" TYPE="STUDY">Mayumi 2011</LINK>; <LINK REF="STD-Neporada-2008B" TYPE="STUDY">Neporada 2008B</LINK>; <LINK REF="STD-Nishiyama-2006" TYPE="STUDY">Nishiyama 2006</LINK>; <LINK REF="STD-Paparella-2014" TYPE="STUDY">Paparella 2014</LINK>; <LINK REF="STD-Paternoster-2000" TYPE="STUDY">Paternoster 2000</LINK>; <LINK REF="STD-Paternoster-2004" TYPE="STUDY">Paternoster 2004</LINK>; <LINK REF="STD-Ranucci-2013" TYPE="STUDY">Ranucci 2013</LINK>; <LINK REF="STD-Sawamura-2009" TYPE="STUDY">Sawamura 2009</LINK>; <LINK REF="STD-Scherer-1997" TYPE="STUDY">Scherer 1997</LINK>; <LINK REF="STD-Shimada-1994" TYPE="STUDY">Shimada 1994</LINK>; <LINK REF="STD-Terao-1989" TYPE="STUDY">Terao 1989</LINK>; <LINK REF="STD-Valsecchi-2008" TYPE="STUDY">Valsecchi 2008</LINK>; <LINK REF="STD-Vinazzer-1995" TYPE="STUDY">Vinazzer 1995</LINK>), for the reasons detailed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>One trial is stated to be ongoing (<LINK REF="STD-D_x0027_angelo-2005" TYPE="STUDY">D'angelo 2005</LINK>); see the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Awaiting classification</HEADING>
<P>No studies are awaiting classification.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-01-04 09:16:50 +0000" MODIFIED_BY="Jane Cracknell">
<P>All of the included studies were randomized controlled trials. However, the risk of bias of the included studies was high (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The trials often failed to report trial methodology in sufficient detail. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<ALLOCATION MODIFIED="2016-01-04 09:16:50 +0000" MODIFIED_BY="Jane Cracknell">
<P>Generation of allocation sequence was adequately reported in 15 trials (<LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>Allocation concealment was adequately reported in 14 trials (<LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-01-04 09:16:50 +0000" MODIFIED_BY="Jane Cracknell">
<P>Nine trials provided sufficient data to be categorized as double-blinded (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>). The remaining 21 trials were either open-label or did not provide sufficient data on how the double-blinding was achieved (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Two trials did not provide sufficient data (high risk) on follow-up (<LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>). Six trials did not provide any data on follow-up (unclear risk) (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>). Twenty-two trials had adequate follow-up (low risk) (<LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-12-23 13:05:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Ten trials provided adequate information to be classified as low-risk trials (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>). This was often due to supplementary information provided based on online registration, protocol availability or authors providing supplementary information while responding to our questions.</P>
<P>Eighteen trials did not provide sufficient data on selective reporting (unclear risk) (<LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>).</P>
<P>Three trials had substantial methodological shortcomings across multiple domains of bias (<LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-01-02 13:27:50 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Fourteen trials performed analysis according to the intention-to-treat (ITT) method or provided sufficient data for us to perform ITT analyses (<LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>).</P>
<P>Eight trials reported sample size calculations (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>).</P>
<P>Three trials (<LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>) reported receiving pharmaceutical company funding.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-01-02 13:27:50 +0000" MODIFIED_BY="Mikkel Allingstrup">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1. Overall mortality (longest follow-up, regardless of the period of follow-up)</HEADING>
<P>Combining all trials showed no statistically significant effect of AT III on mortality, with a risk ratio (RR) of 0.95 (95% CI 0.88 to 1.03, I² statistic = 0%, P value = 0.91), based on data from 3882 participants in 29 trials. Results were analysed using a fixed-effect model because heterogeneity was low. We downgraded the outcome from high to moderate quality of evidence because of 20 trials with high risk of bias. However, trial sequential analysis (TSA) led us to upgrade the overall assessment. Equally, for trials with only low risk of bias (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>) we found no statistically significant effect; RR 0.96 (95% 0.88 to 1.04, I² statistic = 0%, fixed-effect model, 9 trials, 2915 participants). Trials with only high risk of bias (<LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>) had a non-significant RR of 0.94 (95% CI 0.77 to 1.14, I² statistic = 0%, fixed-effect model, 20 trials, 967 participants) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>We conducted three subgroup analyses concerning the use of heparin (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), but detected no statistically significant effects between the groups.</P>
<P>We carried out 15 subgroup and sensitivity analyses in regard to our primary outcome, and found no statistically significant effect in any of them (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>Summarized in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1. Complications during the inpatient stay specific to the trial intervention</HEADING>
<P>Two trials with low risk of bias (<LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>) and one trial with high risk of bias (<LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>) demonstrated a statistically significant increase in complications specific to the trial intervention: RR 1.26 (95% CI 0.83 to 1.92, I² statistic = 9%, P value = 0.33), based on data from 2454 participants in the three trials. We analysed results using a random-effects model. We downgraded the outcome from high to very low quality because of the small number of trials (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Complications during the inpatient stay not specific to the trial intervention</HEADING>
<P>Two trials (<LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>) did not reach statistical significance assessing complications not specific to the trial intervention: RR 0.71 (95% CI 0.08 to 6.11, I² statistic = 28%, P value = 0.24), based on data from 65 participants. We analysed results using a random-effects model. We downgraded the outcome from high to very low quality because of the small number of trials (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Complications specific to the trial intervention other than bleeding</HEADING>
<P>Three trials, one with low risk of bias (<LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>) and two with high risk of bias (<LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>), examined complications specific to the trial intervention other than bleeding: RR 0.72 (95% CI 0.42 to 1.25, I² statistic = 0%, P value = 0.95), based on data from 187 participants in the three trials. We analysed results using a fixed-effect model. We downgraded the outcome from high to very low quality because of the small number of trials (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Bleeding events</HEADING>
<P>Six trials with low risk of bias (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>) and five with high risk of bias (<LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>) demonstrated a statistically significant increase in bleeding events in the intervention group compared to the control group, with a RR of 1.58 (95% CI 1.35 to 1.84, I² statistic = 0%, P value = 0.57), based on data from 3019 participants in the 11 trials. We analysed results using a fixed-effect model. We downgraded the outcome from high to moderate quality because of the proportion of trials with high risk of bias (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Amount of red blood cells administered</HEADING>
<P>Four trials referred to the amount of red blood cells administered; one with low risk of bias (<LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>) and three with high risk of bias (<LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>) with a mean difference (MD) of 138.49 (95% CI -391.35 to 668.34, I² statistic = 88%, P value = 0.0001), based on data from 137 participants. We analysed results using a random-effects model. We downgraded the outcome from high to very low quality because of the small number of trials, three of them with high risk of bias (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Incidence of surgical intervention</HEADING>
<P>Three trials referred to the incidence of surgical intervention, all with low risk of bias (<LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>) with a RR of 1.04 (95% CI 0.85 to 1.27, I² statistic = 0%, P value = 0.61), based on data from 103 participants. We analysed results using a fixed-effect model. We downgraded the outcome from high to very low quality because of the small number of trials with few participants (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Severity of sepsis</HEADING>
<P>Only <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>, of the three different analyses (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>) reached statistical significance, with a MD of -1.24 (95% CI -2.18 to -0.29, I² statistic = 48%, P value = 0.015, random-effects model, 3 trials, 156 participants) (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>) when examining the effect of AT III on various illness scores. Six trials provided data (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>). However, the trials that did provide data adequate for meta-analysis were quite heterogenous in their application of various scores and their choice of time points.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. Incidence of respiratory failure not present at admission</HEADING>
<P>Six trials examined the effect of AT III on the incidence of respiratory failure (not present at admission) (<LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>). There was no statistically significant difference, with a RR of 0.93 (95% CI 0.76 to 1.14, I² statistic = 32%, P value = 0.22), based on data from 2591 participants in six trials. We analysed results using a random-effects model. We downgraded the outcome from high to moderate quality because one trial contributed with the majority of patients (<LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>. It is considered to skew the finding; however, it is rated low risk of bias, and contributes a weighting of only 30.7%. A sensitivity analysis removing it from the plot eliminates all heterogeneity in that subgroup.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">9. Duration of mechanical ventilation</HEADING>
<P>Three trials examined the effect of the trial intervention on duration of mechanical ventilation (<LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>). There was no statistically significant difference, with a MD of 2.20 (95% CI -1.21 to 5.60, I² statistic = 0%, P value = 0.89), based on data from 190 participants. We analysed results using a fixed-effect model. We downgraded the outcome from high to very low quality of evidenc<I>e</I> because of the small number of trials, few participants and imprecision of results with a wide confidence interval. The mean duration of mechanical ventilation in the intervention group was 2.2 days more (1.21 fewer to 5.6 more). (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">10. Length of stay in hospital</HEADING>
<P>Four trials examined the intervention effect on the length of stay in hospital (<LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>) with a MD of 1.10 (95% CI -7.16 to 9.36, I² statistic = 74%, P value = 0.009), based on data from 202 participants. We analysed results using a random-effects model. We downgraded the outcome from high to very low quality of evidence because of the small number of trials, few participants and imprecision of results with a wide confidence interval. The mean length of stay in hospital in the intervention group was 1.1 days more (7.16 fewer to 9.36 more). (<LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">11. Mean length of stay in the ICU</HEADING>
<P>Three trials with low risk of bias (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>) and four trials with high risk of bias (<LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>) examined the intervention effect on length of stay in the ICU. There was insufficient evidence to support any beneficial effect of the intervention, with a MD of 0.24 (95% CI -1.34 to 1.83, I² statistic = 0%, P value = 0.70), based on data from 376 participants. We analysed results using a fixed-effect model. We downgraded the outcome from high to very low quality of evidence because of the small number of trials, most of them with high risk of bias. The mean length of stay in ICU in the intervention group was 0.24 days more (1.34 fewer to 1.83 more). (<LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">12. Overall mortality among participants with severe sepsis and DIC</HEADING>
<P>Twelve trials examined the intervention effect on mortality among participants with severe sepsis and disseminated intravascular coagulation (DIC) (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>). The trials demonstrated a statistically significant decrease in mortality in favour of the trial intervention: RR 0.95 (95% CI 0.88 to 1.03, I² statistic = 0%, P value = 0.98), based on data from 2858 participants. We analysed results using a fixed-effect model. We downgraded the outcome from high to very low quality of evidence, because of numerous trials with high risk of bias. The vast majority of trials were small and poorly described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subjective overall quality-of-life assessment</HEADING>
<P>Only one trial examined the intervention's effect on quality of life (<LINK REF="REF-Rublee-2003" TYPE="REFERENCE">Rublee 2003</LINK>: based on data from <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>). There was an objective assessment of physical performance and dependency, and a subjective overall quality-of-life assessment analysis. Neither assessment supported intervention with AT III, with a MD of -2.00, (95% CI -4.49 to 0.49, fixed-effect model, 897 participants) and a MD of -2.00, (95% CI -5.01 to 1.01, fixed-effect model, 897 participants) respectively, both rated at very low quality (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup and sensitivity analyses</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">The heparin issue</HEADING>
<P>A detrimental interaction between AT III and heparin was suspected before the <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK> trial, and we predefined use of AT III with and without heparin in the protocol for secondary analyses. However, the participants were not stratified according to heparin administration and the protocol allowed concomitant use of heparin by indication, after randomization to AT III or placebo. Even if the baseline comparison of participants allocated to AT III and placebo, in the subgroup without heparin, showed similar characteristics, the randomization is violated in the subgroup analysis.</P>
<P>Pooling all trials with and without concomitant use of heparin, with the <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK> trial as either a trial with concomitant use of heparin or as a trial without use of heparin, does not provide evidence of a statistically significant intervention effect of AT III (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). Even when splitting the <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK> trial into two 'separate trials', with and without concomitant use of heparin, and pooling these results with the other trials, we found no statistically significant intervention effect of AT III in the subgroup of trials without adjuvant heparin administration (RR 0.95, 95% CI 0.88 to 1.03; I² statistic = 0%, fixed-effects model, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). However, splitting the <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK> trial violates the randomization procedure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial sequential analysis</HEADING>
<P>We conducted trial sequential analysis (TSA) of AT III versus control on longest follow-up mortality (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The TSA-adjusted confidence interval for the meta-analysis of the primary outcome with continuity correction for zero events trials (0.001 event in each arm) in a fixed-effect model results in a RR of 0.95 (95% CI 0.88 to 1.03; I² statistic = 0%, Diversity D² = 0%). The point estimate of the potential intervention effect as suggested by the low risk of bias trials in the meta-analysis of the effect of AT III on mortality is a relative risk reduction (RRR) of 5% and the low-bias heterogeneity-adjusted information size (LBHIS) calculated based on this intervention effect (with 80% power and alpha 0.05, assuming a double-sided type I risk of 5% and a type II risk of 20%) is 23,634 participants (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). With an accrued information size of 3882 participants and no boundaries crossed so far, only 16.43% of the required information size is actually available at this stage to reject or accept a 4% RRR for overall mortality.</P>
<P>However, solid evidence may be obtained with fewer participants if eventually the cumulative meta-analysis Z-curve crosses the trial sequential monitoring boundary constructed for a required information size of 23,634 randomized participants.</P>
<P>On the other hand, to demonstrate or reject an a priori anticipated intervention effect of a RRR of 10%, 5037 should be randomized. In this analysis, the cumulative Z-curve breaks through the boundary for futility (non-superiority) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). As 3882 participants are included in the present meta-analyses on mortality without the meta-analysis becoming statistically significant and since the futility boundary is crossed, an intervention effect of 10% RRR or more on mortality is unlikely.</P>
<P>When carrying out the same TSA analyses as above for trials of sepsis and DIC only (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>) with an anticipated RRR of 10%, the required information size is 3794 participants without the meta-analysis becoming statistically significant, and with the boundary for futility being crossed, thus indicating that a RRR of 10% is to be rejected. (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>)</P>
<P>TSA analysis based on a potential RRR of 5% as indicated by the meta-analysis for studies on sepsis and DIC (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>) yields a LBHIS of 21,657 participants and with an accrued information size of 2992 participants and no boundaries being crossed so far, only 13.82% of the required information size is actually available (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-01-04 09:16:50 +0000" MODIFIED_BY="Jane Cracknell">
<SUMMARY_OF_RESULTS MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>In this systematic review of 30 trials with 3933 participants we found no significant beneficial effect of AT III on mortality (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>The analyses on mortality showed no heterogeneity and were robust when performing different subgroup analyses. Conversely, AT III increased the risk of bleeding (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>) and it appeared to improve only one of the reported severity of sepsis scores (multiple organ failure syndrome, MOFS) with limited data included in the analysis (inadequate power and precision) and remains a surrogate outcome (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). None of the other secondary outcomes reached statistical significance.</P>
<P>Neither the meta-analysis nor the subgroup analyses demonstrated a statistically significant effect of AT III on mortality. However, this is not evidence of the absence of a beneficial effect, but the data suggest that a potentially beneficial effect of AT III must be at best modest compared to what had been expected. Trial sequential analysis added valuable information to the level of evidence and as such we are able to reject an intervention effect of 10% RRR or more for all trials, as well as trials including participants with sepsis and DIC. Additionally, based on the existing level of evidence from trials with low risk of bias, only 16.43% of the required information size is available to reject or accept a 5% RRR for overall mortality.</P>
<SUBSECTION>
<HEADING LEVEL="2">Subgroup analysis of duration of intervention and length of follow-up</HEADING>
<P>Based on follow-up less than or longer than the median of all trials, we undertook a subgroup analysis to examine the intervention effect on mortality. However, there was no statistically significant association between follow-up and mortality (see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The median follow-up time was 32 days.</P>
<P>We also examined the intervention effect based on the median duration of intervention being less than or longer than one week (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Only three trials with a total of 208 participants had a median duration of intervention longer than one week (<LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>). The current evidence does not support a longer duration of intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Subgroup analyses on paediatric, obstetric and trauma populations</HEADING>
<P>Based on the existing data, we have to conclude that there is insufficient data to help us support or refute the use of AT III intervention among trauma, obstetric, or paediatric populations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Subgroup analyses regarding septic populations</HEADING>
<P>Very few trials met our requirements in terms of trial intervention effect on various illness scores. We accepted the various definitions provided by the authors and undertook four different meta-analyses. The participant numbers in these analyses ranged from 28 to 156, and only one meta-analysis reached statistical significance (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). The meta-analyses examining the overall mortality in the septic population, based on 2918 participants, also failed to demonstrate a statistically significant reduction of mortality (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">The heparin issue</HEADING>
<P>We examined a potential detrimental interaction of AT III with heparin by carrying out three separate analyses pooling mortality data from trials with concomitant heparin use against those without (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), while examining the impact of data from <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>. The latter trial was either defined as a trial with or without heparin use (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>) and finally we chose to split data from <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK> in order to examine the hypothesis. As such, this is to be considered a post hoc analysis violating the randomization procedure (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). However, none of these analyses demonstrated any statistically significant interaction effects.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>The authors of this updated review are confident that our search strategy obtained all available studies. We have contacted several authors. We identified two additional trials by Neporada et al. One was included (<LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>) and one excluded <LINK REF="STD-Neporada-2008B" TYPE="STUDY">Neporada 2008B</LINK>.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-01-04 09:16:50 +0000" MODIFIED_BY="Jane Cracknell">
<P>The randomized controlled trial (RCT) is considered the most rigorous method of determining whether a cause-effect relationship exists between an intervention and outcome. The strength of the RCT lies in the process of randomization.</P>
<P>We rank the quality of findings from moderate to very low quality of evidence across the different outcomes. The main limiting factors were high risk of bias and small and poorly described trials.</P>
<P>Nine trials were reported as being at completely low risk of bias (<LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). 16 of the of 30 included trials were at high risk or unclear risk of bias in random sequence generation (selection bias) (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>). Only one trial was registered on an available trial database (<LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>) Three trials had received funding from the pharmaceutical industry (<LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>).</P>
<P>The five trials (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>) only published as abstracts lack a great amount of valuable information with regard to methodology and outcomes, and we consequently rate them at high risk of bias.</P>
<P>Application of the GRADE approach enables us to incorporate risk of bias, directness of evidence, heterogeneity, precision of effect estimate, and risk of publication bias. Based on these criteria, the quality of evidence in this review was very low and there was a high risk of bias.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-12-23 15:08:01 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Our systematic review has several potential limitations. As for all systematic reviews, our findings and interpretations are limited by the quality and quantity of the available evidence on the effects of AT III on mortality. We assessed the risk of bias of the included trials by using the published data, which ultimately may not reflect the truth. We tried to contacted all authors but only a few responded and provided further information. Three trials with 260 participants reported zero mortality in both trial groups (<LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>).</P>
<P>We include five trials submitted only as abstracts in this updated review (<LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Blauhut-1985" TYPE="STUDY">Blauhut 1985</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>). These abstracts lack important information. Nevertheless, a sensitivity analysis on the mortality data of only these trials yielded a RR of 0.91 (95% CI 0.55 to 1.52, I² statistic = 0%, fixed-effect model). The result of the sensitivity analysis is highly comparable with and supportive of the overall mortality (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Due to a lack of convincing evidence in favour of AT III in settings without heparin, we chose to implement trial sequential analysis results, since the hypothesis of a beneficial effect of AT III in critically ill people still generates much attention.</P>
<P>Although there was minimal heterogeneity among trial results on mortality, we are aware that we pooled very heterogeneous trials in terms of participants, settings, and treatment regimens. However, all the included conditions cause low levels of AT III, can result in DIC, and have similar inflammatory pathways. We therefore think that there is a biologically plausible reason to perform an inclusive meta-analysis, which also considerably increases the generalizability and usefulness of the review. Furthermore, a broad meta-analysis increases power, reduces the risk of erroneous conclusions, and facilitates exploratory analyses which can generate hypotheses for future research (for example, adjuvant heparin) (<LINK REF="REF-Gotzsche-2000" TYPE="REFERENCE">Gotzsche 2000</LINK>).</P>
<P>We have adhered to Cochrane methodology and applied additional statistical methods, such as TSA, to strengthen our conclusions and reduce the risk of random error.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>The overall results of this updated systematic review are in accordance with the two previously published papers on the same topic, and only highlight the previously stated findings through inclusion of several additional studies. (<LINK REF="REF-Afshari-2007" TYPE="REFERENCE">Afshari 2007</LINK>; <LINK REF="REF-Afshari-2008" TYPE="REFERENCE">Afshari 2008</LINK>)</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<IMPLICATIONS_PRACTICE MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>There is insufficient evidence to support AT III substitution in any category of critically ill people. We did not find a statistically significant effect of AT III on mortality, but AT III increased the risk of bleeding events. Subgroup analyses performed according to duration of intervention, length of follow-up, different patient groups, and use of adjuvant heparin did not show differences in the estimates of intervention effects. Serious methodological shortcomings of the included studies are, however, likely to have influenced the overall intervention effect (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>Trial sequential analysis showed that there is sufficient evidence to reject a beneficial effect of more than 10% RRR (4% absolute risk reduction) on overall mortality and for trials including participants with sepsis and DIC. There also remains the possibility that the use of AT III may be harmful.</P>
<P>The GRADE approach only reaffirmed our interpretation of the level of evidence, and we are confident that at this stage the quality of evidence in regard to our primary outcomes is moderate, despite the fact that many of the trials have high risk of bias.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>To our knowledge only one trial (<LINK REF="STD-D_x0027_angelo-2005" TYPE="STUDY">D'angelo 2005</LINK>) is ongoing. The participants are women with pre-eclampsia occurring before the 30th week of gestation. We have found no trials registered dealing with the effect of AT III in septic patients.</P>
<P>There is a need for a large-scale randomized controlled trial with low risk of bias to evaluate the effectiveness of AT III without heparin, before this intervention can be used routinely in critically ill patients. We recognize the heterogeneity in the patient population in the included trials and, as a consequence of the high mortality rate in the septic population, we believe that a new trial should address the effect of AT III in septic patients. <B>
<BR/>
</B>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>We first thank Dr John Carlisle, Prof Marcus Müllner, Dr Francois Fourrier, Dr Geoffrey Playford, Dr Christian Josef Wiedermann, Kathie Godfrey, and Nete Villebro for their help and editorial advice during the preparation of the protocol (<LINK REF="REF-Afshari-2007" TYPE="REFERENCE">Afshari 2007</LINK>) for the original review (<LINK REF="REF-Afshari-2008" TYPE="REFERENCE">Afshari 2008</LINK>).</P>
<P>We also thank Dr Nadezda Vorobyeva, Dr Elena Neporada, Dr Domenico Paparella, Dr Athina Lavrentieva, and Dr Armando D&#8217;Angelo for providing further information about their trials.</P>
<P>We would like to thank Dr Mikhail Zemtsovski for his help with translation of two manuscripts from Russian, and librarian Tove Svendsen (Medical Research Library, Copenhagen University Hospital, Rigshospitalet) for help with updating our literature search.</P>
<P>From the Cochrane Group we would like to thank Nicola Petrucci (Content Editor) and Jing Xie (Sophia) (Statistical Editor), Karen Hovhannisyan (Trials Search Co-ordinator) for his assistance in providing our different search strategies, and Jane Cracknell (Managing Editor, Cochrane Anaesthesia Critical and Emergency Care Group (ACE)) for her valuable assistance during the entire process.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-12-18 12:38:59 +0000" MODIFIED_BY="[Empty name]">
<P>Mikkel Allingstrup declares that there are no conflicts of interest<BR/>Jørn Wetterslev declares that he is a member of the task force on trial sequential analysis (TSA) at Copenhagen Trial Unit developing and programming TSA (please see <A HREF="http:// www.ctu.dk/tsa">www.ctu.dk/tsa</A>)<BR/>Frederikke B Ravn declares that there are no conflicts of interest<BR/>Ann Merete Møller declares that there are no conflicts of interest<BR/>Arash Afshari declares that there are no conflicts of interest</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<SUBSECTION>
<HEADING LEVEL="4">Updated review</HEADING>
<P>Mikkel Allingstrup (MA), Jørn Wetterslev (JW), Frederikke B Ravn (FR), Ann Merete Møller (AM), Arash Afshari (AA).<BR/>MA, FR and AA were involved in literature searching, quality assessment and data abstraction of trials, and writing the review.<BR/>JW was involved in statistics and TSA analysis.<BR/>AM was involved in proofreading the manuscript</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Original published review</HEADING>
<P>(<LINK REF="REF-Afshari-2008" TYPE="REFERENCE">Afshari 2008</LINK>)</P>
<P>All three authors (Arash Afshari, Jørn Wetterslev and Ann Merete Møller) were involved in protocol development, literature searching, quality assessment and data abstraction of trials, and writing the review.</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-01-04 09:16:50 +0000" MODIFIED_BY="Jane Cracknell">
<P>We decided after publication of our protocol (<LINK REF="REF-Afshari-2007" TYPE="REFERENCE">Afshari 2007</LINK>) for this review to also include randomized trials examining the effect of AT III on malignant diseases and cirrhosis. The decision was based on the desire to increase precision and power without confounding our data. The generalizability and usefulness of meta-analyses are increased considerably if the individual trials cover different patient populations, settings, and treatment regimen. Furthermore, a broad (inclusive) meta-analysis increases power, reduces the risk of erroneous conclusions, and facilitates exploratory analyses, which can generate hypotheses for future research. Usually it is also recommended to pool a broad range of studies (<LINK REF="REF-Gotzsche-2000" TYPE="REFERENCE">Gotzsche 2000</LINK>).<BR/>
</P>
<P>We decided to employ trial sequential analyses (TSA) as a way of estimating the level of evidence of the experimental intervention. In our protocol we defined the secondary outcome 'Bleeding events within 14 days'. However, we changed this to 'Bleeding events', since we found it more relevant to look at the overall bleeding without applying any time constraint. Additionally, we found very few trials reporting bleeding events within the first 14 days.</P>
<P>We defined bleeding events as noted by the authors (requiring transfusions) and related to the intervention.</P>
<P>In this updated review we decided to expand our 'Risk of bias' table. We therefore added the following domains: blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias. We also added two 'Risk of bias' figures <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>We have removed five subgroup analyses from this updated review, since we found them redundant. We present the results in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>We also applied the principles of the GRADE approach to provide an overall assessment of the evidence relating to all of our outcomes. We constructed a '<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>' table using the GRADEpro software.<BR/>
</P>
<P>In this updated review, we also included trials that were only published as abstracts, in order to avoid publication bias.</P>
<P>Four subgroup analyses contained only one individual study. These are listed in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<STUDIES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<INCLUDED_STUDIES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Albert-1992" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Albert 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albert J, Blomqvist H, Gardlund B, Jakobsson J, Svensson J, Blomback M</AU>
<TI>Effect of antithrombin concentrate on haemostatic variables in critically ill patients</TI>
<SO>Acta Anaesthesiologica Scandinavia</SO>
<YR>1992</YR>
<VL>36</VL>
<NO>8</NO>
<PG>745-52</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="1466208"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balk-1995" MODIFIED="2015-12-21 09:42:45 +0000" MODIFIED_BY="[Empty name]" NAME="Balk 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-12-21 09:42:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balk RA, Bedrosian C, McCormick L, Baughman J, Eisele B, Keinecke HO, et al</AU>
<TI>Prospective double blind placebo-controlled trial of ATIII substitution in sepsis</TI>
<SO>Intensive Care Medicine</SO>
<YR>1995</YR>
<VL>21 Suppl 1</VL>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baudo-1992" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Baudo 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baudo F, DeGasperi A, De Cataldo F, Caimi TM, Cattaneo D, Redaelli R, et al</AU>
<TI>Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial</TI>
<SO>Thrombosis Research</SO>
<YR>1992</YR>
<VL>68</VL>
<NO>4-5</NO>
<PG>409-16</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="1290169"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baudo-1998" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Baudo 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baudo F, Caimi TM, De Cataldo F, Ravizza A, Arlati S, Casella G, et al</AU>
<TI>Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study</TI>
<SO>Intensive Care Medicine</SO>
<YR>1998</YR>
<VL>24</VL>
<NO>4</NO>
<PG>336-42</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="9609411"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blauhut-1985" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Blauhut 1985" YEAR="1985">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blauhut B, Kramar H, Vinazzer H, Bergmann H</AU>
<TI>Substitution of antithrombin III in shock and DIC: a randomized study</TI>
<SO>Thrombosis Research</SO>
<YR>1985</YR>
<VL>39</VL>
<NO>1</NO>
<PG>81-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4035650"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz_x002d_Cremades-1994" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Diaz-Cremades 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diaz-Cremades JM, Lorenzo R, Sánchez M, Moreno MJ, Alsar MJ, Bosch JM, et al</AU>
<TI>Use of antithrombin III in critical patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>8</NO>
<PG>577-80</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="7706571"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eisele-1998" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Eisele 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al</AU>
<TI>Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.</TI>
<SO>Intensive Care Medicine</SO>
<YR>1998</YR>
<VL>24</VL>
<NO>7</NO>
<PG>663-72</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="9722035"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fourrier-1993" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Fourrier 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J</AU>
<TI>Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>104</VL>
<NO>3</NO>
<PG>882-8</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="8365305"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fulia-2003" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Fulia 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fulia F, Cordaro S, Meo P, Gitto P, Gitto E, Trimarchi G, et al</AU>
<TI>Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?</TI>
<SO>Biology of the Neonate</SO>
<YR>2003</YR>
<VL>83</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="12566675"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gando-2013" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Gando 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S et al; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT)</AU>
<TI>A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis</TI>
<SO>Critical Care</SO>
<YR>2013</YR>
<VL>17</VL>
<NO>6</NO>
<PG>297</PG>
<IDENTIFIERS MODIFIED="2015-03-18 11:10:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-03-18 11:10:11 +0000" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="24342495"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="OTHER">
<AU>UMIN-CTR Clinical Trial</AU>
<TI>Trial registration</TI>
<SO>upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E</SO>
<YR>(accessed 21 April 2015)</YR>
<IDENTIFIERS MODIFIED="2015-12-21 09:51:35 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-12-21 09:51:35 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="https://"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grenander-2001" MODIFIED="2015-12-21 09:54:34 +0000" MODIFIED_BY="[Empty name]" NAME="Grenander 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-12-21 09:54:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grenander A, Bredbacka S, Rydvall A, Aroch R, Edner G, Koskinen LO, et al</AU>
<TI>Antithrombin treatment in patients with traumatic brain Injury; a pilot study</TI>
<SO>Journal of Neurosurgical Anesthesiology</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>1</NO>
<PG>49-56</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="11145479"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haire-1998" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Haire 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haire WD, Ruby EI, Stephens LC, Reed E, Tarantolo SR, Pavletic ZS, et al</AU>
<TI>A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation</TI>
<SO>Biology of Blood and Marrow Transplantation</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>3</NO>
<PG>142-50</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="9923412"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harper-1991" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Harper 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harper PL, Williamson L, Park G, Smith JK, Carrell RW</AU>
<TI>A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function</TI>
<SO>Transfusion Medicine</SO>
<YR>1991</YR>
<VL>1</VL>
<NO>2</NO>
<PG>121-8</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="9259838"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inthorn-1997" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Inthorn 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-08-27 07:56:29 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffmann JN, Mühlbayer D, Jochum M, Inthorn D</AU>
<TI>Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>9</NO>
<PG>1851-9</PG>
<IDENTIFIERS MODIFIED="2015-08-25 13:52:31 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2015-08-25 13:52:31 +0100" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="15343012"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Inthorn D, Hoffmann JN, Hartl WH, Mühlbayer D, Jochum M</AU>
<TI>Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction</TI>
<SO>Shock</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>5</NO>
<PG>328-34</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="9361342"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inthorn D, Hoffmann JN, Hartl WH, Mühlbayer D, Jochum M</AU>
<TI>Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis</TI>
<SO>Shock</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>2</NO>
<PG>90-6</PG>
<IDENTIFIERS MODIFIED="2015-08-25 13:50:19 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2015-08-25 13:50:19 +0100" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="9721974"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobayashi-2003" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Kobayashi 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi T, Terao T, Ikenoue T, Sameshima H, Nakabayashi M, Kajiwara Y, et al; BI 51 017 Study Group</AU>
<TI>Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>6</NO>
<PG>645-52</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="14719181"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langely-1993" MODIFIED="2015-12-21 09:59:58 +0000" MODIFIED_BY="[Empty name]" NAME="Langely 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-12-21 09:59:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langley PG, Hughes RD, Forbes A, Keays R, Williams R</AU>
<TI>Controlled trial of antithrombin III supplementation in fulminant hepatic failure</TI>
<SO>Journal of Hepatology</SO>
<YR>1993</YR>
<VL>17</VL>
<NO>3</NO>
<PG>326-31</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="8315261"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavrentieva-2008" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Lavrentieva 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lavrentieva A, Kontakiotis T, Bitzani M, Parlapani A, Thomareis O, Scourtis H, et al</AU>
<TI>The efficacy of antithrombin administration in the acute phase of burn injury.</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>2</NO>
<PG>286&#8211;90</PG>
<IDENTIFIERS MODIFIED="2015-02-27 16:17:56 +0000" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-02-27 16:17:56 +0000" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE=" 18690349"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maki-2000" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Maki 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-12-21 10:01:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maki M, Kobayashi T, Terao T, Ikenoue T, Satoh K, Nakabayashi M, et al; BI51.017 Study Group</AU>
<TI>Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>4</NO>
<PG>583-90</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="11057854"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sameshima H, Kodama Y, Ikenoue T, Kajiwara Y</AU>
<TI>Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation;a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>1</NO>
<PG>34&#8211;9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18226126"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-2003" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Mitchell 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al</AU>
<TI>Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>90</VL>
<NO>2</NO>
<PG>235-44</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="12888870"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-27 07:35:04 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al</AU>
<TI>A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase - Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study</TI>
<SO>Cancer</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>2</NO>
<PG>508-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12518376"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muntean-1989" MODIFIED="2015-12-21 10:03:44 +0000" MODIFIED_BY="[Empty name]" NAME="Muntean 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-12-21 10:03:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muntean W, Rossegger H</AU>
<TI>Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract)</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1989</YR>
<VL>62</VL>
<PG>288</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Neporada-2008A" MODIFIED="2015-12-23 12:57:38 +0000" MODIFIED_BY="Mikkel Allingstrup" NAME="Neporada 2008A" YEAR="2008">
<REFERENCE MODIFIED="2015-08-26 16:38:48 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neporada E, Vorobyeva N, Nedashkovsky E</AU>
<TI>Antithrombin III deficiency correction in patients with disseminated intravascular coagulation</TI>
<SO>Obshaya Reanimatologia</SO>
<YR>2008</YR>
<VL>5</VL>
<PG>49-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishiyama-2011" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Nishiyama 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishiyama T, Kohno Y, Koishi K</AU>
<TI>Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>7</NO>
<PG>1219&#8211;23</PG>
<IDENTIFIERS MODIFIED="2015-03-18 08:47:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-03-18 08:47:37 +0000" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="22204993"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palareti-1995" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Palareti 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palareti G, Legnani C, Coccheri S, Ridolfi L, Baudo F, Caimi TM, et al</AU>
<TI>Laboratory effects of antithrombin-III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support - a controlled, double-blind, randomized multicenter study</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>6</NO>
<PG>1251</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1998" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Schmidt 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt B, Gillie P, Mitchell L, Andrew M, Caco C, Roberts R</AU>
<TI>A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<NO>2</NO>
<PG>470-6</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="9700123"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schorr-2000" MODIFIED="2015-12-21 10:07:26 +0000" MODIFIED_BY="[Empty name]" NAME="Schorr 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-12-21 10:07:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schorr M, Siebeck M, Zugel N, Welcker K, Gippner-Steppert C, Czwienzek E, et al</AU>
<TI>Antithrombin III and local serum application: adjuvant therapy in peritonitis</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>4</NO>
<PG>359-66</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="10759886"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuster-1997" MODIFIED="2015-12-21 10:07:42 +0000" MODIFIED_BY="[Empty name]" NAME="Schuster 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-12-21 10:07:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuster HP, Eisele B, Keinecke HO, Heinrichs H, Mescheder A, Knaub S</AU>
<TI>S-AT III study: antithrombin III in patients with sepsis</TI>
<SO>Intensive Care Medicine</SO>
<YR>1997</YR>
<VL>23 Suppl 1</VL>
<PG>76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith_x002d_Erichsen-1996" MODIFIED="2015-12-21 10:08:27 +0000" MODIFIED_BY="[Empty name]" NAME="Smith-Erichsen 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-12-21 10:08:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith-Erichsen N, Aasen AO, Kongsgaard UE, Bakka A, Bergen A, Bjerkelund CE, et al</AU>
<TI>The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients</TI>
<SO>Clinical Intensive Care</SO>
<YR>1996</YR>
<VL>7</VL>
<PG>291-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vorobyeva-2007" MODIFIED="2015-12-21 10:09:31 +0000" MODIFIED_BY="[Empty name]" NAME="Vorobyeva 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-12-21 10:09:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vorob'eva N, Neporada E, Turundaevskaia O, Mel'nikova G</AU>
<TI>Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation</TI>
<SO>Anesteziologiia i Reanimatologiia</SO>
<YR>2007</YR>
<VL>2</VL>
<PG>42-4</PG>
<IDENTIFIERS MODIFIED="2015-04-07 15:05:20 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-04-07 15:05:20 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="17563999"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warren-2001" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Warren 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angstwurm M, Hoffmann J, Ostermann H, Frey L, Spannagl M</AU>
<TI>Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin</TI>
<TO>Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin</TO>
<SO>Anaesthesist</SO>
<YR>2009</YR>
<VL>58</VL>
<NO>2</NO>
<PG>171&#8211;9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE=" 19189066"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eid A, Wiedermann CJ, Kinasewitz GT</AU>
<TI>Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2008</YR>
<VL>107</VL>
<NO>5</NO>
<PG>1633-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18931224"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-23 14:40:14 +0000" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonano C, Sitzwohl C, Meitner E, Weinstabl C, Kettner SC</AU>
<TI>Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>6</NO>
<PG>160</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="  17107615"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-27 07:33:53 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, et al</AU>
<TI>Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2006</YR>
<VL>95</VL>
<NO>5</NO>
<PG>850-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16676077"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-27 07:34:23 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al</AU>
<TI>Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>1</NO>
<PG>90-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16409457"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S</AU>
<TI>Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]</TI>
<SO>Critical Care</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>4</NO>
<PG>349-56</PG>
<IDENTIFIERS MODIFIED="2015-03-26 10:28:35 +0000" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-03-26 10:28:35 +0000" MODIFIED_BY="Mikkel Allingstrup" TYPE="MEDLINE" VALUE="12225612"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Leeuwen HJ, Heezius EC, Dallinga GM, Van Strijp JA, Verhoef J, Van Kessel KP</AU>
<TI>Lipoprotein metabolism in patients with severe sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>5</NO>
<PG>1359-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12771603"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al</AU>
<TI>Caring for the critically ill patient. High-dose antithrombin III in severe sepsis, a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<NO>15</NO>
<PG>1869-78</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="11597289"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-27 07:38:03 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, et al</AU>
<TI>High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety</TI>
<SO>Critical Care Medicine</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>2</NO>
<PG>285-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16424704"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waydhas-1998" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Waydhas 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waydhas C, Nast-Kolb D, Gippner-Steppert C, Trupka A, Pfundstein C, Schweiberer L, et al</AU>
<TI>High-dose antithrombin III treatment of severely injured patients: results of a prospective study</TI>
<SO>Journal of Trauma, Injury, Infection and Critical Care</SO>
<YR>1998</YR>
<VL>45</VL>
<NO>5</NO>
<PG>931-40</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="9820705"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Aibiki-2006" MODIFIED="2015-12-21 10:50:34 +0000" MODIFIED_BY="[Empty name]" NAME="Aibiki 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-12-21 10:50:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aibiki M, Fukuoka N, Nishiyama T, Maekawa S, Shirakawa Y</AU>
<TI>Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study</TI>
<SO>Shock</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>2</NO>
<PG>141-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE=" 17515857"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dietrich-2013" MODIFIED="2015-07-28 19:08:03 +0100" MODIFIED_BY="[Empty name]" NAME="Dietrich 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-07-28 19:08:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dietrich W, Busley R, Spannagl M, Braun S, Schuster T, Lison S</AU>
<TI>The influence of antithrombin substitution on heparin sensitivity and activation of hemostasis during coronary artery bypass graft surgery: a dose-finding study</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2013</YR>
<VL>116</VL>
<NO>6</NO>
<PG>1223-30</PG>
<IDENTIFIERS MODIFIED="2015-04-17 11:16:46 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-04-17 11:16:46 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="23408673"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doi-2012" MODIFIED="2015-07-21 03:31:18 +0100" MODIFIED_BY="Jane Cracknell" NAME="Doi 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-07-21 03:31:18 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doi T, Kozawa O, Enomoto Y, Ogura S</AU>
<TI>Analysis of the anti-inflammatory effects of antithrombin III on human platelets</TI>
<SO>7th Congress of the International Federation of Shock Societies - 35th Annual Conference on Shock Miami Beach, FL United States</SO>
<YR>2012</YR>
<VL>1</VL>
<PG>198</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffmann-2010" MODIFIED="2015-07-21 03:31:18 +0100" MODIFIED_BY="Jane Cracknell" NAME="Hoffmann 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-21 03:31:18 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hoffmann JN, Fertmann JM, Illner W, Arbogast H, Land H, Jauch K</AU>
<TI>High-dose antithrombin can not improve kidney function despite improved graft perfusion in human kidney transplantation-final results of a prospective, controlled trial</TI>
<SO>23rd International Congress of the Transplantation Society, TTS 2010 Vancouver, BC Canada</SO>
<YR>2010</YR>
<VL>1</VL>
<PG>1882</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ilias-2000" MODIFIED="2015-12-21 10:57:35 +0000" MODIFIED_BY="[Empty name]" NAME="Ilias 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-12-21 10:57:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ilias W, List W, Decruyenaere J, Lignian H, Knaub S, Schindel F, et al</AU>
<TI>Antithrombin III in patients with severe sepsis: a pharmacokinetic study</TI>
<SO>Intensive Care Medicine</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>6</NO>
<PG>704-15</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="10945387"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jochum-1995" MODIFIED="2015-12-21 11:05:15 +0000" MODIFIED_BY="[Empty name]" NAME="Jochum 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-12-21 11:05:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jochum M</AU>
<TI>Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation</TI>
<SO>Seminars in Hematology</SO>
<YR>1995</YR>
<VL>32 Suppl 2</VL>
<NO>4</NO>
<PG>19-32</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="8821206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanbak-2011" MODIFIED="2015-07-28 19:08:38 +0100" MODIFIED_BY="[Empty name]" NAME="Kanbak 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-07-28 19:08:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanbak M, Oc B, Salman MA, Ocal T, Oc M</AU>
<TI>Peroperative effects of fresh frozen plasma and antithrombin III on heparin sensitivity andcoagulation during nitroglycerine infusion in coronary artery bypass surgery</TI>
<SO>Blood Coagulation and Fibrinolysis</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>7</NO>
<PG>593-9</PG>
<IDENTIFIERS MODIFIED="2015-04-17 10:53:49 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-04-17 10:53:49 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="21799398"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2013" MODIFIED="2015-12-07 11:51:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Kim 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-12-07 11:51:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim KA, Lim YY, Kim SH, Park JY</AU>
<TI>Bioequivalence of two intravenous formulations of antithrombin III: a two-way crossover study in healthy Korean subjects</TI>
<SO>Clinical Therapeutics</SO>
<YR>2013</YR>
<VL>35</VL>
<NO>11</NO>
<PG>1752-61</PG>
<IDENTIFIERS MODIFIED="2015-04-17 11:38:00 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-04-17 11:38:00 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="24094463"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korninger-1987" MODIFIED="2015-12-21 11:05:46 +0000" MODIFIED_BY="[Empty name]" NAME="Korninger 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-12-21 11:05:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korninger C, Klepteko W, Miholic J, Schwarz C, Lechner K</AU>
<TI>Randomized trial of antithrombin-III versus placebo in patients undergoing peritoneo-venous shunt operation</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1987</YR>
<VL>58</VL>
<NO>1</NO>
<PG>426</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leitner-2006" MODIFIED="2015-12-21 11:06:05 +0000" MODIFIED_BY="[Empty name]" NAME="Leitner 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-12-21 11:06:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B</AU>
<TI>Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2006</YR>
<VL>79</VL>
<NO>1</NO>
<PG>23-34</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="16413239"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maki-1987" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Maki 1987" YEAR="1987">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maki M, Terao T, Ikenoue T, Takemura T, Sekiba K, Shirakawa K, et al</AU>
<TI>Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial</TI>
<SO>Gynecology and Obstetric Investigation</SO>
<YR>1987</YR>
<VL>23</VL>
<NO>4</NO>
<PG>230-40</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="3111953"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayumi-2011" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Mayumi 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="OTHER">
<AU>Mayumi T,Suzuki S.,Yamamoto T,Ichikawa T, Onodera M,Tsuzuki M, et al</AU>
<TI>Levels of antithrombin activity after antithrombin administration indicate prognosis of septic DIC patients</TI>
<SO>Shock Society</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>www.shocksociety.org/assets/docs/shock%202011%20oral%20abstracts.pdf</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Neporada-2008B" MODIFIED="2015-12-23 12:58:15 +0000" MODIFIED_BY="Mikkel Allingstrup" NAME="Neporada 2008B" YEAR="2008">
<REFERENCE MODIFIED="2015-12-23 12:57:09 +0000" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neporada E, Turundayevskaya O, Vorobyeva N</AU>
<TI>Antithrombin III concentrate in comparison with FFP in patients with disseminated intravascular coagulation</TI>
<TO>&#1050;&#1054;&#1053;&#1062;&#1045;&#1053;&#1058;&#1056;&#1040;&#1058; &#1040;&#1053;&#1058;&#1048;&#1058;&#1056;&#1054;&#1052;&#1041;&#1048;&#1053;&#1040; III &#1042; &#1057;&#1056;&#1040;&#1042;&#1053;&#1045;&#1053;&#1048;&#1048; &#1057;&#1054; &#1057;&#1042;&#1045;&#1046;&#1045;&#1047;&#1040;&#1052;&#1054;&#1056;&#1054;&#1046;&#1045;&#1053;&#1053;&#1054;&#1049; &#1055;&#1051;&#1040;&#1047;&#1052;&#1054;&#1049; &#1055;&#1056;&#1048; &#1057;&#1048;&#1053;&#1044;&#1056;&#1054;&#1052;&#1045; &#1044;&#1048;&#1057;&#1057;&#1045;&#1052;&#1048;&#1053;&#1048;&#1056;&#1054;&#1042;&#1040;&#1053;&#1053;&#1054;&#1043;&#1054; &#1042;&#1053;&#1059;&#1058;&#1056;&#1048;&#1057;&#1054;&#1057;&#1059;&#1044;&#1048;&#1057;&#1058;&#1054;&#1043;&#1054; &#1057;&#1042;&#1045;&#1056;&#1058;&#1067;&#1042;&#1040;&#1053;&#1048;&#1071;</TO>
<SO>Human Ecology</SO>
<YR>2008</YR>
<VL>7</VL>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishiyama-2006" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Nishiyama 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishiyama T</AU>
<TI>Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2006</YR>
<VL>102</VL>
<NO>4</NO>
<PG>1007-11</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="16551889"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paparella-2014" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Paparella 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01201070</AU>
<TI>Trial registration</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01201070</SO>
<YR>(accessed 21 April 2015)</YR>
<IDENTIFIERS MODIFIED="2015-12-21 11:16:36 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-12-21 11:16:36 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Paparella D, Rotunno C, De Palo M, Finamore S, Guida P, Rubino G, et al</AU>
<TI>Antithrombin administration in patients with low antithrombin values after cardiac surgery: a randomized controlled trial</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2014</YR>
<VL>97</VL>
<NO>4</NO>
<PG>1207-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE=" 24507941"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paternoster-2000" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Paternoster 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paternoster DM, De Fusco D, Tambuscio B</AU>
<TI>Treatment with antithrombin III (AT III) concentrate in pre-eclampsia</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>2</NO>
<PG>175-6</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="11064016"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paternoster-2004" MODIFIED="2015-12-21 11:19:02 +0000" MODIFIED_BY="[Empty name]" NAME="Paternoster 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-12-21 11:19:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paternoster DM, Fantinato S, Manganelli F</AU>
<TI>Efficacy of AT in pre-eclampsia: a case-control prospective trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>2</NO>
<PG>283-9</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="14961155"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranucci-2013" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Ranucci 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranucci M, Baryshnikova E, Crapelli GB, Woodward MK, Paez A, Pelissero G</AU>
<TI>Preoperative antithrombin supplementation in cardiac surgery: a randomized controlled trial</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2013</YR>
<VL>145</VL>
<NO>5</NO>
<PG>1393-9</PG>
<IDENTIFIERS MODIFIED="2015-04-17 11:52:47 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-04-17 11:52:47 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="23102903"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawamura-2009" MODIFIED="2015-08-27 07:54:18 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Sawamura 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-08-27 07:54:18 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawamura A, Gando S, Hayakawa M, Hoshino H, Kubota N, Sugano M</AU>
<TI>Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness</TI>
<SO>Clinical and Applied Thrombosis/Hemostasis</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>5</NO>
<PG>561-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18840625"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scherer-1997" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Scherer 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scherer R, Kabatnik M, Erhard J, Peters J</AU>
<TI>The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease</TI>
<SO>Intensive Care Medicine</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1150-8</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="9434921"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shimada-1994" MODIFIED="2015-12-21 11:20:52 +0000" MODIFIED_BY="[Empty name]" NAME="Shimada 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-12-21 11:20:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shimada M, Matsumata T, Kamakura T, Hayashi H, Urata K, Sugimachi K</AU>
<TI>Modulation of coagulation and fibrinolysis in hepatic resection: a randomized prospective control study using antithrombin III concentrates</TI>
<SO>Thrombosis Research</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>2</NO>
<PG>105-14</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="8029811"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terao-1989" MODIFIED="2015-12-21 11:21:06 +0000" MODIFIED_BY="[Empty name]" NAME="Terao 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-12-21 11:21:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terao T, Kobayashi T, Imai N, Oda H, Karasawa T</AU>
<TI>Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment</TI>
<SO>Asia-Oceania Journal of Obstetrics and Gynaecology</SO>
<YR>1988</YR>
<VL>15</VL>
<NO>1</NO>
<PG>25-32</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="2735838"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valsecchi-2008" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Valsecchi 2008" YEAR="2009, 2009">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valsecchi L, D&#8217;Angelo A</AU>
<TI>High-dose antithrombin supplementation in early pre-eclampsia: a double-blind, placebo controlled study (on behalf of the ATIII-EPAS study group)</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2009</YR>
<VL>7</VL>
<PG>297-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinazzer-1995" MODIFIED="2015-12-21 11:21:47 +0000" MODIFIED_BY="[Empty name]" NAME="Vinazzer 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-12-21 11:21:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinazzer HA</AU>
<TI>Antithrombin III in shock and disseminate intravascular coagulation</TI>
<SO>Clinical and Applied Thrombosis/Hemostasis</SO>
<YR>1995</YR>
<VL>1</VL>
<NO>1</NO>
<PG>62-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_angelo-2005" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="D'angelo 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'angelo A, Valsecchi L</AU>
<TI>A double-blind trial of high-dose antithrombin supplementation in early pre-eclampsia</TI>
<SO>Thrombosis Research</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>Suppl 1</NO>
<PG>117</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<ADDITIONAL_REFERENCES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Altman-2003" MODIFIED="2008-05-13 22:56:56 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Altman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Interaction revisited: the difference between two estimates</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7382</NO>
<PG>219</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="12543843"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Becker-2000" MODIFIED="2008-05-13 22:56:56 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Becker 2000" TYPE="JOURNAL_ARTICLE">
<AU>Becker BF, Heindl B, Kupatt C, Zahler S</AU>
<TI>Endothelial function and hemostasis</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>2000</YR>
<VL>89</VL>
<NO>3</NO>
<PG>160-7</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="10798271"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2015-07-12 12:06:09 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS MODIFIED="2015-07-12 12:04:18 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="18824466"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" MODIFIED="2015-12-22 09:05:21 +0000" MODIFIED_BY="[Empty name]" NAME="Chan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>20</NO>
<PG>2457-65</PG>
<IDENTIFIERS MODIFIED="2015-06-24 13:18:45 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="15161896"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Diaz-2015" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Diaz 2015" TYPE="JOURNAL_ARTICLE">
<AU>Diaz R, Moffett BS, Karabinas S, Guffrey D, Mahoney DH Jr, Yee DL</AU>
<TI>Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2015</YR>
<VL>167</VL>
<NO>3</NO>
<PG>645-9</PG>
<IDENTIFIERS MODIFIED="2015-07-21 13:16:35 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2015-07-21 13:16:35 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1016/j.jpeds.2015.06.006"/>
<IDENTIFIER MODIFIED="2015-07-11 11:44:04 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="26148660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fourrier-2000" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Fourrier 2000" TYPE="JOURNAL_ARTICLE">
<AU>Fourrier F, Jourdain M, Tournoys A</AU>
<TI>Clinical trial results with antithrombin III in sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2000</YR>
<VL>28</VL>
<NO>9 Suppl</NO>
<PG>S38-43</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="11007196"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gotzsche-2000" MODIFIED="2008-05-13 22:56:56 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Gotzsche 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gotzsche PC</AU>
<TI>Why we need a broad perspective on meta-analysis. It may be crucially important for patients</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<NO>7261</NO>
<PG>585-6</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="10977820"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2008-05-13 22:56:56 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="12111919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/9780470712184"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2000" MODIFIED="2015-12-23 15:07:36 +0000" MODIFIED_BY="Mikkel Allingstrup" NAME="Hutton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hutton JL, Williamson PR</AU>
<TI>Bias in meta-analysis due to outcome variable selection within studies</TI>
<SO>Journal of the Royal Statistical Society Series</SO>
<YR>2000</YR>
<VL>49</VL>
<NO>3</NO>
<PG>359-70</PG>
<IDENTIFIERS MODIFIED="2015-12-23 15:07:14 +0000" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-12-23 15:07:14 +0000" MODIFIED_BY="Mikkel Allingstrup" TYPE="DOI" VALUE="10.1111/1467-9876.00197"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lan-1983" MODIFIED="2008-05-13 22:56:56 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Lan 1983" TYPE="JOURNAL_ARTICLE">
<AU>Lan KKG, DeMets DL</AU>
<TI>Discrete sequential boundaries for clinical trials</TI>
<SO>Biometrika</SO>
<YR>1983</YR>
<VL>70</VL>
<NO>3</NO>
<PG>659-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larsson-2001" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Larsson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Larsson H, Åkerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, Bjork I</AU>
<TI>A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity</TI>
<SO>Journal of Biological Chemistry</SO>
<YR>2001</YR>
<VL>276</VL>
<NO>15</NO>
<PG>11996-2002</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="11278631"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levi-2004" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Levi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Levi M, De Jonge E, Van der Poll T</AU>
<TI>New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology</TI>
<SO>Annals of Medicine</SO>
<YR>2004</YR>
<VL>36</VL>
<NO>1</NO>
<PG>41-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayr-2014" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Mayr 2014" TYPE="JOURNAL_ARTICLE">
<AU>Mayr F, Yende S, Angus D</AU>
<TI>Epidemiology of severe sepsis</TI>
<SO>Virulence</SO>
<YR>2014</YR>
<VL>5</VL>
<NO>1</NO>
<PG>4-11</PG>
<IDENTIFIERS MODIFIED="2015-06-08 12:54:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-06-08 12:54:55 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="24335434"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Opal-2002" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Opal 2002" TYPE="JOURNAL_ARTICLE">
<AU>Opal SM, Kessler CM, Roemisch J, Knaub S</AU>
<TI>Antithrombin, heparin, and heparan sulfate</TI>
<SO>Critical Care Medicine</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>5 Suppl</NO>
<PG>S325-31</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="12004255"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Opal-2003" MODIFIED="2015-07-28 16:15:17 +0100" MODIFIED_BY="[Empty name]" NAME="Opal 2003" TYPE="JOURNAL_ARTICLE">
<AU>Opal SM</AU>
<TI>Clinical trial design and outcomes in patients with severe sepsis</TI>
<SO>Shock</SO>
<YR>2003</YR>
<VL>20</VL>
<NO>4</NO>
<PG>295-302</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="14501941"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Periti-2000" MODIFIED="2008-05-13 22:56:56 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Periti 2000" TYPE="JOURNAL_ARTICLE">
<AU>Periti P</AU>
<TI>Current treatment of sepsis and endotoxaemia</TI>
<SO>Expert opinion of Pharmacotherapy</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>6</NO>
<PG>1203-17</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="11249488"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pogue-1997" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Pogue 1997" TYPE="JOURNAL_ARTICLE">
<AU>Pogue JM, Yusuf S</AU>
<TI>Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>6</NO>
<PG>580-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pogue-1998" MODIFIED="2008-05-13 22:56:56 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Pogue 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pogue J, Yusuf S</AU>
<TI>Overcoming the limitations of current meta-analysis of randomised controlled trials</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<NO>9095</NO>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Polderman-2004" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Polderman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Polderman KH, Girbes ARJ</AU>
<TI>Drug intervention trials in sepsis: divergent results</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9422</NO>
<PG>1721-3</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="15158636"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan--5.3" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="RevMan  5.3" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rublee-2003" MODIFIED="2008-05-13 22:56:56 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Rublee 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S</AU>
<TI>Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial</TI>
<SO>Critical Care</SO>
<YR>2002</YR>
<VL>Aug; 6</VL>
<NO>4</NO>
<PG>349-56</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="12225612"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tagami-2014" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Tagami 2014" TYPE="JOURNAL_ARTICLE">
<AU>Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H</AU>
<TI>Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>September 2014</YR>
<VL>12</VL>
<NO>9</NO>
<PG>1470&#8211;9</PG>
<IDENTIFIERS MODIFIED="2015-07-11 11:28:32 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-11 11:28:32 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="24943516"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tagami-2015" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Tagami 2015" TYPE="JOURNAL_ARTICLE">
<AU>Tagami T, Matsui H, Fushimi K, Yasunaga H</AU>
<TI>Supplemental dose of antithrombin use in disseminated intravascular coagulation patientsafter abdominal sepsis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2015</YR>
<VL>114</VL>
<NO>3</NO>
<PG>537-45</PG>
<IDENTIFIERS MODIFIED="2015-07-11 11:35:03 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-11 11:35:03 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="25948492"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2015-07-12 12:06:09 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS MODIFIED="2015-07-12 12:04:18 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="18824467"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2015-07-12 12:06:09 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS MODIFIED="2015-07-12 12:04:18 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="18083463"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>9</NO>
<PG>86</PG>
<IDENTIFIERS MODIFIED="2015-07-12 12:04:18 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="20042080"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wiedermann-2002" MODIFIED="2008-05-13 22:56:56 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Wiedermann 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wiedermann CJ, Römisch J</AU>
<TI>The anti-inflammatory actions of antithrombin - a review</TI>
<SO>Acta Medica Austriaca</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>3</NO>
<PG>89-92</PG>
<IDENTIFIERS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<IDENTIFIER TYPE="MEDLINE" VALUE="12168569"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wunsch-2008" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Wunsch 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wunsch H, Angus D, Harrison D, Collange O, Fowler R, Hoste E, et al</AU>
<TI>Variation in critical care services across North America and Western Europe</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>10</NO>
<PG>2787-93</PG>
<IDENTIFIERS MODIFIED="2015-06-11 15:35:10 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-06-11 15:35:10 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="18766102"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zarychanski-2015" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NAME="Zarychanski 2015" TYPE="JOURNAL_ARTICLE">
<AU>Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS et al</AU>
<TI>The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis</TI>
<SO>Critical Care Medicine</SO>
<YR>2015</YR>
<VL>43</VL>
<NO>3</NO>
<PG>511&#8211;8</PG>
<IDENTIFIERS MODIFIED="2015-07-11 11:38:35 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-11 11:38:35 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="25493972"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-07-30 17:25:50 +0100" MODIFIED_BY="Mikkel Allingstrup">
<REFERENCE ID="REF-Afshari-2007" MODIFIED="2015-07-28 16:14:54 +0100" MODIFIED_BY="[Empty name]" NAME="Afshari 2007" TYPE="JOURNAL_ARTICLE">
<AU>Afshari A, Wetterslev J, Brok J, Møller A</AU>
<TI>Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>335</VL>
<NO>7632</NO>
<PG>1248-51</PG>
<IDENTIFIERS MODIFIED="2008-04-24 15:54:51 +0100" MODIFIED_BY="Jane Cracknell"/>
</REFERENCE>
<REFERENCE ID="REF-Afshari-2008" MODIFIED="2015-07-30 17:25:50 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Afshari 2008" TYPE="COCHRANE_REVIEW">
<AU>Afshari A, Wetterslev J, Brok J, Møller A</AU>
<TI>Antithrombin III for critically ill patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-10-17 15:40:24 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2014-10-17 15:40:22 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD005370.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-06-24 11:18:25 +0100" MODIFIED_BY="Mikkel Allingstrup"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-12-23 13:59:11 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Albert-1992">
<CHAR_METHODS MODIFIED="2015-12-23 13:59:00 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial<BR/>ITT: no<BR/>No sample size calculation was reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>32 patients in the ICU with plasma AT III levels less than 70%. All participants included in the trial within 2 days after admission to the ICU</P>
<P>AT III group: 16 participants, 8 men, median age: 63.5 years. Median APACHE II score on inclusion: 14, TISS : 34. Reason for admission: surgery 7 patients, trauma 4 patients, infection 3 patients, and other causes: 2 patients</P>
<P>Control group: 16 participants, 9 men, median age: 66 years. Median APACHE II score on inclusion: 15, TISS : 39. Reason for admission: surgery 5 patients, trauma 4 patients, infection 5 patients, and other causes: 2 patients</P>
<P>Exclusion criteria: under 18 years old, liver disease, HIV infection, severe brain damage, patients admitted for postoperative pain relief only, anorexia nervosa, and pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: concentrate by intravenous infusion for 20 - 30 minutes twice daily as long as AT III &lt; 90%, in a dose intended to raise the level above 100% until the patients were discharged from the ICU. First dose: 2000 - 4000 IU, total amount: 3500 - 17000 IU</P>
<P>Control: no placebo</P>
<P>Unfractionated heparin 2500 or 5000 IU x 2 or x 3 daily was given subcutaneously to all patients for thromboprophylaxis. If continuous arteriovenous haemofiltration for acute anuria, then 20000 - 40000 IU heparin per 24 hours was administered as continuous infusion. Blood samples from each patient were taken daily for 7 days or until discharge. Standard intensive care treatments were administered to all patients in both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: mortality</P>
<P>Secondary: days in ICU, bleeding and transfusion, AT III, CRP, tissue plasminogen activator inhibitor, partial thromboplastin time, prothrombin complex (prothrombin time), fibrinogen degradation products, lactoferrin/serum, lactoferrin/plasma, lysozyme, side effects, APACHE II score and TISS (during the first 24 hours)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 13:59:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Sweden<BR/>Letter sent to authors in November 2005. Reply received in December 2005<BR/>2 participants randomized but not evaluated: 1 transferred to another hospital, the other had received AT III although randomized to the non-AT III group. There were 3 cases of cross-over: these participants received AT III despite being allocated to the control group. These participants were evaluated up to the day when they received AT III. No side effects were reported.</P>
<P>Funding bias: No funding by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 15:11:49 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Balk-1995">
<CHAR_METHODS MODIFIED="2015-12-23 13:05:13 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:13 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Adults patients with SEPSIS, cared for in a tertiary care centre, Chicago, IL, USA</P>
<P>34 participants, 20 women, 14 men. 65% hypotensive at the time of enrolment</P>
<P>Median APACHE score for the intervention group was 21.5 (range 2 - 29) and for the control group 17 (range 6 - 31).</P>
<P>The AT III % activity at entry was 75.8 + 18.0% for the intervention group and 78.1 + 16.8% for control group.</P>
<P>The article does not state how many participants there are in each group. In this review we assume that there are 17 in each group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:13 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III (Kypernin) and placebo. No details stated</P>
<P>Use of heparin not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:59:33 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Follow for 28 days. Mortality and organ failure was measured.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 15:11:49 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Germany</P>
<P>Trial only published as an abstract. No data on follow-up, no data on treatment duration</P>
<P>Funding bias: Not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:10:06 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Baudo-1992">
<CHAR_METHODS MODIFIED="2015-12-23 14:10:06 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group randomized clinical trial<BR/>ITT: yes<BR/>No sample size calculation was reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:13 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>29 patients with post-necrotic cirrhosis undergoing liver transplantation were randomized to receive AT III (13 participants) or to control group (no placebo, 16 participants) - before the induction of anaesthesia and during surgery.</P>
<P>AT III group: 13 men, 4 patients with cryptogenetic cirrhosis, 4 with post-necrotic cirrhosis, 5 with alcoholic cirrhosis, average age 44 ± 9 years, duration of surgery (mins): 625 ± 68<BR/>Control group: 16 men, 5 patients with cryptogenetic cirrhosis, 7 with post necrotic cirrhosis, 4 with alcoholic cirrhosis, average age 42 ± 9 years, duration of surgery (mins): 642 ± 113</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:13 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: administered by bolus infusion before the induction of anaesthesia in order to obtain a pre-operative activity of 100%. Thereafter 1000 units per hour were given by continuous infusion until the end of surgery. No systemic heparinization</P>
<P>Control: no placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:13 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Mortality. Blood loss, transfusion requirements, activation of coagulation and fibrinolysis (thrombin-antithrombin complexes), activated partial thromboplastin time, prothrombin time, thrombin time, reptilase time, expressed as ratio, fibrinogen, plasminogen, alfa2-antiplasmin, AT III, platelet count, thrombin-antithrombin complexes, total fibrinogen, fibrinogen and fibrin degradation products</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:08:28 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Italy<BR/>Letter sent to authors in January 2006, no reply received</P>
<P>Funding bias: Unclear. Not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Baudo-1998">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel randomized clinical trial<BR/>ITT: no<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:20 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Multicentre trial, 120 patients admitted to the ICU with an AT III concentration of &lt; 70%</P>
<P>AT III group: 60 participants, 42 men, age distribution: 58.6 ± 13.8 years, MOFS 5.6 ± 2.5, SAPS: 15.6 ± 4.4, 49% sepsis, 33% septic shock, 51% respiratory support, 53% haemodynamic support, haemorrhages: 5%, surgery 47%, surgery with sepsis 43%, AT III: 52.8 ± 15.5%.</P>
<P>Control group: 60 participants, 41 men, age distribution 62±12.2 years, MOFS: 4.8 ± 2.3, SAPS: 16.5 ± 5.5, 51% sepsis, 23% septic shock, 48% respiratory support, 42% haemodynamic support, haemorrhages: 6%, surgery 45%, surgery with sepsis 41%, AT III: 52.9 ± 14.5%</P>
<P>Inclusion criteria:<BR/>1) respiratory and/or haemodynamic support<BR/>2) sepsis: systemic response to infection manifested by 2 or more of a) tp &gt; 38.5º C, b) heart rate &gt; 90/min, c) respiratory rate &gt; 20/min, d) leukocytosis &gt; 15 x 10&#8313;/l or leukopenia &lt; 4 x 10&#8313;/l, e) septic shock with sepsis-induced hypotension requiring vasoactive drugs for &gt; 24 hrs persisting despite adequate fluid replacement along with presence of hypoperfusion abnormalities that may include but are not limited to lactic acidosis, oliguria, or an acute alteration of mental status, f) post-surgical complications requiring respiratory and/or haemodynamic support, g) respiratory support with assisted or controlled ventilation &gt; 24 hrs, h) haemodynamic support inotropic (dopamine/dobutamine &#8805; 5 mg/kg/min) and/or vasoactive (epinephrine or norepinephrine)<BR/>3) 18 - 75 years<BR/>4) AT III activity &lt; 70%</P>
<P>Exclusion criteria: 1) Multiple trauma, 2) liver cirrhosis/acute liver failure, 3) Cancer in a terminal phase, 4) Immunodeficiency, 5) leukaemia, 6) pregnancy, 7) heparin therapy (except prophylaxis heparin, 5000 units subcut)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:20 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: total dose 24,000 units, fixed dose of 4000 AT III and 2000 IU every 12 hours, 5 days, infusion by pump.</P>
<P>Control: human albumin, 50 g/l, 4 g albumin bolus in 30 mins, 1 bottle containing 2 g albumin every 12 hrs for 5 days, pump-driven</P>
<P>Standard intensive care treatment, FFP infused when bleeding and/or prothrombin time ratio &gt; 2, platelet concentration infused when &#8804; 50 (1 unit/10 kg weight)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:21 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: mortality, survival for 30 days, MOFS for 7 days, FFP and PC requirements</P>
<P>Secondary: days in ICU, bleeding and transfusion, MOFS, septic shock survival, AT III plasma concentration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:08:42 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Italy<BR/>Letter sent to authors in December 2005, no reply received.<BR/>Balanced randomization within each centre, post hoc analysis of septic shock subgroup. The distribution of participants with septic shock on haemodynamic support were unbalanced in the 2 groups at admission. SAPS and MOFS recorded for each participant at admission</P>
<P>4 participants received therapy for &lt; 24 hrs; 1 participant in the placebo group was transferred to another hospital after the bolus infusion and was considered not evaluable; 3 participants with septic shock (2 AT III and 1 placebo) died within 24 hrs. A total of 119 were included in the analysis.</P>
<P>Funding bias: ATIII concentrate and placebo (albumin solution 50 g/t) were supplied by Immuno (Wien). No additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:10:15 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Blauhut-1985">
<CHAR_METHODS MODIFIED="2015-12-23 14:09:55 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>3-group parallel randomized clinical trial<BR/>ITT: no<BR/>No sample size calculation was reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:21 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>51 patients with DIC and septic shock</P>
<P>Inclusion criteria: AT III activity &lt; 70% and at least 3 of the following: platelet count &lt; 100, thrombin time &gt; 24 sec, thrombin coagulase time &gt; 22 sec, fibrinogen level &lt; 150 mg/dl, ethanol gelatin test positive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 14:09:52 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Control group 1: Heparin: iv heparin 3000 IU followed by continuous infusion of 250 IU/h</P>
<P>Intervention group 2: AT III substitution with the aim to keep ATIII activity constantly around 100%</P>
<P>Intervention group 3: Same AT III substitution as group 2 with heparin 1000 IU iv and continuous infusion of 100 IU/h</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-29 11:27:35 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Blood loss, concentration of ATIII, duration of symptoms of DIC, platelet count, esterase inhibitor level, blood loss</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:10:15 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Austria<BR/>No primary endpoint, unable to retrieve additional data from authors despite several attempts to contact them. 12 participants died during the trial but no data on distribution between the groups except no statistically significant difference.</P>
<P>Funding bias: No information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:11:12 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Diaz_x002d_Cremades-1994">
<CHAR_METHODS MODIFIED="2015-12-23 14:11:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial<BR/>ITT: no<BR/>No sample size calculation was reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:21 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>195 critically ill patients admitted to ICU, without previous history of hepatic disease, 36 patients were chosen with AT III levels below 70% as inclusion criteria. None of the patients had manifest DIC.</P>
<P>AT III: 20 participants (10 with sepsis, 6 with trauma, 1 with sepsis + trauma, 3 with shock), 12 men, mean age 46.25 ± 11.79 years</P>
<P>Control group: 16 participants (8 with sepsis, 4 with trauma, 2 with sepsis + trauma and 2 with shock), 10 men, mean age 56.37 ± 25.78 years</P>
<P>Inclusion or exclusion criteria were not provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:21 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III group: initial dose 60 U/kg of body weight, then 10 U/kg every 6 hrs, without dose adjustment depending on the AT III levels. The mean AT III dose received was 11.17 ± 5.98 U. Treatment interrupted when the participants were discharged from ICU, or if they achieved AT III levels equal or superior to 90% during at least 48 hrs. Mean length of treatment: 5.8 ± 4.2 days</P>
<P>Control: human albumin 0.6%</P>
<P>Standard intensive care treatment in both groups. All participants received 7500 IU of prophylactic subcutaneous calcium heparin every 12 hrs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:21 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: mortality</P>
<P>Secondary: 1) platelet count, 2) side effects, 3) prothrombin time, 4) activated thromboplastin time, 5) fibrinogen, 6) fibrinogen degradation products, 7) AT III, 8) protein C, 9) APACHE II score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:10:31 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Spain<BR/>Letter sent to authors in December 2005, no reply received.</P>
<P>No adverse effects reported. The only detectable alterations in the haemostasis were a mild thrombocytopenia and low levels of AT III and protein C. Manifest DIC was not reported in any participant.</P>
<P>Funding bias: AT III concentrate infusion provided by Kybernin-P, Institute Behring, Barcelona. No additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:11:04 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Eisele-1998">
<CHAR_METHODS MODIFIED="2015-12-23 14:11:04 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Randomized clinical trial<BR/>ITT: yes<BR/>No sample size calculation was reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Multicentre, multinational trial of patients admitted to ICU</P>
<P>AT III group: 20 participants, 11 men, mean age: 57 ± 16 yrs, weight (kg): 71 ± 14, height (cm): 171 ± 9 Underlying disease: peritonitis 2, mediastinitis 1, neoplasia (non-haematologic) 4, others: 12. Severity of sepsis at trial entry (mean ± SD): APACHE II: 13.5 ± 5.1, MOF: 6.1 ± 2.1, OFS:1.2 ± 0.9, AT III activity: 45.7 ± 14.4% Coagulation failure: 3, acute hepatic dysfunction: 5, acute renal dysfunction: 8, acute respiratory dysfunction: 8, acute neurological dysfunction: 6.</P>
<P>Control group: 22 patients, 10 men, mean age: 58 ± 14 yrs, weight (kg): 73 ± 15, height (cm): 169 ± 8 Underlying disease: peritonitis 3, mediastinitis 1, adult respiratory distress syndrome 1, acute pancreatitis 3, neoplasia (non-haematologic) 3, other: 11. Severity of sepsis at trial enter (mean ± SD): APACHE II: 15.5 ± 5.7, MOF: 6.7 ± 2.0, OFS: 0.9 ± 0.8, AT III activity: 49.0 ± 19.1%. Coagulation failure: 2, acute hepatic dysfunction: 8, acute renal dysfunction: 8, acute respiratory dysfunction: 6, acute neurological dysfunction: 10</P>
<P>Inclusion criteria: &lt; 80 and &gt; 18 years old; fulfilled the following criteria within 6-hr window prior to initiation of treatment: 1) clinical evidence of sepsis with a suspected source of infection; 2) temperature rectally &gt; 38.5º C or &lt; 35.5º C; 3) leukocyte count &gt; 10000/mm³ or &lt; 3500. Furthermore 3 of the following had to be fulfilled: a) heart rate &gt; 100/min; b) breath rate &gt; 24/min or mechanical ventilation because of septic indication; c) hypotension, sys BP &lt; 90 mm Hg when no vasoactive agent or fluid replacement; d) platelet count &lt; 100,000/mm³; e) lactate &gt; 1.6 mmol/l; f) urine output &lt; 20 ml/h.</P>
<P>Exclusion criteria: a) heparin (except sc low dose); b) malignancies (incurable with metastases); c) haematologic neoplasia (except complete remission); d) chronic treatment with high-dose immunosuppressive drugs; e) high-dose NSAID within previous 2 days; f) known bleeding disorder; g) ongoing massive surgical bleeding; h) multiple organ failure, at least 4 organs involved existing for over 24 hrs; i) acute myocardial Infarction; j) chronic compensated organ dysfunction (chronic liver disease, dialysis, NYHA 3 - 4); k) complicated pre-existing diabetes mellitus; l) severe obstructive pulmonary disease; m) burn; n) AIDS; o) transplant; p) severe cranial trauma and/or pathologic changes on CT and GCS &lt; 6; q) pregnancy; r) treatment with plasma expanders (Haes); s) prior enrolment in the trial or another clinical trial within the last 30 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Experimental: AT III iv loading dose: 3000 units AT III, maintenance 1500 IU every 12 hours, 5 days treatment, cumulative dose: 18,000 IU</P>
<P>Control: placebo equivalent amounts, unknown agent</P>
<P>Standard intensive care treatment in both groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: 30-day all-cause mortality</P>
<P>Secondary: survival days, days in ICU, safety (bleeding and transfusion), MOFS, APACHE II, OSFS, AT III activity, AT III plasma concentration, resolution of acute pre-existing organ dysfunction (neurological, respiratory, renal, hepatic and coagulation) and incidence of organ dysfunction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:10:44 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Germany, Belgium, the Netherlands<BR/>A letter sent to authors in December 2005, no answer received</P>
<P>APACHE II, MOF and OSF scores were calculated on days 1, 2, 3, 7, 10, 20 and 30.<BR/>No adverse events reported</P>
<P>Funding bias: AT III by Kybernin R Centeon Pharma GmbH, Marburg, Germany. No additional information provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Fourrier-1993">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel randomized clinical trial<BR/>ITT: yes<BR/>Sample size was calculated to detect a 50% reduction in mortality in ICU</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Critically ill patients with septic shock and DIC and MOF with at least 1 organ failure added to circulatory and haematologic failures</P>
<P>AT III group: 17 participants, 10 men, mean age (SD): 52 ± 22 yrs. Underlying disease: alcoholism 5; chronic cardiac failure 8; COPD 2. No underlying disease 3; recent surgery 6. SAPS: 20 ± 7. Organ failures: 2.8 ± 1.0, renal failure: 57%, respiratory failure: 93%</P>
<P>Control group: 18 patients, 10 men, mean age (SD): 52 ± 18 yrs. Underlying disease: alcoholism 3; chronic cardiac failure 9; COPD 3. No underlying disease 4; recent surgery 6. SAPS: 19 ± 6. Organ failures: 2.8 ± 0.9, renal failure: 56%, respiratory failure: 89%</P>
<P>Inclusion criteria: a) mandatory criteria for septic shock: 1) bacteraemia or evidence of septic focus; 2) fever &gt; 38.5º C; 3) leukocyte count &gt; 15 x 10&#8313;/L or &lt; 4 x 10&#8313;; 4) hypotension, sys BP &lt; 90 mmHg despite adequate vascular filling; 5) requirement of vasoactive agent (dopamine &gt; 15 µg/kg/min, dobutamine, epinephrine or norepinephrine) during more than 12 hrs<BR/>b) Mandatory DIC criteria: 1) platelet counts &lt; 100x10&#8313;/L or a decrease of &gt; 100 x 10&#8313; over the last 24 hrs; 2) decrease in factor V level &lt; 70%; 3) presence of soluble complexes of fibrin monomers</P>
<P>Exclusion criteria: a) &lt; 16 years old; b) suspected pregnancy; c) sepsis or DIC within 8 days after delivery; d) chronically immunocompromised; e) bone marrow aplasia or acute leukaemia; f) chronic liver failure with cirrhosis, recent hepatic surgery or transplant; g) multiple trauma or uncontrolled haemorrhage that required massive blood transfusion or undergone plasma exchange (&lt; 5 days)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Experimental: 90 - 120 IU/kg, loading dose over 3 hrs (3 ml/kg) + 3 ml/kg over 21 hrs, then 90 - 120 IU/kg/day for 3 days by continuous infusion. The aim: supranormal AT III levels. Average of 6000 IU/day</P>
<P>Control: human albumin 0.6%, equivalent amount in ml</P>
<P>Standard intensive care treatment to all participants. FFP, PC, and fibrinogen concentrates restricted to haemorrhages and severe decreases in prothrombin time to &lt; 30%, platelet count to &lt; 50 x 10&#8313;/L (1/10 kg of body weight), and fibrinogen levels to &lt; 1 g/L. LMWH 0.5 mg/kg of body weight when used in lines and filters of haemodialysis or haemofiltration</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: 28-day mortality.</P>
<P>Secondary: recovery of DIC, side effects, length of stay, transfusion and vascular requirements, bleeding, numbers and types of organ failure, organ function scores, protein C and S activity, fibrinogen and AT III activity, fibrin degradation products, factor V and VII, cardiac index, systemic vascular resistances, blood lactate, total bilirubin, blood creatinine, omega score, surgery during treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:11:20 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: France<BR/>Letter sent to authors in November 2005, authors replied in December 2005.</P>
<P>Heparin therapy was not used as control to avoid haemorrhagic hazards and discrepancies related to heparin-induced AT III consumption. Since FFP contains significant amount of AT III, infusion was restricted. No side effects reported.</P>
<P>Funding bias: Supported by a grant from the French National Institute of Health and Medical Research: INSERM</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Fulia-2003">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel randomized clinical trial<BR/>ITT: yes<BR/>No sample size calculation was reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>60 infants born before 30 weeks of gestation randomized to a loading dose of AT III or placebo</P>
<P>AT III: 30 infants, 16 male, gestational age (weeks): 28.5 ± 1.5, birth weight (g): 1060 ± 218, vaginal delivery: 12, elective caesarean: 18, antenatal steroids: 16, APGAR score at 1 min: 5.83 ± 0.75, APGAR score at 5 min: 7 ± 0.64, cord ABG pH: 7.28 ± 0.07</P>
<P>Control: 30 infants, 17 male, gestational age (weeks): 28.5 ± 1.3, birth weight (g): 1054 ± 233, vaginal delivery: 11, elective caesarean: 19; antenatal steroids: 17, APGAR score at 1 min: 5.63 ± 0.82, APGAR score at 5 min: 6.88 ± 0.76, umbilical cord arterial blood gas pH: 7.31 ± 0.08</P>
<P>Inclusion criteria: gestational age &lt; 30 weeks, postnatal age &lt; 12 hrs, AT III activity &lt; 40% (normal value 20 - 72%)</P>
<P>Exclusion criteria: sepsis, congenital malformations, cerebral haemorrhage, bleeding disorders, thrombocytopenia (platelet count of 50 x 10&#8313; or less)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III group: loading dose of 2 ml/kg equivalent to 100 U/kg of AT III followed by 1 ml/kg equivalent to 50 U/kg every 8 hrs for 48 hrs</P>
<P>Control: 5% glucose in equivalent amounts (ml)</P>
<P>Arterial catheters were perfused with 1 ml/h of 5% glucose containing I U/ml of unfractionated heparin. No other anticoagulants were administered. All newborns received the same exogenous surfactant</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: death and intraventricular haemorrhage (grade 0 - IV)</P>
<P>Secondary: partial thromboplastin time, quick prothrombin time, platelet count, surfactant need, pneumothorax, pulmonary haemorrhage, patent ductus arteriosus inotropes, bronchopulmonary dysplasia, level of AT III, degree of IVH measured by ultrasonography.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:11:48 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Italy<BR/>Letter sent to authors in January 2006, no answer received</P>
<P>Funding bias: Not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:12:42 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Gando-2013">
<CHAR_METHODS MODIFIED="2015-12-23 14:12:28 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial</P>
<P>ITT: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>60 DIC patients with sepsis and antithrombin levels of 50 to 80%</P>
<P>Location: 13 critical care centres of tertiary care hospitals from April 2008 to February 2012<BR/>Inclusion criteria: Patients with a diagnosis of DIC (JAAM DIC score &#8805; 4) with sepsis and levels of antithrombin ranging from 50 - 80% were eligible in the trial<BR/>Exclusion criteria: Age &gt; 15 years. A history of haematopoietic malignancy. A history of liver cirrhosis classified as Child-Pugh grade C. Receiving concomitant treatment with chemotherapies or irradiation. A history of known clotting disorders or receiving anticoagulant therapy. In an early phase of trauma or burn injuries. A life expectancy of less than 28 days</P>
<P>Sex: 25 women and 35 men<BR/>Age: Case: 73 ± 15, control 67 ± 17 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: Immediately after the participants met the inclusion criteria, they were randomly assigned to either a group receiving antithrombin at a dose of 30 IU/kg (given over 60 minutes) per day for 3 days, or to the control group with no intervention</P>
<P>The trial reported only whether the participants received blood products or not. The quantity received was not stated</P>
<P>No heparin used under the trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 28 days<BR/>Primary outcome: recovery from DIC on day 3</P>
<P>Secondary outcome: 28-day all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:12:42 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Japan<BR/>
</P>
<P>Unable to contact the authors for additional data despite attempts in 2015</P>
<P>Funding bias: Funded and supported by the Japanese Association for Acute Medicine (JAAM).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Grenander-2001">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel prospective randomized trial<BR/>ITT: no<BR/>No sample size calculation was provided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:24 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>28 patients with purely traumatic brain injury and no other major trauma</P>
<P>AT III group: 13 participants, 10 men, mean age: 48 yrs. Mean APACHE II score: 14.2, mean GCS: 7.7, median: 7.0; 50% had positive blood alcohol detection</P>
<P>Control group: 15 participants, 10 men, mean age: 44 years. Mean APACHE II score: 14.8, mean GCS: 7.5, median: 7.0; 50% had positive blood alcohol detection</P>
<P>Inclusion criteria: 1) 14 - 70 yrs old; 2) brain injury was CT-verified and assessed by GCS; 3) only GCS between 4 - 12 included; 4) inclusion within 12 hrs from the time of injury</P>
<P>Exclusion criteria: 1) ongoing dialysis-dependent renal disorder; 2) bleeding or coagulation disorder such as haemophilia or von Willebrand's disease; 3) anticoagulant therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:24 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: 60 IU/kg body weight initially. 8 and 16 hrs later an additional 20 IU/kg body weight was given - a total of 100 IU/kg body weight during 24 hrs. The doses were adjusted to the nearest 500 IU. Duration: 24 hrs. Average total dose of AT given was 8269 ± 1562 IU</P>
<P>Control: no placebo</P>
<P>Both groups received additional treatment according to local standards for brain injury including surgery, ventricular drain, or intraparenchymatous intracranial pressure (ICP) device, moderate hyperventilation (pCO&#8322; 4 - 4.5 kPa), sedation, drainage of cerebrospinal fluid, low-dose barbiturates, mannitol infusion, inotropic drugs, clonidine and dihydroergotamine. Treatment goals were ICP &lt; 20 mm Hg and CPP &gt; 60 mm Hg.<BR/>LMWH 2500 IU sc only to a random group of participants in few events (1 in AT group and 3 in control group). 3 participants in each group received FFP for volume replacement.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:24 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary outcome: time of coagulopathy in participants with brain contusion and with or without intracranial haemorrhage, coagulation parameters improvement: soluble fibrin (SF), AT III-activity, D-dimer, thrombin-antithrombin complex (TAT), platelet count, prothrombin complex and fibrinogen, mortality at 3 months</P>
<P>Secondary: duration of mechanical ventilation, APACHE II score (slightly modified in order to estimate the severity of illness), improved outcome assessed by GCS (once daily and at 3 months), brain injury progress monitored by CT, bleeding events, days with mechanical ventilation, need for intensive care, and evaluation of severe disability</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:12:58 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Sweden<BR/>Letter sent to authors in December 2005, no answer received.</P>
<P>2 withdrawals (late presentation of exclusion criteria and a revoked consent), 1 late exclusion resulting from the revelation of improper dosage of antithrombin because of incorrect information regarding body weight 1 case of cross-over. 1 participant in the control group was given AT III by the attending physician as part of the treatment for a septic reaction. Partially missing data on this participant</P>
<P>Funding bias: This trial was supported by Pharmacia &amp; Upjohn, Stockholm, Sweden. They provided antithrombin concentrate and funded the trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:15:42 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Haire-1998">
<CHAR_METHODS MODIFIED="2015-12-23 14:15:41 +0000" MODIFIED_BY="Mikkel Allingstrup"/>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:25 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>49 people undergoing haematopoietic stem cell transplantation</P>
<P>AT III group: 24 participants, 10 men. Mean age (SD): 46.1 ± 10.3 yrs. Underlying disease: acute myeloid leukaemia 5, breast carcinoma 8, chronic myeloid leukaemia 1, multiple myeloma 3, lymphoma 7</P>
<P>Control group: 25 participants, 11 men. Mean age (SD): 46.0 ± 10.5 yrs. Underlying disease: acute lymphocytic leukaemia 1, acute myeloid leukaemia 4, breast carcinoma 4, chronic lymphocytic leukaemia 2, chronic myeloid leukaemia 4, Hodgkin's disease 1, multiple myeloma 3, lymphoma 6</P>
<P>Inclusion criteria: malignant disease admitted for HSCT, not committed to other confounding clinical trials, English their first language (to allow reliable use of the mini mental status examination)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:25 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: 70 U/kg within 24 hrs of organ dysfunction detection, followed by 50 U/kg 8,16, 48 and 72 hrs later. Total dose of AT III: 270 U/kg. Estimated to provide an increment of about 250% activity above pretreatment levels after the 3rd dose. Mean total dose: 20,520 U/participant based on the mean weight of the randomized participants (76 kg)</P>
<P>Control: 5% human albumin, volume equal to the calculated volume of AT III concentrate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:25 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: mortality, severity-of-illness score, length of hospital stay</P>
<P>Secondary: daily screening for pulmonary, hepatic or CNS dysfunction, MODS. Correlation between AT III, number of organ failure and MODS. Number of participants progressing from single through multiple organ dysfunction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:15:42 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: USA<BR/>Letter sent to authors in December 2005, no answer received.<BR/>One participant was randomized and received the 1st dose of the trial drug based on an erroneous laboratory report. This participant was not included in the final analysis.<BR/>Organ dysfunction defined as: 1) CNS - a drop in the score of standardized mini mental status examination of at least 4 points from the pre-chemotherapy score; 2) pulmonary - finger oximetry reading of SpO&#8322; &lt; 90% on 2 occasions on the same day separated by at least 2 hours; 3) peptic - a combination of bilirubin &gt; 2.0 mg%, a weight gain of &gt; 5% over pre-chemotherapy weight, and abdominal pain of possible hepatic origin<BR/>Participants with single-organ dysfunction with a concomitant AT III activity of &lt; 84% of normal were defined as having MODS</P>
<P>Funding bias: Trial drugs were provided by Baxter Healthcare, Glendale, CA, USA. No additional information is provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:15:45 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Harper-1991">
<CHAR_METHODS MODIFIED="2015-12-23 14:15:44 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized controlled trial<BR/>ITT: yes<BR/>No sample size calculation was provided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:25 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Patients with AT III activity of &lt; 70% admitted to the ICU. Patients with an initial AT activity &gt; 70% monitored daily and were randomized into the trial if their AT activity at any time during their stay fell below 70%.</P>
<P>AT III group: 44 participants, median age: 49 yrs (range 19 - 78). Admission AT III activity: 51% (range 12 - 68); APACHE II score median: 16 (range 6 - 33)</P>
<P>Control group: 49 participants, median age: 49 yrs (range 16 - 77). Admission AT III activity: 50% (range 12 - 64); APACHE II score median: 14 (range 4 - 26)</P>
<P>Exclusion criteria: acute or chronic renal failure prior to admission to the ICU. If readmitted to ICU, the participants were allocated to the same randomization as on their previous admission. Participants were excluded if they stayed less than 4 days on ICU.<BR/>10 liver transplant recipients and 15 participants with septicaemia, major trauma, or following major surgery in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:26 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Treatment: AT III, aiming at 120%. Loading dose was calculated from the initial AT III activity and the participant's weight ((120-AT III activity (%)) x weight (kg)). Maintenance doses were given iv over 10 mins. Treatment was continued until the participant was discharged from the ICU, twice daily.</P>
<P>Control: no placebo</P>
<P>Standard intensive care treatment to all participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:26 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: mortality, coagulation parameters (AT III activity, AT-antigen concentration, fibrinogen concentration, platelet count). Renal function impaired if creatinine clearance &lt; 20 ml/min at any time during their stay on the ICU</P>
<P>Secondary: days in ICU, side effects, APACHE II</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:15:45 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: UK<BR/>Letter sent to authors in November 2005, no answer received.</P>
<P>81 participants had an AT III activity below 70% on admission to the ICU and in a further 12 participants the plasma AT III fell below 70% whilst on the ICU. Thus a total of 93 patients were randomized: 44 to the treatment arm and 49 in the no-treatment arm. 9 participants in the AT III arm did not receive AT III replacement; 3 died before treatment began; and 6 were transferred from the ICU within a few hours of randomization. A total of 35 participants received AT III replacement. Of these 25 remained on the ICU for at least 4 days. 32 participants in the control arm remained on the ICU for at least 4 days. 25 of these were selected by diagnosis to act as controls. The authors provided mortality data on all participants randomized, and we have chosen to include these in our analysis.</P>
<P>Funding bias: Unable to assess</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Inthorn-1997">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel randomized clinical trial<BR/>ITT: yes<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:26 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>40 surgical patients with severe sepsis, post-traumatic or postoperative admitted to surgical ICU</P>
<P>AT III group: 20 participants. Demographic characteristics only provided for the 14 participants included: 13/14 were men. Source of sepsis: peritonitis (10), pneumonia (2), catheter-related infection (1), late abscess (1). Age: 62.3 ± 3.8 y, MOF score: 4.1 ± 0.5</P>
<P>Control group: 20 participants. Demographic characteristics only provided for the 15 participants included: 11/15 were men. Source of sepsis: peritonitis (12), pneumonia (2), Mediastinitis (1). Age: 61.5 ± 3.6 yrs, MOF score: 3.9 ± 0.4</P>
<P>Inclusion criteria: a) 1 or more blood cultures positive for gram-positive or -negative bacteria or evidence of septic focus; b) temperature above 38.5º C; c) leukocyte count &gt; 15 g/L or &lt; 5% or &gt; 20% of immature (band) forms; d) thrombocyte count &lt; 100 g/L or a decrease of &gt; 20% during the last 24 hours; e) at least 1 organ dysfunction</P>
<P>Exclusion criteria: 1) &lt; 18 yrs old; 2) received AT within 21 days prior to the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:26 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: continuous AT III infusion over 14 days in order to obtain plasma AT III &gt; 120%. Average of 6000 IU AT III was administered on 1st day and 4000 IU on the subsequent days.</P>
<P>Control: no placebo treatment</P>
<P>All participants received standard relevant intensive care treatment that was comparable between groups and continuous low-dose heparinization (4 IU/kg bodyweight/h). FFP was only given to participants with severe haemorrhage and markedly impaired plasmatic coagulation (contains AT III); prothrombin complex given only during excessive clinical bleeding; platelets given only when &lt; 50 g/L; packed red blood given when &lt; 10 g/dL</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:26 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: 14- and 90-day mortality; mortality between days 7 - 14, hospital discharge</P>
<P>Secondary: transfusions, MOFS, frequency of surgical interventions, frequency of DIC, AT III plasma activity, severity of organ dysfunction, effect of AT III on clotting system and MOF, haemodynamic and respiratory profile</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:20:55 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Germany<BR/>Letter sent to authors in November 2005, no answer received.<BR/>The results of this trial were also published in 2 additional articles (See <LINK TAG="INCLUDED_STUDIES" TYPE="SECTION">Included studies</LINK>, <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>). Comparable participants in both groups and no significant baseline differences in measured outcomes. Peritonitis most frequent source of sepsis (70%).</P>
<P>Due to the presumed mechanisms of AT III action, only long-term supplementation was assumed to affect parameters of organ function. Thus, 11 participants were prospectively excluded from the final evaluation since they died during the 14-day period. However their data were included in an intention-to-treat analysis. No side effects were reported.</P>
<P>Funding bias: Unable to assess</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 15:11:13 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Kobayashi-2003">
<CHAR_METHODS MODIFIED="2015-12-23 15:11:13 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial<BR/>ITT: yes<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:26 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>29 severe pre-eclamptic women (24 to 36 weeks of gestation, gestosis index (GI &#8805; 6). Severe pre-eclampsia was defined by the presence of hypertension plus proteinuria.</P>
<P>AT III: 14 women; age: 30 ± 6 yrs; pregnancy weight (kg): 51 ± 7 SD; systolic BP (mm Hg): 163 ± 21, diastolic BP (mmHg): 104 ± 15; gestosis index: 7.2 ± 1.6; gestational age (weeks): 32.3 ± 3.1; biophysical profile score: 7.0 ± 2.0; primigravida (%): 71.4</P>
<P>Control: 15 women; age: 30 ± 4 y; pregnancy weight (kg): 53 ± 9; systolic BP (mm Hg): 165 ± 12, diastolic BP (mmHg): 100 ± 14; gestosis index: 6.6 ± 1.8; gestational age (weeks): 29.8 ± 3.7; biophysical profile score: 7.4 ± 1.9; primigravida (%): 60.0.</P>
<P>Inclusion criteria: systolic BP &#8805; 160 mm Hg and/or diastolic BP &#8805; 110 mm Hg on 2 occasions 6 hours or more apart; and/or proteinuria &#8805; 2 g/L in a 24-hr urine collection; and a GI &#8805; 6 points on 2 occasions at least 6 hours apart at bed rest</P>
<P>Gestosis index score was calculated as: a) oedema after bed rest: 0 (none), 1 (tibia), 2 (generalized); b) proteinuria (g protein/L) 0 (&lt; 0.5), 1 (&#8805; 0.5 - 1.99), 2 (&#8805; 2.0 - 4.99), 3 (&#8805; 5.0); c) systolic BP (mm Hg) 0 (&lt; 140), 1 (140 - 159), 2 (160 - 179), 3 (&gt; 180); d) diastolic (BP mm Hg) 0 (&lt; 90), 1 (90 - 99), 2 (100 - 109), 3 (&#8805; 110).</P>
<P>Exclusion criteria: patients with chronic hypertension, renal disease, diabetes mellitus, systemic lupus erythematosus, multiple pregnancies, AT deficiency and other severe medical conditions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: 1500 U/day once daily for 7 consecutive days</P>
<P>Control group: unknown placebo</P>
<P>5000 U/day of unfractionated heparin was given simultaneously in both groups. Heparin was infused by 24-hr intravenous drip with saline.<BR/>Concomitant therapy with other anticoagulants, antiplatelet agents, and blood preparations except albumin was not permitted during the trial. Only hydralazine hydrochloride at a 30 mg/day was allowed in both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Neonatal and foetal outcomes: mortality (neonatal and foetal), bleeding disorder, weeks of gestation at delivery, birth weight (g), APGAR score at 1 minute, neonatal distress (%), response on the biophysical profile score</P>
<P>Maternal outcomes: gestosis index improvement, improvement of coagulation index, adverse events, blood loss</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:21:12 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Japan<BR/>Letter sent to authors in December 2005, reply received in January 2006.<BR/>No adverse event related to AT III was reported.</P>
<P>The criteria used to initiate a preterm delivery were based on sustained severe hypertension (&#8805; 180/110 mm Hg), thrombocytopenia (&#8804; 100 x (10&#8313;/L), markedly worsened liver or renal function (serum aspartate aminotransferase or serum alanine amino transferase &#8805; 100 IU/L, serum creatinine &#8805; 15 mg/L, blood urea nitrogen &#8805; 200 mg/L), severe maternal symptoms (eclampsia, HELLP syndrome, placental abruption, pulmonary oedema, etc) or impaired foetal status evidenced by intrauterine growth retardation (&#8804; -2 standard deviations) and oligohydramnios (amniotic pocket &#8805; 1 cm), or persistently severe abnormal foetal heart rates or worsened biophysical profile test results (based on foetal breathing movements, foetal tone, reactive foetal heart rate, gross body movements, qualitative amniotic fluid volume).</P>
<P>Funding bias: Appears to be based on institutional funding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Langely-1993">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel randomized clinical trial<BR/>ITT: yes<BR/>Sample size calculation was not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>25 patients in grade III or IV coma were selected on the basis of evidence of sepsis, intravascular coagulation, and a high risk of developing multiorgan failure.</P>
<P>AT III: 13 participants, 7 men, 12 with severe hepatic dysfunction on entry of which 9 also had further complications of fulminant hepatic failure. Underlying aetiology: paracetamol overdose (9), hepatotoxicity to phenytoin (1), hepatitis B (1), non-A non-B hepatitis (2). Time from the onset of illness to entry into the trial: median 3 (2 - 28) hrs</P>
<P>Control: 12 participants, 4 men, all with severe hepatic dysfunction on entry of which 6 also had further complications of FHF. Underlying aetiology: paracetamol overdose (8), hepatitis B (2), non-A non-B hepatitis (1), halothane hepatitis (1). Time from the onset of illness to entry into the trial: median 3 (2 - 37) hrs</P>
<P>No statistically significant differences between the 2 groups on admission with respect to age, sex, prothrombin ratio, and initial AT III level</P>
<P>Inclusion criteria: 1) severe hepatic dysfunction, prothrombin ratio expressed as an international normalized ratio (INR) &gt; 6.7 for paracetamol overdose or INR &gt; 3.3 for other aetiologies; 2) evidence of sepsis with temperature higher than 39º C, white cell count &gt; 15 x 10&#8313;/L, or microbiologically proven sepsis; 3) presence of disseminated intravascular coagulation with spontaneous bleeding and a platelet count of less than 50 x 10&#8313;/L; 4) multiorgan failure with systolic blood pressure &lt; 80 mm Hg, requiring inotropic support to maintain blood pressure and blood pH &#8804; 7.3</P>
<P>Exclusion criteria: not provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III group: 13 participants received 3000 units of AT III on entry into the trial followed by a further 1000 units every 6 hours unless AT III levels were within the normal range. Total amount of AT III given to the participants during the course of their illness ranged from 3000 units to 23,000 U (mean 7000 ± 5000 U).</P>
<P>Control: no placebo</P>
<P>All participants received standard supportive therapy for FHF which included haemodynamic monitoring, haemodialysis or haemofiltration for renal failure, and continuous intracranial monitoring with treatment for raised intracranial pressure where necessary. Mechanical ventilation was used to treat respiratory dysfunction or pulmonary complications.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: mortality, plasma levels of AT III</P>
<P>Secondary: renal failure, cerebral oedema, incidence of infection, liver transplantation, coma grade, effect of AT III on bleeding and coagulation parameters, transfusion requirements</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:21:25 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: United Kingdom<BR/>Letter sent to authors in December 2005, no reply received.</P>
<P>Funding bias: This trial was supported by Behringwerke AG including provision of the antithrombin III concentrate, and assay kits for antithrombin III, thrombin-antithrombin Ill complex and prothrombin fragment (Fl +2)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:22:17 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Lavrentieva-2008">
<CHAR_METHODS MODIFIED="2015-12-23 14:22:06 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel prospective randomized clinical trial.<BR/>ITT: Not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>31 patients with severe burn injury</P>
<P>Location: Burn Unit in Papanicolau General Hospital, Thessaloniki, Greece from April 2004 to December 2005<BR/>Inclusion criteria: Patients with severe burn injury admitted to the Burn Unit<BR/>Exclusion criteria: Patients with known haematological disease, hepatic and renal failure, malignancies and associated trauma</P>
<P>Sex: 7 women 24 men<BR/>Age: Case: 37.1 ± 13.6, control 44.1 ± 21.5 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: AT administration was started from the 1st post-burn day and continued for the next 3 consecutive days at a dose of 64.9 ± 11.4 U/kg/day. The AT dose was titrated depending on the desired target value of plasma AT activity &gt; 150%</P>
<P>Use of heparin not stated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:28 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 28 days<BR/>Primary outcome: Diagnosis af DIC</P>
<P>Secondary outcome: 28-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:22:17 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Greece<BR/>We contacted the author 23rd April 2015 and he replied on the same day with detailed answers.</P>
<P>Funding bias: The authors received no funding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Maki-2000">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel randomized clinical trial<BR/>ITT: yes<BR/>No sample size calculation was reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:28 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Severe pre-eclamptic women (24 to 35 weeks of gestation)</P>
<P>AT III: 74 women, age: 30 ± 5 yrs; pregnancy weight (kg): 66 ± 12; systolic BP (mm Hg): 170 ± 16, diastolic BP (mmHg): 103 ± 12; gestosis index: 7.7 ± 1.4; gestational age (weeks): 31.8 ± 3.2; biophysical profile score: 8.6 ± 2.0; primigravida (%): 34.8</P>
<P>Control: 72 women, age: 30 ± 5 yrs; pregnancy weight (kg): 65 ±12; systolic BP (mm Hg): 169 ± 17, diastolic BP (mmHg): 105 ± 12; gestosis index: 7.7 ± 1.6; gestational age (weeks): 31.7 ± 2.7; biophysical profile score: 8.7 ± 1.7; primigravida (%): 37.3</P>
<P>Inclusion criteria: systolic BP &#8805; 160 mmHg and/or diastolic BP &#8805; 110 mmHg on 2 occasions 6 hrs or more apart; and/or proteinuria &#8805; 2 g/L of protein in a 24-hr urine collection; GI &#8805; 6 points on 2 occasions at least 6 hrs apart despite bedrest. GI is calculated based on oedema, proteinuria, systolic BP and diastolic BP.</P>
<P>Exclusion criteria: chronic hypertension, multiple pregnancy, renal disease, diabetes mellitus, systemic lupus erythematosus, other severe medical conditions and people with AT deficiency.</P>
<P>Similar baseline characteristics, proportion of severe early-onset pre-eclampsia was equally distributed within the trial groups.<BR/>For definitions of GI and bio-profile scoring technique, please see <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK> characteristics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:28 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Treatment: 3000 IU intravenous AT III once daily for 7 consecutive days</P>
<P>Control: 582 mg albumin intravenously, once daily for 7 consecutive days as placebo</P>
<P>Concomitant therapy with other anticoagulants, antiplatelet agents and blood preparations except albumin was not permitted during the trial. Other relevant treatment such as antihypertensive agents, magnesium sulfate allowed in both groups. No heparin was used.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:28 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary endpoints: improvement of GI, improvement in foetal findings (biophysical profile score, and the estimated foetal weight gain), duration of pregnancy, birth weight, gestational age at delivery, improvement of coagulation parameters (TAT-complexes, plasmin-plasmin inhibitor complexes, PC, D-dimer, AT activity, AT antigen), stillbirth or neonatal death ascribed to pre-eclampsia, maternal death from any cause, or death of neonate at any time attributed to pre-eclampsia or associated with intra-uterine growth retardation.</P>
<P>Secondary: adverse events related to AT<BR/>Stillbirth included all intrauterine deaths at or after 24 weeks, and neonatal death included all deaths after birth up to the age of 28 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:22:36 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Japan<BR/>Letter sent to authors in December 2005, reply received in January 2006.<BR/>Intervention had to be stopped in 23 participants in the AT III group and 29 participants in the control group prematurely due to worsening of maternal and foetal findings.</P>
<P>Funding bias: Appears to be based on institutional funding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:22:53 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Mitchell-2003">
<CHAR_METHODS MODIFIED="2015-12-23 14:22:48 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial<BR/>ITT: no<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:29 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Paediatric acute lymphoblastic leukaemia (ALL) patients</P>
<P>AT III: 25 participants, 15 boys, median age 3.8 (1.6 - 17.2) yrs, weight 18.3 (9.7 - 76.7) kg</P>
<P>Control: 60 participants, 37 boys, median age 5.9 (1.9 - 16.7) yrs, weight 20.6 (10.8 - 83.4) kg</P>
<P>Inclusion criteria: age &gt; 6 months and &lt; 18 years, newly diagnosed with ALL at the beginning of the induction of chemotherapy, a functioning central venous line placed within 2 weeks of initiating induction chemotherapy and obtaining informed consent</P>
<P>Exclusion criteria: previous treatment with L-asparaginase, a known hypersensitivity to any of the ingredients in antithrombin concentrate, medical conditions that could have interfered with participation or assessment of the trial drug, received other investigational drugs within 30 days of enrolment, or required treatment with therapeutic anticoagulation</P>
<P>All participants received unfractionated heparin for prophylaxis of central venous line blockage either by continuous infusion (1 - 3 units/mL) or intermittent flushes (50 - 100 units/mL up to 4 times per day). The decision to use additional anticoagulants was left to the patient's physician.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: infusions once weekly for 4 weeks (days 1, 8, 15, 22) to increase plasma concentrations of AT to approximately 3.0 units/mL but no more than 4.0 units/mL</P>
<P>Control: no placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: prevalence of thrombotic events</P>
<P>Secondary: bleeding events, plasma markers, efficacy and safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:22:53 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>
<BR/>Country: Canada and USA<BR/>Letter sent to authors in December 2005, no answer received.<BR/>No data were provided on mortality. Based on the detailed follow-up, we concluded that there was no mortality in either group.</P>
<P>The trial was not powered to prove efficacy or safety of AT III supplementation but rather to look for trends.</P>
<P>24 participants excluded from analysis (12 in each group). The reasons for exclusion in the AT III group were: 3 participants due to withdrawal of consent, 2 participants categorized as noncompliant due to an underdosing with AT concentrate, 7 participants due to the absence of an exit venogram. In the control group: 3 participants due to withdrawal of consent, 1 participant had an adverse event, and 8 participants were excluded due to the absence of an exit venogram.</P>
<P>Funding bias: Unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Muntean-1989">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel open randomized clinical trial.<BR/>ITT: Not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>98 preterm neonates</P>
<P>
<BR/>Inclusion criteria: premature infants<BR/>Exclusion criteria: Not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Intervention group: n = 45. Single bolus AT III immediately after birth. Birth weight under 1500 g was given 100 U, over 1500 g 200 U</P>
<P>Control group: n = 53, standard treatment. No details</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 14:23:48 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: Not stated<BR/>Outcomes: Participants received artificial ventilation. Duration of artificial ventilation. Intraventricular haemorrhage and mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:23:53 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: Department of Gynaecology and Obstetrics, University of Graz, Austria<BR/>Trial only published as an abstract. Letter sent to authors, no reply received.</P>
<P>Funding bias: Not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:24:40 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Neporada-2008A">
<CHAR_METHODS MODIFIED="2015-12-23 14:24:32 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>3-group parallel randomized clinical trial.<BR/>ITT: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>43 patients with DIC and AT activity &#8804; 70%</P>
<P>
<BR/>Inclusion criteria: 43 consecutive patients were enrolled with DIC diagnostic criteria by the JAAM and AT activity &#8804; 70% admitted to the ICU<BR/>Exclusion criteria: age &lt; 16 and &gt; 75 yrs; body weight &lt; 50 or &gt; 100 kg, malignant neoplasms, bleeding, haemostatic therapy, platelet count over 50 10&#8313;/L</P>
<P>Interventions group: 15 participants were randomized into AT III group, mean age 42 (95% CI 32 to 52), the proportion of men was 53%. Sepsis was present in 9 participants (60%).</P>
<P>Control group: 15 participants were randomized to FFP group. Mean age 56 (95% CI 48 to 64), the proportion of men 60%. 8 participants had sepsis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Intervention group 1: 15 participants received AT III 500 - 1000 IU/day</P>
<P>Control group: 15 participants received FFP (10 - 17 ml/kg)</P>
<P>Intervention group 2 (initiated at a later stage): n = 13, same intervention as group 1 and control group combined.</P>
<P>If AT activity persists &lt; 70% therapy protocol continued during 4 days. Concomitant therapy with nadroparin (95 IU/kg/day) was used in all groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 30-days<BR/>Outcomes: Respiratory function, organ failure assessment, DIC JAAM score, bleeding complications, allergy and all-cause 30-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:24:40 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: ICU, City Hospital #1, Arkhangelsk, Russia<BR/>Article sent by e-mail. Published in Russian magazine in 2008.</P>
<P>The author, Elena Neporada, contributed with further details about the trial.</P>
<P>Funding bias: No funding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Nishiyama-2011">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel prospective randomized clinical trial.<BR/>ITT: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>16 patients</P>
<P>
<BR/>Inclusion criteria: 16 adults were enrolled, diagnosed as having DIC with infection assessed with an acute DIC score 4 or higher at admission to the ICU.<BR/>Exclusion criteria: Haematologic diseases, liver cirrhosis classified as Child-Pugh grade C, burn, or obstetric diseases or patients who had received anticancer agents, radiation, or anticoagulant were excluded from the trial</P>
<P>Sex: 5 women and 11 men<BR/>Age: range 30 - 85 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Intervention group: received antithrombin (Mitsubishi Tanabe Pharm, Co, Ltd, Osaka, Japan) as a 1500 unit infusion for 30 min/d for 5 days.</P>
<P>Control group: received gabexate mesilate (Ono Pharm, Co, Ltd, Osaka, Japan) as a 2000 mg infusion for 24 hrs/d for 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 28 days<BR/>Outcomes: White blood cell counts, C-reactive protein, platelet counts, antithrombin, fibrin and fibrinogen degradation product, D-dimer, fibrinogen, thrombin antithrombin complex, plasmin plasminogen complex, prothrombin time, activated partial thrombin time, as ordinally measurable parameters of inflammation, coagulation, and fibrinolysis, were monitored on the day of ICU admission and on days 1, 3, 5, and 7 thereafter. Mortality over 28 days was compared between the 2 groups.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:25:16 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Japan<BR/>Attempts to reach the author failed. No reply.</P>
<P>Funding bias: None stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Palareti-1995">
<CHAR_METHODS MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>119 participants who met the inclusion criteria: 18 - 75 yrs, AT III &lt; 70%, Sepsis and/or post-surgical complications requiring haemodynamic or respiratory support. 60 participants in the intervention group, 59 in the control group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: loading dose 4000 U followed by 2000 U/12hrs by continuous dose over 5 days</P>
<P>Control: Placebo (no details described).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III activity, 7(6)-day mortality, D-dimer, plasinogen, PAP-complex, &#945;2-antiplasmin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Trial only published as abstract</P>
<P>Available data are based on only the 1st included 59 participants (30 in the intervention group, 29 in the placebo group) on day 6.</P>
<P>Use of heparin was an exclusion criterion, so it is assumed that no heparin was given during the trial.</P>
<P>Funding bias: Not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Schmidt-1998">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel randomized clinical trial<BR/>ITT: yes<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Premature infants with respiratory distress syndrome (RDS) in the neonatal ICU, 942 screened with birth weights 750 - 1900 g</P>
<P>AT III: 61 participants. 33 male, gestational age (weeks) 28.3 ± 2.03, birth weight: 1.198 ± 300.9 g, venous cord blood pH: 7.31 ± 0.10, APGAR score at 1 min: 5.4 ± 1.95, APGAR score at 5 min: 7.6 ± 1.24, AT III, U/mL: 0.33 ± 0.08, maternal age: 28.1 ± 6.68, maternal steroids: 40 (65.6%)</P>
<P>Control: 61 participants. 31 male, gestational age (weeks) 28.8 ± 2.25, birth weight: 1.201 ± 314.4 g, venous cord blood pH: 7.28 ± 0.15, APGAR score at 1 min: 5.3 ± 2.22, APGAR score at 5 min: 7.7 ± 1.16, AT III, U/mL: 0.32 ± 0.08, maternal age: 28.9 ± 5.16, maternal steroids: 35 (57.4%).</P>
<P>Inclusion criteria: 224 met inclusion criteria; (1) age between 2 - 12 hrs; 2) endotracheal intubation and positive pressure ventilation for RDS; 3) indwelling arterial catheter; 4) ratio of arterial to alveolar oxygen pressure PO&#8322; &lt; 0.3 after the 1st dose of exogenous surfactant)</P>
<P>Exclusion criteria: 1) congenital infection; 2) congenital malformation(s); 3) hydrops; 4) pulmonary hypoplasia; 5) clinically apparent bleeding disorder; 6) thrombocytopenia (platelets &#8804; 50 x 10&#8313;/L); 7) moribund</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: loading dose 100 U/kg followed by 50 U/kg every 6 hrs for 48 hrs</P>
<P>Control: human albumin 1%, equivalent dose</P>
<P>All participants received the same standard intensive care treatment and the same exogenous surfactant. Arterial catheters were perfused with 1 ml/h of 5% dextrose containing 1 IU/ml of unfractionated heparin. No additional administration of anticoagulants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: mortality.</P>
<P>Secondary: days in ICU, plasma AT activity, TAT-complex (thrombin-AT), prothrombin fragment (F1 + 2), ratio of arterial to alveolar oxygen pressure (a/A) PO&#8322; and ventilator efficiency index (VEI), thrombin formation, improved gas exchange, duration of mechanical ventilation, duration of supplemental oxygen therapy, safety of AT therapy evaluated primarily by comparing the incidence of severe (Grade 3) intraventricular haemorrhage and of periventricular echodensities in the 2 groups, bleeding events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:25:39 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Canada<BR/>Letter sent to authors in November 2005, no answer received.<BR/>AT levels in healthy preterm infants are about 40% of normal adult values, and even lower levels have been reported in sick premature infants with RDS. The therapy was initiated on average 7.2 hrs after delivery in each group.<BR/>Having observed for some time an apparent imbalance in deaths between the treatment groups, the external safety and efficacy monitoring committee decided to break the code and make its recommendation because 7 deaths had occurred in participants receiving AT and 2 with placebo.</P>
<P>Funding bias: Supported by Physicians&#8217; Services Incorporated Foundation, Toronto, and Behringwerke AG, Germany.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Schorr-2000">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel randomized clinical trial<BR/>ITT: yes<BR/>Sample size calculation was not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 14:31:09 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Patients with secondary peritonitis, surgical population in ICU</P>
<P>AT III: 24 participants, 12 men, median age 60 yrs (33 - 86), APACHE II 14.4 (6 - 30), MOF 4.6 (0 - 10), SOFA 7.7 (0 - 18), MPI 26.7 (12 - 38), malignant diseases (%) 33.</P>
<P>Control: 26 participants, 12 men, median age: 62 yrs (28 - 85), APACHE II 14.6 (4 - 28), MOF 4.9 (0 - 11), SOFA 8.7 (0 - 16), MPI 27.8 (16 - 38), malignant diseases (%) 35.</P>
<P>Inclusion criteria: 1) &gt; 18 years; 2) diffuse secondary peritonitis affecting 2+ quadrants after perforation of an intraperitoneal organ or failed anastomosis; 3) focus of infection had to be surgically eliminated</P>
<P>Exclusion criteria: 1) acute pancreatitis; 2) peritonitis due to peritoneal dialysis; 3) primary peritonitis; 4) ascites due to cirrhosis of the liver or due to malignant underlying disease; 5) pregnancy; 6) incapacitated persons; 7) prisoners</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: continuous IV AT III and 2 intraperitoneal installations of fresh frozen serum. The aim was to achieve AT III level of at least 140% of the normal plasma value for 4 days. A calculated bolus was given in 1 hr followed by a continuous infusion of AT III (200 IU-800 IU per hr) depending on the 6-hourly measurements of plasma AT III. 300 ml of blood group-compatible FFS was applied intraperitoneally after the operation and 6 hours postoperatively through especially installed drains. The first FFS was supplemented with 1500 IU AT III to equalize the lack of AT III in FFS. Mean AT III administered was 26196 (± 299 SEM) IU.</P>
<P>Control: no placebo</P>
<P>All participants: routine intensive care treatment. If no risk of postoperative bleeding, heparin iv 200 - 400 IU/h 6 hrs after operation until discharge from ICU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: 90-day mortality.</P>
<P>Secondary: number of days at ICU, mechanical ventilation, organ function scores, side effects, organ failure and function, bleeding and transfusions, AT III activity, prothrombin concentrations in exudate, TAT-complex in exudate, opsonic capacity and opsonin concentration in exudate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:25:57 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Germany<BR/>Letter sent to authors in November 2005, no reply received.</P>
<P>Funding bias: This trial was supported by the Bundesministerium für Forschung und Technologie (National research grant). ATIII was a gift from Pharmacia, Stockholm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:32:46 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Schuster-1997">
<CHAR_METHODS MODIFIED="2015-12-23 14:32:08 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial<BR/>ITT: Unclear<BR/>Sample size calculation: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-17 08:32:58 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>45 patients with sepsis without DIC</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Intervention group: allocated to AT III supplementation (loading dose of 3000 IU followed by 500 IU every 4 hrs for 7 days, total dose 17,000 IU)</P>
<P>Control: placebo (albumin)</P>
<P>Both groups received iv heparin (6 IU/kg/h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 14:32:46 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Secondary outcomes (not reported) number of days at ICU, mechanical ventilation, organ function scores, side effects, organ failure and function, bleeding and transfusions, AT III activity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Germany<BR/>Only presented as abstract. No additional data are available. Several previous attempts to reach the authors or find a manuscript failed to provide more information.</P>
<P>Funding bias: Not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:33:17 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Smith_x002d_Erichsen-1996">
<CHAR_METHODS MODIFIED="2015-12-23 14:33:05 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial<BR/>ITT: no<BR/>No sample size calculation was reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Critically ill and trauma patients in ICU<BR/>83 participants allocated to intervention and control groups. Within each of these groups, the participants were then allocated to 2 groups (group 1 and group 2) according to the type of surgery or trauma.</P>
<P>Group 1: multiple trauma, defined as injury of at least 2 body regions, but without abdominal injury</P>
<P>Group 2: abdominal operations and multiple trauma with abdominal injury: 2.1) total gastrectomy, oesophageal resection, rectal resection/amputation in participants over 70 years old; 2.2) pancreatic resection; 2.3) liver resection; 2.4) secondary gastro-intestinal interventions due to postoperative complications; 2.5) multiple trauma with abdominal injury. The participants were randomized in blocks with 4 participants in each block.</P>
<P>AT III group: 43 participants, 30 men, age: 60.1 ± 16.3 yrs. 5 allocated to group 1 (trauma). Number of participants in group 2 as defined above; Group 2.1 17; Group 2.2 9; Group 2.3 5; Group 2.4 6; Group 2.5 1</P>
<P>Control group: 40 participants, 25 men, age: 59.0 ± 16.2 yrs. 5 allocated to group 1 (trauma). Number of participants in group 2 as defined above; Group 2.1 17; Group 2.2 8; Group 2.3 4; Group 2.4 5; Group 2.5 1</P>
<P>Inclusion criteria: AT III plasma level less than 80% measured the day after trauma or major abdominal surgery</P>
<P>Exclusion criteria: trauma patients with head injury and patients below the age of 18 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: the aim was to maintain plasma AT III activity in the range of 100% ± 10%. No data were provided on average or total dose. Based on daily samples, the substitution dose was calculated. A maintenance dose of 500 IU was given at midnight and 10 hours the following day. Treatment was continued until the plasma AT III activity was maintained within the normal range for 3 consecutive days without AT III substitution but was discontinued after 14 days, irrespective of the plasma activity.</P>
<P>Control: no placebo</P>
<P>All participants were treated according to the standard management routines of each hospital.</P>
<P>500 ml of dextran-70 was given every 2nd day during the 1st week as antithrombotic prophylaxis. No participant received heparin or LMWH during the observations period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: plasma protease changes, mortality, days in ICU, days in hospital<BR/>Secondary: AT III level, prothrombin, prekallikrein, functional kallikrein inhibition, plasma kallikrein-like activity, plasminogen, functional antiplasmin activity and plasmin-like activity, proenzyme functional inhibition index and adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:33:17 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Norway<BR/>Letter sent to authors in December 2006, no answer received.</P>
<P>Funding bias: Unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:34:03 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Vorobyeva-2007">
<CHAR_METHODS MODIFIED="2015-12-23 14:33:51 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Prospective randomized clinical trial<BR/>ITT: Not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>38 patients with DIC. 26 participants in the control group, 12 participants in the intervention group. Age 16 - 69 years. Gender is not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Intervention group (AT III): (100% minus measured AT III%) x kg bodyweight, 1000 IU/h, max 1500 IU/day</P>
<P>Control group (FFP): 10 - 17 ml/kg, max 1000 ml/day</P>
<P>The duration of treatment not described.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 14:33:59 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Mortality. Other outcomes are not described in the paper.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:34:03 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Russia<BR/>We tried to contact the author, Nadejda Vorobeva on April 28th 2015, but received no reply.</P>
<P>Funding bias: Supported by grants from the Arkhangelsk region Government</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Warren-2001">
<CHAR_METHODS MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<P>2-group parallel randomized multicentre clinical trial<BR/>ITT: yes<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Critically ill population of ICU patients with severe sepsis and septic shock</P>
<P>AT III: 1157 participants, men 62%; age mean (SD) 57 (17) years; SAPS II (SD) 49 (17); body weight mean (SD) 77 (19) kg. Underlying problem or site of infection: 1) respiratory system 35%; 2) intra-abdominal infection 27%; 3) genitourinary system 6%; 4) injury 7%; 5) other 24%. Surgical status: A) no 54%, yes 46%. Circulatory shock: 49%; blood culture results: a) gram-negative 15%, b) gram-positive 15%, c) other/mixed 4%, d) not done/not verified 66%.</P>
<P>Control: 1157 participants, men 61%; age mean (SD) 58 (17) years; SAPS II (SD) 49 (16); body weight mean (SD) 77 (20) kg. Underlying problem or site of infection: 1) respiratory system 34%; 2) intra-abdominal infection 28%; 3) genitourinary system 8%; 4) injury 6%; 5) other 24%. Surgical status: A) no 53%, yes 47%. Circulatory shock: 47%; blood culture results: a) gram-negative 16%, b) gram-positive 17%, c) other/mixed 2%, d) not done/not verified 64%.</P>
<P>Inclusion criteria: 18 years or above, and met following criteria within 6 hours: 1) clinical evidence of sepsis with a suspected source of infection; 2) body temperature (rectal or core) &gt; 38.5º C or &lt; 35.5º C; 3) leukocyte count &gt; 10,000/µL or &lt; 3500/µL. Additionally, 3 of the following 6 signs had to be met within the same 6-hour period: a) heart rate &gt; 100/min; b) tachypnoea &gt; 24/min or mechanical ventilation because of septic indication; c) hypotension, systolic BP &lt; 90 mmHg despite sufficient fluid replacement or the need for vasoactive agents to maintain systolic BP of 90 mmHg or greater; d) platelet count &lt; 100,000/µL; e) elevated lactate above upper limits of normal range or metabolic acidosis (pH &lt; 7.3 or BE&#8804; -10 mmol/L) not secondary to respiratory alkalosis; f) oliguria (&lt; 20 ml/h despite sufficient fluid replacement).</P>
<P>Exclusion criteria: a) advanced directive to withhold life-sustaining treatment (except cardiopulmonary resuscitation); b) condition other than sepsis anticipated to be fatal within 28 days; c) pregnancy or breast feeding; d) history of hypersensitivity to trial medication; e) treatment with other investigational drugs within the last 30 days; f) treatment with an AT III concentrate within the last 48 hours; g) treatment with heparin (except sc low dose or iv line flushing) or coumarin derivatives; h) NSAID treatment within previous 2 days; i) known bleeding disorder or ongoing massive surgical bleeding; j) platelet count &lt; 30 x 1000/µL; k) immunocompromised status; l) acute myocardial infarction (within previous 7 days); m) 3rd-degree burns &#8805; 20% of total body area; n) incurable malignancy with metastases and life expectancy of &lt; 3 months; o) haematologic neoplasia during cytostatic treatment; p) bone marrow aplasia; q) pre-existing dialysis-dependent renal failure; r) end-stage liver disease; s) transplantation (postoperative state); t) history of stroke within the last year; u) severe cranial or spinal trauma within the last year; v) planned cranial or spinal surgery (except nontraumatic lumbar puncture) within the next 48 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: loading dose of 6000 IU given over 30 minutes, followed by a continuous iv infusion of 6000 IU per day for 4 days, total of 30000 IU</P>
<P>Control: equivalent volume of placebo solution (1% of human albumin)</P>
<P>Heparin was permitted to be used in prophylactic doses as an adjunct to standard therapy. Administration of heparin was left to the attending physicians. Not all participants received heparin (698 participants received no heparin while receiving AT). Heparin dosage: unfractionated or LMWH for venous thrombosis prophylaxis (&#8804; 1000 IU subcutaneous per day) and heparin flushes for vascular catheter patency (iv of &#8804; 2I U/kg body weight/h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: all-cause mortality at 28 days (subgroup 28- and 90-day survival for participants not receiving heparin).</P>
<P>Secondary: mortality at 56 and 90 days, survival time, length of ICU stay, occurrence of new organ dysfunction within 7 days (according to logistic organ dysfunction score), severity of sepsis (SAPSII), circulatory shock index (i.e. ratio of heart rate (beats/minute) and systolic BP (mmHg) exceeded the value of 1.5); surgical interventions and bleeding events for 28 days, major bleeding if intracranial or required transfusion of &gt; 3 units of blood, other serious adverse events, AT III plasma concentration, activated partial thromboplastin time and prothrombin time</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:34:26 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: KyberSept Trial trial Group, 211 contributing centres in 19 countries including USA, Germany</P>
<P>Letter sent to authors November 2005, reply by authors in December 2005 and January 2006.</P>
<P>Funding bias: Aventis Behring sponsored the trial and the manuscript.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-23 14:36:17 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Waydhas-1998">
<CHAR_METHODS MODIFIED="2015-12-23 14:35:28 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>2-group parallel randomized clinical trial<BR/>ITT: yes<BR/>Sample size calculation not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:36 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Trauma patients in ICU.</P>
<P>AT III: 20 participants, 13 men, age 32 yrs (26 - 42), systolic blood pressure (SBP) on the scene 120 mmHg (90 - 130), 2 participants with SBP &lt; 80 mmHg, GCS 13 (6 - 15), use of catecholamines on the scene in 2 cases, intubation on the scene 15 (75%), fluids on the scene 1.5 L (1.0 - 3.0), time from accident until admission 53 mins (33 - 75), lactate 3.2 mmol/L (2.7 - 8.0), haemoglobin 8.9 g/100 mL (7.0 - 12-0), PH 7.30 (7.27 - 7.36), base deficit 6.2 (8.3 - 3.7)</P>
<P>Control: 20 participants, 13 men, age 35 yrs (27 - 47), SBP on the scene 100 mmHg (93 - 120), 2 patients on the scene with SBP &lt; 80 mmHg, GCS 13 (4 - 15), use of catecholamines on the scene in 2 cases, intubation on the scene 10 (50%), fluids on the scene 2.0 L (1.0 - 3.0), time from accident until admission 58 mins (30 - 105), lactate 3.7 mmol/L (2.1 - 6.0), haemoglobin 9.5 g/100 mL (8.0 - 11-0), PH 7.29 (7.10 - 7.32), base deficit 7.6 (13.1 - 4.2)</P>
<P>Inclusion criteria: 1) ISS of 29 or greater (because an ISS of 29 or greater was associated with an organ failure rate of &gt; 60%); 2) admission within 6 hrs after injury; 3) 18 - 70 yrs; 4) blunt trauma; 5) if the head region contributed to calculation of the ISS, the sum of squared abbreviated ISS of the 2 other regions that were included in the calculation had to be equal to or greater than 20 points in order to rule out predominant head injury and ensure severe multiple injuries.</P>
<P>Exclusion criteria: a) resuscitation with epinephrine; b) if closed chest compression performed; c) severe brain injury with uncertain outcome (both pupils unresponsive to light for more than 30 minutes, midline shift &gt; 1 cm, or extensive intracerebral haemorrhage on the initial computed tomographic scan)<BR/>The only post hoc exclusion criterion was survival of &lt; 24 hrs after trauma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-23 13:05:36 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>AT III: a total of 20,000 IU (16,125 - 22,875), vials containing 500 IU diluted in 8 mL of water. Infusion rate of 96mL/h via a pump. AT III levels assessed every 6 hrs during the first 48 hrs. Additional AT III or placebo was substituted to keep the AT III concentration at 140% of normal. In addition, on the next 2 days the test substance was administered once daily in the morning.</P>
<P>Control: placebo, 20% human albumin in corresponding doses and volume</P>
<P>For prophylaxis of DVT and pulmonary embolism: standard sodium heparin iv at a rate of 400 IU/h, started within the first 24 hrs after trauma unless contraindications (active bleeding, intracranial haemorrhage, or others). Participants with traumatic intracranial bleeding were started on heparin on day 5, when the acute phase of brain swelling had subsided and there were no signs of ongoing haemorrhage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:36 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary: incidence and severity of multiple organ dysfunction, mortality, incidence of respiratory failure, severity of organ failure, duration of mechanical ventilation and length of stay in the ICU and hospital</P>
<P>Secondary: plasma concentration of indicators of DIC and systemic inflammatory response (prothrombin, prothrombin fragment F1 + F2, TAT-complex lower, partial thromboplastin time, prothrombin time, PC, plasminogen activator inhibitor I, soluble TNF receptor II, IL1 receptor antagonist, IL6, IL8, neutrophil elastase), transfusions, respiratory dysfunction, ARDS, renal and liver dysfunction, incidence of DIC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-23 14:36:17 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Country: Germany<BR/>Letters sent to authors in November and December 2005, authors replied both times.</P>
<P>Funding bias: This trial was supported by a grant from the Sonderforschungsbereich SFB 207 (project G5), the University of Munich, and the Bundesministerium fuer Bildung und Forschung (FKZ: 01 KE 8912). Antithrombin III (Atenativ) was supplied by Pharmacia &amp; Upjohn (Erlangen, Germany).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CABG = coronary artery bypass graft; ALL = acute lymphatic leukaemia; APACHE = acute physiology and chronic health evaluation; APGAR = appearance, pulse, grimace, activity, and respiration; APTT = activated partial thromboplastin time; ARDS = acute respiratory distress syndrome; BP = blood pressure; CI = confidence interval; CNS = central nervous system; COPD = chronic obstructive pulmonary disease; CPP = cerebral perfusion pressure; CRP = C-reactive protein; DIC = disseminated intravascular coagulation; DVT = deep vein thrombosis; FFP = fresh frozen plasm; GCS = Glasgow coma scale; hr = hour; HELLP = haemolysis, elevated liver enzymes, and low platelet count; HIV = human immunodeficiency virus; HSCT = haematopoietic stem cell transplantation; ICP = intracranial pressure; INR = international normalized ratio; ISS = injury severity score; ITT = intention-to-treat; IU = international unit; JAAM = Japanese association for acute medicine; LMWH = low molecular weight heparin; MODS = multiorgan dysfunction syndrome ; MOFS = multiorgan failure score; MPI = Mannheimer peritonitis index; NSAID = nonsteroidal anti-inflammatory drug; NYHA = New York Heart Association functional classification; OFS = organ failure score; OSFS = organ system failure scoring; RDS = respiratory distress syndrome; SAPS = simplified acute physiology score; SBP = systolic blood pressure; SD = standard deviation; sys = systolic; TAT = thrombin-antithrombin complex; TISS = therapeutic intervention scoring system; Tp = temperature; yr = year</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-01-04 09:21:50 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Aibiki-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>This randomized controlled trial compared 2 active interventions of AT-III, 500 U/8 hrs and 1500 U/24 hrs. Reason for exclusion: No placebo group, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Dietrich-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>41 participants scheduled for primary CABG. Reason for exclusion: elective participants with heart disease, meets our exclusion criteria: <I>AT III administration for the reduction of cardiovascular events</I>. No primary endpoints.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-16 08:40:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Doi-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-16 08:40:30 +0100" MODIFIED_BY="[Empty name]">
<P>Trial only published as abstract. Contains no relevant endpoints.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-26 16:39:11 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Hoffmann-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-26 16:39:11 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Trial only published as abstract. Trial on elective participants. Contains no relevant endpoints.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Ilias-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>An open randomized clinical trial, evaluating the safety, pharmacokinetics and practicability of 2 different regimens of AT III treatment (intermittent bolus infusions vs continuous infusion), both aiming at a total dose of 30,000 IU AT III with concomitant heparin during a 4-day period. Reason for exclusion: 2 different regimens of AT III treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-25 18:14:26 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Jochum-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-25 18:14:26 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>This review includes 1 unpublished, not double-blinded trial of AT III supplementation in a septic population aiming at AT III activity &gt; 120%. AT III group (n = 20) received 2000 - 8000 U/d AT III over 21 days and heparin (4 U/kg body weight/hour). Control group (n = 20) received no placebo. Outcome measures were various organ dysfunction analyses, inflammatory and coagulatory parameters and mortality (control: 80%; AT III: 65%). The results were not statistically significant. Study excluded due to lack of outcomes of relevance and since we were unable to contact the authors in order to retrieve additional information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-26 16:39:11 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Kanbak-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-26 16:39:11 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Randomized trial made in CABG participants. Reason for exclusion: Meets our exclusion criteria: <I>AT III administration for the reduction of cardiovascular events</I>. No primary endpoints.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Kim-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>The purpose of this trial was to compare the pharmacokinetic and pharmacodynamic characteristics of 2 AT III formulations. Reason for exclusion: Trial on healthy Korean volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Korninger-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>A randomized trial of AT III in participants undergoing peritoneo-venous shunt operation because of intractable ascites. 10 participants with alcoholic liver cirrhosis were randomized according to the stage of liver disease and pre-operative AT III levels. AT III was infused in 5 participants, twice daily for 4 days, at a dose of 20 U/kg body weight starting 12 hours prior to operation. 5 participants were allocated to placebo. Coagulatory parameters were examined. Reason for exclusion: only published as abstract, no data on mortality</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Leitner-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>This randomized, double-blinded, placebo-controlled trial examined 30 healthy male volunteers. The active treatment groups received infusions of AT III to achieve levels of 200% and 500% before infusion of 2 ng/kg endotoxin. Reason for exclusion: experimental trial among healthy volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Maki-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>This randomized controlled trial compared 2 active interventions, in participants with obstetric complications. Reason for exclusion: 2 different active interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Mayumi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Trial only published as an abstract. We assume that the abstract is a subgroup analysis of an earlier trial. We cannot contact the author as it is not possible to find contact information.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:01:07 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Neporada-2008B">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:01:07 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Data based on the same trial as <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Nishiyama-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>This randomized, unblinded trial investigated the effects of AT III on coagulation, fibrinolysis, production of cytokines and adhesion molecules in abdominal aortic aneurysm repair surgery. 16 participants for Y-shaped graft replacement of abdominal aortic aneurysm were divided into an AT III group and a control group. In the AT III group, 3000 U AT III was infused over 30 min before heparin administration and 24 hrs later. Reason for exclusion: no data on mortality, nor any data relevant for our review. We emailed the author on 17th April 2015, but received no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-26 16:39:11 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Paparella-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-26 16:39:11 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Randomized trial made in CABG participants. Reason for exclusion: Meets our exclusion criteria: <I>AT III administration for the reduction of cardiovascular events</I>. No primary endpoints.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Paternoster-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>This prospective trial evaluated the modifications of clotting and clinical parameters before and immediately after delivery amongst a pre-eclamptic population either treated with AT III (n = 18) or acting as control (n = 21). Reason for exclusion: only published as a brief communication, no data on mortality, randomization or blinding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Paternoster-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>In this trial, 23 pre-eclamptic women were randomly subdivided into 2 groups: 1st group (n = 10) were treated with 3000 units AT III once daily for 5 days or until delivery, while the 2nd group (n = 13) were treated with doses of AT III sufficient to maintain at least 80% of the activity. The endpoints were the prolongation of pregnancy, assessment of the maternal bleeding and haemostasis, and inflammatory markers. Reason for exclusion: comparison of 2 different regimens of AT III</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-26 16:39:12 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Ranucci-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-26 16:39:12 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>200 participants given preoperative AT supplementation in elective participants during cardiac surgery with CPB. Reason for exclusion: elective participants with heart disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Sawamura-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>23 DIC participants were treated with either high-dose (60 IU/kg/day) or low-dose (30 IU/kg/day) antithrombin concentrates for 3 days. The trial tested the hypotheses that AT III (antithrombin) improves DIC when applied to DIC participants. Reason for exclusion: No placebo group, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Scherer-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>A randomized prospective trial examining the effects of AT III substitution in order to achieve supranormal values in participants with liver cirrhosis scheduled for liver transplantation.<BR/>19 participants were given AT III aiming at either 100% (n = 10) or 175% (n = 9) AT III activity. Control group (n = 5) received saline 0.9%. The endpoints were various coagulatory variables measured prior to AT III infusion and 60 min thereafter. Reason for exclusion: no data on mortality, 3 groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Shimada-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>A randomized prospective trial of AT III efficacy in hepatic resection among 24 participants with hepatocellular carcinoma. 13 participants were given 1500 IU AT III immediately before operation, during hepatectomy, and immediately after operation. Control group (n = 11) received no placebo. Coagulant and fibrinolytic profiles were determined. Reason for exclusion: no data on mortality, different population than defined in our review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Terao-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>A randomized trial of 40 participants with pre-eclampsia comparing AT III intervention with no treatment on coagulatory findings, gestosis index, abortion times, and incidence of newborn asphyxia. Reason for exclusion: no data on mortality</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-23 15:08:01 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Valsecchi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-23 15:08:01 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Only published as an abstract. Trial was terminated by the sponsor with insufficient information.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-25 18:14:49 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Vinazzer-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-25 18:14:49 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>This review mentioned one unpublished trial of participants with DIC due to sepsis or septic shock in which 170 participants were evenly allocated to 2 groups (heparin versus AT III). This uncontrolled open clinical trial showed positive outcome of AT III substitution. Study excluded due to lack of outcomes of relevance and since we were unable to contact the authors in order to retrieve additional information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ALL = acute lymphatic leukaemia; AT III = Antithrombin III ; CABG = coronary artery bypass graft; CPB = cardiopulmonary bypass; DIC = disseminated intravascular coagulation; d = day: H =; Hours; Kg = Kilogram; min= minute(s); U= units; U/d = units/day</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-D_x0027_angelo-2005">
<CHAR_STUDY_NAME MODIFIED="2015-07-28 19:35:47 +0100" MODIFIED_BY="[Empty name]">
<P>EPAS</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Double-blind RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Women with pre-eclampsia occurring before the 30th week of gestation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<P>7-day course of antithrombin 3000 IU/day. No heparin prophylaxis will be permitted during the time of AT III administration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary outcome: reduction of the combined endpoint of foetoneonatal mortality and severe neonatal morbidity.<BR/>Secondary outcomes: reduction in maternal complications and stay in neonatal ICU and the evaluation of the changes in coagulation and inflammation parameters.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<P>December 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan">
<P>D'angelo A (1),Valsecchi L (2)<BR/>1): Coagulation Service and Thrombosis Research Unit<BR/>2): Department of Obstetrics and Gynecology, Irccs<BR/>H S. Raffaele Milano, Italy</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-12-23 13:05:38 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>D'angelo A,Valsecchi L; A double-blind trial of high-dose antithrombin supplementation in early pre-eclampsia. Thrombosis Research. 2005; 115 Suppl 1:117</P>
<P>Prof. Dr. Armando D'Angelo was contacted 9th April 2015 and answer the same day. The trial results will be published in the near future.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>AT III = Antithrombin III; EPAS = Early pre-eclampsia antithrombin trial; IU = international unit</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-12-23 14:39:59 +0000" MODIFIED_BY="Mikkel Allingstrup">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-12-23 14:39:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:39:16 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Albert-1992">
<DESCRIPTION>
<P>Random computer number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:41:17 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Balk-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:13 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Baudo-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:43:03 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Baudo-1998">
<DESCRIPTION>
<P>Randomization was balanced within each centre by coded envelopes centrally provided and centrally generated by computer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 07:45:15 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Blauhut-1985">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 07:46:40 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Diaz_x002d_Cremades-1994">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 07:56:48 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Eisele-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fourrier-1993">
<DESCRIPTION>
<P>Central computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:48:00 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fulia-2003">
<DESCRIPTION>
<P>Central number generation (computer)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-29 12:07:13 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Gando-2013">
<DESCRIPTION>
<P>Web-based randomization was generated by the University Hospital Medical Information Network centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 08:40:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grenander-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:11:08 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Haire-1998">
<DESCRIPTION>
<P>Computer-generated list of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:56:22 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Harper-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:57:46 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Inthorn-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Kobayashi-2003">
<DESCRIPTION>
<P>A central 24-hrs registration service</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:59:35 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Langely-1993">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:28 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Lavrentieva-2008">
<DESCRIPTION>
<P>Randomly-generated zeros and ones according to SPSS 14 statistical software</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:28 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Maki-2000">
<DESCRIPTION>
<P>24 hrs registration service (randomization co-ordinating centre)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Mitchell-2003">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-26 16:55:43 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Muntean-1989">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 08:40:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neporada-2008A">
<DESCRIPTION>
<P>Randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Nishiyama-2011">
<DESCRIPTION>
<P>Participants were stratified randomly into 2 groups using an envelope method. No further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 10:24:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Palareti-1995">
<DESCRIPTION>
<P>Randomized, but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Schmidt-1998">
<DESCRIPTION>
<P>Computer programme developed by Hoechst AG</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schorr-2000">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:33:27 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schuster-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:09:14 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Smith_x002d_Erichsen-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 08:40:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vorobyeva-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Warren-2001">
<DESCRIPTION>
<P>Phone to a randomization centre, available on a 24-hr basis. Randomization plans had been prepared in advance with a block size of 4 participants and investigators were told the medication package number to be used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:13:16 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Waydhas-1998">
<DESCRIPTION>
<P>Computer number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-12-23 14:39:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:39:16 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Albert-1992">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:13 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Balk-1995">
<DESCRIPTION>
<P>Double-blinded but no additional information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:14 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Baudo-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:43:03 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Baudo-1998">
<DESCRIPTION>
<P>Randomization was balanced within each centre by coded envelopes centrally provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 07:45:16 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Blauhut-1985">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 07:46:47 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Diaz_x002d_Cremades-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 07:56:51 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Eisele-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fourrier-1993">
<DESCRIPTION>
<P>Central computer-generated with central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:48:00 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fulia-2003">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-29 12:07:20 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Gando-2013">
<DESCRIPTION>
<P>Web-based allocation ratio of 1:1 for the control and antithrombin groups was generated by the University Hospital Medical Information Network centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:24 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Grenander-2001">
<DESCRIPTION>
<P>Sealed randomization envelopes were opened in numerical order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:54:45 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Haire-1998">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:56:25 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Harper-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:57:46 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Inthorn-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:58:36 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Kobayashi-2003">
<DESCRIPTION>
<P>A randomization envelope in order to allocate the drug treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:59:35 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Langely-1993">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:24:14 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Lavrentieva-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:01:09 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Maki-2000">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:03:13 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Mitchell-2003">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-26 16:56:01 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Muntean-1989">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:04:26 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Neporada-2008A">
<DESCRIPTION>
<P>State envelope method. No further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 08:40:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishiyama-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 08:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palareti-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:06:28 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Schmidt-1998">
<DESCRIPTION>
<P>Adequate strata and central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schorr-2000">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:33:28 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schuster-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:09:14 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Smith_x002d_Erichsen-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 08:40:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vorobyeva-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Warren-2001">
<DESCRIPTION>
<P>Packages for individual participants consisted of vials and labels identical in appearance for antithrombin III and placebo. Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:42:11 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Waydhas-1998">
<DESCRIPTION>
<P>Closed envelopes that had been prepared in blocks of 10, each block containing 5 decisions for placebo and 5 for the test substance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-02-13 17:39:46 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-12-23 14:39:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-16 08:40:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albert-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-08-05 15:41:21 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Balk-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:14 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Baudo-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:21 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Baudo-1998">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-17 07:45:18 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Blauhut-1985">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-17 07:46:55 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Diaz_x002d_Cremades-1994">
<DESCRIPTION>
<P>Open, unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-17 07:56:54 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Eisele-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fourrier-1993">
<DESCRIPTION>
<P>The treatment-allocation code, randomization, preparation of AT III, and placebo vials were designed and conducted by a co-ordinator blinded to clinical data and patients&#8217; inclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fulia-2003">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Gando-2013">
<DESCRIPTION>
<P>Open-label trial. Neither the physicians nor the patients were blinded to the treatment assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-16 08:40:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Grenander-2001">
<DESCRIPTION>
<P>Not blinded. Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-28 12:58:22 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Haire-1998">
<DESCRIPTION>
<P>An unblinded research pharmacist reconstituted the requisite volume of trial drug and provided it to the ward personnel in unmarked containers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:26 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Harper-1991">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-08-05 15:57:46 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Inthorn-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Kobayashi-2003">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-08-05 15:59:35 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Langely-1993">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-16 08:40:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lavrentieva-2008">
<DESCRIPTION>
<P>No blinding of participants and personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:28 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Maki-2000">
<DESCRIPTION>
<P>Double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-16 08:40:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mitchell-2003">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Muntean-1989">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Neporada-2008A">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-28 12:58:23 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Nishiyama-2011">
<DESCRIPTION>
<P>Single-blinded trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-16 08:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palareti-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-17 08:31:15 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Schmidt-1998">
<DESCRIPTION>
<P>Adequate blinding on all levels</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-16 08:40:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schorr-2000">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-17 08:33:30 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schuster-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-08-05 16:09:14 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Smith_x002d_Erichsen-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-16 08:40:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vorobyeva-2007">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Warren-2001">
<DESCRIPTION>
<P>Double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-28 12:58:24 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Waydhas-1998">
<DESCRIPTION>
<P>The envelopes were opened by a person not involved in the care of the patient or the collection of the data. This person also prepared the test infusion. The attending team and the trial group were thus blinded to the type of substance given to the patient.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-12-23 14:39:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-08-05 15:39:52 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Albert-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-08-05 15:41:23 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Balk-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:20 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Baudo-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-16 10:07:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baudo-1998">
<DESCRIPTION>
<P>The attending physicians, evaluating the clinical course, were blind to treatment allocation and to sequential measurements of ATIII levels. Bottles, syringes, and infusion sets were black and identical. The analysis was carried out before the codes were broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-17 07:45:19 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Blauhut-1985">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-24 17:25:12 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Diaz_x002d_Cremades-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-17 07:56:56 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Eisele-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:22 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fourrier-1993">
<DESCRIPTION>
<P>Clinical analysis was done by physicians blinded to the treatment allocation and results of AT III measurements.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fulia-2003">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-16 08:40:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gando-2013">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:24 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Grenander-2001">
<DESCRIPTION>
<P>Open-label. No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:25 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Haire-1998">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:26 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Harper-1991">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-08-05 15:57:46 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Inthorn-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Kobayashi-2003">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-08-05 15:59:35 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Langely-1993">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-16 08:40:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lavrentieva-2008">
<DESCRIPTION>
<P>No blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:29 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Maki-2000">
<DESCRIPTION>
<P>Double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-08-05 16:03:13 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Mitchell-2003">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:31 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Muntean-1989">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-16 08:40:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neporada-2008A">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-16 08:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishiyama-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-16 08:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palareti-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Schmidt-1998">
<DESCRIPTION>
<P>Double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-22 22:58:44 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Schorr-2000">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-17 08:33:31 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schuster-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-08-05 16:09:14 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Smith_x002d_Erichsen-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-16 08:40:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vorobyeva-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Warren-2001">
<DESCRIPTION>
<P>Double-blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-23 13:05:36 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Waydhas-1998">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-12-23 14:39:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:13 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Albert-1992">
<DESCRIPTION>
<P>No withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-05 15:41:14 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Balk-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:20 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Baudo-1992">
<DESCRIPTION>
<P>No withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:21 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Baudo-1998">
<DESCRIPTION>
<P>No withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-22 22:03:20 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Blauhut-1985">
<DESCRIPTION>
<P>Unable to retrieve relevant data on mortality</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-22 22:31:25 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Diaz_x002d_Cremades-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-05 15:46:13 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Eisele-1998">
<DESCRIPTION>
<P>No indications of incomplete data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-05 15:47:16 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fourrier-1993">
<DESCRIPTION>
<P>No indications of incomplete data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fulia-2003">
<DESCRIPTION>
<P>No withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Gando-2013">
<DESCRIPTION>
<P>No withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:24 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Grenander-2001">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:25 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Haire-1998">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-22 22:31:51 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Harper-1991">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:26 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Inthorn-1997">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Kobayashi-2003">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Langely-1993">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:28 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Lavrentieva-2008">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:29 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Maki-2000">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-17 08:26:10 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Mitchell-2003">
<DESCRIPTION>
<P>Incomplete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-05 16:03:36 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Muntean-1989">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Neporada-2008A">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Nishiyama-2011">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-16 08:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palareti-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Schmidt-1998">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Schorr-2000">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-17 08:33:32 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schuster-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:34 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Smith_x002d_Erichsen-1996">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Vorobyeva-2007">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Warren-2001">
<DESCRIPTION>
<P>Reason for dropouts specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-23 13:05:37 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Waydhas-1998">
<DESCRIPTION>
<P>No dropouts or withdrawals were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-12-23 14:39:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 08:40:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albert-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:41:14 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Balk-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:20 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Baudo-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:21 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Baudo-1998">
<DESCRIPTION>
<P>Published paper appears to include all outcomes expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 10:08:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blauhut-1985">
<DESCRIPTION>
<P>No information or protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-24 17:26:19 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Diaz_x002d_Cremades-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 07:57:07 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Eisele-1998">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:47:16 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fourrier-1993">
<DESCRIPTION>
<P>All outcomes assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:23 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fulia-2003">
<DESCRIPTION>
<P>All expected outcomes appear included.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:24 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Gando-2013">
<DESCRIPTION>
<P>Trial registration available on UMIN Clinical Trials Registry. Protocol not published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:24 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Grenander-2001">
<DESCRIPTION>
<P>Published report appears to repot all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-14 16:56:05 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Haire-1998">
<DESCRIPTION>
<P>Unable to assess adequately but published report does not appear to exclude outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:12:32 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Harper-1991">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:57:46 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Inthorn-1997">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:27 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Kobayashi-2003">
<DESCRIPTION>
<P>Published report include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:23:04 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Langely-1993">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:28 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Lavrentieva-2008">
<DESCRIPTION>
<P>Protocol or trial registration not available. The trial was not registered online according to the author.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:29 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Maki-2000">
<DESCRIPTION>
<P>Published report includes all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:26:20 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-2003">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:03:36 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Muntean-1989">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Neporada-2008A">
<DESCRIPTION>
<P>Protocol or trial registration not available. The trial was not registered online according to the author.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-28 12:28:48 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Nishiyama-2011">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-16 08:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palareti-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:06:53 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Schmidt-1998">
<DESCRIPTION>
<P>Appears to report on all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:32:13 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schorr-2000">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:33:33 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schuster-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-17 08:34:48 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Smith_x002d_Erichsen-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:10:21 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Vorobyeva-2007">
<DESCRIPTION>
<P>Unable to assess</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:11:23 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Warren-2001">
<DESCRIPTION>
<P>Reported outcomes prespecified in an available study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:13:30 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Waydhas-1998">
<DESCRIPTION>
<P>Appears to include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2015-11-13 19:49:13 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="9">
<NAME>Funding bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-12-23 14:39:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-13 19:40:58 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Albert-1992">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:41:27 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Balk-1995">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:20 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Baudo-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:43:12 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Baudo-1998">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:44:27 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Blauhut-1985">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:35:12 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Diaz_x002d_Cremades-1994">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:46:13 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Eisele-1998">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-13 19:42:54 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fourrier-1993">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:48:17 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Fulia-2003">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Gando-2013">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 15:54:07 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Grenander-2001">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:25 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Haire-1998">
<DESCRIPTION>
<P>Appears to be free of other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:37:18 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Harper-1991">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:37:36 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Inthorn-1997">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:38:13 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Kobayashi-2003">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:38:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Langely-1993">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:39:03 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Lavrentieva-2008">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:39:22 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Maki-2000">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:03:13 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-2003">
<DESCRIPTION>
<P>Unabel to assess adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-26 16:57:23 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Muntean-1989">
<DESCRIPTION>
<P>Only published as abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:32 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Neporada-2008A">
<DESCRIPTION>
<P>Baseline and design questions remain unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:05:10 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Nishiyama-2011">
<DESCRIPTION>
<P>Unable to assess adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:44:36 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Palareti-1995">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:41:07 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Schmidt-1998">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:41:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schorr-2000">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:41:57 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Schuster-1997">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 17:42:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Smith_x002d_Erichsen-1996">
<DESCRIPTION>
<P>Unable to assess, insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-23 13:05:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Vorobyeva-2007">
<DESCRIPTION>
<P>Country: Russia</P>
<P>Abstracts and article were written in Russian. Poorly-described section of participants, inclusion criteria, outcome and intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:11:57 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Warren-2001">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 16:13:40 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Waydhas-1998">
<DESCRIPTION>
<P>Appears free of such biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-12-23 15:08:01 +0000" MODIFIED_BY="Mikkel Allingstrup">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-12-23 15:08:01 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="1">
<TITLE MODIFIED="2015-08-07 12:42:48 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="25">
<TR>
<TD COLSPAN="7">
<P>
<B>AT III compared to control for critically ill patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Setting</B>: Worldwide<BR/>
<B>Intervention</B>: AT III<BR/>
<B>Comparison</B>: Control</P>
<P>
<B>Patient or population</B>: critically ill participants</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Anticipated absolute effects<SUP>*</SUP> </B>(95% CI) </P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Risk with control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Risk with AT III</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Mortality (subgroup analysis on bias risk)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population </B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.95</B>
<BR/>(0.88 to 1.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>3882<BR/>(29 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>9 trials had low risk of bias, 20 trials high risk of bias.</P>
<P>Trial sequential analysis (TSA) adjusted RR 0.95 (95% CI 0.87 to 1.04).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>385 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>366 per 1000</B>
<BR/>(339 to 396)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate </B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>310 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>295 per 1000</B>
<BR/>(273 to 320)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Bleeding events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population </B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.58</B> (1.35 to 1.84)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>3019<BR/>(11 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>
<B>moderate<SUP>3</SUP>
</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>6 trials had low risk of bias, 5 trials high risk of bias. Based on the TSA analysis, there seem to be evidence indicating that AT III increases risk of bleeding (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>). TSA adjusted meta-analysis yields a RR of 1.85 (95% CI 1.35 to 1.85).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>385 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>366 per 1000</B>
<BR/>(339 to 396)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate </B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>102 per 1000</B>
<BR/>(87 to 119)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Incidence of respiratory failure not present at admission</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.93</B>
<BR/>(0.76 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2591<BR/>(6 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>1,4</SUP>
</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>5 trials had low risk of bias, 1 trial high risk of bias.</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>106 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>98 per 1000</B>
<BR/>(80 to 120)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate </B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>317 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>294 per 1000</B>
<BR/>(241 to 361)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Duration of mechanical ventilation</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>The mean duration of mechanical ventilation in the intervention group was 2.2 more (1.21 fewer to 5.6 more)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>190<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>5</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2 trials had low risk of bias, 1 trial high risk of bias</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Length of stay in hospital</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>The mean length of stay in hospital in the intervention group was 1.1 more (7.16 fewer to 9.36 more)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>202<BR/>(4 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>6</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2 trials had low risk of bias, 2 trials high risk of bias</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean length of stay in ICU</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>The mean length of stay in ICU in the intervention group was 0.24 more (1.34 fewer to 1.83 more)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>376<BR/>(7 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,7</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>3 trials had low risk of bias, 4 trials high risk of bias</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Overall mortality among patients with severe sepsis &amp; DIC</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.95</B>
</P>
<P>(0.88 to 1.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2858<BR/>(12 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,8</SUP>
</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>4 trials had low risk of bias, 8 trials high risk of bias</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>462 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>439 per 1000</B>
<BR/>(407 to 476)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate </B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>392 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>372 per 1000</B>
<BR/>(345 to 404)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>With the exception of <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK> there was a high risk of bias in all trials.</P>
<P>
<SUP>2</SUP>The entry refers to trials in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. The outcome was downgraded two levels because of the substantial number of trials with high risk of bias but TSA led to an upgrade of one level to <I>moderate quality of evidence,</I> indicating no benefit for survival. The choice for this TSA upgrade was based on increased precision with continuity correction for zero event trials, adjustment for the risk of random error, a calculation of the required information size leading to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials.</P>
<P>
<SUP>3</SUP>The entry refers to trials in <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>. The outcome was downgraded from high to <I>moderate quality of evidence</I> because majority of trials had high risk of bias.</P>
<P>
<SUP>4</SUP>The entry refers to trials in <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>. The outcome was downgraded from high to <I>moderate quality of evidence</I> since one large trial provided most of the data (<LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>).</P>
<P>
<SUP>5</SUP>The entry refers to trials in <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>. The outcome was downgraded from high to <I>very low quality of evidence</I> because of a small number of trials, high risk of bias, a small numbers of participants and imprecision of results with a wide confidence interval.</P>
<P>
<SUP>6</SUP>The entry refers to trials in <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>. The outcome was downgraded from high to <I>very low quality of evidence</I> because of a small number of trials, high risk of bias, a small numbers of participants and imprecision of results with a wide confidence interval.</P>
<P>
<SUP>7</SUP>The entry refers to trials in <LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>. The outcome was downgraded from high to <I>very low quality of evidence</I> because of a small number of trials, most of them with high risk of bias.</P>
<P>
<SUP>8</SUP>The entry refers to trials in <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>. The outcome was downgraded from high to <I>very low quality of evidence</I> because of numerous trials with high risk of bias. The vast majority of trials were small and poorly described.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-01-02 13:24:02 +0000" MODIFIED_BY="Mikkel Allingstrup">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-01-02 13:24:02 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="1">
<TITLE MODIFIED="2015-11-17 14:11:17 +0000" MODIFIED_BY="Mikkel Allingstrup">Subgroup analysis (Overall mortality)</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD>
<P/>
</TD>
<TD>
<P>AT III</P>
<P>n/N</P>
</TD>
<TD>
<P>Control</P>
<P>n/N</P>
</TD>
<TD>
<P>Low risk of bias trials</P>
<P>RR (95% CI)</P>
</TD>
<TD>
<P>High risk of bias trials</P>
<P>RR (95% CI)</P>
</TD>
<TD>
<P>Overall RR (95% CI)</P>
</TD>
<TD>
<P>Heterogeneity</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall mortality (subgroup analysis on random sequence generation)<SUP>1</SUP>
</P>
</TD>
<TD>
<P>720/1915</P>
</TD>
<TD>
<P>757/1967</P>
</TD>
<TD>
<P>0.95 (0.88 to 1.03)</P>
</TD>
<TD>
<P>0.98 (0.79 to 1.21)</P>
</TD>
<TD>
<P>0.95 (0.88 to 1.03)</P>
</TD>
<TD>
<P>I² = 0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall mortality (subgroup analysis on allocation concealment)<SUP>2</SUP>
</P>
</TD>
<TD>
<P>720/1915</P>
</TD>
<TD>
<P>757/1967</P>
</TD>
<TD>
<P>0.96 (0.88 to 1.04)</P>
</TD>
<TD>
<P>0.93 (0.75 to 1.15)</P>
</TD>
<TD>
<P>0.95 (0.88 to 1.03)</P>
</TD>
<TD>
<P>I² = 0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall mortality (subgroup analysis on blinding)<SUP>3</SUP>
</P>
</TD>
<TD>
<P>720/1915</P>
</TD>
<TD>
<P>757/1967</P>
</TD>
<TD>
<P>0.96 (0.88 to 1.04)</P>
</TD>
<TD>
<P>0.94 (0.77 to 1.14)</P>
</TD>
<TD>
<P>0.95 (0.88 to 1.03)</P>
</TD>
<TD>
<P>I² = 0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall mortality (subgroup analysis on completeness of follow-up)<SUP>4</SUP>
</P>
</TD>
<TD>
<P>720/1915</P>
</TD>
<TD>
<P>757/1967</P>
</TD>
<TD>
<P>0.95 (0.88 to 1.02)</P>
</TD>
<TD>
<P>1.08 (0.77 to 1.51)</P>
</TD>
<TD>
<P>0.95 (0.88 to 1.03)</P>
</TD>
<TD>
<P>I² = 0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall mortality (subgroup analysis on ITT)<SUP>5</SUP>
</P>
</TD>
<TD>
<P>705/1856</P>
</TD>
<TD>
<P>736/1895</P>
</TD>
<TD>
<P>0.98 (0.79 to 1.22)</P>
</TD>
<TD>
<P>0.95 (0.88 to 1.03)</P>
</TD>
<TD>
<P>0.95 (0.88 to 1.03)</P>
</TD>
<TD>
<P>I² = 0%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Low risk of bias trials (adequate random sequence generation): <LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>. High risk of bias trials (inadequate or unclear random sequence generation): <LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>.</P>
<P>
<SUP>2</SUP>Low risk of bias trials (adequate allocation concealment): <LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>. High risk of bias trials (inadequate or unclear allocation concealment): <LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>
</P>
<P>
<SUP>3</SUP>Low risk of bias trials (blinded): <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>. High risk of bias trials (not blinded or unclear blinding): <LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>
</P>
<P>
<SUP>4</SUP>Low risk of bias trials (complete follow-up): <LINK REF="STD-Balk-1995" TYPE="STUDY">Balk 1995</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Palareti-1995" TYPE="STUDY">Palareti 1995</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>. High risk of bias trials (absence of complete follow-up): <LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Vorobyeva-2007" TYPE="STUDY">Vorobyeva 2007</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>.</P>
<P>
<SUP>5</SUP>Low risk of bias trials (ITT): <LINK REF="STD-Baudo-1992" TYPE="STUDY">Baudo 1992</LINK>; <LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>; <LINK REF="STD-Fourrier-1993" TYPE="STUDY">Fourrier 1993</LINK>; <LINK REF="STD-Fulia-2003" TYPE="STUDY">Fulia 2003</LINK>; <LINK REF="STD-Gando-2013" TYPE="STUDY">Gando 2013</LINK>; <LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>; <LINK REF="STD-Harper-1991" TYPE="STUDY">Harper 1991</LINK>; <LINK REF="STD-Inthorn-1997" TYPE="STUDY">Inthorn 1997</LINK>; <LINK REF="STD-Langely-1993" TYPE="STUDY">Langely 1993</LINK>; <LINK REF="STD-Maki-2000" TYPE="STUDY">Maki 2000</LINK>; <LINK REF="STD-Schmidt-1998" TYPE="STUDY">Schmidt 1998</LINK>; <LINK REF="STD-Schorr-2000" TYPE="STUDY">Schorr 2000</LINK>; <LINK REF="STD-Smith_x002d_Erichsen-1996" TYPE="STUDY">Smith-Erichsen 1996</LINK>; <LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>; <LINK REF="STD-Waydhas-1998" TYPE="STUDY">Waydhas 1998</LINK>. High risk of bias trials (no ITT): <LINK REF="STD-Albert-1992" TYPE="STUDY">Albert 1992</LINK>; <LINK REF="STD-Baudo-1998" TYPE="STUDY">Baudo 1998</LINK>; <LINK REF="STD-Diaz_x002d_Cremades-1994" TYPE="STUDY">Diaz-Cremades 1994</LINK>; <LINK REF="STD-Grenander-2001" TYPE="STUDY">Grenander 2001</LINK>; <LINK REF="STD-Kobayashi-2003" TYPE="STUDY">Kobayashi 2003</LINK>; <LINK REF="STD-Lavrentieva-2008" TYPE="STUDY">Lavrentieva 2008</LINK>; <LINK REF="STD-Mitchell-2003" TYPE="STUDY">Mitchell 2003</LINK>; <LINK REF="STD-Muntean-1989" TYPE="STUDY">Muntean 1989</LINK>; <LINK REF="STD-Neporada-2008A" TYPE="STUDY">Neporada 2008A</LINK>; <LINK REF="STD-Nishiyama-2011" TYPE="STUDY">Nishiyama 2011</LINK>; <LINK REF="STD-Schuster-1997" TYPE="STUDY">Schuster 1997</LINK>.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-12-29 20:31:19 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="2">
<TITLE MODIFIED="2015-12-23 14:56:18 +0000" MODIFIED_BY="Mikkel Allingstrup">Secondary outcomes; refers to 'Data and analyses' 1.11; 1.12; 1.13; 1.14; 1.16; 1.19</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TD>
<P>Secondary outcomes</P>
</TD>
<TD>
<P>AT III</P>
<P>n/N</P>
</TD>
<TD>
<P>Control</P>
<P>n/N</P>
</TD>
<TD>
<P>Low risk of bias trials</P>
<P>RR (95% CI)</P>
</TD>
<TD>
<P>High risk of bias trials</P>
<P>RR (95% CI)</P>
</TD>
<TD>
<P>Overall RR (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>: Intracranial bleeding</P>
</TD>
<TD>
<P>36/1226</P>
</TD>
<TD>
<P>26/1228</P>
</TD>
<TD>
<P>1.62 (0.96 to 2.73)</P>
</TD>
<TD>
<P>0.92 (0.51 to 1.66)</P>
</TD>
<TD>
<P>1.26 (0.83 to 1.92)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>: Renal failure</P>
</TD>
<TD>
<P>2/33</P>
</TD>
<TD>
<P>3/32</P>
</TD>
<TD>
<P>3.00 (0.13 to 69.52)</P>
</TD>
<TD>
<P>0.31 (0.04 to 2.57)</P>
</TD>
<TD>
<P>0.71 (0.08 to 6.11)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>: Complications other than bleeding</P>
</TD>
<TD>
<P>14/75</P>
</TD>
<TD>
<P>33/112</P>
</TD>
<TD>
<P>0.75 (0.18 to 3.07)</P>
</TD>
<TD>
<P>0.72 (0.40 to1.30)</P>
</TD>
<TD>
<P>0.72 (0.42 to 1.25)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>: Bleeding events</P>
</TD>
<TD>
<P>317/1492</P>
</TD>
<TD>
<P>201/1527</P>
</TD>
<TD>
<P>1.58 (1.35 to 1.85)</P>
</TD>
<TD>
<P>1.57 (0.71 to 3.49)</P>
</TD>
<TD>
<P>1.58 (1.35 to 1.84)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>: Incidence of surgical intervention</P>
</TD>
<TD>
<P>31/51</P>
</TD>
<TD>
<P>30/52</P>
</TD>
<TD>
<P>1.04 (0.85 to 1.27)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>1.04 (0.85 to 1.27)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>: Respiratory failure not present at admission</P>
</TD>
<TD>
<P>115/1293</P>
</TD>
<TD>
<P>137/1298</P>
</TD>
<TD>
<P>0.97 (0.77 to 1.22)</P>
</TD>
<TD>
<P>0.73 (0.45 to 1.18)</P>
</TD>
<TD>
<P>0.93 (0.76 to 1.14)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="3">
<TITLE MODIFIED="2015-07-21 03:31:18 +0100" MODIFIED_BY="Jane Cracknell">Severity of sepsis III</TITLE>
<TABLE COLS="8" ROWS="3">
<TR>
<TD>
<P>Trial</P>
</TD>
<TD COLSPAN="3">
<P>AT III</P>
</TD>
<TD COLSPAN="3">
<P>Control</P>
</TD>
<TD>
<P>Mean Difference</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Mean</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>SD</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Total</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Mean</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>SD</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Total</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>IV, Fixed, 95% CI</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<LINK REF="STD-Eisele-1998" TYPE="STUDY">Eisele 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.7</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>13</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-0.20 (-0.66 to 0.26)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Subgroup analysis where only one trial had the relevant endpoints.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="4">
<TITLE MODIFIED="2015-07-21 03:31:18 +0100" MODIFIED_BY="Jane Cracknell">Subjective overall quality of life assessment</TITLE>
<TABLE COLS="8" ROWS="3">
<TR>
<TD ALIGN="LEFT">
<P>Trial</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="3">
<P>At III</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="3">
<P>Control</P>
</TD>
<TD ALIGN="LEFT">
<P>Mean Difference</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Mean</P>
</TD>
<TD ALIGN="CENTER">
<P>SD</P>
</TD>
<TD ALIGN="CENTER">
<P>Total</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean</P>
</TD>
<TD ALIGN="CENTER">
<P>SD</P>
</TD>
<TD ALIGN="CENTER">
<P>Total</P>
</TD>
<TD ALIGN="CENTER">
<P>IV, Fixed, 95% CI</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>47</P>
</TD>
<TD ALIGN="CENTER">
<P>23</P>
</TD>
<TD ALIGN="CENTER">
<P>460</P>
</TD>
<TD ALIGN="CENTER">
<P>49</P>
</TD>
<TD ALIGN="CENTER">
<P>23</P>
</TD>
<TD ALIGN="CENTER">
<P>437</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.00 (-5.01 to 1.01)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Subgroup analysis where only one trial had the relevant endpoints.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="5">
<TITLE MODIFIED="2015-07-21 03:31:18 +0100" MODIFIED_BY="Jane Cracknell">Objective assessment of physical performance and dependency (Karnofsky)</TITLE>
<TABLE COLS="8" ROWS="3">
<TR>
<TD>
<P>Trial</P>
</TD>
<TD COLSPAN="3">
<P>AT III</P>
</TD>
<TD COLSPAN="3">
<P>Control</P>
</TD>
<TD>
<P>Mean Difference</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Mean</P>
</TD>
<TD ALIGN="CENTER">
<P>SD</P>
</TD>
<TD ALIGN="CENTER">
<P>Total</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean</P>
</TD>
<TD ALIGN="CENTER">
<P>SD</P>
</TD>
<TD ALIGN="CENTER">
<P>Total</P>
</TD>
<TD ALIGN="CENTER">
<P>IV, Fixed, 95% CI</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Warren-2001" TYPE="STUDY">Warren 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>53</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER">
<P>460</P>
</TD>
<TD ALIGN="CENTER">
<P>55</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER">
<P>437</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.00 (-4.49 to 0.49)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Subgroup analysis where only one trial had the relevant endpoints.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="6">
<TITLE MODIFIED="2015-10-22 14:59:27 +0100" MODIFIED_BY="Jane Cracknell">Severity of illness score</TITLE>
<TABLE COLS="8" ROWS="3">
<TR>
<TD>
<P>Trial</P>
</TD>
<TD COLSPAN="3">
<P>AT III</P>
</TD>
<TD COLSPAN="3">
<P>Control</P>
</TD>
<TD>
<P>Mean Difference</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Mean</P>
</TD>
<TD ALIGN="CENTER">
<P>SD</P>
</TD>
<TD ALIGN="CENTER">
<P>Total</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean</P>
</TD>
<TD ALIGN="CENTER">
<P>SD</P>
</TD>
<TD ALIGN="CENTER">
<P>Total</P>
</TD>
<TD ALIGN="CENTER">
<P>IV, Fixed, 95% CI</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Haire-1998" TYPE="STUDY">Haire 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>15.7</P>
</TD>
<TD ALIGN="CENTER">
<P>19.2</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>25.7</P>
</TD>
<TD ALIGN="CENTER">
<P>17.9</P>
</TD>
<TD ALIGN="CENTER">
<P>25</P>
</TD>
<TD ALIGN="CENTER">
<P>-10.00 (-20.40 to 0.40)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Subgroup analysis where only one trial had the relevant endpoints.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell">
<COMPARISON ID="CMP-001" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NO="1">
<NAME>AT III versus control</NAME>
<DICH_OUTCOME CHI2="16.14299607896699" CI_END="1.0291596534219445" CI_START="0.8848705087966382" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.954291897773657" ESTIMABLE="YES" EVENTS_1="720" EVENTS_2="757" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.012482752043093594" LOG_CI_START="-0.05312027894029315" LOG_EFFECT_SIZE="-0.020318763448599796" METHOD="MH" MODIFIED="2015-12-18 09:50:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9105037503408331" P_Q="0.8228867717873272" P_Z="0.22471276813522" Q="0.05010148829502023" RANDOM="NO" SCALE="189.2198557998494" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1915" TOTAL_2="1967" WEIGHT="100.00000000000003" Z="1.2140916043872874">
<NAME>Mortality (subgroup analysis on bias risk)</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.507507453073598" CI_END="1.0398484966313002" CI_START="0.8830476264944385" DF="6" EFFECT_SIZE="0.9582461828069443" ESTIMABLE="YES" EVENTS_1="598" EVENTS_2="625" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.016970068269915484" LOG_CI_START="-0.05401587245195436" LOG_EFFECT_SIZE="-0.018522902091019446" MODIFIED="2015-11-16 09:26:43 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.48055002470924824" P_Z="0.3063756397333842" STUDIES="9" TAU2="0.0" TOTAL_1="1457" TOTAL_2="1458" WEIGHT="82.71884555063241" Z="1.022856656356882">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="1.3256957751694363" CI_START="0.6629773334592302" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.1224438722406761" LOG_CI_START="-0.1785013194411632" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2015-06-25 20:50:29 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1" O_E="0.0" SE="0.17677669529663687" STUDY_ID="STD-Baudo-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.031249999999999997" WEIGHT="4.238886668041191"/>
<DICH_DATA CI_END="1.7127813243352565" CI_START="0.3959645533295018" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.23370191889266265" LOG_CI_START="-0.4023436902927345" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2015-06-25 20:50:30 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="2" O_E="0.0" SE="0.37361633931204574" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" VAR="0.13958916900093368" WEIGHT="1.1581243932326826"/>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-06-25 20:50:31 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="3" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Fulia-2003" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.26493041675257445"/>
<DICH_DATA CI_END="1.2479270939418843" CI_START="0.3593331359654989" EFFECT_SIZE="0.6696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09618921385312493" LOG_CI_START="-0.44450273241008803" LOG_EFFECT_SIZE="-0.1741567592784816" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="4" O_E="0.0" SE="0.31760512570331084" STUDY_ID="STD-Haire-1998" TOTAL_1="24" TOTAL_2="25" VAR="0.10087301587301586" WEIGHT="1.8166657148747962"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="6" O_E="0.0" SE="0.0" STUDY_ID="STD-Maki-2000" TOTAL_1="74" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.605569357503649" CI_START="0.6326652215866633" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9347796091949032" LOG_CI_START="-0.19882603860571438" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="7" O_E="0.0" SE="0.6658855689565396" STUDY_ID="STD-Schmidt-1998" TOTAL_1="61" TOTAL_2="61" VAR="0.4434035909445745" WEIGHT="0.3973956251288617"/>
<DICH_DATA CI_END="1.0411079701631492" CI_START="0.8768152318090525" EFFECT_SIZE="0.9554367201426025" ESTIMABLE="YES" EVENTS_1="536" EVENTS_2="561" LOG_CI_END="0.017495771215173817" LOG_CI_START="-0.05709191434195657" LOG_EFFECT_SIZE="-0.019798071563391383" MODIFIED="2015-08-16 18:36:53 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="8" O_E="0.0" SE="0.04381317571125655" STUDY_ID="STD-Warren-2001" TOTAL_1="1157" TOTAL_2="1157" VAR="0.0019195943659054409" WEIGHT="74.31298189909714"/>
<DICH_DATA CI_END="5.589897580584607" CI_START="0.7155766169836816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-11-16 09:26:43 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="20" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="0.5298608335051489"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.696866371227674" CI_END="1.1370014253296308" CI_START="0.7694854315598143" DF="18" EFFECT_SIZE="0.9353641175787614" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="132" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.05576100911377308" LOG_CI_START="-0.11379959812369904" LOG_EFFECT_SIZE="-0.029019294504962982" MODIFIED="2015-11-16 09:26:43 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.9067747785086557" P_Z="0.5023017770370237" STUDIES="20" TAU2="0.0" TOTAL_1="458" TOTAL_2="509" WEIGHT="17.281154449367612" Z="0.6708724746052811">
<NAME>Trials with high bias risk</NAME>
<DICH_DATA CI_END="2.445397859258201" CI_START="0.2617161038139376" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38834952768196396" LOG_CI_START="-0.5821695536980768" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2015-06-26 18:43:32 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="9" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-Albert-1992" TOTAL_1="16" TOTAL_2="16" VAR="0.325" WEIGHT="0.6623260418814361"/>
<DICH_DATA CI_END="9.504094853510903" CI_START="0.420871220421623" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.977910762038508" LOG_CI_START="-0.3758507707105457" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-06-01 12:05:38 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="290" O_E="0.0" SE="0.7952062255644573" STUDY_ID="STD-Balk-1995" TOTAL_1="17" TOTAL_2="17" VAR="0.6323529411764706" WEIGHT="0.26493041675257445"/>
<DICH_DATA CI_END="1.852723919459713" CI_START="0.032704125714532246" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.26781070847802796" LOG_CI_START="-1.4853974564518895" LOG_EFFECT_SIZE="-0.6087933739869308" MODIFIED="2015-06-26 18:43:32 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="10" O_E="0.0" SE="1.0298431546002154" STUDY_ID="STD-Baudo-1992" TOTAL_1="13" TOTAL_2="16" VAR="1.060576923076923" WEIGHT="0.593809554790253"/>
<DICH_DATA CI_END="2.869173173549007" CI_START="0.4371991246692082" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.45775676157713835" LOG_CI_START="-0.3593207162367751" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2015-06-26 18:43:33 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="11" O_E="0.0" SE="0.47995535506663833" STUDY_ID="STD-Diaz_x002d_Cremades-1994" TOTAL_1="20" TOTAL_2="16" VAR="0.23035714285714287" WEIGHT="0.7359178243127068"/>
<DICH_DATA CI_END="1.5184772305541139" CI_START="0.24594164641321434" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18140828409172643" LOG_CI_START="-0.6091679239818885" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2015-06-26 18:43:34 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="12" O_E="0.0" SE="0.46438837803778604" STUDY_ID="STD-Eisele-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.21565656565656566" WEIGHT="1.1354160717967476"/>
<DICH_DATA CI_END="3.51077932597227" CI_START="0.410165341167152" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.54540353224961" LOG_CI_START="-0.38704104015436036" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2015-11-16 09:26:21 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="577" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Gando-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="0.6623260418814361"/>
<DICH_DATA CI_END="77.58264493737863" CI_START="0.151517160188397" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8897645814270687" LOG_CI_START="-0.8195381780323703" LOG_EFFECT_SIZE="0.5351132016973492" MODIFIED="2015-06-26 18:43:34 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="13" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Grenander-2001" TOTAL_1="13" TOTAL_2="15" VAR="2.532738095238095" WEIGHT="0.061817097242267374"/>
<DICH_DATA CI_END="2.2648150660783553" CI_START="0.6350726771849305" EFFECT_SIZE="1.1993006993006994" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3550327453949" LOG_CI_START="-0.197176571567445" LOG_EFFECT_SIZE="0.07892808691372752" MODIFIED="2015-06-26 18:43:35 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="14" O_E="0.0" SE="0.3243704862638854" STUDY_ID="STD-Harper-1991" TOTAL_1="44" TOTAL_2="49" VAR="0.1052162123590695" WEIGHT="1.6294644987362643"/>
<DICH_DATA CI_END="1.1990340733435727" CI_START="0.550573386258422" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.07883152476259658" LOG_CI_START="-0.2591847854607726" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2015-06-26 18:43:36 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="15" O_E="0.0" SE="0.1985524538329278" STUDY_ID="STD-Inthorn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.03942307692307692" WEIGHT="2.1194433340205956"/>
<DICH_DATA CI_END="1.6839967374164937" CI_START="0.7558487395059267" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.22634124576019476" LOG_CI_START="-0.12156510684081832" LOG_EFFECT_SIZE="0.05238806945968822" MODIFIED="2015-06-26 18:43:36 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="16" O_E="0.0" SE="0.20436191368205514" STUDY_ID="STD-Langely-1993" TOTAL_1="13" TOTAL_2="12" VAR="0.04176379176379176" WEIGHT="1.2398743504020484"/>
<DICH_DATA CI_END="2.022360458515672" CI_START="0.006891508454313888" EFFECT_SIZE="0.11805555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.30585856529674815" LOG_CI_START="-2.1616857067306996" LOG_EFFECT_SIZE="-0.9279135707169758" MODIFIED="2015-06-26 18:43:37 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="609" O_E="0.0" SE="1.4494477199300628" STUDY_ID="STD-Lavrentieva-2008" TOTAL_1="15" TOTAL_2="16" VAR="2.100898692810458" WEIGHT="0.5780300001874351"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-26 20:14:57 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="17" O_E="0.0" SE="0.0" STUDY_ID="STD-Mitchell-2003" TOTAL_1="25" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.148592865493405" CI_START="0.5575903506739612" EFFECT_SIZE="1.325" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.49811650703194305" LOG_CI_START="-0.25368475048628975" LOG_EFFECT_SIZE="0.12221587827282664" MODIFIED="2015-06-26 20:15:16 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="382" O_E="0.0" SE="0.44161178014245384" STUDY_ID="STD-Muntean-1989" TOTAL_1="45" TOTAL_2="53" VAR="0.195020964360587" WEIGHT="0.9732137758257837"/>
<DICH_DATA CI_END="1.520874489743392" CI_START="0.42457615350315736" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.18209337535414225" LOG_CI_START="-0.37204440181585574" LOG_EFFECT_SIZE="-0.09497551323085672" MODIFIED="2015-06-26 18:43:40 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="356" O_E="0.0" SE="0.3255032733358928" STUDY_ID="STD-Neporada-2008A" TOTAL_1="28" TOTAL_2="15" VAR="0.10595238095238095" WEIGHT="1.3801026361064344"/>
<DICH_DATA CI_END="2.978685547154268" CI_START="0.149208245519253" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4740246581852024" LOG_CI_START="-0.8262071762965648" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-06-26 18:43:41 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="935" O_E="0.0" SE="0.7637626158259733" STUDY_ID="STD-Nishiyama-2011" TOTAL_1="8" TOTAL_2="8" VAR="0.5833333333333333" WEIGHT="0.3973956251288617"/>
<DICH_DATA CI_END="1.582047245986341" CI_START="0.2625134255812828" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.19921944905089536" LOG_CI_START="-0.5808484808036704" LOG_EFFECT_SIZE="-0.19081451587638756" MODIFIED="2015-06-25 20:50:47 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="327" O_E="0.0" SE="0.45821576339510056" STUDY_ID="STD-Palareti-1995" TOTAL_1="30" TOTAL_2="29" VAR="0.2099616858237548" WEIGHT="1.212393432596527"/>
<DICH_DATA CI_END="2.904573690925772" CI_START="0.40405623543916597" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4630823992858058" LOG_CI_START="-0.39355818676738197" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2015-06-26 18:43:47 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="18" O_E="0.0" SE="0.5031949206869324" STUDY_ID="STD-Schorr-2000" TOTAL_1="24" TOTAL_2="26" VAR="0.2532051282051282" WEIGHT="0.7629996002474144"/>
<DICH_DATA CI_END="1.8667096196429565" CI_START="0.47426225698922797" EFFECT_SIZE="0.9409090909090909" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.2710767655147337" LOG_CI_START="-0.3239814362453107" LOG_EFFECT_SIZE="-0.02645233536528848" MODIFIED="2015-06-25 21:13:24 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1125" O_E="0.0" SE="0.34954013329945455" STUDY_ID="STD-Schuster-1997" TOTAL_1="22" TOTAL_2="23" VAR="0.12217830478700045" WEIGHT="1.295215370790364"/>
<DICH_DATA CI_END="2.9554575520408863" CI_START="0.3985216544524382" EFFECT_SIZE="1.0852713178294573" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4706247261458107" LOG_CI_START="-0.3995480753878326" LOG_EFFECT_SIZE="0.03553832537898904" MODIFIED="2015-06-26 18:43:48 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="19" O_E="0.0" SE="0.511143811045699" STUDY_ID="STD-Smith_x002d_Erichsen-1996" TOTAL_1="43" TOTAL_2="40" VAR="0.26126799557032115" WEIGHT="0.8235186448453519"/>
<DICH_DATA CI_END="2.8241094577359798" CI_START="0.5130476095184937" EFFECT_SIZE="1.2037037037037037" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.45088152523015596" LOG_CI_START="-0.28984233159038175" LOG_EFFECT_SIZE="0.08051959681988707" MODIFIED="2015-06-26 18:43:49 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="337" O_E="0.0" SE="0.43510486013860994" STUDY_ID="STD-Vorobyeva-2007" TOTAL_1="12" TOTAL_2="26" VAR="0.18931623931623934" WEIGHT="0.7529601318231063"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.274967694434007" CI_END="1.0262390732552011" CI_START="0.8822302540044846" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9515141398146761" ESTIMABLE="YES" EVENTS_1="716" EVENTS_2="755" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.011248546059059318" LOG_CI_START="-0.05441805319792822" LOG_EFFECT_SIZE="-0.02158475356943444" METHOD="MH" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.9124545211109663" P_Q="0.7911246471993187" P_Z="0.19757585690373905" Q="0.07014578063084916" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1898" TOTAL_2="1950" WEIGHT="100.0" Z="1.288488823540292">
<NAME>Overall mortality (subgroup analysis on median follow-up)</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.768989700117805" CI_END="1.125141848068772" CI_START="0.7684328147097639" DF="16" EFFECT_SIZE="0.9298365002833735" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="138" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.05120727795861344" LOG_CI_START="-0.11439409755437978" LOG_EFFECT_SIZE="-0.03159340979788316" MODIFIED="2015-07-28 19:05:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8235148889373871" P_Z="0.45455464489318664" STUDIES="18" TAU2="0.0" TOTAL_1="487" TOTAL_2="537" WEIGHT="18.060414620345274" Z="0.747843369789008">
<NAME>Mortality in trials with follow up less than median of all trials</NAME>
<DICH_DATA CI_END="2.445397859258201" CI_START="0.2617161038139376" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38834952768196396" LOG_CI_START="-0.5821695536980768" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="121" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-Albert-1992" TOTAL_1="16" TOTAL_2="16" VAR="0.325" WEIGHT="0.6640854061154509"/>
<DICH_DATA CI_END="1.852723919459713" CI_START="0.032704125714532246" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.26781070847802796" LOG_CI_START="-1.4853974564518895" LOG_EFFECT_SIZE="-0.6087933739869308" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="122" O_E="0.0" SE="1.0298431546002154" STUDY_ID="STD-Baudo-1992" TOTAL_1="13" TOTAL_2="16" VAR="1.060576923076923" WEIGHT="0.5953869158276455"/>
<DICH_DATA CI_END="1.3256957751694363" CI_START="0.6629773334592302" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.1224438722406761" LOG_CI_START="-0.1785013194411632" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="123" O_E="0.0" SE="0.17677669529663687" STUDY_ID="STD-Baudo-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.031249999999999997" WEIGHT="4.250146599138885"/>
<DICH_DATA CI_END="2.869173173549007" CI_START="0.4371991246692082" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.45775676157713835" LOG_CI_START="-0.3593207162367751" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="124" O_E="0.0" SE="0.47995535506663833" STUDY_ID="STD-Diaz_x002d_Cremades-1994" TOTAL_1="20" TOTAL_2="16" VAR="0.23035714285714287" WEIGHT="0.737872673461612"/>
<DICH_DATA CI_END="1.5184772305541139" CI_START="0.24594164641321434" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18140828409172643" LOG_CI_START="-0.6091679239818885" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="125" O_E="0.0" SE="0.46438837803778604" STUDY_ID="STD-Eisele-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.21565656565656566" WEIGHT="1.1384321247693443"/>
<DICH_DATA CI_END="1.7127813243352565" CI_START="0.3959645533295018" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.23370191889266265" LOG_CI_START="-0.4023436902927345" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="126" O_E="0.0" SE="0.37361633931204574" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" VAR="0.13958916900093368" WEIGHT="1.161200767264731"/>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="127" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Fulia-2003" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.2656341624461803"/>
<DICH_DATA CI_END="3.51077932597227" CI_START="0.410165341167152" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.54540353224961" LOG_CI_START="-0.38704104015436036" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2015-06-22 10:25:09 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="302" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Gando-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="0.6640854061154509"/>
<DICH_DATA CI_END="2.2648150660783553" CI_START="0.6350726771849305" EFFECT_SIZE="1.1993006993006994" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3550327453949" LOG_CI_START="-0.197176571567445" LOG_EFFECT_SIZE="0.07892808691372752" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="128" O_E="0.0" SE="0.3243704862638854" STUDY_ID="STD-Harper-1991" TOTAL_1="44" TOTAL_2="49" VAR="0.1052162123590695" WEIGHT="1.6337929131098403"/>
<DICH_DATA CI_END="1.6839967374164937" CI_START="0.7558487395059267" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.22634124576019476" LOG_CI_START="-0.12156510684081832" LOG_EFFECT_SIZE="0.05238806945968822" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="129" O_E="0.0" SE="0.20436191368205514" STUDY_ID="STD-Langely-1993" TOTAL_1="13" TOTAL_2="12" VAR="0.04176379176379176" WEIGHT="1.2431678802481239"/>
<DICH_DATA CI_END="2.022360458515672" CI_START="0.006891508454313888" EFFECT_SIZE="0.11805555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.30585856529674815" LOG_CI_START="-2.1616857067306996" LOG_EFFECT_SIZE="-0.9279135707169758" MODIFIED="2015-06-03 12:46:04 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="615" O_E="0.0" SE="1.4494477199300628" STUDY_ID="STD-Lavrentieva-2008" TOTAL_1="15" TOTAL_2="16" VAR="2.100898692810458" WEIGHT="0.5795654453371206"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="130" O_E="0.0" SE="0.0" STUDY_ID="STD-Mitchell-2003" TOTAL_1="25" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.148592865493405" CI_START="0.5575903506739612" EFFECT_SIZE="1.325" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.49811650703194305" LOG_CI_START="-0.25368475048628975" LOG_EFFECT_SIZE="0.12221587827282664" MODIFIED="2015-06-26 17:12:41 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="388" O_E="0.0" SE="0.44161178014245384" STUDY_ID="STD-Muntean-1989" TOTAL_1="45" TOTAL_2="53" VAR="0.195020964360587" WEIGHT="0.9757989640880094"/>
<DICH_DATA CI_END="1.520874489743392" CI_START="0.42457615350315736" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.18209337535414225" LOG_CI_START="-0.37204440181585574" LOG_EFFECT_SIZE="-0.09497551323085672" MODIFIED="2015-06-22 10:25:23 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="362" O_E="0.0" SE="0.3255032733358928" STUDY_ID="STD-Neporada-2008A" TOTAL_1="28" TOTAL_2="15" VAR="0.10595238095238095" WEIGHT="1.3837686601847534"/>
<DICH_DATA CI_END="2.978685547154268" CI_START="0.149208245519253" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4740246581852024" LOG_CI_START="-0.8262071762965648" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-06-03 14:32:15 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="941" O_E="0.0" SE="0.7637626158259733" STUDY_ID="STD-Nishiyama-2011" TOTAL_1="8" TOTAL_2="8" VAR="0.5833333333333333" WEIGHT="0.3984512436692705"/>
<DICH_DATA CI_END="1.582047245986341" CI_START="0.2625134255812828" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.19921944905089536" LOG_CI_START="-0.5808484808036704" LOG_EFFECT_SIZE="-0.19081451587638756" MODIFIED="2015-06-04 07:54:58 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="332" O_E="0.0" SE="0.45821576339510056" STUDY_ID="STD-Palareti-1995" TOTAL_1="30" TOTAL_2="29" VAR="0.2099616858237548" WEIGHT="1.2156139637367576"/>
<DICH_DATA CI_END="8.605569357503649" CI_START="0.6326652215866633" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9347796091949032" LOG_CI_START="-0.19882603860571438" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="131" O_E="0.0" SE="0.6658855689565396" STUDY_ID="STD-Schmidt-1998" TOTAL_1="61" TOTAL_2="61" VAR="0.4434035909445745" WEIGHT="0.3984512436692705"/>
<DICH_DATA CI_END="2.8241094577359798" CI_START="0.5130476095184937" EFFECT_SIZE="1.2037037037037037" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.45088152523015596" LOG_CI_START="-0.28984233159038175" LOG_EFFECT_SIZE="0.08051959681988707" MODIFIED="2015-06-04 10:56:20 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="341" O_E="0.0" SE="0.43510486013860994" STUDY_ID="STD-Vorobyeva-2007" TOTAL_1="12" TOTAL_2="26" VAR="0.18931623931623934" WEIGHT="0.7549602511628283"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.68079542800089" CI_END="1.0381976496489322" CI_START="0.8808483170380419" DF="7" EFFECT_SIZE="0.9562921376055085" ESTIMABLE="YES" EVENTS_1="589" EVENTS_2="617" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.0162800413549527" LOG_CI_START="-0.05509887109411372" LOG_EFFECT_SIZE="-0.01940941486958048" MODIFIED="2015-06-22 10:27:11 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.6988512750407236" P_Z="0.28646427026828414" STUDIES="10" TAU2="0.0" TOTAL_1="1411" TOTAL_2="1413" WEIGHT="81.93958537965473" Z="1.0659101631036827">
<NAME>Mortality in trials with follow up longer than median of all trials</NAME>
<DICH_DATA CI_END="77.58264493737863" CI_START="0.151517160188397" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8897645814270687" LOG_CI_START="-0.8195381780323703" LOG_EFFECT_SIZE="0.5351132016973492" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="132" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Grenander-2001" TOTAL_1="13" TOTAL_2="15" VAR="2.532738095238095" WEIGHT="0.06198130457077541"/>
<DICH_DATA CI_END="1.2479270939418843" CI_START="0.3593331359654989" EFFECT_SIZE="0.6696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09618921385312493" LOG_CI_START="-0.44450273241008803" LOG_EFFECT_SIZE="-0.1741567592784816" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="133" O_E="0.0" SE="0.31760512570331084" STUDY_ID="STD-Haire-1998" TOTAL_1="24" TOTAL_2="25" VAR="0.10087301587301586" WEIGHT="1.8214913996309507"/>
<DICH_DATA CI_END="1.1990340733435727" CI_START="0.550573386258422" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.07883152476259658" LOG_CI_START="-0.2591847854607726" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="134" O_E="0.0" SE="0.1985524538329278" STUDY_ID="STD-Inthorn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.03942307692307692" WEIGHT="2.1250732995694426"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="135" O_E="0.0" SE="0.0" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Maki-2000" TOTAL_1="74" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.904573690925772" CI_START="0.40405623543916597" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4630823992858058" LOG_CI_START="-0.39355818676738197" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="137" O_E="0.0" SE="0.5031949206869324" STUDY_ID="STD-Schorr-2000" TOTAL_1="24" TOTAL_2="26" VAR="0.2532051282051282" WEIGHT="0.7650263878449993"/>
<DICH_DATA CI_END="1.8667096196429565" CI_START="0.47426225698922797" EFFECT_SIZE="0.9409090909090909" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.2710767655147337" LOG_CI_START="-0.3239814362453107" LOG_EFFECT_SIZE="-0.02645233536528848" MODIFIED="2015-06-22 10:27:11 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1148" O_E="0.0" SE="0.34954013329945455" STUDY_ID="STD-Schuster-1997" TOTAL_1="22" TOTAL_2="23" VAR="0.12217830478700045" WEIGHT="1.2986559052924371"/>
<DICH_DATA CI_END="2.9554575520408863" CI_START="0.3985216544524382" EFFECT_SIZE="1.0852713178294573" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4706247261458107" LOG_CI_START="-0.3995480753878326" LOG_EFFECT_SIZE="0.03553832537898904" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="138" O_E="0.0" SE="0.511143811045699" STUDY_ID="STD-Smith_x002d_Erichsen-1996" TOTAL_1="43" TOTAL_2="40" VAR="0.26126799557032115" WEIGHT="0.825706191700175"/>
<DICH_DATA CI_END="1.0411079701631492" CI_START="0.8768152318090525" EFFECT_SIZE="0.9554367201426025" ESTIMABLE="YES" EVENTS_1="536" EVENTS_2="561" LOG_CI_END="0.017495771215173817" LOG_CI_START="-0.05709191434195657" LOG_EFFECT_SIZE="-0.019798071563391383" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="139" O_E="0.0" SE="0.04381317571125655" STUDY_ID="STD-Warren-2001" TOTAL_1="1157" TOTAL_2="1157" VAR="0.0019195943659054409" WEIGHT="74.51038256615358"/>
<DICH_DATA CI_END="5.589897580584607" CI_START="0.7155766169836816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="140" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="0.5312683248923606"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.274967694434007" CI_END="1.0262390732552011" CI_START="0.8822302540044845" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RR" EFFECT_SIZE="0.951514139814676" ESTIMABLE="YES" EVENTS_1="716" EVENTS_2="755" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.011248546059059318" LOG_CI_START="-0.05441805319792827" LOG_EFFECT_SIZE="-0.02158475356943449" METHOD="MH" MODIFIED="2015-11-16 14:20:58 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="3" P_CHI2="0.9124545211109663" P_Q="0.7414534845852724" P_Z="0.19757585690373797" Q="0.10885328761642744" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1898" TOTAL_2="1950" WEIGHT="100.0" Z="1.2884888235402951">
<NAME>Overall mortality (subgroup analysis on duration of intervention)</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.562122315844235" CI_END="1.0296181873569739" CI_START="0.8828611243186534" DF="22" EFFECT_SIZE="0.9534200913075578" ESTIMABLE="YES" EVENTS_1="696" EVENTS_2="733" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.012676205418292199" LOG_CI_START="-0.05410760637203406" LOG_EFFECT_SIZE="-0.020715700476870935" MODIFIED="2015-07-28 19:05:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8803347139326608" P_Z="0.22401381659415665" STUDIES="25" TAU2="0.0" TOTAL_1="1810" TOTAL_2="1830" WEIGHT="97.04922050873039" Z="1.2159242115936713">
<NAME>Median duration of AT III intervention equal to or less than one week</NAME>
<DICH_DATA CI_END="2.445397859258201" CI_START="0.2617161038139376" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38834952768196396" LOG_CI_START="-0.5821695536980768" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="141" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-Albert-1992" TOTAL_1="16" TOTAL_2="16" VAR="0.325" WEIGHT="0.6640854061154509"/>
<DICH_DATA CI_END="1.852723919459713" CI_START="0.032704125714532246" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.26781070847802796" LOG_CI_START="-1.4853974564518895" LOG_EFFECT_SIZE="-0.6087933739869308" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="142" O_E="0.0" SE="1.0298431546002154" STUDY_ID="STD-Baudo-1992" TOTAL_1="13" TOTAL_2="16" VAR="1.060576923076923" WEIGHT="0.5953869158276455"/>
<DICH_DATA CI_END="1.3256957751694363" CI_START="0.6629773334592302" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.1224438722406761" LOG_CI_START="-0.1785013194411632" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="143" O_E="0.0" SE="0.17677669529663687" STUDY_ID="STD-Baudo-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.031249999999999997" WEIGHT="4.250146599138885"/>
<DICH_DATA CI_END="2.869173173549007" CI_START="0.4371991246692082" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.45775676157713835" LOG_CI_START="-0.3593207162367751" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="144" O_E="0.0" SE="0.47995535506663833" STUDY_ID="STD-Diaz_x002d_Cremades-1994" TOTAL_1="20" TOTAL_2="16" VAR="0.23035714285714287" WEIGHT="0.737872673461612"/>
<DICH_DATA CI_END="1.5184772305541139" CI_START="0.24594164641321434" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18140828409172643" LOG_CI_START="-0.6091679239818885" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="145" O_E="0.0" SE="0.46438837803778604" STUDY_ID="STD-Eisele-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.21565656565656566" WEIGHT="1.1384321247693443"/>
<DICH_DATA CI_END="1.7127813243352565" CI_START="0.3959645533295018" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.23370191889266265" LOG_CI_START="-0.4023436902927345" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="146" O_E="0.0" SE="0.37361633931204574" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" VAR="0.13958916900093368" WEIGHT="1.161200767264731"/>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="147" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Fulia-2003" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.2656341624461803"/>
<DICH_DATA CI_END="3.51077932597227" CI_START="0.410165341167152" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.54540353224961" LOG_CI_START="-0.38704104015436036" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2015-06-22 10:37:07 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="303" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Gando-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="0.6640854061154509"/>
<DICH_DATA CI_END="77.58264493737863" CI_START="0.151517160188397" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8897645814270687" LOG_CI_START="-0.8195381780323703" LOG_EFFECT_SIZE="0.5351132016973492" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="148" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Grenander-2001" TOTAL_1="13" TOTAL_2="15" VAR="2.532738095238095" WEIGHT="0.06198130457077541"/>
<DICH_DATA CI_END="1.2479270939418843" CI_START="0.3593331359654989" EFFECT_SIZE="0.6696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09618921385312493" LOG_CI_START="-0.44450273241008803" LOG_EFFECT_SIZE="-0.1741567592784816" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="149" O_E="0.0" SE="0.31760512570331084" STUDY_ID="STD-Haire-1998" TOTAL_1="24" TOTAL_2="25" VAR="0.10087301587301586" WEIGHT="1.8214913996309507"/>
<DICH_DATA CI_END="2.2648150660783553" CI_START="0.6350726771849305" EFFECT_SIZE="1.1993006993006994" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3550327453949" LOG_CI_START="-0.197176571567445" LOG_EFFECT_SIZE="0.07892808691372752" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="150" O_E="0.0" SE="0.3243704862638854" STUDY_ID="STD-Harper-1991" TOTAL_1="44" TOTAL_2="49" VAR="0.1052162123590695" WEIGHT="1.6337929131098403"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="151" O_E="0.0" SE="0.0" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6839967374164937" CI_START="0.7558487395059267" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.22634124576019476" LOG_CI_START="-0.12156510684081832" LOG_EFFECT_SIZE="0.05238806945968822" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="152" O_E="0.0" SE="0.20436191368205514" STUDY_ID="STD-Langely-1993" TOTAL_1="13" TOTAL_2="12" VAR="0.04176379176379176" WEIGHT="1.2431678802481239"/>
<DICH_DATA CI_END="2.022360458515672" CI_START="0.006891508454313888" EFFECT_SIZE="0.11805555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.30585856529674815" LOG_CI_START="-2.1616857067306996" LOG_EFFECT_SIZE="-0.9279135707169758" MODIFIED="2015-06-03 12:47:30 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="616" O_E="0.0" SE="1.4494477199300628" STUDY_ID="STD-Lavrentieva-2008" TOTAL_1="15" TOTAL_2="16" VAR="2.100898692810458" WEIGHT="0.5795654453371206"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="153" O_E="0.0" SE="0.0" STUDY_ID="STD-Maki-2000" TOTAL_1="74" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.148592865493405" CI_START="0.5575903506739612" EFFECT_SIZE="1.325" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.49811650703194305" LOG_CI_START="-0.25368475048628975" LOG_EFFECT_SIZE="0.12221587827282664" MODIFIED="2015-06-26 17:13:03 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="389" O_E="0.0" SE="0.44161178014245384" STUDY_ID="STD-Muntean-1989" TOTAL_1="45" TOTAL_2="53" VAR="0.195020964360587" WEIGHT="0.9757989640880094"/>
<DICH_DATA CI_END="1.520874489743392" CI_START="0.42457615350315736" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.18209337535414225" LOG_CI_START="-0.37204440181585574" LOG_EFFECT_SIZE="-0.09497551323085672" MODIFIED="2015-06-22 10:37:52 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="363" O_E="0.0" SE="0.3255032733358928" STUDY_ID="STD-Neporada-2008A" TOTAL_1="28" TOTAL_2="15" VAR="0.10595238095238095" WEIGHT="1.3837686601847534"/>
<DICH_DATA CI_END="2.978685547154268" CI_START="0.149208245519253" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4740246581852024" LOG_CI_START="-0.8262071762965648" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-06-03 14:33:17 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="942" O_E="0.0" SE="0.7637626158259733" STUDY_ID="STD-Nishiyama-2011" TOTAL_1="8" TOTAL_2="8" VAR="0.5833333333333333" WEIGHT="0.3984512436692705"/>
<DICH_DATA CI_END="1.582047245986341" CI_START="0.2625134255812828" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.19921944905089536" LOG_CI_START="-0.5808484808036704" LOG_EFFECT_SIZE="-0.19081451587638756" MODIFIED="2015-06-04 07:55:23 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="333" O_E="0.0" SE="0.45821576339510056" STUDY_ID="STD-Palareti-1995" TOTAL_1="30" TOTAL_2="29" VAR="0.2099616858237548" WEIGHT="1.2156139637367576"/>
<DICH_DATA CI_END="8.605569357503649" CI_START="0.6326652215866633" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9347796091949032" LOG_CI_START="-0.19882603860571438" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="154" O_E="0.0" SE="0.6658855689565396" STUDY_ID="STD-Schmidt-1998" TOTAL_1="61" TOTAL_2="61" VAR="0.4434035909445745" WEIGHT="0.3984512436692705"/>
<DICH_DATA CI_END="2.904573690925772" CI_START="0.40405623543916597" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4630823992858058" LOG_CI_START="-0.39355818676738197" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="155" O_E="0.0" SE="0.5031949206869324" STUDY_ID="STD-Schorr-2000" TOTAL_1="24" TOTAL_2="26" VAR="0.2532051282051282" WEIGHT="0.7650263878449993"/>
<DICH_DATA CI_END="1.8667096196429565" CI_START="0.47426225698922797" EFFECT_SIZE="0.9409090909090909" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.2710767655147337" LOG_CI_START="-0.3239814362453107" LOG_EFFECT_SIZE="-0.02645233536528848" MODIFIED="2015-06-22 10:39:03 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1149" O_E="0.0" SE="0.34954013329945455" STUDY_ID="STD-Schuster-1997" TOTAL_1="22" TOTAL_2="23" VAR="0.12217830478700045" WEIGHT="1.2986559052924371"/>
<DICH_DATA CI_END="2.8241094577359798" CI_START="0.5130476095184937" EFFECT_SIZE="1.2037037037037037" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.45088152523015596" LOG_CI_START="-0.28984233159038175" LOG_EFFECT_SIZE="0.08051959681988707" MODIFIED="2015-06-04 10:56:42 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="342" O_E="0.0" SE="0.43510486013860994" STUDY_ID="STD-Vorobyeva-2007" TOTAL_1="12" TOTAL_2="26" VAR="0.18931623931623934" WEIGHT="0.7549602511628283"/>
<DICH_DATA CI_END="1.0411079701631492" CI_START="0.8768152318090525" EFFECT_SIZE="0.9554367201426025" ESTIMABLE="YES" EVENTS_1="536" EVENTS_2="561" LOG_CI_END="0.017495771215173817" LOG_CI_START="-0.05709191434195657" LOG_EFFECT_SIZE="-0.019798071563391383" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="156" O_E="0.0" SE="0.04381317571125655" STUDY_ID="STD-Warren-2001" TOTAL_1="1157" TOTAL_2="1157" VAR="0.0019195943659054409" WEIGHT="74.51038256615358"/>
<DICH_DATA CI_END="5.589897580584607" CI_START="0.7155766169836816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="157" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="0.5312683248923606"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.35711031575776736" CI_END="1.3387442150673552" CI_START="0.5901174628209241" DF="1" EFFECT_SIZE="0.8888286334056399" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.12669760718650105" LOG_CI_START="-0.22906153348072406" LOG_EFFECT_SIZE="-0.051181963147111466" MODIFIED="2015-06-24 19:30:30 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.55011571763366" P_Z="0.5727896143519604" STUDIES="3" TAU2="0.0" TOTAL_1="88" TOTAL_2="120" WEIGHT="2.9507794912696177" Z="0.5639478678650659">
<NAME>Median duration of AT III intervention longer than one week</NAME>
<DICH_DATA CI_END="1.1990340733435727" CI_START="0.550573386258422" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.07883152476259658" LOG_CI_START="-0.2591847854607726" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2015-06-24 19:30:19 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="158" O_E="0.0" SE="0.1985524538329278" STUDY_ID="STD-Inthorn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.03942307692307692" WEIGHT="2.1250732995694426"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-24 19:30:24 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="159" O_E="0.0" SE="0.0" STUDY_ID="STD-Mitchell-2003" TOTAL_1="25" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.9554575520408863" CI_START="0.3985216544524382" EFFECT_SIZE="1.0852713178294573" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4706247261458107" LOG_CI_START="-0.3995480753878326" LOG_EFFECT_SIZE="0.03553832537898904" MODIFIED="2015-06-24 19:30:30 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="160" O_E="0.0" SE="0.511143811045699" STUDY_ID="STD-Smith_x002d_Erichsen-1996" TOTAL_1="43" TOTAL_2="40" VAR="0.26126799557032115" WEIGHT="0.825706191700175"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10495351273137642" CI_END="5.7189277125569795" CI_START="0.8077198792966913" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1492537313432836" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.7573146070841745" LOG_CI_START="-0.0927392282953282" LOG_EFFECT_SIZE="0.3322876893944232" METHOD="MH" MODIFIED="2015-11-16 14:20:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="4" P_CHI2="0.7459643403903399" P_Q="0.7477043706052777" P_Z="0.12544658859790736" Q="0.10347020197318144" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="35" WEIGHT="100.0" Z="1.5323074295132004">
<NAME>Overall mortality (trauma)</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="77.5826449373787" CI_START="0.15151716018839692" DF="0" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="1.8897645814270692" LOG_CI_START="-0.8195381780323705" LOG_EFFECT_SIZE="0.5351132016973492" MODIFIED="2015-11-16 10:57:19 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="1.0" P_Z="0.4387987840002805" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="15" WEIGHT="10.447761194029852" Z="0.774223256752582">
<NAME>Trials with high bias risk</NAME>
<DICH_DATA CI_END="77.58264493737863" CI_START="0.151517160188397" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8897645814270687" LOG_CI_START="-0.8195381780323703" LOG_EFFECT_SIZE="0.5351132016973492" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="161" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Grenander-2001" TOTAL_1="13" TOTAL_2="15" VAR="2.532738095238095" WEIGHT="10.447761194029852"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.589897580584607" CI_START="0.7155766169836816" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-11-16 10:57:51 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="1.0" P_Z="0.1862414830200649" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="89.55223880597015" Z="1.321779811009935">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="5.589897580584607" CI_START="0.7155766169836816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-11-16 10:57:19 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="162" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="89.55223880597015"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6233263993529956" CI_END="3.2102250163442534" CI_START="0.3275681823091252" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0254596888260255" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.5065354747511881" LOG_CI_START="-0.4846982892029996" LOG_EFFECT_SIZE="0.010918592774094288" METHOD="MH" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NO="5" P_CHI2="0.42981406332846406" P_Q="1.0" P_Z="0.9655591550555913" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="166" TOTAL_2="166" WEIGHT="100.0" Z="0.04317861109515866">
<NAME>Overall mortality (obstetrics)</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-11-17 15:24:48 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>Overall maternal mortality, trials with low bias risk</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-11-17 15:24:48 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="163" O_E="0.0" SE="0.0" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="164" O_E="0.0" SE="0.0" STUDY_ID="STD-Maki-2000" TOTAL_1="74" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6233263993529956" CI_END="3.2102250163442534" CI_START="0.3275681823091252" DF="1" EFFECT_SIZE="1.0254596888260255" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.5065354747511881" LOG_CI_START="-0.4846982892029996" LOG_EFFECT_SIZE="0.010918592774094288" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.42981406332846406" P_Z="0.9655591550555913" STUDIES="2" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="0.04317861109515866">
<NAME>Overall foetal and neonatal mortality, trials with low bias risk</NAME>
<DICH_DATA CI_END="7.545522164113119" CI_START="0.014725436980300866" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8776892991343043" LOG_CI_START="-1.8319318085736291" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="165" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="27.58132956152758"/>
<DICH_DATA CI_END="4.585697861240958" CI_START="0.36236188671544395" EFFECT_SIZE="1.2890625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6614054368922863" LOG_CI_START="-0.44085748776021055" LOG_EFFECT_SIZE="0.11027397456603792" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="166" O_E="0.0" SE="0.6474746982303516" STUDY_ID="STD-Maki-2000" TOTAL_1="64" TOTAL_2="66" VAR="0.4192234848484849" WEIGHT="72.41867043847242"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.341209672430964" CI_END="2.826735606074182" CI_START="0.7298668087084003" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4363636363636365" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.4512851893905324" LOG_CI_START="-0.13675638579813718" LOG_EFFECT_SIZE="0.15726440179619763" METHOD="MH" MODIFIED="2015-11-16 14:20:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="6" P_CHI2="0.5113992129001736" P_Q="0.7895858531527329" P_Z="0.2944838641966414" Q="0.07120809605014833" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="204" WEIGHT="100.00000000000001" Z="1.0483359564224315">
<NAME>Overall mortality (paediatrics)</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2649390007732133" CI_END="4.7183493732749" CI_START="0.5425626204155295" DF="1" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="20.944804501344752" ID="CMP-001.06.01" LOG_CI_END="0.6737900953600404" LOG_CI_START="-0.2655501300481908" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="1" P_CHI2="0.2607183685832848" P_Z="0.39432179076680074" STUDIES="2" TAU2="0.0" TOTAL_1="91" TOTAL_2="91" WEIGHT="40.49586776859505" Z="0.8518059883077748">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="167" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Fulia-2003" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="16.198347107438018"/>
<DICH_DATA CI_END="8.605569357503649" CI_START="0.6326652215866633" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9347796091949032" LOG_CI_START="-0.19882603860571438" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="168" O_E="0.0" SE="0.6658855689565396" STUDY_ID="STD-Schmidt-1998" TOTAL_1="61" TOTAL_2="61" VAR="0.4434035909445745" WEIGHT="24.297520661157026"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.148592865493405" CI_START="0.5575903506739612" DF="0" EFFECT_SIZE="1.325" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.49811650703194305" LOG_CI_START="-0.25368475048628975" LOG_EFFECT_SIZE="0.12221587827282664" MODIFIED="2015-06-26 17:13:18 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="1.0" P_Z="0.523968871435869" STUDIES="2" TAU2="0.0" TOTAL_1="70" TOTAL_2="113" WEIGHT="59.50413223140497" Z="0.6372394761466922">
<NAME>Trials with high bias risk</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="169" O_E="0.0" SE="0.0" STUDY_ID="STD-Mitchell-2003" TOTAL_1="25" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.148592865493405" CI_START="0.5575903506739612" EFFECT_SIZE="1.325" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.49811650703194305" LOG_CI_START="-0.25368475048628975" LOG_EFFECT_SIZE="0.12221587827282664" MODIFIED="2015-06-26 17:13:18 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="390" O_E="0.0" SE="0.44161178014245384" STUDY_ID="STD-Muntean-1989" TOTAL_1="45" TOTAL_2="53" VAR="0.195020964360587" WEIGHT="59.50413223140497"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.914290106777443" CI_END="1.0297729168819147" CI_START="0.8846926294184594" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9544802300415539" ESTIMABLE="YES" EVENTS_1="711" EVENTS_2="742" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.012741465658425771" LOG_CI_START="-0.05320759092253252" LOG_EFFECT_SIZE="-0.0202330626320534" METHOD="MH" MODIFIED="2015-12-18 11:23:27 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9355240217658598" P_Q="0.8743207731827397" P_Z="0.22912052836278296" Q="0.025018587219259883" RANDOM="NO" SCALE="121.85210281023461" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1871" TOTAL_2="1908" WEIGHT="100.0" Z="1.2026274858712056">
<NAME>Overall mortality (heparin; Warren 2001 as a trial with adjuvant heparin therapy)</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.045673647644645" CI_END="1.0350604431988897" CI_START="0.8839689423165509" DF="13" EFFECT_SIZE="0.9565360867255469" ESTIMABLE="YES" EVENTS_1="646" EVENTS_2="670" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.014965711513982021" LOG_CI_START="-0.05356299337775177" LOG_EFFECT_SIZE="-0.019298640931884853" MODIFIED="2015-07-28 19:05:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8997824987796027" P_Z="0.26963371906937983" STUDIES="16" TAU2="0.0" TOTAL_1="1547" TOTAL_2="1574" WEIGHT="90.49972146356599" Z="1.1039064939815428">
<NAME>Trials with complete or partially adjuvant heparin therapy</NAME>
<DICH_DATA CI_END="2.445397859258201" CI_START="0.2617161038139376" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38834952768196396" LOG_CI_START="-0.5821695536980768" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="170" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-Albert-1992" TOTAL_1="16" TOTAL_2="16" VAR="0.325" WEIGHT="0.673067667087567"/>
<DICH_DATA CI_END="1.3256957751694363" CI_START="0.6629773334592302" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.1224438722406761" LOG_CI_START="-0.1785013194411632" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="171" O_E="0.0" SE="0.17677669529663687" STUDY_ID="STD-Baudo-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.031249999999999997" WEIGHT="4.3076330693604294"/>
<DICH_DATA CI_END="2.869173173549007" CI_START="0.4371991246692082" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.45775676157713835" LOG_CI_START="-0.3593207162367751" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="172" O_E="0.0" SE="0.47995535506663833" STUDY_ID="STD-Diaz_x002d_Cremades-1994" TOTAL_1="20" TOTAL_2="16" VAR="0.23035714285714287" WEIGHT="0.7478529634306301"/>
<DICH_DATA CI_END="1.5184772305541139" CI_START="0.24594164641321434" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18140828409172643" LOG_CI_START="-0.6091679239818885" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="173" O_E="0.0" SE="0.46438837803778604" STUDY_ID="STD-Eisele-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.21565656565656566" WEIGHT="1.1538302864358292"/>
<DICH_DATA CI_END="1.7127813243352565" CI_START="0.3959645533295018" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.23370191889266265" LOG_CI_START="-0.4023436902927345" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="174" O_E="0.0" SE="0.37361633931204574" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" VAR="0.13958916900093368" WEIGHT="1.1769068921645458"/>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="175" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Fulia-2003" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.26922706683502684"/>
<DICH_DATA CI_END="77.58264493737863" CI_START="0.151517160188397" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8897645814270687" LOG_CI_START="-0.8195381780323703" LOG_EFFECT_SIZE="0.5351132016973492" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="176" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Grenander-2001" TOTAL_1="13" TOTAL_2="15" VAR="2.532738095238095" WEIGHT="0.06281964892817293"/>
<DICH_DATA CI_END="1.1990340733435727" CI_START="0.550573386258422" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.07883152476259658" LOG_CI_START="-0.2591847854607726" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="177" O_E="0.0" SE="0.1985524538329278" STUDY_ID="STD-Inthorn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.03942307692307692" WEIGHT="2.1538165346802147"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="178" O_E="0.0" SE="0.0" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="179" O_E="0.0" SE="0.0" STUDY_ID="STD-Mitchell-2003" TOTAL_1="25" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.520874489743392" CI_START="0.42457615350315736" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.18209337535414225" LOG_CI_START="-0.37204440181585574" LOG_EFFECT_SIZE="-0.09497551323085672" MODIFIED="2015-06-22 10:40:59 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="364" O_E="0.0" SE="0.3255032733358928" STUDY_ID="STD-Neporada-2008A" TOTAL_1="28" TOTAL_2="15" VAR="0.10595238095238095" WEIGHT="1.4024851853731632"/>
<DICH_DATA CI_END="8.605569357503649" CI_START="0.6326652215866633" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9347796091949032" LOG_CI_START="-0.19882603860571438" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="180" O_E="0.0" SE="0.6658855689565396" STUDY_ID="STD-Schmidt-1998" TOTAL_1="61" TOTAL_2="61" VAR="0.4434035909445745" WEIGHT="0.40384060025254026"/>
<DICH_DATA CI_END="2.904573690925772" CI_START="0.40405623543916597" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4630823992858058" LOG_CI_START="-0.39355818676738197" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="181" O_E="0.0" SE="0.5031949206869324" STUDY_ID="STD-Schorr-2000" TOTAL_1="24" TOTAL_2="26" VAR="0.2532051282051282" WEIGHT="0.7753739524848773"/>
<DICH_DATA CI_END="1.8667096196429565" CI_START="0.47426225698922797" EFFECT_SIZE="0.9409090909090909" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.2710767655147337" LOG_CI_START="-0.3239814362453107" LOG_EFFECT_SIZE="-0.02645233536528848" MODIFIED="2015-06-22 10:41:40 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1150" O_E="0.0" SE="0.34954013329945455" STUDY_ID="STD-Schuster-1997" TOTAL_1="22" TOTAL_2="23" VAR="0.12217830478700045" WEIGHT="1.3162212156379092"/>
<DICH_DATA CI_END="1.0411079701631492" CI_START="0.8768152318090525" EFFECT_SIZE="0.9554367201426025" ESTIMABLE="YES" EVENTS_1="536" EVENTS_2="561" LOG_CI_END="0.017495771215173817" LOG_CI_START="-0.05709191434195657" LOG_EFFECT_SIZE="-0.019798071563391383" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="182" O_E="0.0" SE="0.04381317571125655" STUDY_ID="STD-Warren-2001" TOTAL_1="1157" TOTAL_2="1157" VAR="0.0019195943659054409" WEIGHT="75.51819224722503"/>
<DICH_DATA CI_END="5.589897580584607" CI_START="0.7155766169836816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="183" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="0.5384541336700537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.990089515501355" CI_END="1.2275666746793041" CI_START="0.7120026811455142" DF="8" EFFECT_SIZE="0.9348961245275048" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="72" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.08904508992650317" LOG_CI_START="-0.14751837096355144" LOG_EFFECT_SIZE="-0.029236640518524128" MODIFIED="2015-06-26 17:13:35 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.6483421900972165" P_Z="0.6280594753790425" STUDIES="10" TAU2="0.0" TOTAL_1="324" TOTAL_2="334" WEIGHT="9.500278536434003" Z="0.4844599603814878">
<NAME>Trials without adjuvant heparin</NAME>
<DICH_DATA CI_END="1.852723919459713" CI_START="0.032704125714532246" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.26781070847802796" LOG_CI_START="-1.4853974564518895" LOG_EFFECT_SIZE="-0.6087933739869308" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="184" O_E="0.0" SE="1.0298431546002154" STUDY_ID="STD-Baudo-1992" TOTAL_1="13" TOTAL_2="16" VAR="1.060576923076923" WEIGHT="0.6034399773888532"/>
<DICH_DATA CI_END="3.51077932597227" CI_START="0.410165341167152" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.54540353224961" LOG_CI_START="-0.38704104015436036" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2015-06-23 13:31:31 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="617" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Gando-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="0.673067667087567"/>
<DICH_DATA CI_END="1.2479270939418843" CI_START="0.3593331359654989" EFFECT_SIZE="0.6696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09618921385312493" LOG_CI_START="-0.44450273241008803" LOG_EFFECT_SIZE="-0.1741567592784816" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="185" O_E="0.0" SE="0.31760512570331084" STUDY_ID="STD-Haire-1998" TOTAL_1="24" TOTAL_2="25" VAR="0.10087301587301586" WEIGHT="1.8461284582973267"/>
<DICH_DATA CI_END="2.2648150660783553" CI_START="0.6350726771849305" EFFECT_SIZE="1.1993006993006994" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3550327453949" LOG_CI_START="-0.197176571567445" LOG_EFFECT_SIZE="0.07892808691372752" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="186" O_E="0.0" SE="0.3243704862638854" STUDY_ID="STD-Harper-1991" TOTAL_1="44" TOTAL_2="49" VAR="0.1052162123590695" WEIGHT="1.6558912067702727"/>
<DICH_DATA CI_END="1.6839967374164937" CI_START="0.7558487395059267" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.22634124576019476" LOG_CI_START="-0.12156510684081832" LOG_EFFECT_SIZE="0.05238806945968822" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="187" O_E="0.0" SE="0.20436191368205514" STUDY_ID="STD-Langely-1993" TOTAL_1="13" TOTAL_2="12" VAR="0.04176379176379176" WEIGHT="1.2599826727879255"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="188" O_E="0.0" SE="0.0" STUDY_ID="STD-Maki-2000" TOTAL_1="74" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.148592865493405" CI_START="0.5575903506739612" EFFECT_SIZE="1.325" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.49811650703194305" LOG_CI_START="-0.25368475048628975" LOG_EFFECT_SIZE="0.12221587827282664" MODIFIED="2015-06-26 17:13:35 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="391" O_E="0.0" SE="0.44161178014245384" STUDY_ID="STD-Muntean-1989" TOTAL_1="45" TOTAL_2="53" VAR="0.195020964360587" WEIGHT="0.988997388373568"/>
<DICH_DATA CI_END="2.978685547154268" CI_START="0.149208245519253" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4740246581852024" LOG_CI_START="-0.8262071762965648" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-06-23 13:31:30 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="943" O_E="0.0" SE="0.7637626158259733" STUDY_ID="STD-Nishiyama-2011" TOTAL_1="8" TOTAL_2="8" VAR="0.5833333333333333" WEIGHT="0.40384060025254026"/>
<DICH_DATA CI_END="1.582047245986341" CI_START="0.2625134255812828" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.19921944905089536" LOG_CI_START="-0.5808484808036704" LOG_EFFECT_SIZE="-0.19081451587638756" MODIFIED="2015-06-04 07:59:02 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="334" O_E="0.0" SE="0.45821576339510056" STUDY_ID="STD-Palareti-1995" TOTAL_1="30" TOTAL_2="29" VAR="0.2099616858237548" WEIGHT="1.232056068567072"/>
<DICH_DATA CI_END="2.9554575520408863" CI_START="0.3985216544524382" EFFECT_SIZE="1.0852713178294573" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4706247261458107" LOG_CI_START="-0.3995480753878326" LOG_EFFECT_SIZE="0.03553832537898904" MODIFIED="2015-06-23 13:31:29 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="189" O_E="0.0" SE="0.511143811045699" STUDY_ID="STD-Smith_x002d_Erichsen-1996" TOTAL_1="43" TOTAL_2="40" VAR="0.26126799557032115" WEIGHT="0.8368744969088786"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.914290106777445" CI_END="1.0297729168819145" CI_START="0.8846926294184593" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9544802300415538" ESTIMABLE="YES" EVENTS_1="711" EVENTS_2="742" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.012741465658425677" LOG_CI_START="-0.05320759092253258" LOG_EFFECT_SIZE="-0.02023306263205345" METHOD="MH" MODIFIED="2015-11-16 14:20:59 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="8" P_CHI2="0.9355240217658598" P_Q="0.9324050939849118" P_Z="0.22912052836278196" Q="0.007194304243721128" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1871" TOTAL_2="1908" WEIGHT="100.0" Z="1.2026274858712085">
<NAME>Overall mortality (heparin; Warren 2001 as a trial without adjuvant heparin therapy)</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.098650438339509" CI_END="1.1743759677045411" CI_START="0.7881577700989267" DF="12" EFFECT_SIZE="0.9620777224132052" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="109" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.06980715531033295" LOG_CI_START="-0.10338683857005761" LOG_EFFECT_SIZE="-0.01678984162986232" MODIFIED="2015-07-28 19:05:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8510260458459301" P_Z="0.7039400493906077" STUDIES="15" TAU2="0.0" TOTAL_1="390" TOTAL_2="417" WEIGHT="14.981529216340958" Z="0.3800072296200716">
<NAME>Trials with complete or partially adjuvant heparin therapy</NAME>
<DICH_DATA CI_END="2.445397859258201" CI_START="0.2617161038139376" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38834952768196396" LOG_CI_START="-0.5821695536980768" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="190" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-Albert-1992" TOTAL_1="16" TOTAL_2="16" VAR="0.325" WEIGHT="0.673067667087567"/>
<DICH_DATA CI_END="1.3256957751694363" CI_START="0.6629773334592302" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.1224438722406761" LOG_CI_START="-0.1785013194411632" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="191" O_E="0.0" SE="0.17677669529663687" STUDY_ID="STD-Baudo-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.031249999999999997" WEIGHT="4.3076330693604294"/>
<DICH_DATA CI_END="2.869173173549007" CI_START="0.4371991246692082" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.45775676157713835" LOG_CI_START="-0.3593207162367751" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="192" O_E="0.0" SE="0.47995535506663833" STUDY_ID="STD-Diaz_x002d_Cremades-1994" TOTAL_1="20" TOTAL_2="16" VAR="0.23035714285714287" WEIGHT="0.7478529634306301"/>
<DICH_DATA CI_END="1.5184772305541139" CI_START="0.24594164641321434" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18140828409172643" LOG_CI_START="-0.6091679239818885" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="193" O_E="0.0" SE="0.46438837803778604" STUDY_ID="STD-Eisele-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.21565656565656566" WEIGHT="1.1538302864358292"/>
<DICH_DATA CI_END="1.7127813243352565" CI_START="0.3959645533295018" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.23370191889266265" LOG_CI_START="-0.4023436902927345" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="194" O_E="0.0" SE="0.37361633931204574" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" VAR="0.13958916900093368" WEIGHT="1.1769068921645458"/>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="195" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Fulia-2003" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.26922706683502684"/>
<DICH_DATA CI_END="77.58264493737863" CI_START="0.151517160188397" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8897645814270687" LOG_CI_START="-0.8195381780323703" LOG_EFFECT_SIZE="0.5351132016973492" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="196" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Grenander-2001" TOTAL_1="13" TOTAL_2="15" VAR="2.532738095238095" WEIGHT="0.06281964892817293"/>
<DICH_DATA CI_END="1.1990340733435727" CI_START="0.550573386258422" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.07883152476259658" LOG_CI_START="-0.2591847854607726" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="197" O_E="0.0" SE="0.1985524538329278" STUDY_ID="STD-Inthorn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.03942307692307692" WEIGHT="2.1538165346802147"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="198" O_E="0.0" SE="0.0" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="199" O_E="0.0" SE="0.0" STUDY_ID="STD-Mitchell-2003" TOTAL_1="25" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.520874489743392" CI_START="0.42457615350315736" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.18209337535414225" LOG_CI_START="-0.37204440181585574" LOG_EFFECT_SIZE="-0.09497551323085672" MODIFIED="2015-06-22 10:49:14 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="365" O_E="0.0" SE="0.3255032733358928" STUDY_ID="STD-Neporada-2008A" TOTAL_1="28" TOTAL_2="15" VAR="0.10595238095238095" WEIGHT="1.4024851853731632"/>
<DICH_DATA CI_END="8.605569357503649" CI_START="0.6326652215866633" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9347796091949032" LOG_CI_START="-0.19882603860571438" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="200" O_E="0.0" SE="0.6658855689565396" STUDY_ID="STD-Schmidt-1998" TOTAL_1="61" TOTAL_2="61" VAR="0.4434035909445745" WEIGHT="0.40384060025254026"/>
<DICH_DATA CI_END="2.904573690925772" CI_START="0.40405623543916597" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4630823992858058" LOG_CI_START="-0.39355818676738197" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="201" O_E="0.0" SE="0.5031949206869324" STUDY_ID="STD-Schorr-2000" TOTAL_1="24" TOTAL_2="26" VAR="0.2532051282051282" WEIGHT="0.7753739524848773"/>
<DICH_DATA CI_END="1.8667096196429565" CI_START="0.47426225698922797" EFFECT_SIZE="0.9409090909090909" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.2710767655147337" LOG_CI_START="-0.3239814362453107" LOG_EFFECT_SIZE="-0.02645233536528848" MODIFIED="2015-06-22 10:49:52 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1151" O_E="0.0" SE="0.34954013329945455" STUDY_ID="STD-Schuster-1997" TOTAL_1="22" TOTAL_2="23" VAR="0.12217830478700045" WEIGHT="1.3162212156379092"/>
<DICH_DATA CI_END="5.589897580584607" CI_START="0.7155766169836816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="202" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="0.5384541336700537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.89526131132346" CI_END="1.0346976497537823" CI_START="0.8780135926732197" DF="9" EFFECT_SIZE="0.9531414379780448" ESTIMABLE="YES" EVENTS_1="601" EVENTS_2="633" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.014813462617426528" LOG_CI_START="-0.056498760657361" LOG_EFFECT_SIZE="-0.020842649019967237" MODIFIED="2015-06-26 17:13:50 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.7503535671323225" P_Z="0.25192356817975914" STUDIES="11" TAU2="0.0" TOTAL_1="1481" TOTAL_2="1491" WEIGHT="85.01847078365904" Z="1.1456897442149347">
<NAME>Trials without adjuvant heparin</NAME>
<DICH_DATA CI_END="1.852723919459713" CI_START="0.032704125714532246" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.26781070847802796" LOG_CI_START="-1.4853974564518895" LOG_EFFECT_SIZE="-0.6087933739869308" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="203" O_E="0.0" SE="1.0298431546002154" STUDY_ID="STD-Baudo-1992" TOTAL_1="13" TOTAL_2="16" VAR="1.060576923076923" WEIGHT="0.6034399773888532"/>
<DICH_DATA CI_END="3.51077932597227" CI_START="0.410165341167152" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.54540353224961" LOG_CI_START="-0.38704104015436036" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2015-06-22 10:50:15 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="618" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Gando-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="0.673067667087567"/>
<DICH_DATA CI_END="1.2479270939418843" CI_START="0.3593331359654989" EFFECT_SIZE="0.6696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09618921385312493" LOG_CI_START="-0.44450273241008803" LOG_EFFECT_SIZE="-0.1741567592784816" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="204" O_E="0.0" SE="0.31760512570331084" STUDY_ID="STD-Haire-1998" TOTAL_1="24" TOTAL_2="25" VAR="0.10087301587301586" WEIGHT="1.8461284582973267"/>
<DICH_DATA CI_END="2.2648150660783553" CI_START="0.6350726771849305" EFFECT_SIZE="1.1993006993006994" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3550327453949" LOG_CI_START="-0.197176571567445" LOG_EFFECT_SIZE="0.07892808691372752" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="205" O_E="0.0" SE="0.3243704862638854" STUDY_ID="STD-Harper-1991" TOTAL_1="44" TOTAL_2="49" VAR="0.1052162123590695" WEIGHT="1.6558912067702727"/>
<DICH_DATA CI_END="1.6839967374164937" CI_START="0.7558487395059267" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.22634124576019476" LOG_CI_START="-0.12156510684081832" LOG_EFFECT_SIZE="0.05238806945968822" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="206" O_E="0.0" SE="0.20436191368205514" STUDY_ID="STD-Langely-1993" TOTAL_1="13" TOTAL_2="12" VAR="0.04176379176379176" WEIGHT="1.2599826727879255"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="207" O_E="0.0" SE="0.0" STUDY_ID="STD-Maki-2000" TOTAL_1="74" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.148592865493405" CI_START="0.5575903506739612" EFFECT_SIZE="1.325" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.49811650703194305" LOG_CI_START="-0.25368475048628975" LOG_EFFECT_SIZE="0.12221587827282664" MODIFIED="2015-06-26 17:13:50 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="392" O_E="0.0" SE="0.44161178014245384" STUDY_ID="STD-Muntean-1989" TOTAL_1="45" TOTAL_2="53" VAR="0.195020964360587" WEIGHT="0.988997388373568"/>
<DICH_DATA CI_END="2.978685547154268" CI_START="0.149208245519253" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4740246581852024" LOG_CI_START="-0.8262071762965648" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-06-03 14:37:55 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="944" O_E="0.0" SE="0.7637626158259733" STUDY_ID="STD-Nishiyama-2011" TOTAL_1="8" TOTAL_2="8" VAR="0.5833333333333333" WEIGHT="0.40384060025254026"/>
<DICH_DATA CI_END="1.582047245986341" CI_START="0.2625134255812828" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.19921944905089536" LOG_CI_START="-0.5808484808036704" LOG_EFFECT_SIZE="-0.19081451587638756" MODIFIED="2015-06-04 07:56:47 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="335" O_E="0.0" SE="0.45821576339510056" STUDY_ID="STD-Palareti-1995" TOTAL_1="30" TOTAL_2="29" VAR="0.2099616858237548" WEIGHT="1.232056068567072"/>
<DICH_DATA CI_END="2.9554575520408863" CI_START="0.3985216544524382" EFFECT_SIZE="1.0852713178294573" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4706247261458107" LOG_CI_START="-0.3995480753878326" LOG_EFFECT_SIZE="0.03553832537898904" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="208" O_E="0.0" SE="0.511143811045699" STUDY_ID="STD-Smith_x002d_Erichsen-1996" TOTAL_1="43" TOTAL_2="40" VAR="0.26126799557032115" WEIGHT="0.8368744969088786"/>
<DICH_DATA CI_END="1.0411079701631492" CI_START="0.8768152318090525" EFFECT_SIZE="0.9554367201426025" ESTIMABLE="YES" EVENTS_1="536" EVENTS_2="561" LOG_CI_END="0.017495771215173817" LOG_CI_START="-0.05709191434195657" LOG_EFFECT_SIZE="-0.019798071563391383" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="209" O_E="0.0" SE="0.04381317571125655" STUDY_ID="STD-Warren-2001" TOTAL_1="1157" TOTAL_2="1157" VAR="0.0019195943659054409" WEIGHT="75.51819224722503"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.912169113074341" CI_END="1.0296272467879592" CI_START="0.8845562302584455" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9543391409714576" ESTIMABLE="YES" EVENTS_1="711" EVENTS_2="742" I2="0.0" I2_Q="57.55623625082362" ID="CMP-001.09" LOG_CI_END="0.012680026682936933" LOG_CI_START="-0.05327455425821434" LOG_EFFECT_SIZE="-0.020297263787638672" METHOD="MH" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NO="9" P_CHI2="0.8590028279487556" P_Q="0.12479729348108048" P_Z="0.22768549098014024" Q="2.3560587272833575" RANDOM="NO" SCALE="89.22" SORT_BY="EFFECT_SIZE" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1871" TOTAL_2="1908" WEIGHT="99.99999999999997" Z="1.2063424690387072">
<NAME>Overall mortality (heparin; Warren 2001 data split based on heparin administration)</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.585588723724194" CI_END="1.0911228000562123" CI_START="0.9074742201557737" DF="13" EFFECT_SIZE="0.995070757320903" ESTIMABLE="YES" EVENTS_1="488" EVENTS_2="488" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.03787363086844833" LOG_CI_START="-0.042165703705757146" LOG_EFFECT_SIZE="-0.0021460364186544206" MODIFIED="2015-07-28 19:05:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8695120464406335" P_Z="0.916294733169487" STUDIES="16" TAU2="0.0" TOTAL_1="1195" TOTAL_2="1228" WEIGHT="65.7967016250324" Z="0.10510217538538894">
<NAME>Trials with complete or partially adjuvant heparin therapy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="218" O_E="0.0" SE="0.0" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="219" O_E="0.0" SE="0.0" STUDY_ID="STD-Mitchell-2003" TOTAL_1="25" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="215" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Fulia-2003" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.26917007386447844"/>
<DICH_DATA CI_END="1.5184772305541139" CI_START="0.24594164641321434" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18140828409172643" LOG_CI_START="-0.6091679239818885" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="213" O_E="0.0" SE="0.46438837803778604" STUDY_ID="STD-Eisele-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.21565656565656566" WEIGHT="1.1535860308477648"/>
<DICH_DATA CI_END="2.445397859258201" CI_START="0.2617161038139376" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38834952768196396" LOG_CI_START="-0.5821695536980768" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="210" O_E="0.0" SE="0.570087712549569" STUDY_ID="STD-Albert-1992" TOTAL_1="16" TOTAL_2="16" VAR="0.325" WEIGHT="0.6729251846611961"/>
<DICH_DATA CI_END="1.520874489743392" CI_START="0.42457615350315736" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.18209337535414225" LOG_CI_START="-0.37204440181585574" LOG_EFFECT_SIZE="-0.09497551323085672" MODIFIED="2015-06-22 10:51:17 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="366" O_E="0.0" SE="0.3255032733358928" STUDY_ID="STD-Neporada-2008A" TOTAL_1="28" TOTAL_2="15" VAR="0.10595238095238095" WEIGHT="1.4021882917591437"/>
<DICH_DATA CI_END="1.1990340733435727" CI_START="0.550573386258422" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.07883152476259658" LOG_CI_START="-0.2591847854607726" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="217" O_E="0.0" SE="0.1985524538329278" STUDY_ID="STD-Inthorn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.03942307692307692" WEIGHT="2.1533605909158275"/>
<DICH_DATA CI_END="1.7127813243352565" CI_START="0.3959645533295018" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.23370191889266265" LOG_CI_START="-0.4023436902927345" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="214" O_E="0.0" SE="0.37361633931204574" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" VAR="0.13958916900093368" WEIGHT="1.1766577514647198"/>
<DICH_DATA CI_END="1.3256957751694363" CI_START="0.6629773334592302" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.1224438722406761" LOG_CI_START="-0.1785013194411632" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="211" O_E="0.0" SE="0.17677669529663687" STUDY_ID="STD-Baudo-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.031249999999999997" WEIGHT="4.306721181831655"/>
<DICH_DATA CI_END="1.8667096196429565" CI_START="0.47426225698922797" EFFECT_SIZE="0.9409090909090909" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.2710767655147337" LOG_CI_START="-0.3239814362453107" LOG_EFFECT_SIZE="-0.02645233536528848" MODIFIED="2015-06-22 10:51:51 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1152" O_E="0.0" SE="0.34954013329945455" STUDY_ID="STD-Schuster-1997" TOTAL_1="22" TOTAL_2="23" VAR="0.12217830478700045" WEIGHT="1.3159425833374503"/>
<DICH_DATA CI_END="1.1147800425367775" CI_START="0.9056615754829093" EFFECT_SIZE="1.0047952277159573" ESTIMABLE="YES" EVENTS_1="378" EVENTS_2="379" LOG_CI_END="0.04718918510967842" LOG_CI_START="-0.04303405768479739" LOG_EFFECT_SIZE="0.0020775637124405043" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="222" O_E="0.0" SE="0.05299757942972979" STUDY_ID="STD-Warren-2001" TOTAL_1="805" TOTAL_2="811" VAR="0.0028087434254105183" WEIGHT="50.81834386490287"/>
<DICH_DATA CI_END="2.904573690925772" CI_START="0.40405623543916597" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4630823992858058" LOG_CI_START="-0.39355818676738197" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="221" O_E="0.0" SE="0.5031949206869324" STUDY_ID="STD-Schorr-2000" TOTAL_1="24" TOTAL_2="26" VAR="0.2532051282051282" WEIGHT="0.7752098127296979"/>
<DICH_DATA CI_END="2.869173173549007" CI_START="0.4371991246692082" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.45775676157713835" LOG_CI_START="-0.3593207162367751" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="212" O_E="0.0" SE="0.47995535506663833" STUDY_ID="STD-Diaz_x002d_Cremades-1994" TOTAL_1="20" TOTAL_2="16" VAR="0.23035714285714287" WEIGHT="0.7476946496235513"/>
<DICH_DATA CI_END="5.589897580584607" CI_START="0.7155766169836816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="223" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="0.5383401477289569"/>
<DICH_DATA CI_END="8.605569357503649" CI_START="0.6326652215866633" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9347796091949032" LOG_CI_START="-0.19882603860571438" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="220" O_E="0.0" SE="0.6658855689565396" STUDY_ID="STD-Schmidt-1998" TOTAL_1="61" TOTAL_2="61" VAR="0.4434035909445745" WEIGHT="0.40375511079671766"/>
<DICH_DATA CI_END="77.58264493737863" CI_START="0.151517160188397" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8897645814270687" LOG_CI_START="-0.8195381780323703" LOG_EFFECT_SIZE="0.5351132016973492" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="216" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Grenander-2001" TOTAL_1="13" TOTAL_2="15" VAR="2.532738095238095" WEIGHT="0.0628063505683783"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.778750698374255" CI_END="1.00175691120951" CI_START="0.766002081394369" DF="9" EFFECT_SIZE="0.875983949075369" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="254" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="7.623473511058612E-4" LOG_CI_START="-0.11577005029316498" LOG_EFFECT_SIZE="-0.05750385147102955" MODIFIED="2015-06-26 17:14:05 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.6601422531389675" P_Z="0.05307378695075662" STUDIES="11" TAU2="0.0" TOTAL_1="676" TOTAL_2="680" WEIGHT="34.203298374967574" Z="1.9343200712235498">
<NAME>Trials without adjuvant heparin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="228" O_E="0.0" SE="0.0" STUDY_ID="STD-Maki-2000" TOTAL_1="74" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.852723919459713" CI_START="0.032704125714532246" EFFECT_SIZE="0.24615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.26781070847802796" LOG_CI_START="-1.4853974564518895" LOG_EFFECT_SIZE="-0.6087933739869308" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="224" O_E="0.0" SE="1.0298431546002154" STUDY_ID="STD-Baudo-1992" TOTAL_1="13" TOTAL_2="16" VAR="1.060576923076923" WEIGHT="0.603312234523831"/>
<DICH_DATA CI_END="1.582047245986341" CI_START="0.2625134255812828" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.19921944905089536" LOG_CI_START="-0.5808484808036704" LOG_EFFECT_SIZE="-0.19081451587638756" MODIFIED="2015-06-04 07:57:14 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="336" O_E="0.0" SE="0.45821576339510056" STUDY_ID="STD-Palareti-1995" TOTAL_1="30" TOTAL_2="29" VAR="0.2099616858237548" WEIGHT="1.2317952532781218"/>
<DICH_DATA CI_END="2.978685547154268" CI_START="0.149208245519253" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4740246581852024" LOG_CI_START="-0.8262071762965648" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-06-03 14:38:06 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="945" O_E="0.0" SE="0.7637626158259733" STUDY_ID="STD-Nishiyama-2011" TOTAL_1="8" TOTAL_2="8" VAR="0.5833333333333333" WEIGHT="0.40375511079671766"/>
<DICH_DATA CI_END="1.2479270939418843" CI_START="0.3593331359654989" EFFECT_SIZE="0.6696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09618921385312493" LOG_CI_START="-0.44450273241008803" LOG_EFFECT_SIZE="-0.1741567592784816" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="225" O_E="0.0" SE="0.31760512570331084" STUDY_ID="STD-Haire-1998" TOTAL_1="24" TOTAL_2="25" VAR="0.10087301587301586" WEIGHT="1.8457376493564235"/>
<DICH_DATA CI_END="0.9943961160043415" CI_START="0.732282826592127" EFFECT_SIZE="0.8533341658341659" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="182" LOG_CI_END="-0.0024405806668706476" LOG_CI_START="-0.13532115076514242" LOG_EFFECT_SIZE="-0.06888086571600656" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="230" O_E="0.0" SE="0.0780547046451552" STUDY_ID="STD-Warren-2001" TOTAL_1="352" TOTAL_2="346" VAR="0.006092536917242411" WEIGHT="24.705030962828"/>
<DICH_DATA CI_END="2.9554575520408863" CI_START="0.3985216544524382" EFFECT_SIZE="1.0852713178294573" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4706247261458107" LOG_CI_START="-0.3995480753878326" LOG_EFFECT_SIZE="0.03553832537898904" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="229" O_E="0.0" SE="0.511143811045699" STUDY_ID="STD-Smith_x002d_Erichsen-1996" TOTAL_1="43" TOTAL_2="40" VAR="0.26126799557032115" WEIGHT="0.8366973380365715"/>
<DICH_DATA CI_END="1.6839967374164937" CI_START="0.7558487395059267" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.22634124576019476" LOG_CI_START="-0.12156510684081832" LOG_EFFECT_SIZE="0.05238806945968822" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="227" O_E="0.0" SE="0.20436191368205514" STUDY_ID="STD-Langely-1993" TOTAL_1="13" TOTAL_2="12" VAR="0.04176379176379176" WEIGHT="1.259715945685759"/>
<DICH_DATA CI_END="2.2648150660783553" CI_START="0.6350726771849305" EFFECT_SIZE="1.1993006993006994" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3550327453949" LOG_CI_START="-0.197176571567445" LOG_EFFECT_SIZE="0.07892808691372752" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="226" O_E="0.0" SE="0.3243704862638854" STUDY_ID="STD-Harper-1991" TOTAL_1="44" TOTAL_2="49" VAR="0.1052162123590695" WEIGHT="1.6555406693600179"/>
<DICH_DATA CI_END="3.51077932597227" CI_START="0.410165341167152" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.54540353224961" LOG_CI_START="-0.38704104015436036" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2015-06-22 10:52:27 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="619" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Gando-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="0.6729251846611961"/>
<DICH_DATA CI_END="3.148592865493405" CI_START="0.5575903506739612" EFFECT_SIZE="1.325" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.49811650703194305" LOG_CI_START="-0.25368475048628975" LOG_EFFECT_SIZE="0.12221587827282664" MODIFIED="2015-06-26 17:14:05 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="393" O_E="0.0" SE="0.44161178014245384" STUDY_ID="STD-Muntean-1989" TOTAL_1="45" TOTAL_2="53" VAR="0.195020964360587" WEIGHT="0.9887880264409412"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.597261923672554" CI_END="1.0272432800538418" CI_START="0.8750577483826639" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9481018888733094" ESTIMABLE="YES" EVENTS_1="629" EVENTS_2="659" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.011673308906816214" LOG_CI_START="-0.05796328529042294" LOG_EFFECT_SIZE="-0.02314498819180336" METHOD="MH" MODIFIED="2015-12-18 09:58:56 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9802546472742092" P_Q="0.6029863052651067" P_Z="0.19262279044853983" Q="0.2705153900973908" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1433" TOTAL_2="1425" WEIGHT="100.00000000000001" Z="1.302859331404175">
<NAME>Overall mortality among patients with severe sepsis &amp; DIC</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3416019164155676" CI_END="1.036861438258904" CI_START="0.8788748538759296" DF="3" EFFECT_SIZE="0.9546053870785459" ESTIMABLE="YES" EVENTS_1="579" EVENTS_2="607" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.01572072300403244" LOG_CI_START="-0.05607296126353887" LOG_EFFECT_SIZE="-0.020176119129753218" MODIFIED="2015-07-28 19:05:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.952023453794251" P_Z="0.27062950040773215" STUDIES="4" TAU2="0.0" TOTAL_1="1264" TOTAL_2="1265" WEIGHT="91.87182513901952" Z="1.1016140833426453">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="1.3256957751694363" CI_START="0.6629773334592302" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.1224438722406761" LOG_CI_START="-0.1785013194411632" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="283" O_E="0.0" SE="0.17677669529663687" STUDY_ID="STD-Baudo-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.031249999999999997" WEIGHT="4.8453778562677465"/>
<DICH_DATA CI_END="1.7127813243352565" CI_START="0.3959645533295018" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.23370191889266265" LOG_CI_START="-0.4023436902927345" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="284" O_E="0.0" SE="0.37361633931204574" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" VAR="0.13958916900093368" WEIGHT="1.3238264500160093"/>
<DICH_DATA CI_END="3.51077932597227" CI_START="0.410165341167152" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.54540353224961" LOG_CI_START="-0.38704104015436036" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2015-06-03 09:56:43 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="305" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Gando-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="0.7570902900418354"/>
<DICH_DATA CI_END="1.0411079701631492" CI_START="0.8768152318090525" EFFECT_SIZE="0.9554367201426025" ESTIMABLE="YES" EVENTS_1="536" EVENTS_2="561" LOG_CI_END="0.017495771215173817" LOG_CI_START="-0.05709191434195657" LOG_EFFECT_SIZE="-0.019798071563391383" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="285" O_E="0.0" SE="0.04381317571125655" STUDY_ID="STD-Warren-2001" TOTAL_1="1157" TOTAL_2="1157" VAR="0.0019195943659054409" WEIGHT="84.94553054269393"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9158636470373387" CI_END="1.2036494565774036" CI_START="0.6354956218948211" DF="7" EFFECT_SIZE="0.8745935970215084" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="52" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.08050002409744325" LOG_CI_START="-0.19688743707452055" LOG_EFFECT_SIZE="-0.058193706488538645" MODIFIED="2015-06-22 11:14:29 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.8926748885286623" P_Z="0.41086633281478735" STUDIES="8" TAU2="0.0" TOTAL_1="169" TOTAL_2="160" WEIGHT="8.128174860980488" Z="0.8223700405385065">
<NAME>Trials with high bias risk</NAME>
<DICH_DATA CI_END="9.504094853510903" CI_START="0.420871220421623" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.977910762038508" LOG_CI_START="-0.3758507707105457" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-06-01 12:32:16 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="296" O_E="0.0" SE="0.7952062255644573" STUDY_ID="STD-Balk-1995" TOTAL_1="17" TOTAL_2="17" VAR="0.6323529411764706" WEIGHT="0.30283611601673416"/>
<DICH_DATA CI_END="1.5184772305541139" CI_START="0.24594164641321434" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18140828409172643" LOG_CI_START="-0.6091679239818885" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="286" O_E="0.0" SE="0.46438837803778604" STUDY_ID="STD-Eisele-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.21565656565656566" WEIGHT="1.2978690686431464"/>
<DICH_DATA CI_END="3.301716901302548" CI_START="0.4361367261475116" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5187398328659169" LOG_CI_START="-0.36037734077066724" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="287" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Inthorn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.2666666666666667" WEIGHT="0.7570902900418354"/>
<DICH_DATA CI_END="1.520874489743392" CI_START="0.42457615350315736" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.18209337535414225" LOG_CI_START="-0.37204440181585574" LOG_EFFECT_SIZE="-0.09497551323085672" MODIFIED="2015-06-22 11:13:56 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1157" O_E="0.0" SE="0.3255032733358928" STUDY_ID="STD-Neporada-2008A" TOTAL_1="28" TOTAL_2="15" VAR="0.10595238095238095" WEIGHT="1.5775648834360105"/>
<DICH_DATA CI_END="2.978685547154268" CI_START="0.149208245519253" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4740246581852024" LOG_CI_START="-0.8262071762965648" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-06-22 11:14:05 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1158" O_E="0.0" SE="0.7637626158259733" STUDY_ID="STD-Nishiyama-2011" TOTAL_1="8" TOTAL_2="8" VAR="0.5833333333333333" WEIGHT="0.45425417402510126"/>
<DICH_DATA CI_END="1.582047245986341" CI_START="0.2625134255812828" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.19921944905089536" LOG_CI_START="-0.5808484808036704" LOG_EFFECT_SIZE="-0.19081451587638756" MODIFIED="2015-06-22 11:14:18 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1159" O_E="0.0" SE="0.45821576339510056" STUDY_ID="STD-Palareti-1995" TOTAL_1="30" TOTAL_2="29" VAR="0.2099616858237548" WEIGHT="1.385860191940987"/>
<DICH_DATA CI_END="2.904573690925772" CI_START="0.40405623543916597" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4630823992858058" LOG_CI_START="-0.39355818676738197" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="288" O_E="0.0" SE="0.5031949206869324" STUDY_ID="STD-Schorr-2000" TOTAL_1="24" TOTAL_2="26" VAR="0.2532051282051282" WEIGHT="0.8721680141281943"/>
<DICH_DATA CI_END="1.8667096196429565" CI_START="0.47426225698922797" EFFECT_SIZE="0.9409090909090909" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.2710767655147337" LOG_CI_START="-0.3239814362453107" LOG_EFFECT_SIZE="-0.02645233536528848" MODIFIED="2015-06-22 11:14:29 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1160" O_E="0.0" SE="0.34954013329945455" STUDY_ID="STD-Schuster-1997" TOTAL_1="22" TOTAL_2="23" VAR="0.12217830478700045" WEIGHT="1.4805321227484782"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.196880758315505" CI_END="1.9165962803102439" CI_START="0.8342011484117267" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.264447238154463" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" I2="8.961831795844322" I2_Q="48.5478420723732" ID="CMP-001.11" LOG_CI_END="0.2825306409434484" LOG_CI_START="-0.07872921661373988" LOG_EFFECT_SIZE="0.10190071216485425" METHOD="MH" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NO="11" P_CHI2="0.3333909021732092" P_Q="0.16328354513233656" P_Z="0.26885829264854355" Q="1.9435530797495637" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01306813658747356" TOTALS="YES" TOTAL_1="1226" TOTAL_2="1228" WEIGHT="100.0" Z="1.105695646300699">
<NAME>Complications during the inpatient stay specific to the trial intervention</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.1311482483679816E-4" CI_END="2.731551124614609" CI_START="0.9563010017255121" DF="1" EFFECT_SIZE="1.6162255649300317" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="18" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.43640933332588305" LOG_CI_START="-0.019405389299975123" LOG_EFFECT_SIZE="0.20850197201295398" MODIFIED="2015-07-28 19:05:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9837839324353541" P_Z="0.07295997567372352" STUDIES="2" TAU2="0.0" TOTAL_1="1213" TOTAL_2="1216" WEIGHT="56.20021636018649" Z="1.7930809847333582">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="2.938303489443121" CI_START="0.8941381085858486" EFFECT_SIZE="1.620879120879121" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.46809665087677" LOG_CI_START="-0.04859539489059368" LOG_EFFECT_SIZE="0.2097506279930882" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="231" O_E="0.0" SE="0.30350746535062556" STUDY_ID="STD-Schmidt-1998" TOTAL_1="56" TOTAL_2="59" VAR="0.09211678152356119" WEIGHT="42.81156889985614"/>
<DICH_DATA CI_END="4.876265061160199" CI_START="0.5249919698563117" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6880873047130627" LOG_CI_START="-0.2798473394012129" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="232" O_E="0.0" SE="0.5685696013064878" STUDY_ID="STD-Warren-2001" TOTAL_1="1157" TOTAL_2="1157" VAR="0.3232713915298185" WEIGHT="13.388647460330349"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6604826262478225" CI_START="0.5131465951213093" DF="0" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.2202343359029833" LOG_CI_START="-0.2897585484214072" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2015-08-05 19:11:34 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="1.0" P_Z="0.7893229451956708" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="43.799783639813505" Z="0.2671899094634145">
<NAME>Trials with high bias risk</NAME>
<DICH_DATA CI_END="1.6604826262478225" CI_START="0.5131465951213093" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.2202343359029833" LOG_CI_START="-0.2897585484214072" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="233" O_E="0.0" SE="0.29957234475763905" STUDY_ID="STD-Langely-1993" TOTAL_1="13" TOTAL_2="12" VAR="0.08974358974358974" WEIGHT="43.799783639813505"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3926800222288014" CI_END="6.114147157900285" CI_START="0.0819794174604907" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7079789702190173" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="28.195997354824453" I2_Q="27.79513541008224" ID="CMP-001.12" LOG_CI_END="0.7863358873005952" LOG_CI_START="-1.0862951720721306" LOG_EFFECT_SIZE="-0.14997964238576764" METHOD="MH" MODIFIED="2016-01-04 09:22:58 +0000" MODIFIED_BY="Jane Cracknell" NO="12" P_CHI2="0.2379532368361409" P_Q="0.23926027623205626" P_Z="0.7535602826605529" Q="1.3849482381546268" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.7351962504091429" TOTALS="YES" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.31394833063248173">
<NAME>Complications during the inpatient stay not specific to the trial intervention</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.5152908317231" CI_START="0.12946791838627933" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-08-05 19:14:26 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="1.0" P_Z="0.49327758741034344" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="36.5927229103469" Z="0.6851051308492764">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-08-05 19:14:26 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="235" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="36.5927229103469"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.570642941500426" CI_START="0.036829135110362066" DF="0" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.41004175797114606" LOG_CI_START="-1.4338084799288948" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2015-08-05 19:14:26 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="1.0" P_Z="0.2764905467332214" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="63.40727708965311" Z="1.088236919877545">
<NAME>Trials with high bias risk</NAME>
<DICH_DATA CI_END="2.570642941500426" CI_START="0.036829135110362066" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41004175797114606" LOG_CI_START="-1.4338084799288948" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="234" O_E="0.0" SE="1.0830867569483633" STUDY_ID="STD-Langely-1993" TOTAL_1="13" TOTAL_2="12" VAR="1.1730769230769231" WEIGHT="63.40727708965311"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09117435099983998" CI_END="1.2491718282088693" CI_START="0.4186741861124124" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7231846226862838" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.09662218129671778" LOG_CI_START="-0.3781238152600415" LOG_EFFECT_SIZE="-0.14075081698166186" METHOD="MH" MODIFIED="2015-12-18 09:58:47 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.955436309883163" P_Q="0.9549907891301613" P_Z="0.2451685686978089" Q="0.003185549215850871" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="112" WEIGHT="100.0" Z="1.162164753697566">
<NAME>Complication specific to the trial intervention other than bleeding</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0683219164168825" CI_START="0.18332496241361623" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.4869009221574032" LOG_CI_START="-0.7367783953740032" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="1" P_CHI2="1.0" P_Z="0.6889885207073794" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="16.943521594684384" Z="0.40022809982635676">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="3.0683219164168825" CI_START="0.18332496241361632" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4869009221574032" LOG_CI_START="-0.736778395374003" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="237" O_E="0.0" SE="0.7187952884282608" STUDY_ID="STD-Fulia-2003" TOTAL_1="30" TOTAL_2="30" VAR="0.5166666666666666" WEIGHT="16.943521594684384"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0883593131599601" CI_END="1.2968828845029547" CI_START="0.3971937651993846" DF="1" EFFECT_SIZE="0.7177142857142856" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="29" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="0.11290075872816124" LOG_CI_START="-0.4009975772983956" LOG_EFFECT_SIZE="-0.14404840928511717" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="2" P_CHI2="0.7662734182041459" P_Z="0.27186560475074273" STUDIES="2" TAU2="0.0" TOTAL_1="45" TOTAL_2="82" WEIGHT="83.05647840531562" Z="1.098776448322747">
<NAME>Trials with high bias risk</NAME>
<DICH_DATA CI_END="1.8304347698732377" CI_START="0.21585147273163321" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.26255425679642225" LOG_CI_START="-0.6658449838525611" LOG_EFFECT_SIZE="-0.20164536352806942" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="238" O_E="0.0" SE="0.5453463096075717" STUDY_ID="STD-Eisele-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.2974025974025974" WEIGHT="28.239202657807308"/>
<DICH_DATA CI_END="1.5549891675784555" CI_START="0.37501257759620166" EFFECT_SIZE="0.7636363636363637" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="22" LOG_CI_END="0.19172736797553247" LOG_CI_START="-0.42595416616821924" LOG_EFFECT_SIZE="-0.11711339909634337" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="239" O_E="0.0" SE="0.3628291907289457" STUDY_ID="STD-Mitchell-2003" TOTAL_1="25" TOTAL_2="60" VAR="0.13164502164502165" WEIGHT="54.817275747508305"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.66255402758727" CI_END="1.8443283710636278" CI_START="1.3492615114223647" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.577492087302012" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="201" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.26583824700221637" LOG_CI_START="0.13009613200009038" LOG_EFFECT_SIZE="0.19796718950115338" METHOD="MH" MODIFIED="2015-12-21 08:59:05 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.5684773255665097" P_Q="0.991220417609595" P_Z="1.0851770683656077E-8" Q="1.2108354400383825E-4" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1492" TOTAL_2="1527" WEIGHT="100.0" Z="5.716848621915163">
<NAME>Bleeding events</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.311938449645201" CI_END="1.850355874518655" CI_START="1.3453534805551728" DF="4" EFFECT_SIZE="1.577777777777778" ESTIMABLE="YES" EVENTS_1="306" EVENTS_2="194" I2="36.628025892349385" ID="CMP-001.14.01" LOG_CI_END="0.2672552632550223" LOG_CI_START="0.12883640663244098" LOG_EFFECT_SIZE="0.19804583494373165" MODIFIED="2015-11-16 09:27:40 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.17703245660466305" P_Z="2.04060016917261E-8" STUDIES="6" TAU2="0.0" TOTAL_1="1396" TOTAL_2="1395" WEIGHT="96.02788820589745" Z="5.608523480818208">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="2.5838077352322197" CI_START="0.2687678479227214" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4122601940620972" LOG_CI_START="-0.5706226861573468" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="240" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Baudo-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.33333333333333337" WEIGHT="2.9704626751690943"/>
<DICH_DATA CI_END="1.9917413161804456" CI_START="0.39669983766031425" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.299232932355423" LOG_CI_START="-0.4015379772501856" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="241" O_E="0.0" SE="0.4116363011742823" STUDY_ID="STD-Fulia-2003" TOTAL_1="30" TOTAL_2="30" VAR="0.16944444444444445" WEIGHT="4.455694012753642"/>
<DICH_DATA CI_END="15.539663588267699" CI_START="0.07387284654863233" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1914416127055374" LOG_CI_START="-1.1315151659506513" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="242" O_E="0.0" SE="1.3645163106041502" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="15" VAR="1.861904761904762" WEIGHT="0.4780054879582451"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="243" O_E="0.0" SE="0.0" STUDY_ID="STD-Maki-2000" TOTAL_1="74" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7077516836337563" CI_START="0.8907097710332741" EFFECT_SIZE="1.2333333333333334" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" LOG_CI_END="0.23242472216816004" LOG_CI_START="-0.050263783473494854" LOG_EFFECT_SIZE="0.09108046934733258" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="244" O_E="0.0" SE="0.16605262754457914" STUDY_ID="STD-Schmidt-1998" TOTAL_1="61" TOTAL_2="61" VAR="0.027573475114458724" WEIGHT="14.852313375845473"/>
<DICH_DATA CI_END="2.0739803460982955" CI_START="1.4313712621144712" EFFECT_SIZE="1.722972972972973" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="148" LOG_CI_END="0.31680463651710056" LOG_CI_START="0.15575229356089498" LOG_EFFECT_SIZE="0.2362784650389978" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="245" O_E="0.0" SE="0.09460294347443018" STUDY_ID="STD-Warren-2001" TOTAL_1="1157" TOTAL_2="1157" VAR="0.008949716914026233" WEIGHT="73.271412654171"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3471267429672877" CI_END="3.4886264240709224" CI_START="0.7070801240237904" DF="4" EFFECT_SIZE="1.5705853700467034" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.5426544659654464" LOG_CI_START="-0.15053137057401972" LOG_EFFECT_SIZE="0.19606154769571335" MODIFIED="2015-11-16 09:27:40 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.8533306177220816" P_Z="0.2675521645042642" STUDIES="5" TAU2="0.0" TOTAL_1="96" TOTAL_2="132" WEIGHT="3.972111794102551" Z="1.1087173221979179">
<NAME>Trials with high bias risk</NAME>
<DICH_DATA CI_END="8.3444766693104" CI_START="0.26963943805788637" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9213991047351494" LOG_CI_START="-0.569216586623787" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2015-11-16 09:27:40 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="304" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Gando-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="0.9901542250563649"/>
<DICH_DATA CI_END="77.58264493737863" CI_START="0.151517160188397" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8897645814270687" LOG_CI_START="-0.8195381780323703" LOG_EFFECT_SIZE="0.5351132016973492" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="246" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Grenander-2001" TOTAL_1="13" TOTAL_2="15" VAR="2.532738095238095" WEIGHT="0.23103598584648513"/>
<DICH_DATA CI_END="3.3138380098347344" CI_START="0.40175800470462913" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5203312750083746" LOG_CI_START="-0.3960354615106857" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="247" O_E="0.0" SE="0.5382783571197989" STUDY_ID="STD-Langely-1993" TOTAL_1="13" TOTAL_2="12" VAR="0.28974358974358977" WEIGHT="2.059520788117239"/>
<DICH_DATA CI_END="18.57250990961889" CI_START="0.03293061684900747" EFFECT_SIZE="0.782051282051282" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2688705987446076" LOG_CI_START="-1.4824001341040343" LOG_EFFECT_SIZE="-0.10676476767971337" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="248" O_E="0.0" SE="1.6161100474850645" STUDY_ID="STD-Mitchell-2003" TOTAL_1="25" TOTAL_2="60" VAR="2.6118116855821776" WEIGHT="0.44386223881837045"/>
<DICH_DATA CI_END="96.12715085961011" CI_START="0.260072204121721" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2015-06-24 18:09:00 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="367" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Neporada-2008A" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.24753855626409121"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="24.884680752630338" CI_END="668.3379226962502" CI_START="-391.3491785939572" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="138.4943720511465" ESTIMABLE="YES" I2="87.94439024626467" I2_Q="84.1823325934886" ID="CMP-001.15" MODIFIED="2015-12-18 10:42:12 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.6321973488997443E-5" P_Q="0.011924624132615302" P_Z="0.6084342917416483" Q="6.322044675110228" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="208536.0459125892" TOTALS="YES" TOTAL_1="67" TOTAL_2="70" UNITS="" WEIGHT="99.99999999999999" Z="0.5123096826435746">
<NAME>Amount of red blood cells administered</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-300.82028598253476" CI_START="-899.1797140174652" DF="0" EFFECT_SIZE="-600.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.01" MODIFIED="2015-07-28 19:05:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="8.470751340109613E-5" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="18" WEIGHT="31.52223027530737" Z="3.930675562633175">
<NAME>Trials with low bias risk</NAME>
<CONT_DATA CI_END="-300.82028598253476" CI_START="-899.1797140174652" EFFECT_SIZE="-600.0" ESTIMABLE="YES" MEAN_1="500.0" MEAN_2="1100.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="249" SD_1="400.0" SD_2="500.0" SE="152.64551613058026" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" WEIGHT="31.52223027530737"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.197257685307022" CI_END="1477.3403816480363" CI_START="-287.139322636104" DF="2" EFFECT_SIZE="595.1005295059662" ESTIMABLE="YES" I2="82.13848375906908" ID="CMP-001.15.02" MODIFIED="2015-06-23 14:19:50 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.003702944442964262" P_Z="0.1861475735190284" STUDIES="3" TAU2="471545.2091366128" TOTAL_1="50" TOTAL_2="52" WEIGHT="68.47776972469262" Z="1.322061797798479">
<NAME>Trials with high bias risk</NAME>
<CONT_DATA CI_END="1306.4362418383048" CI_START="-166.4362418383048" EFFECT_SIZE="570.0" ESTIMABLE="YES" MEAN_1="1500.0" MEAN_2="930.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="250" SD_1="938.0" SD_2="1050.0" SE="375.7396807529219" STUDY_ID="STD-Baudo-1992" TOTAL_1="13" TOTAL_2="15" WEIGHT="20.896963361326563"/>
<CONT_DATA CI_END="2957.1782506416307" CI_START="560.8217493583693" EFFECT_SIZE="1759.0" ESTIMABLE="YES" MEAN_1="2847.0" MEAN_2="1088.0" MODIFIED="2015-06-23 14:19:50 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="1154" SD_1="2094.0" SD_2="1403.0" SE="611.3266672718008" STUDY_ID="STD-Blauhut-1985" TOTAL_1="17" TOTAL_2="17" WEIGHT="12.551189786544453"/>
<CONT_DATA CI_END="-16.64527476166219" CI_START="-53.35472523833781" EFFECT_SIZE="-35.0" ESTIMABLE="YES" MEAN_1="195.0" MEAN_2="230.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="251" SD_1="35.0" SD_2="23.0" SE="9.364827814754525" STUDY_ID="STD-Inthorn-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="35.02961657682161"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9836927833489012" CI_END="1.265050217941413" CI_START="0.8472291861370536" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0352716873212584" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.10210776578216525" LOG_CI_START="-0.07199909166362461" LOG_EFFECT_SIZE="0.01505433705927031" METHOD="MH" MODIFIED="2015-12-18 09:58:36 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.6114963444651473" P_Q="1.0" P_Z="0.7346543311710005" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="52" WEIGHT="100.0" Z="0.3389407962461612">
<NAME>Incidence of surgical intervention</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9836927833489012" CI_END="1.265050217941413" CI_START="0.8472291861370536" DF="2" EFFECT_SIZE="1.0352716873212584" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="30" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.10210776578216525" LOG_CI_START="-0.07199909166362461" LOG_EFFECT_SIZE="0.01505433705927031" MODIFIED="2015-08-05 19:10:48 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.6114963444651473" P_Z="0.7346543311710005" STUDIES="3" TAU2="0.0" TOTAL_1="51" TOTAL_2="52" WEIGHT="100.0" Z="0.3389407962461612">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="15.619811043133367" CI_START="0.07177470094485151" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1936757758011496" LOG_CI_START="-1.144028608351085" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="254" O_E="0.0" SE="1.373179127074352" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" VAR="1.8856209150326797" WEIGHT="3.241182078169685"/>
<DICH_DATA CI_END="1.297207292520502" CI_START="0.6477590610403521" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.11300938148452361" LOG_CI_START="-0.1885865032633232" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="255" O_E="0.0" SE="0.17715891562459227" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="14" VAR="0.031385281385281405" WEIGHT="40.03813155386082"/>
<DICH_DATA CI_END="1.3785024360948266" CI_START="0.9061536021913553" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.13940753792935562" LOG_CI_START="-0.04279817878024559" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2015-08-05 19:10:48 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="256" O_E="0.0" SE="0.10702853992806366" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.011455108359133118" WEIGHT="56.72068636796949"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.8342313658737432" CI_END="-0.289311256216506" CI_START="-2.184948291799053" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2371297740077793" ESTIMABLE="YES" I2="47.83830684290903" I2_Q="72.68658143380325" ID="CMP-001.17" MODIFIED="2015-12-18 09:58:32 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.1470305625785222" P_Q="0.05569357745368719" P_Z="0.01052090258003461" Q="3.6612040985510537" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.3542301578093293" TOTALS="YES" TOTAL_1="80" TOTAL_2="76" UNITS="" WEIGHT="100.00000000000001" Z="2.558221595952605">
<NAME>Severity of sepsis I</NAME>
<GROUP_LABEL_1>ATIII</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.17987499341163482" CI_START="-1.2201250065883655" DF="0" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.01" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="1" P_CHI2="1.0" P_Z="0.008345096162724767" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="43" WEIGHT="55.07050368366619" Z="2.6377789412148753">
<NAME>Final MOF score among survivors, trials with low bias risk</NAME>
<CONT_DATA CI_END="-0.17987499341163482" CI_START="-1.2201250065883655" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="4.5" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="257" SD_1="0.7" SD_2="1.6" SE="0.26537477764440826" STUDY_ID="STD-Baudo-1998" TOTAL_1="45" TOTAL_2="43" WEIGHT="55.07050368366619"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1730272673226917" CI_END="-0.7839909743621609" CI_START="-3.051613600656252" DF="1" EFFECT_SIZE="-1.9178022875092064" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.02" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" NO="2" P_CHI2="0.6774355682727399" P_Z="9.157406856091907E-4" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="33" WEIGHT="44.929496316333825" Z="3.3152107139886056">
<NAME>Final MOF score among survivors, trials with high bias risk</NAME>
<CONT_DATA CI_END="0.2782540250495653" CI_START="-3.4782540250495657" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="2.5" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="258" SD_1="1.4" SD_2="3.2" SE="0.9583104791031842" STUDY_ID="STD-Eisele-1998" TOTAL_1="15" TOTAL_2="13" WEIGHT="18.376634884178927"/>
<CONT_DATA CI_END="-0.6778438661330268" CI_START="-3.5221561338669742" EFFECT_SIZE="-2.1000000000000005" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="4.4" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="259" SD_1="1.8" SD_2="2.7" SE="0.7256031973468695" STUDY_ID="STD-Inthorn-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="26.552861432154895"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2461137537282023" CI_END="-0.0019992124841374803" CI_START="-4.364999659740723" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.18349943611243" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2015-12-18 09:58:28 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.8842133741874704" P_Q="1.0" P_Z="0.0497904125905892" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="1.9617601725137759">
<NAME>Severity of sepsis II</NAME>
<GROUP_LABEL_1>ATIII</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.2461137537282023" CI_END="-0.0019992124841374803" CI_START="-4.364999659740723" DF="2" EFFECT_SIZE="-2.18349943611243" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.01" MODIFIED="2015-06-03 10:00:33 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.8842133741874704" P_Z="0.0497904125905892" STUDIES="3" TAU2="0.0" TOTAL_1="52" TOTAL_2="50" WEIGHT="100.0" Z="1.9617601725137759">
<NAME>Final APACHE I &amp; II scores among survivors, trials with high bias risk</NAME>
<CONT_DATA CI_END="1.566295860816676" CI_START="-6.766295860816675" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="14.4" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="260" SD_1="5.9" SD_2="4.5" SE="2.1257002137181527" STUDY_ID="STD-Diaz_x002d_Cremades-1994" TOTAL_1="13" TOTAL_2="11" WEIGHT="27.416392519034247"/>
<CONT_DATA CI_END="1.588644697654518" CI_START="-4.788644697654517" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.6" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="261" SD_1="4.8" SD_2="3.8" SE="1.6268894340947793" STUDY_ID="STD-Eisele-1998" TOTAL_1="15" TOTAL_2="13" WEIGHT="46.80564823745845"/>
<CONT_DATA CI_END="1.4966600663118603" CI_START="-7.096660066311858" EFFECT_SIZE="-2.799999999999999" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="11.6" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="262" SD_1="6.1" SD_2="9.2" SE="2.1922137856630863" STUDY_ID="STD-Schorr-2000" TOTAL_1="24" TOTAL_2="26" WEIGHT="25.77795924350731"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.383561830112525" CI_END="1.1380858520808586" CI_START="0.7602273265966151" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9301634075606617" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="137" I2="31.562502908211727" I2_Q="8.87708751817069" ID="CMP-001.19" LOG_CI_END="0.05617502451830703" LOG_CI_START="-0.11905652360844653" LOG_EFFECT_SIZE="-0.03144074954506977" METHOD="MH" MODIFIED="2015-12-18 10:53:33 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.2229146628801003" P_Q="0.2948337497404121" P_Z="0.4818505906029197" Q="1.097418829978035" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01348836680958425" TOTALS="YES" TOTAL_1="1293" TOTAL_2="1298" WEIGHT="100.00000000000001" Z="0.7033292510856106">
<NAME>Incidence of respiratory failure not present at admission</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3165212775225115" CI_END="1.2152637540416218" CI_START="0.7706820249708177" DF="2" EFFECT_SIZE="0.9677716315528343" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="123" I2="39.695848974199" ID="CMP-001.19.01" LOG_CI_END="0.08467054500728985" LOG_CI_START="-0.11312477017841631" LOG_EFFECT_SIZE="-0.014227112585563225" MODIFIED="2015-12-18 10:53:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1904701850274213" P_Z="0.7779784872410733" STUDIES="5" TAU2="0.016320207597601267" TOTAL_1="1282" TOTAL_2="1282" WEIGHT="85.75274246307094" Z="0.2819543854769276">
<NAME>Trials with low bias risk</NAME>
<DICH_DATA CI_END="1.295825620355941" CI_START="0.8651683134093593" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.11254656232732962" LOG_CI_START="-0.0628993948772653" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="265" O_E="0.0" SE="0.10305782373347373" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" VAR="0.010620915032679742" WEIGHT="43.94561289074922"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="266" O_E="0.0" SE="0.0" STUDY_ID="STD-Kobayashi-2003" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="267" O_E="0.0" SE="0.0" STUDY_ID="STD-Maki-2000" TOTAL_1="74" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1211498217229072" CI_START="0.6349856626708272" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="96" LOG_CI_END="0.04966365220231276" LOG_CI_START="-0.19723608052415006" LOG_EFFECT_SIZE="-0.07378621416091867" MODIFIED="2015-12-18 10:53:33 +0000" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.14503012517691224" STUDY_ID="STD-Warren-2001" TOTAL_1="1157" TOTAL_2="1157" VAR="0.02103373720883084" WEIGHT="30.690399587143823"/>
<DICH_DATA CI_END="1.751768239998783" CI_START="0.5708517697527697" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.2434766482090442" LOG_CI_START="-0.2434766482090442" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-05 19:09:49 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="270" O_E="0.0" SE="0.2860387767736777" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.08181818181818183" WEIGHT="11.116729985177896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1795486655803789" CI_START="0.4484135629744967" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.07171586362518814" LOG_CI_START="-0.34832125995775104" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2015-08-05 19:09:49 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="1.0" P_Z="0.1968121023059798" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="16" WEIGHT="14.247257536929066" Z="1.2906873804791266">
<NAME>Trials with high bias risk</NAME>
<DICH_DATA CI_END="1.1795486655803789" CI_START="0.4484135629744967" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.07171586362518814" LOG_CI_START="-0.34832125995775104" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="269" O_E="0.0" SE="0.24673188560991335" STUDY_ID="STD-Eisele-1998" TOTAL_1="11" TOTAL_2="16" VAR="0.06087662337662336" WEIGHT="14.247257536929066"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.23334261772867704" CI_END="5.59718782073639" CI_START="-1.2050366628107563" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.196075578962817" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.20" MODIFIED="2015-12-18 09:58:19 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.8898776431605779" P_Q="0.9467525139362915" P_Z="0.2056793759025266" Q="0.004460295135928119" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="96" UNITS="" WEIGHT="100.0" Z="1.265535723646259">
<NAME>Duration of mechanical ventilation</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.22888232259274893" CI_END="6.215360560850996" CI_START="-1.6862108962011204" DF="1" EFFECT_SIZE="2.264574832324938" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.01" MODIFIED="2015-08-05 19:10:03 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.6323538315452017" P_Z="0.2612491414432555" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="81" WEIGHT="74.10968656384007" Z="1.1234436430215113">
<NAME>Trials with low bias risk</NAME>
<CONT_DATA CI_END="7.9685104435904295" CI_START="-1.9685104435904295" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="4.8" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="271" SD_1="14.0" SD_2="14.0" SE="2.5350008891905187" STUDY_ID="STD-Schmidt-1998" TOTAL_1="61" TOTAL_2="61" WEIGHT="46.85862223006088"/>
<CONT_DATA CI_END="7.5152221733928695" CI_START="-5.5152221733928695" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="12.0" MODIFIED="2015-08-05 19:10:03 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="273" SD_1="5.0" SD_2="14.0" SE="3.3241540277189325" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="27.251064333779194"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.684244239478112" CI_START="-4.684244239478111" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.02" MODIFIED="2015-08-05 19:10:03 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="1.0" P_Z="0.5575778858786284" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="15" WEIGHT="25.89031343615993" Z="0.5864429587908306">
<NAME>Trials with high bias risk</NAME>
<CONT_DATA CI_END="8.684244239478112" CI_START="-4.684244239478111" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="9.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="272" SD_1="9.0" SD_2="9.0" SE="3.410391360352831" STUDY_ID="STD-Grenander-2001" TOTAL_1="13" TOTAL_2="15" WEIGHT="25.89031343615993"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.677708958800963" CI_END="9.355216069505527" CI_START="-7.164947465206396" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0951343021495656" ESTIMABLE="YES" I2="74.31002938518145" I2_Q="79.27206876751227" ID="CMP-001.21" MODIFIED="2015-12-18 09:58:15 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.00857285897885729" P_Q="0.028059608400937686" P_Z="0.7949756014731911" Q="4.824408132118169" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="51.43717510052459" TOTALS="YES" TOTAL_1="102" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="0.2598550293933254">
<NAME>Length of stay in hospital</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.1323849566676483" CI_END="4.900888597678231" CI_START="-16.24030372113502" DF="1" EFFECT_SIZE="-5.669707561728394" ESTIMABLE="YES" I2="53.10415237768632" ID="CMP-001.21.01" MODIFIED="2015-08-05 19:10:17 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.1442162768463091" P_Z="0.29314017671107684" STUDIES="2" TAU2="30.970341666666663" TOTAL_1="44" TOTAL_2="45" WEIGHT="45.14845465623585" Z="1.05125789087811">
<NAME>Trials with low bias risk</NAME>
<CONT_DATA CI_END="-1.1111907370486485" CI_START="-20.48880926295135" EFFECT_SIZE="-10.799999999999999" ESTIMABLE="YES" MEAN_1="14.9" MEAN_2="25.7" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="274" SD_1="16.7" SD_2="17.9" SE="4.943360867534016" STUDY_ID="STD-Haire-1998" TOTAL_1="24" TOTAL_2="25" WEIGHT="23.40882299706747"/>
<CONT_DATA CI_END="10.782028916732509" CI_START="-10.782028916732509" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="34.0" MODIFIED="2015-08-05 19:10:17 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="276" SD_1="19.5" SD_2="15.0" SE="5.5011362462676745" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="21.739631659168378"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.25676188994017585" CI_END="11.587819256945625" CI_START="2.751194572459293" DF="1" EFFECT_SIZE="7.169506914702459" ESTIMABLE="YES" I2="0.0" ID="CMP-001.21.02" MODIFIED="2015-08-05 19:10:17 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.6123535976255279" P_Z="0.0014707478845793068" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="55" WEIGHT="54.85154534376416" Z="3.180394288873102">
<NAME>Trials with high bias risk</NAME>
<CONT_DATA CI_END="12.846669394878376" CI_START="2.7533306051216266" EFFECT_SIZE="7.800000000000001" ESTIMABLE="YES" MEAN_1="28.8" MEAN_2="21.0" MODIFIED="2015-06-23 16:08:41 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="368" SD_1="7.2" SD_2="6.9" SE="2.5748786379167465" STUDY_ID="STD-Neporada-2008A" TOTAL_1="15" TOTAL_2="15" WEIGHT="30.58734715929187"/>
<CONT_DATA CI_END="14.243198156588184" CI_START="-4.043198156588188" EFFECT_SIZE="5.099999999999998" ESTIMABLE="YES" MEAN_1="34.3" MEAN_2="29.2" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="275" SD_1="22.0" SD_2="20.5" SE="4.664982738819981" STUDY_ID="STD-Smith_x002d_Erichsen-1996" TOTAL_1="43" TOTAL_2="40" WEIGHT="24.26419818447229"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.8160610306425107" CI_END="1.8300572940380817" CI_START="-1.3406918649765205" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.24468271453078058" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.22" MODIFIED="2015-12-18 09:58:12 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.7015520213310908" P_Q="0.377913648286773" P_Z="0.7622740599347563" Q="0.7774778778538445" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="191" TOTAL_2="185" UNITS="" WEIGHT="99.99999999999999" Z="0.3024958986467821">
<NAME>Mean length of stay in ICU</NAME>
<GROUP_LABEL_1>AT III</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.067676551397814" CI_END="1.9520419314323028" CI_START="-3.405473723229958" DF="2" EFFECT_SIZE="-0.7267158958988275" ESTIMABLE="YES" I2="3.2730724422087523" ID="CMP-001.22.01" MODIFIED="2015-11-17 10:15:26 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.35563944659542324" P_Z="0.5949230764912141" STUDIES="3" TAU2="0.0" TOTAL_1="97" TOTAL_2="98" WEIGHT="35.02651060796542" Z="0.5317154721573097">
<NAME>Trials with low bias risk</NAME>
<CONT_DATA CI_END="1.685408748074733" CI_START="-5.085408748074732" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="14.5" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="277" SD_1="9.0" SD_2="9.9" SE="1.7272811004581738" STUDY_ID="STD-Baudo-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="21.93014768252564"/>
<CONT_DATA CI_END="8.749271359030073" CI_START="-2.7492713590300735" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="11.0" MODIFIED="2015-11-17 10:15:26 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="280" SD_1="10.0" SD_2="7.0" SE="2.9333556148886366" STUDY_ID="STD-Fourrier-1993" TOTAL_1="17" TOTAL_2="18" WEIGHT="7.603930974899152"/>
<CONT_DATA CI_END="4.764715677803376" CI_START="-8.764715677803377" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="21.0" MODIFIED="2015-08-05 19:10:28 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="282" SD_1="6.5" SD_2="14.0" SE="3.4514489710844636" STUDY_ID="STD-Waydhas-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.492431950540629"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9709066013908516" CI_END="2.7351695582253206" CI_START="-1.1984630043096343" DF="3" EFFECT_SIZE="0.7683532769578433" ESTIMABLE="YES" I2="0.0" ID="CMP-001.22.02" MODIFIED="2015-11-17 10:15:26 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.8082912154507238" P_Z="0.44386889713373734" STUDIES="4" TAU2="0.0" TOTAL_1="94" TOTAL_2="87" WEIGHT="64.97348939203457" Z="0.7656763697676048">
<NAME>Trials with high bias risk</NAME>
<CONT_DATA CI_END="6.934930695491358" CI_START="-6.934930695491358" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.0" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="278" SD_1="11.5" SD_2="8.25" SE="3.53829496367954" STUDY_ID="STD-Albert-1992" TOTAL_1="16" TOTAL_2="16" WEIGHT="5.226121833500375"/>
<CONT_DATA CI_END="2.84453957461322" CI_START="-3.2645395746132198" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="3.05" MEAN_2="3.26" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="279" SD_1="4.28" SD_2="4.92" SE="1.5584671956765725" STUDY_ID="STD-Diaz_x002d_Cremades-1994" TOTAL_1="20" TOTAL_2="16" WEIGHT="26.9384292005234"/>
<CONT_DATA CI_END="4.991467854834393" CI_START="-2.3914678548343913" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="12.0" MODIFIED="2015-06-05 21:13:56 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="369" SD_1="6.1" SD_2="4.0" SE="1.8834365753412916" STUDY_ID="STD-Neporada-2008A" TOTAL_1="15" TOTAL_2="15" WEIGHT="18.444445295287146"/>
<CONT_DATA CI_END="6.382989152149874" CI_START="-1.982989152149874" EFFECT_SIZE="2.2" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="6.2" MODIFIED="2008-01-14 14:15:14 +0000" MODIFIED_BY="Karen Hovhannisyan" ORDER="281" SD_1="9.4" SD_2="10.0" SE="2.1342173555967143" STUDY_ID="STD-Smith_x002d_Erichsen-1996" TOTAL_1="43" TOTAL_2="40" WEIGHT="14.364493062723657"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-01-04 10:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup">
<FIGURE FILENAME="Skærmbillede 2016-01-04 kl. 10.55.58.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-01-04 10:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABTAAAAHZCAYAAACxaRQ7AACAAElEQVR42uy9C7xN1d7//8idyLWD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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-01-04 09:16:50 +0000" MODIFIED_BY="Jane Cracknell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-01-04 09:16:50 +0000" MODIFIED_BY="Jane Cracknell" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias graph summarized</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWEAAATZCAIAAACKPDI/AABGVUlEQVR42u3dvW4kRf/28ZGQEIED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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot, overall mortality regardless of follow-up and bias Analysis 1.1</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Skærmbillede 2015-07-29 kl. 14.02.18.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of all trials with low risk of bias of the effect of AT III on mortality. Cumulative Z-curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low-bias heterogeneity-adjusted information size of 23,634 participants corresponding to a RRR of 5% with an &#945; = 0.05 and a power of 80% (&#946; = 0.20). Only 16.43 % of the required information size has been reached so far.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7AAAAJXCAYAAACqi7hMAACAAElEQVR42uzdB3hUdaL38feue9/t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</FILE>
</FIGURE>
<FIGURE FILENAME="Skærmbillede 2015-07-29 kl. 13.54.56.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis (TSA) of all trials of the effect of AT III on mortality. Cumulative Z-curve in blue does not cross the boundary constructed for an information size of 5037 in the meta-analysis (full red line with open diamonds) with a RRR of 10% (&#945; = 0.05) and a power of 80% (&#946; = 0.20). However, the cumulative Z-curve breaks through the boundary for futility (non-superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 3882.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7QAAAJyCAYAAAD0AYyzAACAAElEQVR42uzdB3hVdYL//312dnbn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</FILE>
</FIGURE>
<FIGURE FILENAME="Skærmbillede 2015-07-29 kl. 14.23.21.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis (TSA) of all trials of sepsis and DIC examining the effect of AT III on mortality. Cumulative Z-curve in blue does not cross the boundary constructed for an information size of 3794 in the meta-analysis (full red line with open diamonds) with a RRR of 10% (&#945; = 0.05) and a power of 80% (&#946; = 0.20). However, the cumulative Z-curve breaks through the boundary for futility (non-superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 2992.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7IAAAJUCAYAAAAo6hrfAACAAElEQVR42uy9B5gc1Zmvf59n7967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</FILE>
</FIGURE>
<FIGURE FILENAME="Skærmbillede 2015-07-29 kl. 14.25.55.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of all trials of Sepsis and DIC with low risk of bias examining the effect of AT III on mortality. Cumulative Z-curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low bias heterogeneity adjusted information size of 21,657 participants corresponding to a RRR of 5% with an &#945; = 0.05 and a power of 80% (&#946; = 0.20). Only 13.82 % of the required information size has been reached so far.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7UAAAJFCAYAAAACvNCYAACAAElEQVR42uzdB2CV9aH//9v2dtze
2/v799qldVWrdbbeWutiaK2KCggqLqyKKDiQIQoCsvc2kABh77DDLnvvDSEhYYQkZBCy19knn//3
+5xzIAyteqmE8n7Zb0/ynJEznoS8832e5/ybAAAAAAC4TP0bTwEAAAAAgKgFAAAAAICoDfF73HK7
fRfvBgNlysjIV+AffV13hdz+StYMAAAAACBqv4FKj9J2zdbUcfFaFD9Jc3dk/MMQ/Qo3qmB5gvq2
XajyC51XcUqnygOqrAzq1P712p3rZc0AAAAAAKL268dnedYGtXz+XjV8oYv6dm2khoPWqMJEZ8ap
CucSFbkZOlUWUEVBrnLzspS0P0k5xWXKT0/W/kMZqrAFbGdl0/KcGA7Y6+aWK1C0UU//YqgKTTTn
HjeX3X9QafnlqvSXKnnJ5xqxdL8OpyRr4+T+mp1crFNpGTKda0LXr7y0NJUGKuUuylLC/j1KySi4
CKENAAAAAPiXilo7U3o47i3d+cYiucPLyktKVZI8S91mHHLOT57VR3EJZUpZEq2uY2do1MD++mxw
tGZNHaN+ffpoblKhMyvb58MFKq80kRy+bqB4i56/N1r5vhytmjFJsSNjNKjPbOWVn9D0j+ro+Y6j
NHvWdI3q00pLUnK0fFBbrcn2KeDJ0vBWw5RceEKzB4/RqNgojRo+SntPeVh7LsmfPUIDAAAAAKpf
1AYD2jXgMX26KrfqQhVv660/d9nsnL+t35PqvDFPO4Y8oXs6LNWhhHjd9Zs/auyGg9o56TU9NmSn
Myv75FWDVWiuW7Ktn7nuptNRW+DO0trFy7V6+TT95UdPa1uJS4fm9FaXeQnKzUnVgpY3qtfmLG3s
cZ9enJmqwtQ5evC+oUpNmqqbf/CuFq9frejX7lX7pSdYe/5J0fplFWtnyP1mBHmqAAAAAFTHqE0Y
/YLqd96sCidk/CotLFbhjn6q2X2LOd+rtZ/dr95b8kz8NlT/XeUKBnM04J0YFZuArdg7VI/12moC
dpPq3jTEidpTq7vrsT5bw1H7uXJO7VLP/iMUM7yv7v7RC9pWGlDh1hj1XXVKQb9XOwc+rz7b8lWc
Mkt3Nu6oYd3e1/vzDitv62B9//oWGjt+nIZ1/1ij12ew9vwTgjYYadjKKgvCC+2n9tBh3nDcAgAA
AED12qfWRuje8XrwzrYaMzde8fEzNHfZHhUkxOrRRn0Uv3KJuj3w7xq8rcBEbQP12lZoorZAoz6K
1Sk7o7trgBO1wbI9anLTe5o6b6Wmt3xUTw7eHoraBwbp+K5oXf/X/lq3YZHe/vnLTtTm74zWy21G
am9GgXYOfUl9thcq4M3U0Kd/oR/8+k1tLfCpJDlO97/SQ7M3btWmBat1vMTP2vNPiNpAeFRWVgnb
yjNRGwiHLTO1AAAAAKpf1DoxU6GtM3qpQYMGatjwOfWNPyB/+WHFmM8btGyp1s89p8VHK3Q0vq9m
pZSZDi7VsvHLVWIqqOJovLrMSjHLSrQ2ppW5jZb6zN7G4mMKViSrf9fFKji5R70btlSHnn30Udth
OuwKqiJjg1o//4JGbU7XkeXDNOdwubkNv5IXdlGjbiuc/XuDgSKtsbf5aQ91fr6t1qa7WXsusmA4
WP3mtQyYUfkF4Xt6NhcAAAAAUXtlPuyAfN9w+9WAz6cA277+86LWxKzL45HP71fwS8KWqAUAAABw
BUctqqNKE7HFJSVasGiRtm7bKr8J2y+asQUAAAAAohbVKmjdLpdmTI/TnXfdpXr16+lgQoKzPFBZ
JWuZpgUAAABwOUdtwO+TzxcZ/gu8BYzfiSNfkPK5nILWjsJT+Xrr5cb60b9/X9f84peaNG6Cc34w
GCRqAQAAAPwLRG1lQBl712nVuo3auGqqpk2bobwqByGu9ORr19w4LVg0S9M2HnUOOoTLJ2q9bo9W
xi/SY3+8X3979gUdTU4xL3lQlUFmagEAAAD8C0RtZaVHu2YOVe8h0Rrw/o363q01lOw+Uzvu4/P1
yPUPqFPv1nqu73KVmaVBV4GOJSYo6Vhu6K1gvMU6aj5PSDmuEq8JpkCFsrNPKj0lSTnlfgXdxUq1
5x/Jlpt4+nYFTNh6vJoXO0mzo8eFNj32+ELv73OBt/gBAAAAgMtyn9qgK1ux7d7U42P36PSBiO37
1B4cq1se7aT5m5JV6PKbRWXaO26kRg4fpuFjFirLW6p9Uz5X1Oef6/OYYYqemqDy0mQN6dhFI6OG
a33aKe2fNF7jRozQ8BFjNC+pgDXk2/yjhT8ov8+nlNUbtHbUJPP6BRV0+80L7jNdGwx1LFELAAAA
4HKO2spKr44u6qLba3VXmrdSpZmJWr1mjTbtOyGfO11jGtTXo2/31ICxK3Wq7ICa/7Kh1h7NVsqW
9Tqaf0Dv/exeLUzMUOquabr35+/rYM4WPXnNvYrbmqjsk/v03g9+q+FL12th1Nu6td1y+VlHvr3X
1kasidpjc+dp18DhoT9g2PdeqnTJ5K7zWoTCtjI0AAAAABC1l1n2qCxzm9575gFNOVDihE3Gpslq
1aq1uozcoDK3S56AR4e3TNGd3/u9lhxer7p/GKAie1W/R2V5G/T4rX1VaK7nd2Wp4y31tC5ts55/
ZJhKTTZ5CzboL9//jXqOGavooV30Qr+1crOOfGuC4ahNnz1L+/t/7iwL+GzKltt3FpaXqAUAALjM
fn2vtEd6lczveLK/1wUqnS0sQ5+HDwYaNMs9LvP7euX51/X7wpcND3/wYv3iaW4vUB1+ATaP3XPO
fTGPOxgIPVdnXc6Uiccbel7s+aefk0D48fjOXkbUVtPviaBXWwfV1/ce7a31GzdqzfxNyioPnl7p
85M2atKseK2aO02tbn9Ay47u13t/eFuj4uM1f8YKHc5N1Id/flcxc+Zp7vTBaly7n46cNFH74FAT
vpXyldnz31HM3I3atmmB9hwv4QfRJYna2dpH1AIAAFz+yvOl7SukWcukzVulzCLpVLq0fKW0ZZ/k
Mr/rZR6XFm+UyoJnh12pue7OtdKyJeb6s6R1W6Tkk//HXzhN8OUclpaY+7My7dI+NxXF0r7N0uwF
5v6skQpMtHpN3KeY52WZeX4iLWIvt9tcbubfpW27pUKz/NA2ae5saYN9TrLNMvO8bF4lrVpunstF
0tpd0hXUtZdZ1JZraacGatCglTp1+kytn+uiLTm+01F7ctcMc159tXi2gbpM3SJXpV8JC4eoQf36
avhcXyWWBpS8Itp8Xk8Nnmuk+XtPyV92SP27LTXZZG/fnj9WDRt8qp6dX1Ds2nR+EBG1AAAA+KaO
75Q6vCA16iSNGGXiLMmE2EypyUfSoH7SgWMm1mKlj6bp7E0kTeDmHJUmD5JavCPde780MFpaZGIu
t1hOsVWUSll5Jn4LTBhnmrgzsZobDkFPhZR2xCwzt1/qPTuyl46Unm4ovTj/nF9G/aE4PJRsbrcg
NBvqMl8j44S5LRPAxWVmeYZ0wnxcaG6/olA6bB7PEbOsws6QeqQ8E5gZpiEyC8/EuTPrGhlVwj3X
3LeJA8xz8YHU8BVpfIK5vrmt6O7m85elOcn2KLfSHhO0TdpIb5nnK26e+Zpm+bhPzWN4SRpunruV
5j5kJEqje0s9PpFeNY+tcV/JS9Rexkz+nLspQcB39h8qzOdfurXBPzofRC0AAAC+QtTukgabKJ24
VEowkXnKBOG6qdKAKdKCMdKkidIQE3FpZV9wIFDzS/l2E3Vtu5nodZkINlEbE28+NtG4d500YZmJ
ZBOn/UZLQ00Aj5luvoYJ0gPrpZF2mRkzt+r0gXJKTRAf3CTNnSO1mXf21zlhInr8WBPfJnrjFpj7
niPtXyt162k+ny1t3WFC3NyPyXHS5j3SWnP/o8zvrJ+b0/gtJmRTpVnDpGHmMS1PCN2sjeJkc9kN
5jFsMvdjrwlQdyDyy6+5X+aO5R8y1zFf4/3lJpZNpG80j2neKHNbJl7dJrInmvv0sDl/i3nsCcfN
4zPP45zBUpfJJngPSgXlZx5G9v5Q3MbuuaJWs3/jOw1ELQAAAP4pcg+bSGwpvfqq1NmE2JzdJvJM
AH7WWerYSWrX0YThNBNydjPavAvcgM9ErQnUj0xMusxvg5tN8L3ZQtpnYnlqHxOxJpYnDJTeMOG3
Zq6J39el2auk4a2kT8yyqCjpkdZSXpUZq0CRtNpc791ZZ5ZVmjBcYCLxzw3MfTTR2t/ct1GrzTJz
G0+9YWLymLTCxHSjutJKE47rzNf65Flzus8EsonYNz400bpB6tXURPrq8GyyQjOvM0eYx9vDxLEZ
seax5leZQvVVmFhdKHVobx5bTmhZsYnrv5tQjjNRW2xCeXQXqVYTqZO5TFfzeHab5QtjpMaNzfNn
nsfxJuq9dt9lt7mPM6T3mklZV9aRgYhaELUAAAD4J/2CVxk6cFFppjR2pFRnVOg3OmfT2+EmVu2M
48fSwGHSoBX/IGptJCeZ630qtTaf9zaReCRFWmrCc6JZfuqQCchB0tDpJqCfl5r1k/oOMOEXLWV7
z47aVTZq51RZVmhi1lzu94+ZmDX3a9BQadq60OU+mR+6H1vWmNvqKXnMx+tNXDdrE9oPOMEs72dC
cqm5/Liu5j5VnLnd8uLQ7PJa8xjWmbE7QaoIb4Lsd4dmjTv0MrG6xNni+kzUmscUZx5b6XFzv8xz
1tdcN+eAeZzm609PcrYsldfcdpx53urUlwpMtOfbPyCY57PtsituNSNqQdQCAADgn6AytI/qppXS
isVSryEmTheGNh1ePUPq2S+0SW7nLibcTDzGrvzHUes3IbfYhNzv7jQhaK5Tkm4iz87U9jHRHGNC
9zNppQnFse2lqMnm9rebkDxyJhg9ZVKyic/B5mvWMzGZkB46L1gurTFh+aKJ0kWrpZ0bQ/vprjDL
Ws87E7WfmKh0myvsXWWWvyiNn22+Tl+pvQnz7eaxjOlsbr/szN0vKzDLze3NXyQtNGOdCdzi8BtV
ZptI7fC2dP+70nJzn/eZgC0xl99knpt+LczzEmduy0b7zND+tBNizePrLS0w19tlLh9vbq+vub/v
tQ/tN7zt7+b+tTSPqZCoBS511KZVjVrncORELQAAwGX42510fJ/U/yOpZTvp4ygp1URpQaq0aooJ
s1ypKMtE2ihpgAnSzRc6SKv5XfDwQROPM8IHPjKf75gvvVlL2mCuW5ImTewg/ekx6eVm0ojVoYNE
7TEx+vHrJgxNDI5YdGafWvv15poIbtZAeq25CcXVZ86zmwqPNcHc+ENpSCdzG+Z+HtgtTdkR+rrJ
CeZrzQzdj4o8E79jpWfrS+9/YoLXBGmOieeV000Mu7/ac3Nks4nQV6S/tZI+NTE+apmUdkgabm7v
HXP/mrc1UW0ee4aJ2N4mVus3kbrEm+fU3K+x/c3nTc3z+qkJcPMcBM1j3mRCt/fsM4+HqL2M/v5j
4sbGUOUFIieyrKSkRGVlZWctO/djVIMfe4FQ1KbOX6CdQ2KccA167Xely/wY8du/jxG1AAAAl90v
eeEDIlX93PsND81b6TERt1Tq0FoqDoaidrU96NQRnZmO/YKv+5VuPxh6X92v9Ha44SMbX6z3zv06
z+HXup9EbTX8nggqEAg4QerxeJR06JA2b96sw4cPm9fZ75x/+u864cutXbvWuUxkGVFbHf86Yf7n
r5TP7dXqSdO0aNgo871aqUCFx57hvFaV4agN2o957QAAAK7AQHZL2cek7UdCn3tKpLRE6Ughzw1R
e/mw4er1ep14TU5OVpcuXdSrVy/16NFDWVlZp8+3wVteXi63262hQ4dqwoQJZ4UuUVTNmta8Hn6v
T3u27NCrT9bVJ83e18msbPNzyxd6P6/K0+3rbFHBH6UAAAAAXHZRG9nU2Ear/XjDhg1q90k77dy5
Ux07dlRiYqITtZs2bdLaNWu0cuVKrVu3Ti1bttTUqVNPRy2q3+tqR3FhkVo2bab/+M53deu112vB
rDmhGdxzojaoL3gbMwAAAABE7eUQP5GotTO1fXr30YIFCzRq1ChlZGQ458XGxurzzz/X50OHavjw
4WrQoIGmTJlC1Fbz17WsuFS9u/fQDTfcoBoPPqg1K1eG9pe2h4KvUrGVRC0AAACAyzFqI/vT+ny+
0/vKDhkyRKmpqc7mxwkJCc7l7KbHdrhcLidy7WXGjh1L1F4GYVtYWOi8XouXLJHdi9Zn95O+0EHA
eMoAAAD4HfICI6gLT4JU6ssnRyovMIsSMN3hKi6R3+PlySZqLw4bpHbYTYxtAB06dEj9+vVTTEyM
Bg4Y4OxTa5fby9gQsvFrQzgqKkpjxowhai+DH0o+87q5PR557WttlviDAQIWAAAA4Xe/OJOlkYC1
w/6GbzfusyNge8DutlgZXuBMnoQu449c9rwYNpdX+B1VAqEDmAZMR5TlntKx1RtUnJoRvgv8ZkrU
/p/X49BKFLTRGn4bn3379mnOnDlKSUk5HbyRg0FFDihlN0Umai+PqPXbH0LhHzY2ZyM/dM67IAAA
AK6w3xXP/Hf6V8JzyzZSrYFzKrYydBFfeJwVt855lWZZOGrtcUpN1HoDQRUdTdW+mHHK2bInHMf8
IkrUXqSwPT0bGw7byMc2aCOjsspMLVF7+USt8/PI/mVNX7KJCD9LAFzSf4eC8pYXq6DY9bV+HNk/
yFYUF6nM/S3/O2Tur89dqsKiCn58Arisf08M6OxZ1rPO8IeHLVZvleGrcqXg2e3r15nJX1MT5qKh
Y7lUmut4TdRWmI4oPnJMCUNjlbuRqCVqL6JIyNrTYPjUvm1PZD/byEytRdRenj+wKolXXNSVKiB3
0Qnt2rRN27Zt09atZmzcrZMV5mdIwKuTR/drwaLF2n4wQ57wOhfwlOnYlqXanFZy1trpcxUoYdMa
bdq2ydzWLu3atUtbt2zRlo2bdOxUxT+5S/wqzjmuvZt2KKusev0cC/rcOpm8RctXHpHnYtye36u8
1H1au3aT85rt2rlTO7du0cYtG7UrJUeBb+UxuZRzaItWrDp63mPyu4p0aM0kRY/Z9TUeb6VchTla
N3mEpuw99e1+C/jKlZmwViNG77gorw8AXMqorTLxGloenhWpjAxn0+HQBZ2Pg5FwPbMpspwJlMjm
yeG3ljQfeJ2olRO1rkClimzUHj6qpMEjlbduF1FL1F6klbnKLG1khYoEbmS2NjKYqb3Mq/bcvfz5
+YFvukr5K5SxeZweu7eh3nnvA73b/D29+2Ynrct0qSTnoHq997oe/stf9eZL7bXhRLn5B9CrzL0L
1eLh+9R2ZVrVG1LZyT3q1/QFNXm/id567TX99fHX1ezdd9Xszbc1eVPmP+2bwu8t1eHtizX0s/f0
zH2PKy6prFo9x77SXK0b8a7qNJig/Itxe+WF2ja1u15o1ETNmjTWM489rsdfelNNmzdR+9g1cn0L
j8lbkq3V0eb5fn6SCs45z1OYpvldHtctf5qg0q+eySo4ukPd/nKzakw48O3+0cGdp+2zB+r2u77O
/QWA6if4JcNubRyZqPWH+9Vv/g312j9Kh/eYdSo3GLBBEP44GNp/1naDOd8TiVpzQxXmBvPNZQtT
jih5YIzy1u4kaonai7QiB4NnxW1kRCK26qbIzi9GRO3lGbVBXWjvfeCbrVK+MiUvG6Sf3fSRlq/f
rPXrN2j9xp3KLinVsU0j9YtbXtem3VsVU+N2NZuVorJTSerfoo4ef3G8coJn/1Pqc+Vp3+YNWrd+
haYO/lC/vLqDVm7erA0bN2l3QorSswrD+4DbEC1XZmqa8svcKshKV15pqXLTj+pQYoqy8spOr9J2
tjg/87gSEw4qOTVDJZ5z9yIPqCzvoKI+rKsaNe7T7665XhMSir/wGyhgAjjj2CEl7E9UalaBvM73
j/mHuixPaSdydDIzVYeST6jM6zX364ROFRboxJFkHTlR5PzVOuApVeaxFCUcTNSR9GxzueDpx5Od
nqlTp7KUknRIWcVn5vwC3gql7VqmaYv2yG1vw1ehnPQjSjqYpOPmPvjOu48Vys04FnrMR9NV5Dr7
53LA51F2yi6tWbdO8eP76s8/v1ZPDl+kbVs2acueRKUdz1CxfWDOZsAFSj+eI7dzNwPymseZnpHr
PO6g32MeY5oOma+TmJKqU8XuL3jazPNTmqfjKUlKPHRMueZyAU+5ju9cpulL7GOyN+1XyakMJR9K
VOLBXYrr2lC3Ph+nCufqAVUU5uhIYoISk44qt8h15g8S5rnITjtilicrcecq9XzqZjWZmnTer2l+
d4l53g8r6VCKjqWn60RGtnlefHKb+5WeaV63E6lKPpypCn9A7pJ8pR1J0UH7/GbmyVllzH1wl+Yr
IytPBbnmfprX75h5HuzzEnTna/u8z/W728cq/WSGkhKTlJZd6PzyBwCX46+KlTp/V9rIVscendni
2MasOxy2wdPbH4dHZGo3PFNrNz+2s7XOwabMMo/5oNR0Q1FkpnY9M7VE7cVaib/GSsRM7b/ATyvg
YkXtyqH61X19TWCZODiVr3ITanb54TVDdfWfeyotPVkLWtZSk0lbtWlSe936WCNtOuH5ktssUcrK
YbrhxslO8NjNlZNXx+rjrjE66bUB5FFuygp1avWJ1iYf14J+LdUjeqR6fNZBLd5pro4Dx+lwgdfZ
bDdtz2IN6NhKHTp1VKdObRU7c4eKq1agCbWKolQtnr1cu7fN1fNfGLXmZ15ZrrZPGan27Tqoy6ed
9FmHIZqTcFIBv0sZu+eqRdvO6t6+gz7pOFYJ2Sc0v+9H6jZwoD5u/ZG6jlqnktIcbZsUow4ftNWn
HTqoY4vOGjd3p7k/PhVl7dHgFm3Vu1dHtf2orSZvyTrzlf0m3A4sU6/+G1Rh4vfY1hnq0babunfp
rv6D5yi7yo/doDk/zZzfq11Xde7YXp+2/Ugx0/aqPHihh+TRiYT5avSbWzX9iMvZHqwwY5eiW3fU
/JRSc1tlOrpputp+3Fd78v0KuAt1aKW5/5/FK89dodRdCzW4c1t1+ORTtWv3sfqNmqmj+Z7zgtJd
lKnVsQP1Wbcu6tq9n0bM2S+vr1wn9i1Tn4EbTRj6lHd8t4b3+ljvt2ppnr939VrDP+rWt+LM/bb3
6YDGfd5dHTp0NI+pi/qMnKGjhR75PSVK3jRVXT9qro/bd1SXlu/qxXtv1tvTks563bzludq9YIQ6
fdpV3bp2UZsWrdWpc5S2peXr2I7Z+rDtZ+rWrqM6dJmopOwcrR8xUG279lCH9u30SYdBmpeY5/wx
49iOOWr1SW8N7tNNHdq20Tuf9NfshFwTzDZq++uXv2yinj266aOPWqtltxizjjNvC+BfJ3CrRm7w
AsuqREKVoygrfACp0EyuPWbC6QOVmqgN+MP71EbZfWp3E7VE7aUJYKIWgN2f8OjaIfrtbx5Vz0GD
1LlHH42duUjphWXKSlioJ2rUVQ/zi36nhx5Rr5GD9cZDNdRu9nYl7U9QanaRLtRaQW+JEpdF6fob
J6jc+bxUCUt76Z5fX6/Zh8vlKz+ldSMb6Zr762n74UT1qvED/ccdtfR86x7q1PoNPXDXNWoZl6Ti
3EMa8sofdO+Tz2vKgpka9tGjuufa+lqd5bvAA/EqJ3mRnv6CqK0MuJW1e44a/OS3qtd2tJYsmKzW
te/XdX8bpVxXqfYv7qUf/fjX+suzn2hYzDwlpO5Xj1o/0I9veUDPfdxb0ZNW6/DWODX48XV65pVe
mjVjiro8WlN3Xd9ACw8XKPvgfNX54X/o7ppPq/uQAZq/I+fM8+Ep0v6FA3XTb8coJ++oxrx1p67+
cxfFL1yo2B4TlFqlI31ledo2sY3+9vogzZ43WX2b1db1N7dRsvvCUZu+b67q3XiLJifa/Zv9yj+y
We3/fKcaxexx9pVe0OVR/fTam9VzbbbKc5I14bV79XDDecrO3K8BL9+jPz7RSLHTZ2hkz8Z66I83
6sMpB+WvPHNgQRv8mQcW66WfX62XB03WgnkT1fPztSpzF2j3vIG65bZxyi/N0tLhjfXT22urTa8B
6t7yUf3h9l/p1mZxKirN1rLhb+uqP9ZRr2nxmhnbXbVr3qM2C1JUcHy7ete/Rfc91UgjY4epRW07
036z3otLqrqC6mTySrX68zV66qNYzZgwRA3vvFZ/qN9JB7NzTYx21Y//63o93rC9omMX6ODhQxr3
6ut6K2aqZo77XA0f/F/d0X6pXOb+bp/XQ//5kzv17KvtNXxEPz388P267Z3xyiu353Vzzqv/6ica
NKSLHr7/Lj07YAuztQD4PSESwZV20+Og804czs9Ge8CocNQeiBrNgaKIWqIWwCX8WRDwqiB5jfp0
7qV+XdvpmSdq6u6rfqVPl6fJ5ynV7gWj1faVVxQ1cZxavf5X/eWtYYrt20Gd27dX564xSinx/cOo
tRs5FWVsV8d7b9FLQ7erIPugetf7lR4btFnFOYnq++QvdE/f1fKYfzorCkz0Nb9R1786RakmUp/7
f1fplW6jFR8/R5Niuuupq6/X6H3FXztqA65CbZ3woX76sxoaOCVe82ZN09BPG+vq61/TriITtUsH
6tq7m2tPQehv1sVZ+819/KXu7bhQdg9df0W+No1vret+31yJZaGvl5v0dzW56Xp9MPOgsg6a+3rN
/2rkBfYdDnqLTTRHmaidoFN5RxT7bk39slEXzV26TMknCs46sFOlPXBXcY6Sdm5S/LyZGjm4g669
6Q3tq/gqUSt5bMj2a6Rb6o5U2rHdGvDov+umP/xJj7RbqbQDq9XCBG6PNcd1wlyv4XU36/ONOc6v
LOW5SRrz/m265cVJysw8oLi4ODNmaeGi1Uo6uFxvP3iP3jIB/vflCcop9phQLzTrRpRuvW2SCeS9
GvjiNbq/89+d17A8L0njP7pLt74yXTkn9mpA3f/Rrxt20uz4eM2YHKsWr96vOz+J1+Hds9Twht9p
4KaTzvN5ct8SfXj7zXqt6ubHQbfSds5So9/8TtHbsnQicZOGNa+lF6cdNmeZGJ3fXzf9qYX2Fob+
vBL0+5R/4rC2rovX7Kmj1bHpE7r9xWkqdi47RLfc11fHzOvnL8/V+nFtdfMdTXSwIN+cN9A576h5
nl15xzSj85O6veE09rEFwO8JRC1RS9QCuLwEVJq5W5/ecpV+3W6Zs++Ns/lnWaZWDG6tP9ZpqaVL
R+uhn9dS3Nxp+vChW/TZupyvELUyt5GrZUNe0jV/7qLlKybpL9fcr5nJJSo1UTvwmWv0/ORQyHhK
sjS/20O6/omxOnJoker/8D/0+5p19Gz9eqpbr55efbOpVqVXXDBqTyYvUX0btYkl553tLT2lv/dq
oP/48Z16ol591TO3Va/eC3qz6XAdLS3R/uXDdFOtqQrdsvlHOnO/Bta9To2nHgpf/6SWRzXVb2qN
V3H4MkXHd6vHPeYyU/Yp04TfCzc31oELzKieidqJKvO7dHTXfNV75gk9UvN+vdFpuJKKvad/dfCZ
eN49o6/eePl1PVbnaf21dk3dflNTHfiKUVvpPPfRuveGpzRmxni9/Kt71aVne/3hhnc1bcZAPXDL
09qaX6H0vXP17E2/04K00B8l3AVpmte1jn5bJ1b7N09S3aef1tNPP6s33+mupPxcrZ7SU0899rhq
3Pu6eo9Zr2JXJGonKit9t/rUu1H1JieGXsNCE9a9X9St9acp68Qu9frrf+i/7qipes+a571uPdVv
9KZaRK3UoV2zVP+3d2hqcoXzfBYe26H+T92sF6tGrd3Ees9Cvfqzq/VC52GKGdBTbz75ooZsygrt
C7tomO54PC78ugVUcvKwJnZ5V6+8UktPPVVHD9d4WHe8Fqcy57JR5rLTnANpBV152j6rqxO1BwrO
vh3nuej9ku5oOFMV/FAAQNQStUQtUQugerMHCzp5/Lhyi8vkdpUp4+A6vfvXq3RfpxXOwSSCvlId
WtVf9e96QuN2ntDRNZ/r17+OVkF+uha2u1cvTUn5SlFbGXApbVec/vdXv1WDl+rp9scGKscXVOnJ
RA2oc5Xu/2S6MvJLdcqETa+X79E9b83S8eQVanTV1fpw+h6VVVSopLRIJ3Nyz9u/1P4881QU6+ju
WXrk6usUuztXLrfnrBnQgKtI2ye11y9/3Uxrj+Wp3FWuksJTysoukN/c30h0nhW1z5hgnXjQWeIv
z9OG2Ja6xsTh+ox8uUzUJa2ZqMa/ukGfLkp2ovb5mxprb8WXR22pz6Pc9BPKzz+hVVP76M5rf6Po
PZHjBwdVcmK/etf8uW5oPlWpOdnasShG93/JTG2GidoGVaLWbq57KnmVWt75n7qvbkP99rGR2r9z
gV65/kf6a73H9ef6M1Vsrpe5b6EaXX2jOs5LUmmFfXueTerx2p90/3sLVO73ylVWprKycpWXVaii
JFdpJ3KVm7pDI1o/oRtvbab9xWdmanOyDmrIK3frt21mKKekTJmJ69XxbzV160vTzHn7NOSl23Rz
s0lKN+tYRUmpCnJPKq+wWBkm7l+69hZ1XnxYpWV52rdsuF4/d59as94c3zpdT/z0f/R8k+Z64502
ipm9Xidd/vABnkyo3hX+Y0TQpdRdM/TktTep+/y9yslI1PSBTXXHi9NCUTtvgG68pZ22pOaqJPew
Cdcm+u0dHymp+OzbcRekmvOeJWoBgKglaolaAJfDP1Xu0hwtGNxN3YeN0uSJo9Wz7Wv63UN1FL0j
1/zjZQLp8Fp1eOEWNRi8UW4TGCd2TNIDdz6nYRNGquWzNTR2X9FXilr7T2JZbpIG17lOP77qGjWd
nhBelqiBf/2BfvLTh9Wm/whFdf9Ad9zxqHqsSFV5TpKGP1JDdz7+vkZPm6m4yRM0fNA8ZZxzLCOv
Cdrts8eob5e39J//3//o7e4xipu1XnlV4zdgQi5hvh554B690Haw4ubM0KTxIxQ9fatcXyFqbVyl
756pmg/+Uc+27a+J44fr0zceVc36r2pXbtlXjNoJOlWUoXlDPlX0hCkaH9VV9e+rozkppadfj7KT
hxX9yoP67Vt9NH36WH3S/AVdd1NzHfyCqLWbEb/sRO2ZDWUr8o9oatub9IOf36A6o3epJNtEZ/1f
6r+vuUntFqfaB6Pi9D3qV/Nh3Vm7uWLGT9DgTu+r5gN11W99+tlfwleurN0L1LPDIE2ZPln9Wr+s
WvW760hJJGonq6j0lNaN+ED33lZbXaLHqH+79/WbO+4M7VNblqt1o9/TA/c8q87REzVj+iSNjY7S
gm0ZKkrdpf41HtStT7dWzJihat74bv3kmpvVYuahM3fAX66jG8brwZ/9Uk0+7aNBUUMUFRWliSZs
C0rzzo5aG+sJS9T0/t/rwwFjNWlER71Z9xrd0WSmsw/w9nmd9ZOrfq5XPu2uEZ9308v33GVCeZEK
3edG7XETtc8RtQBA1BK1RC2Ay+GfKm9FvtaM+0zPPP2U6tR5Sg0bvaJRS/aED/BUruTVI/XCq711
1B2KPXdpqmb1fkbPPPuC/tZ3gXIvdMwmf4UJwIVq8tZKVe1PX7n5WsOb6BfX1tLfnaMnm6g9aaL2
if/SNf/7mp555mk99eyLemPYShUEQ/v75iasUq9nntFTderoqacb6Y0mccr2nf0YKgrSNa15XdWt
GxnP6/Umw5R2zn3zu8uco+hGHmv9Ro3VOW6nvOb+Ht+5UG+/szp8f81t5h/X3O5vatDqM5HncxVp
W3x06PpPPaWX/tZEi/blOLOj+SYS+7w9SMc8F3o+ysO3v0pFJelaNPQZPf2UeTzPv6q3xq5zHuvp
9vZW6Mj6ODWzz0W9+qrbvJXefDta6Rc62LT9uqmbNeCtZlpT5QJBT6kOrR2nV998R0uSi83zXqBt
s3rob02baUtO+BHaA0DtXKKO9uvY1/3Fv2ngrB067x1+7ZGqD64KXc485hdfe0uztqTL7yvT0W0L
1ezdNfJU+lVyYqdGtTGv01MN9PLLHRU7eqDeGbxedr683ET2tH5tQo/5qaf1SpNmWnAgL3R05o0z
9I55Pp9q8LzqtumgRq+/o1Ebqhw52leq5JWj9NC196vn1DmaN2ucurV8Rjf87nGtychXypaFeu+D
tadfN1dxlpaO7GC+1tNq+Hxdten+ut4buiF0oKj4nvrZjX9Uq9b2+W+gN5oN0Z6THudrVL0dn4n0
LTMH6r3eG+ThhwQAopaoJWqJWgCXxz9ZNiDdbrd8gao/J+z7t5aoqNx37g8QBXy+r/01KvKPaUzz
Z3T7ExMV2uA2qNKsRPV76Bo9OfGgc5Akj8d3wZ9XXnPfPL7gxXmsfvtYPfpmNxe+vscj3ze+C/Z9
bb/88XzRc3Hx/y3wO8+t7x88GaHLfflzFnqdzlwmGDz/MbvNYwpe4Pn8osca9BRoz/yBuvOGVzV1
6SKtWTlL0QNb6fraz2tNlucLn9+A16fTq2gwvA9t/BDd8cQ0Vdh//8zrF+QbHwCIWqKWqAWAr86v
osyd6vzMc86RlSP/VJbnHNe4ug308vwUniKcL+BW9v7lalXncT3xeC29/HIt/eXZV9V8+s6vtWmw
PVpz0poJeu2NRVU2iQcAELVELVELAF/jn0W/v1xZaSdUWmVSLuj3Ky/zuLKL2NATX7TqmF+iXMXK
yjiuY6nHlZNX9vVnWSv9cpedUnpWITO0AEDUErVELQAAAACilqglaolaAAAAAEQtiFqiFgAAAABR
C6KWqAUAAABA1BK1RC0AAAAAohZELVELAAAAgKgFUUvUAgAAACBqiVqiFgAAAABRS9QStUQtAAAA
AKIWRO1XjNeqg6gFAAAAQNQStdU+Ym2sRk4jwwZrsMr5Xq/3dNSOHj2aqAUAAABA1BK1l44NVL/f
74RpZJSUlKigoMA5dbvd8ptldobWDo/H41xn6NChRC0AAAAAopaorV5Rm56erqlTp2revHmaHhen
/Px8Z3nVqLWfDxs2TOPHjydqAQAAABC1RO0lXOnCmxU7mxmb040bN+qDDz7QhAkT9Nxzz+nQoUPO
ZQoLC5WXl+cMG7qDBg3SxIkTiVoAAAAARC1Re+lEZmEjM7anTp1Sbm6uTp48qd69ezsf2/MXLVqk
GXFxmjFjhubPn68mTZpo8qRJRC0AAAAAopaovYQrnVmJqu5PG5m5jY+PV3R0tHMZl8vlxOy4sWM1
1ozJkyfrtddeczZTJmoBAAAAELVE7SUP26pHQLYzs1FRUVqzZo1zvv286vk2YmNiYnhLHwAAAABE
LVFb/VRUVGjUqFHOvrNVDyRlP7YHirKf26MfE7UAAAAAiFqittqx0ZqTk+PEqn1fWmfT5GDQOS+y
/619n1qiFgAAAABRS9RWO5H9a23Ano7acLgStQAAAACIWqK22ket2+0+vclxZD9aohYAAAAAUUvU
Vv8VscqBoyqrrGj2lKgFAAAAQNQStZdt7BK1AAAAAIhaopaoBQAAAEDUErVELVELAAAAgKgFUUvU
AgAAACBqQdQCAAAAIGqJWqKWqAUAAABA1IKoJWoBAAAAELUgaolaAAAAAEQtUUvUAgAAACBqiVqi
lqgFAAAAQNSCqCVqAQAAABC1IGoBAAAAELVELVFL1AIAAAAgakHUErUAAAAAiFoQtUQtAAAAAKKW
qCVqAQAAABC1RC1RS9QCAAAAIGpB1BK1AAAAAIhaELUAAAAAQNQStZckVCMrUtUVKrL83POJWgAA
AABELVFbbdhAtcOuTFVP/X6/E6tVzydqAQAAABC1RG31WunCEWvDNBKu9nOv13s6YCPDImoBAAAA
ELVEbbWK2siMrD21w87SZmVlKTMz04nYyPJI7NqPiVoAAAAARC1RW62i1gasDdojR45o4oQJmjxp
kkpKShQ050fi1katvUxUVJRGjx5N1AIAAAAgaonaS6vqTGxeXp7GjRvnzMIuWLBAhYWFTsTaWdu0
tLTTo2/fvho7dixRCwAAAICoJWov4UoXnqmN7FO7d+9edenSRdOnT9fu3bud5S6XS5MnT1Z0dLRG
xMQoNjZWL774oqZNm0bUAgAAACBqidpLJ3IQKLt5sV2hFi9erDfeeEOLFi1SfHy8ioqKnPNWrFih
BfPna+HChc5lPvjgA02dOpWoBQAAAEDUErWXTmSG1m5ibON29uzZ6tGjhw4cOOCE7MmTJ08fETly
MCl7OmrUKA4UBQAAAICoJWovfdRWPfJxamqqc2Tj/v37a9myZXK73aePemyH3RTZBrC9DPvUAgAA
ACBqidpLKljl6Mc2Vu3HxcXFzgytDdpI7EaGx+NxLjt8+HCNHz+eqAUAAABA1BK1l3ClC69INlQj
myFXXbEimyVHLmNna+0p71MLAAAAgKglaqtd4F7o46rLiFoAAAAARC1Re9lGrz0SMlELAAAAgKgl
aolaAAAAAEQtiFqiFgAAAABRC6KWqAUAAABA1BK1RC0AAAAAopaoJWqJWgAAAABELYhaohYAAAAA
UQuilqgFAAAAQNQStUQtAAAAAKKWqCVqiVoAAAAARC2IWqIWAAAAAFELohYAAAAAUUvUErVELQAA
AACiFkQtUQsAAACAqAVRS9QCAAAAIGqJWqIWAAAAAFFL1BK1RC0AAAAAohZELVELAAAAgKjFv2bU
Vl3JiFoAAAAARC1Re1mw4WpXMHsaGUQtAAAAAKKWqL0s2FC1wwZs5JSoBQAAAEDUErXVXiRkfX7/
6Y8jKxtRCwAAAICoJWqrNRupXq9X/nNma4laAAAAAEQtUVvt5efnKzk5WUePHpXb7T69by1RCwAA
AICoJWqr34oXXpEimxlPnTpVHTt2VHR0tPLy8pxlkfMiURsVFUXUAgAAACBqidpLywaqP7zvrMfj
cQK1VatW6tGjh7Zu3aqKiorT59lNkiOnzNQCAAAAIGqJ2kvO2XfWRG0kWG2gjhw5Ul26dFFcXJzK
ysqc83bu2KHNW7Zoixnbtm1TmzZtNHHiRKIWAAAAAFFL1F46Nkht1NrNim28lpeXO/vT7tmzR02a
NNG+ffucywwfPlz9+vdX3759NXDgQNWrV0/Tp08nagEAAAAQtUTtJV7x7IoWDtvU1FSNHz/emZH9
8MMPlZCQ4JxvZ3HtsDO39uBRQ4cO1aRJk4haAAAAAEQtUXtp2X1mI/vW2pna+fPnO/vUzpo1ywnZ
yJGP7QpnZ3MjB4oaO3YsUQsAAACAqCVqL/GKd4GVyQbuheI3cvRjO1PLgaIAAAAAELVEbbWM3C9a
zvvUAgAAACBqidrLMmyJWgAAAABELVF7WYcuUQsAAACAqCVqiVoAAAAARC1RS9QStQAAAACIWhC1
RC0AAAAAohZELQAAAACilqglaolaAAAAAEQtiFqiFgAAAABRC6KWqAUAAABA1BK1RC0AAAAAopao
JWqJWgAAAABELYhaohYAAAAAUYtvELWVKkhLUa7LvJjuU9q6cpVWrTqqsmraiEQtAAAAAKKWqK3C
o7nvvK6FmX6dXNNdNf7woP78u9Zak+0nagEAAAAQtajuUVusQVffpJitq9T7yRvUd9MRbehTRz02
FhK1AAAAAIhaVPeo9Wr94Jr603N/VI1HRyov6NPmPg0Vva+MqAUAAABA1KK6R21AJxM3a+2GXUov
CpgX1KP9q9Yr3VVNV1CiFgAAAABRS9SeUa5pzetqWnLpV1g7gk5MXmh8W6sBUQsAAACAqCVqq3Br
yhP/phd6T9LatWudsW7dOmWW+c9bNcrS92n58uXnjRUrVuh4ybdzYCmiFgAAAABRS9RW4dWixg/o
gQfOjAcfelgzD5WeE5NBHYnvqVq1appR6+xR+1HFJZZ+OysoUQsAAACAqCVqzwgoZVWc4uLOjBkz
Zirx1AUisdInt7vcDPdZo7zcLf+31JRELQAAAACilqitwqUFrWqrdm07HlHtmg/opv/+fxq1v/y8
VYPNjwEAAAAQtahmUesUoROFtguDrkwNrXWLxiZVnBOTQR2Z1101ajxsRo2zR83ams7mxwAAAACI
Wnz7URtQVsLa0weJWrN6hfrX/6UG7y45b9UoS9+tRYvmm7HorLFgwWIdLby4M7WV4ZWr6gpmP7Yx
S9QCAAAAIGqJ2jCX5n7yoB58MDIeVu2/fKYDRYFzIvOfd6CoSKxGIjbyNkF5eXlKSEiQx+Nxlvv9
fideI1EbFRWl8ePHE7UAAAAAiNorN2ql0qI85WSm6ejRo0o9nq2yL+zDgLxelxnes4bL5dX/pSmD
4U2KA+HNoO1tlpWVadq0aXr55Zed+1VZ5TI2cu3psGHDNG7cOKIWAAAAAFF7JUdtxakULZw5TuNM
RE4fPVl/X3dUFcFv784GTu/TG3BmY+0s7JYtWxQbG6t33nlHW7dudVa0kpISFRUVnR6DBw/W2LFj
iVoAAAAARO2VG7V+bRz4su58oJbe6tBBrWrX1h+ue0sb887fR9bvKlOF/+K/4JHNiiNRa+O1R48e
2r5jhz7++GNtWL/eWdGWLl2qefPmKT4+XosXL1azZs00ZcoUohYAAAAAUXvlRm2h+t99t+ZkeEIr
QNCrRS3uUa+theesGZXK3DRd67K8F/3ORjYpjuw7m5SUpDfffFNDhw51jq48depUZ/Z2woQJzibH
I0aM0OjRo51Nk+0mykQtAAAAAKL2io3aUo2tW0u956xSUsoRJe5erSF/u0/Ru88+8FNlMKCt3R5Q
uzXZqigvV2lp6elh93/1/B9mcCP70dqotYqLi7Vp0yYtXLjQidro6OhwV599IKmRI0ey+TEAAAAA
ovbKjlopfV20Hr7/XrVp30Wt/va/eviRNjpQpPOidtewZ1X/0yGaM3OmM0MaGWPGTNfenP/7DO65
b99TWFjovGXPihUrzjr6sY1f+7GdyeUtfQAAAAAQtVd01Ibep3b75vVatmyl1u84oFzX+YFoo3bP
sPq66Y811aRJk7PGX/7ythamui7qA4gcMCoyIvvcRo6CzPvUAgAAACBqiVo571Pb9l592Gu4Rk+f
r3U7E5SRUyBv8Pyo3T34RfXbfv770Qb9XvkCF3dFiISsDdjIzGwkXIlaAAAAAEQtUXta6ckU/X16
tGrXvF+316ihdzsM1O5zjn5sV4ijC4do3uFw1FYGVFGSp+PJO7Ri0VwdOOm5uCuiWbFsqNp4jbwv
LVELAAAAgKglas/jKsxRyt61WrNkiro3vUF333u/JiaWXnD18FQUKfPYAa1dtUQTo3upSdMn9UDN
RzQjqfSiPoCqmxzbiI3sU0vUAgAAACBqidoqAto/b7haNb5HD9V6RE37jNX6A6k6f7faSpVk7NTs
SVHq1bGp7n+4tmr86VZd9d50pRe5/jkr4zkrWORzohYAAAAAUUvUhrm0cdwAfT51sfakpCs9LV0Z
aRkqcgXPCUwTv+Nf0TU//a5qNu2vtQdzlL6+r54YuOfbXUGJWgAAAABELVF7RlCZWyZpUP/e6tj8
Q/XuO0Btm76nJUfc59akCpPXaGCrR1SrxivqMChWw9vXV833xuhQWo4q/N/OikDUAgAAACBqidoq
KhT7xFV6O3q0WvzmWg2YN0uNb7tGww9UfPE1CtO0MT5WTR6prYcfuFctug7TzovwPrVELQAAAACi
Fl8zaksU9eBDWlMa0I7+72vYyt1a1LaO+m8t+grX9avwxEEtiBmi1amub2cFJWoBAAAAELVE7RkB
revxoEYfLFfu1ijd94dX1eDeh7TgW4pUohYAAAAAUYtvFLUVp9J1qsLEoCtP6WmZKnS5dGzPem0+
kKXqmohELQAAAACilqh1JExqr0kJofeXPbzwc81Nqqj+KyhRCwAAAICoJWqtbb0eU7dN+c7LvqXH
Y+q8wXxsXngbjNX1ZSVqAQAAABC1RK1jz5AX1HjIHK1du0pRTR5SU/vxquVasWKFjpf4iVoAAAAA
RC2qb9Qe+/sg1a5VSzXNqFV11H5UcYmlRC0AAAAAohbVN2qdGPR65TLDW2W4XF5V10YkagEAAAAQ
tUTt5buCErUAAAAAiFqilqgFAAAAQNQStUQtUQsAAACAqAVRS9QCAAAAIGpB1AIAAAAgaolaopao
BQAAAEDUgqglagEAAAAQtSBqiVoAAAAARC1RWy1D9dzPqw6Fz4987vV6iVoAAAAARC1RWz3YILWR
akfkY7/fL4/Hc9Z5dpk9jURtVFSUxo4dS9QCAAAAIGqJ2ksnEqo2Wu2mxTZmMzIytGXLFh05ckQ+
s9xGqz3PDrfb7Vxn+PDhGj9+PFELAAAAgKglai+dQHiG1g4btunp6Zo8ebJ69OihVq1aKScn5/S+
tJGotZezM7VsfgwAAACAqCVqq0XU2mC1sZqVlaXExERt3bpVH374oTNba8/Pzc11zsvOznZOBw4c
yEwtAAAAAKKWqL3EK114FtaGaWR/Wfux3bx4yJAhKisrk8tVoalTpyomJkYjR47U6NGj9eqrryou
Lo6oBQAAAEDUErWXTrDK5sd2hSoqKlJmZqazX62dqU1IOOict2TJEs2aNUuzZ8/W3Llz1bRpU02a
NImoBQAAAEDUErWXTuSoxv7wAaHspsU2Xu1b9rRr104nTpxwVjR7mcipvdyoUaMUGxtL1AIAAAAg
aonaSyfylj122M2Q7andj9bOyB47dsxZySKbJttTe6Aoe7mhQ4dyoCgAAAAARC1Re+mjNhKuVTdD
jiy3M7iR2dzI/rf2YzuTS9QCAAAAIGqJ2kvKBmnV/WojR0G2M7J2djbyVj5ELQAAAACilqitfitd
eFbWjsjnVd+X1ln/wkFL1AIAAAAgaonay3cFJWoBAAAAELVELVELAAAAgKglaolaohYAAAAAUQui
lqgFAAAAQNSCqAUAAABA1BK1RC1RCwAAAICoBVFL1AIAAAAgakHUErUAAAAAiFqilqgFAAAAQNQS
tUQtUQsAAACAqAVRS9QCAAAAIGpB1AIAAAAgaolaopaoBQAAAEDUgqglagEAAAAQtSBqiVoAAAAA
RC1RS9QCAAAAIGqJWqKWqAUAAABA1IKoJWoBAAAAELUgaolaAAAAAEQtUUvUAgAAACBqQdR+zVC1
kWpXOHtadZmzPLyiRQZRCwAAAICoJWqrjYBZ0bxerxOmNljtihX52Of3OyuZ35w65xlELQAAAACi
lqitPlFrgtRGbWU4ZoPhyLXDH47byDKiFgAAAABRS9RWr5UuvBJFgtae5ubm6vjx4yoqKnJmaSOb
IkfiNhK1o0ePJmoBAAAAELVE7aUTidnIZsYFBQUaMWKEunbtqmnTpqmkpMSZnXVmbs35Ho/HOf18
aGim1q6CAX8gtPo6KySDwWAwGAwGg8G4Uof9L2hHpe0Mv3wmbgM2XgNmqS+gIhO1+4ebqN0Ujtrw
cX1A1H7zv6SENzuOxG1SUpIzC7t69Wq1aNFChw4dcpZnZmY6s7fp6enOaNOmjRO1QRvDPo+5jE/B
gC90GvQzGAwGg8FgMBiMK26Et/40p4Gg1/SBx3SG6QO/We4JyOPy6MDOHZreu7eOb9991gFqqx6o
FkTt145aOxNrZ1/tcLlcTuCWl5dr48aNzsyt2+1WTEyMepuVr2fPnmrerLl+fe2v1fr995V/PF1l
eYUqzStQWX5haOQxGAwGg8FgMBiMK3KcCp86bVCgUjvM5yUnC7R//wF98Glb1bz/z5o3cZJcFRXO
gWsjB6b1hw9UC6L2a4nEbGTzYjuysrKUkJCgvLw8J27tCrZ7925t27ZN8fHxuu7a6/Sd73xHN1/9
K836tLu2TZqrDePitH3KPG2ZPFdbJs7WVrNs66Q5DAaDwWAwGAwG40oZE00DjJuvLZPitXnabDNm
asP02dpgGmHl2Jnq83EnXXfdtfr5j/9THzRqpOOHD4dmdsPH8SFoidpvJFjlLyN2ZGdna9y4cc7m
x9HR0UpMTDw9o2svay8zoH9/XXXVVXrh2We1bMJUbZo4S2vHTNWWqXO1cUKcNo6f4SzbNHEmg8Fg
MBgMBoPBuFLGhFnaPHaeNpq4XT9thjZMm6Z1cXFaO3mmVprzJ44ao+defV4P3XabJvXpp6KCgtBu
kFV2hwRR+402P47Eql2RDh8+rI4dO6p79+5q27atM2sb2UTZboZsA7iiokKvv/66xo8ff2Y7+MrQ
X1YYDAaDwWAwGAzGlTvsMXfsgaH8zqk9+nG4FUwzuP0ebd+2QaPbfawTO3afnmCLvAuLHczWErXf
aKY28pY8doWKrEz2KMeRFTOyzIatXW6vY2dx7YGi7HKXiV2v3QbefOwMu3JGPmYwGAwGg8FgMBhX
yAjK6w+q3B9Qmd+n8oBbpWa4/V75XS75TTeUpKbqYOxYndy0ywldZ9PjKjO1RC1R+41mav9R9Fb9
y0skfIcOHepEreU1K6997ykGg8FgMBgMBoNxZY6A0w7m/zxmuGwkmI7w+8JHRA69R23Q51PRkSPa
P3yEcjfvCjUGmxwTtd9m6EY2Q7aha9/2JxK1fl/AWYEZDAaDwWAwGAzGlTkq7TBlGzSFGwhUOm/r
Y9/mx20Wuk1HeO0ujwG/io4d1b4RI3Ry667Q+9QyM0vUftuxe6GoDfjs2isGg8FgMBgMBoNxBQ8b
t3aStkSV5jQgv/mv3Hxc4UzcVjqbKJccOaqDn4/QqY1ELVFbjaLWrpx2VWQwGAwGg8FgMBhX7gg4
Wx5XqqwyIF/Qp8qA3zlYlOlZVfpNwPpM1KYcVdLAEcpbR9QStdUoan12p27+MMVgMBgMBoPBYFzx
o9I50rHfRIJX8vhM6Qad4q20mySbj4uOHdP+mFid3LybqCVqmallMBgMBoPBYDAY1WuEPgjaHWtt
KDhv8ePM1Jr/C4ajdl/MaBO1e4haorb6RG3kLYEAAAAAXNlsop6ZsQ0671drj46s8BGQi48c04Go
0crdSNQStUQtAAAAAKIWRC1RCwAAAICoBVGLS/zDAwAAACBqQdQStZcF+xrY593+oLCvSyB8apcH
q3wcOY2cb69jPwcAAACIWhC1RO0ljVr7Wvj9fueIcvY0YIbb7Q4tC0evHfZz5wjV5nIejycUw/zw
AAAAAFELopaovZRRa5/3SNg6UWs+d7lcOnnypPbu3euMw4cPnz4vclmiFgAAAEQtiFqi9pK/FpFA
tcPOwNpRUVGhkSNH6q677tLvf/97NW7c+PTsbeSyvF4AAAAgakHU/ktH7em3jq4W96LyAgsDgaCz
SbGN1VN5edq5Y6d27dqlFStW6OGHHtZ3v/tdfe9739Pdd9+tHTt2KDkl5UzU2jfBDvLDAwAAAEQt
iNqvEbWVX3F82bn2v2B4fNllql4uNM58pC8coa9uP/KHR/DL7/6Zb9mz74H9Bq4ML7ffpPbjysoz
n9ugDFa5uh3mKawMhM9yhj34U+gAUPY06HzDy4nRgPlh4PMEVVHiU2FeqSZPiNNtt92mu+66Wzfe
eKO+893v6Ac/+IG+//1/10/++ye644479Wrjxua184bDNmiuV853KgAAAIhaELVfPWrD5fYPhs3R
gLns2SPyn7/KiJxXec6oevmq//nC1wtUue7ZXz3UmfYjrxm+M2FbWSVOg5FRGTrycNCWaCAcrqHP
g8HQUYntaSDgV9DvN8EaCIWuvY6JSvsNXRmoDA2/iVafubw59Zvb9ZpTV4VPpcUVKsovU+HJCuVn
eXUyzafUg6VK3pmnAxsztXnxUa2OT9CH73TRd77zHX3vuz90Zmi//8Pv6Sc/+Yl+9KMfmrD9vjNj
+9DDD6qoqFDl5eVO1CYnZH+l19yJ6MCZcaEfOfYx+LyVvK0QAAAAiFqi9l85aqtOS37ZsLnpucDw
mmG+tvmWCJ7+L5KnVf+rPG9WNjRH6jHDFT71yX5rOTO64W+kymBohMoseE6E+8Oh6zHnu83l3eZ7
0utEXjAQul4wPPzhTXttvzqbCPvtAZrsCDrBGnAuYx6NnWktC6q0MKD8bK9y0sqVeaxYGceKdGh/
vnasT9XKhQe0YMp2xY8+oDlR6ZrRN08TO6ZpdJs9iu22QtNGrtaK+P3q3H6Qrrv2ev3kv/5HP/jh
D52YffGlF/XUU3V0442/0VX/8wvdfudtiho+RAsWzXfu3//P3n3Ax3kX9h8PkP4pq4HSElZICAm0
ZRRKW6CUQhlNgIQQQjZZOHESh4QQx3bsOPHeU5KHJEtesrz3HvG2bMlD3ra2ZVt7Szefe+7u+39+
z93JshOHTHl93ubHDd1pnH7SS5/8ntFY7//r3zHncfUn/Co4FlDREb+OHAzI03Hx2nmtfPWWig76
tX+vX0UlIQX4nQQAAEDUErVE7ZUetVIgPpyINCum0fCZTXhf95QOm/OeuyWwdOZOd3X1zIqqezsa
3+Y36vyYRZyPE7Hcj3H2mrITotGIu9LrxrUTtOGoz3l6QHY44oar2UTYcuLVsm2FwraCIWf4wvI0
h9Rc51dDrVe11T6dqvCqsLjJicNq7c2p1PbVddowz6MFExs0dcBxpb6Sq7RBOcocnatZyfs1L+2A
Fmbkac2cQ85jT+porkfVpZba6gMKekMKBWx3U+TyEyed70eKE7XXuJscX3PNNdqxY7vKyko1K2uO
7vvdE/rgB6/W1c7bbvnlL5zPMfKWfnmEnRjft6BBaZMaNOXV0/pTt2qVBs68PeR8Dq+lVqtfnxpN
HlenUf0bddLv/KJqisS+HVZYLZ7YanRrS1hNtSHndljNnviG3kHnemvsPwq01IVUXW3LH+IXCAAA
AFELovaijdozK6Ovr8/E9XOj1j4Tomdt/ms2+03EaCh+3Y4FaiJWE6us5uMldpM9a3vjROiG3BVY
8zHND59tHu780IUSw2xea34Yo4mVVidxnWDze8Nqa7HVVO9XTWWbKsqadKqoWcX7Pdq/0a8tc2u0
Iq1Q86fs18yMg8qYfEiTxu9T8vAdShm0RRkj9mjB5AptmO9T3vpmJ1prdeJYrWpOt8rbFHa/LPNa
ReIjtsLc5nwZLe7nYPudzyUQC9SK0xW6+aabddNNX9E3v/kNbdu21b0/EAhq2OAx7mbJZj/bW395
q/M9NJHpf8vf97DPVs7Mag2d7Tuzl7HzOrQ6gf7cn2p1MhD71llOsLY1BbRoepsCztvbSlu1cFNQ
VmtAS7KbtHh6g7bmtmjuSr+7yt14sFmLNwfVWOrT8uxGZU1r1Jb8UOyXHgAAAIhaELUXV9TGnu+u
bIbD7vt4/Q9AImqD8ciM79vaHql27LYbu06URX3OZXyYx0cTIRyMP9dyPmbQ3c81Gu7YxvHNjd3d
YaPxzYUjsXO/mq/R+TBBf1geJ8aaG71qqvOosTqg2pO2ThWEVLSvTQe3Vyl3w2m9tvSUlmYVaNaE
vUodtFmT+m5T5sCjyh5Wr0Uj67V0XJlWZR3WxtVHtXdXhU44AdfYFJHfisgyAe1uTm02rTabRlvx
g1wlfhlEnKgOKxhyRth5pNlH1+yz63ziYSdMzcGizH645vNubGzUypUrtXz5MudyuWpra2VZlnve
2vSMVH3/+9/XD//nh3r+L39xg3jXlpK39j1zvl+VeY3q1ateFc5LGnZel5MllsqLLef+er04wdPx
Gyy/81q92qVBrSZa99brpUkeeWs8erlLlVbm+VRe0KpXnqhTVYutbaMrlbkjoHWDKzR6sUeHtzep
V7cG1UX4JQIAAEDUgqi9yKLWPNfr8aqoqMgdJSUl7uloIpFY4LrBGw9Ld2U1HD1rt9bEQZXcKjWb
AptNgMOheKDGD74Ujv3guAdsipr3G1LYDjrDcoIw4q62WmZTYROJAVuetrBaGiNqqA6r6oRfp4vb
dKK4Wcf2N2vfjmptWV2sVXP3a9mMvVqRWarFyc2aM6xV03ufUvpLucocsUULpu3X+sUnlLuxVsfz
61ReVK/q061qbbLceHQPX5U4GnL07BP0xPb7tZ0v1fkcI2aTZl/sc47abrhGoh32EY7qrHHmZ//1
R11O/GJIrIq3tbWqouK0KqoqVN/Q4H79Ozcfe0u/kbw1fmV2r9Kyo7FDM3vKPEoZVKvk4Y06srtB
zw1pljcUe2zICd62Wo8GPtXoRm3drnq9muGVz7lvSPdG9z8/WF5bK/tUat7GNqU9V6ti53Wa9cxp
DZ3UoNnp9UoZ3Bhb+QUAAABRC6L2YonaSDxWd+3apV/96lfuuPPO36murl6WFTpzcKX4rq9mNdd9
jjnibsicwsZs8mtGYutjc1RhJwSdqI2t/EbdrYjDtnlu7NJyCsrTFFZTdUD1VV7VVHpVXuHR8aIG
7c+vUO72Um1cflprshu1aFKLpr56QhN75Culz3alDslx92ldMrVQa+Ye1WuLjij3tVMq3N/qrtQ2
VIWcKLbcjx2NH1uq/QDJ0cQPslmD9SsUMUcb9jufXzAe4bEjIyeOoNx+aV5CdzXabBZsTrfTYZ9i
t+qj5zmd0JnyD4et+Gtid/jlEI0fF/rMwbHOjuI3+b6FIjo0u1rP9m7SiTJL5SWWWq32yaBAjUeD
XqjS6ryASgqCyt/h0akar4Y/WatDx4Lall6lfjPjUftco9rM+3R+kZ3cXK9ufzitkdle5/tka3W/
Ki3YEdCpcksnTttioRYAAICoBVF7UUVtYnPjxYuX6KqrrnLHxz72cZWXn3QC1BwZ2HbD1o1TJ/qs
iN+Z/AGFI7Ys57lBO7YJrjnAkXM1diCmQEg+jx3bp7UhoNqqNlWUN+l0cZNK97fp0OaAtsxu0fKk
Ms1N2a+ZE/ZrqjOmjN+ryaNzNGHIOmWO3qX56SVaP69Ve9Z5dCzPeX5ho+oqW+RpdqLZinY4QrLc
1d9YaPqcRPS6q7/m83F+Np3LqLuvqvs1tO8HGz/TbTSx364p7khsFTqxNXVixNtVUXOwqmDssv20
QmdOOHTm10THd9Dx7ef+UjEHugo5n6PPGX73unvSo8hfT0c7aGvdsBoN6V2rpGG1GtevXntrznwM
s3J+MqdJg1+q0eA+NRo1sUW1fltbU2s15CXnOX1rlbk2oECTX1OTWt2VWncT5QafJvSv06YTsdMa
NRxp1Sjn+RPG1iplpsd9hQEAAEDUgqh91wH7XkftqlWr9clPfkof/vDf6vOf/6JKnAnd2NDoRm37
+VCdkA1EPPIGvfJ6LLU4QdRQ41F9pVeVJwMqO27pWH6z9mw+ra2rT2jd4pNaNLNA05L3KGXABiX1
Xq+0vvs0fXCFFo1u1aqUCq3NLtLWVYXan3tK5UUetTbEjg91hjllUIvzA9cYD0rFN3MOx1eFY6vB
ZtU40r5fbmxz4tjpfMyqcsRdhVQkcs6y7TlHZz7riM0dD3oVjl9/g4Y969eD3SF2E0EbfZNfKece
IDq2yfPF98sj9h8FAAAAQNSCqH1XEWsuW1paVFFR8YZvMwcfemebH0dVcLxQTz3eXf9y8/f18Y9f
o549e2nEsCTVVLSpsTagqtOtOlXSqJKCJh3Ia9K29ae1et4xzZ2cq6xRezRzeJlmDKlTZv9ypfXO
U/rQrcpO36NV84uUu7lexw8169SJJtU5Edzcaskym/q6ARdpX21t/5oSB4tKbM4csdxNmiNmP9j2
QI3t2xuNd2MksZ9vNLaiHI3G49JdhY2P1x1m2Y5v/hvtcAbdcPygUIH4uXO97lGNo+6mxx22Zz7v
ymyoQ/lG/sqvlGiHmE0chIpfHgAAACBqcRlFbeyoxLHVVHPwpq1bt6p3797ufYm3JcYbR21I59v8
tT1sw7GwzV/dpsfvTNIHPvAhXfWBD+iav/2W5qSc0MIp5UofmatxL63W5P4bNWtcvhamH9WKrCKt
X3hUW5YXaP/2KpUf9aupKuqeUvavMUcVNpvdhiL+9v16E/vuRiPR1++nGu3wZXRYWY1G3jgWY5sj
/7Vz7obbc/JM1EY67OdqxUfQvf36Uxy92fl9o2/6mp/z2caTFgAAACBqcRlF7blBa26fOHFC9913
n3s6GPM22xllZWXuUYsLCwtVWlqqV155RdOmTXvLUWvbIXf/2WXjy9XzsTn6yEf/Vh/+6If1+X/8
npbOKNaudS06stejyuJWNVW2yd8UVDgQaf8co9GORzeKrz227+saf0zkzP6vb7H3AAAAABC1uJSj
1oRsMBh0o9bsL2smlTnHadeuXd2oNbfN5ciRI/VK375uzA4aNEi33HKLZs+eHY9a+69/nLAlOxTR
pB5bNS15re667zb9+s5f6NHHnlCbz9Meru2nvgnHdgQ1Rwt2T/0TNvvd2vHT/xCsAAAAAFELolZq
36TYhKMZ5nZlZaX++Mc/qrW1tT12m5qa3NitqqpSfX29RowYoRkzZsTehx0+z3Q+M6yIJZ8nrKFP
bFTBwWoFrTo1+U46QeuVJ9DqrgaH7JBC4TbnY1rOD4BZNY6dvzUcSZzixlL7PqcRwhYAAAAganHF
R20iaE24mhXbhoYGZWVl6bbbbtPSpUvl8Xjiq6Oxyeaumjq3J0xIUWZmZnvUJuZiYrXV7G/a8QBN
5hQ3p4ttjf5TgapOe939SiNRW4FASAGrJXZuVXNan0ij8xaP5B5AyQlctcZvnxO1rNYCAAAARC2I
2mg0dkqaxEGhTp8+7R4EauyYMUpJSVFjY6P7uMSBlkwEm8eOGzdO6enpsdA155kNxSatiVPLCrav
/CZO11NZWaWVC/PV/8mdKio8Fdu62JzFxjZxG1QkFHYP6ht1z1JqtR9ESe0jcWTh6JmfFgAAAABE
La7sqD1f6L6d89SGrPi5XJ2IbW2NnQ7IjPq6evl9QfcgUYOHDdXNN31bN3zuFj3/5xfcyW7O++qe
NseErDmFjjvbw2+yEnvuoYoBAAAAELUgas8J1zOnv4m8adSmp8eiNhiw3XA1Y8nSRXryya7ugaYG
9B+o/L2HVXG6Rg8/8gddddUH9KEPfUK33XGrO91tszrrnhan1SzZmuVguauyb3TWmvaOjerMOWD5
AQAAAACIWhC1byN43yhqzSbJiU2O+/Xv68TrVbr66qud8VH927f/UxPHZul3v7lbX/jCF3Tdddfp
4YcfcGM2ZJlNjUNu1EbbNzkOxI5+fN6oPetHhdkGAAAAELUgat9J1Ca1b35sBeNRG7Y1ctRQffQj
H9c1f/dp/e2HP6m/+ZuPKWvqIm3ZsF1pk9OUnpqm9evWORNaCluxKW9i1pnucjLXHVHFV3DPneBs
fQwAAAAQtSBq3z4zLcPuEY3bo3ZcijKmxI5+7B4oypwOKBLS8pXL9Isf36d/+NQ/6frrr9dXvnKj
igqLO5yHNj7s2IGiOh73KRL/F5v2tl63iTFRCwAAABC1IGrf8mxsv2KmYchdUY0dzdhE7UQnaqe5
jwhbYXfChqJehcNRLUmrUI+uMzV37mxlzZqq2poa9yjHJn7NkZMj4cgbfJxzPzj1CgAAABC1IGrf
k6iN7eBqNgsOWYmoTdaU+EptOBSLWlte2XZYM4ae1u41vvhBp5yItUOxdwEAAACAqCVqidrOm4rn
3HvWPrXmPLVp7n3h+OptWAFZIUuTXj6q/E0B95y1/oBPYdtELxMDAAAAIGqJWqK2U5h9We2zZ2Y0
dtym9qhNGqcpGWnu5sQmWiNRc6CnoAJBS6P+vFPHckPuU21n4ppNj6MRJisAAABA1BK1RG2niO1D
275am4jasIlay92keMzYUZqcOlFNTU3uKX1M1NrRoNo8Ab3yyCLVlAXcp5rTz0Y5pSwAAABA1BK1
RG3nSazUnolas/lwOBR1V2a9Xo/uve9u3fX732nsmDEqKChy5mhEftuvpka/Xn50ttoa/LE8tkzU
xosYAAAAAFFL1BK1nTMVz55c7r6z4bC7CXJp6Ql94hPX6ANXfUj/7/99WKtXrXEfE4zYqjwd0KBn
lsvTHIzlsYla99w9IWYGAAAAQNQStURtJ87G9ithJ2iD7qbHZtKdPFGhT3/qS7r6A3+vj33077V+
3WvuI21n0h490KQxvbco6I+tzEZNy0Ytk7zMDAAAAICoJWqJ2k6ciS5zJeDMQZ8TtX53tba2qlHf
+/db9dEP3aT/+f5t2rd3v/N2s5Ib0db1p5Q+Yp/CdtTMW2fimvfncf7Px8wAAAAAiFqilqjt7Kg1
K65+N0oty6uAP+ge/XjShNn67Ef+T+sXHnBjNhiyFQxaWrvsmLImHHSPiOzcrYgTt1G1Oc/3MjMA
AAAAopaoJWrffxF3RN1/saNEBd2ojURs2eacs87Emzltg770wee0KPWI+xxfKKSdubv06kuT1fvF
CSosLJYdkkLOxLUjPue9WMwMAAAAgKglaonazonasJu14fiMNDvGBtxzzZrzzsaidrO+/MEhSnph
h3vwKG/Q0q2/+rX+5urr9ZGPflxDhg92Z3QwFJQ/5HePjgwAAACAqCVqidoLELXmZLNO1IYj7sqr
mXizpm3SP189XiOeyJE5uLHXb+nH//szXXXVp3T11VdrwLA+7vvyB30KRWxOUwsAAAAQtUQtUXuh
otbsVxt0J1woFHFXbGdM2aiffDpbY7ucUFtT1InXkO5/4BFd+5mv6Kabb1bSpJHuRPZZHlkhm1kB
AAAAELVELVHbmVEbPitqo2al1pmUQSuiiDMhp05ep99/a7lSuteorNCjsPO2vXuP6cVnJ2nR4pWq
rDopOxKUFQ4o4ARvhMkKAAAAELVELVHbOVFrctY+e6U2armbHwct212pnTppvX7/n3M14MWNWrpk
k6qra1R92q/kgbvclVvzLxQOOZPYdoPXHDEZAAAAAFFL1L5Hr/X7+NpdBlEbcXI2JHf6uTPSTMiQ
IiGzmbEV26c2c7P+8eP36OYbf6GvfvXrGjVurEqONWroc1vka41FbDgae19REbQAAAAAUUvUvlcx
6/ZWOOxeRt+H1/EyiFqz8bF1TtTasoNhBayQu1KblbFVV131I139oS+4B4Z6vnt3Hd9Xr1EvrHNn
ctg9oFQsaiNELQAAAEDUErXvadQmgjZxSdS+adRG3UlpWyZqYyu1WZmb9MmP365rP/Pv+od/+IL6
DxyiI3ualTEkx30fdiSxRmu7lwAAAACIWjdqk4nadxu1idFxxZaoPV/UhtW+X23YjkWte6CoSWv1
8K0Z6tdrih5/dJj25R/R6gUntDjzqDuV7YjzOCUGExUAAAC4kqM2Gj5npXYHUftuojaxOmuC1ufz
yev1vqev5VWX/kQ0J/QJxfaFjW9+LBO55mjGIct9AdPGrNL04bt1MLdCs6YcVSgY0cTB+dq1qdF5
rO08xutusmymcDg+uXFhJ324w/b2/PIAAADA+xm1ETdqwwqZ04I6d5qgjYTCaikq0cGxqarZti8W
tRxQ9l1FrQna/Px8bdy4UW1tbe2bJb/bTZKvuvRfJjs+4rPSnNJHXieKmuTzt8q2w8ocuU4zh+1Q
0cF6jeq3VS31loY9t1fHjpjz2TovZsiJWst5scNRdyLbHbb7ZnTusG1boVBIgUDADVvLsto3UWAw
GAwGg8FgMN67EXWH7YywE7SRsC3LiVvLtIATtHbQUktxiY4kpavOiVoTtBH+Ln1Hw/w9b4b5G3/P
nj0aM3q0VqxYoaamJvdv/2Aw6HbAFRy1obOj1hGO+pzJ2eQEkV91tfVKGbhQmUPX6ERhs4b33qzq
Ez71fWydamt9zovbJtvyKBxwJq4zeYNOBFvOC2ozLsgwE73jxDbXeV0YDAaDwWAwGO/HCMX/9g/Z
ltMEltMCIVlOfIWCzt+j/oCai0p0LGWK6rbviz3eeQyv29t8jZ2/5zsOs2iVv2+fhg8froULF6q1
tdW9/93sZ3uZRG3ozLYD7hK38wKGW93/GjBm9Dh995s/0/e+eZeGDpyp5P47dSinUcOe3au6ukbV
19c7oy5+ybgYRmNjozt4LRgMBoPBYDAYF3Kc3Juv/WMm6eSGHF6P93iYFdsRI0ZowYIFamlpeVe7
HV4+K7Xte3mb/0Wd2ve6UXv77bfrqquu0gc+8DH91/fu0DN3ZWpAt0164o7lmpyapfSMNGWkpToj
Q1PS05U2ZYo70p3rjM4daWlp7uXkyZOVlJSkKc73ITF4fRgMBoPBYDAY7/3IcP/2n5JumiDNuZ6m
1HTnb880M5z7ho9Q9sNPal7v/s7fpGf+XmW89b/vz33NEveZv/F79uypO++8U6tXr77So9Y+O2rj
YRuyg27U/uGhB/SRj35EH/vYx3X7bffpuXunq/t9r6nnY1s1e84SZc+erdmzZjljtrKzszUre7Y7
zHVG546srCx3dO/eXffcc4/mzJnj3ua1YTAYDAaDwWC8P8P87W8uZ7lNkD17VqwFTBuYRkhO0dJu
L2jFoFGa7TxmlnkMr9vbGue+Zua2GZmZmerRo4ceffRRbdq06UqP2siZ7Y47RK1th5yoDWrO3Fn6
35/+RLf+8hatWLFaM4Yc07jnCrR6TlPsSFztR9g9+2i7jAszzPb0GzZs0JgxY3g9GAwGg8FgMBid
OiIdb0eiais9oaL0LDXtPsrr8x4OcxTknTt3atKkScrLy2s/mNQVHLUdjsfdYQQCQSeQAu4LNGHi
eE2fMVVhO6rUPkV67uc7tGpugfPCRRQI2s79QWd43Qg2O4Zb8aNzMTp3JI56vHTpUg0ePNjdsdwc
MIrXhsFgMBgMBoPxfgzb/A0aNgeKCskOWQqYvz9t537Llh0MqbGwSAfGp6p6697YgY9CIV63t/sa
O6+bOTiUGeZve7P/rDmlz5AhQ9xLE7J2/ABSV3bUJmI2fsUcmjsYtNxhXsik5LGakpHmvFhRZQ/1
6A/f2K2dm8tiGy/bZidcs1+u190/15ynNszppC7Mmnsk4obtsmXLNHTo0PaVW85TCwAAgPcrI9wN
Pd3z1EbcU3u651VxesKcq7aluFSHktJVuz0/dp5a/i59e69vh1Olmi7zer3uCq3ZKnPr1q3u2xPh
e2Uf/bjDUY9jOWoOB207L5hPAX/QfXGSklKcqJ2isBO1C0f49dg3D+vI4Wb3ae7pkNyo9TjDImov
wCRv/+7FV2tzcnI0e/Zs9+0d/4tNlF8kAAAAIGovmr/l/9rrkfh7P3Fptso8cuSIu8lxImYTp/ox
t9/qx738ojbSMWrtWJiGA+4mBCEr9l8FksdPUGbmdLW1epQ98oju+/oq7cs/qZD74ppXxjzP1x61
EeZop/wQJM5d1fF2YhNkj8fTfrv9uxt//Lv5rzgAAAAAUfv2/3ZPrLgmYtb8XZ7YD/aNXpf2/ZTj
z3MfH/87vmMLhN7kb/yO7zfxvt5o39vLY6U2em7hxl4Qy4q9OGPHjNXs2XO0Zctm/cvNP9DnP/Uf
euihLvJbofhWy+bxsZw9693hff3BMOFqtqlP/HC0tbWpqampfaKaEzGb24kfBHPbPAcAAAAgajvv
7/ZzA7Xj9URoJu5PPCexT+15D8p1zvs6N57PjeiO18911eX84ptVPvPFjx49WvPnz3c3aTXnrP3g
Bz+ob3zjG+2rgGxGAAAAABC1RO2l6YqIWrMj8rx589yw/cxnPqNrr71WP/zhD92jbxG1AAAAAFFL
1BK1F3XUjhs3TjNmzFBhYaF7VN0RI0Zo5syZb3lnZAAAAABELVFL1F6wqB0/frzS09Pb7+84AAAA
ABC1RC1Re9FH7ZQpU9zr5hQxiVPHcBRdAAAAgKglaonaSyZqDTY5BgAAAEDUErVELd4F5xeG872x
Ix1+KTi/SEJWSOGz7oqdpzb6Zs8DAAAAiNq3Gknu15n4MmKnynkHX5Pzd7oV8Mnjt9+z74Rt+dTU
0KBmT5CoJWov8u9LxFJ9Sa525mzX1rz9arEiioQ8OrknRzk7dilnb7m8tvO989Rr786dys3L0d7S
BoVe9zzCFgAAAETt2/lqgy31Kjt4UIUVbc6XGFJLXYNKjtbp7e6UGfZW69j+zVq+u+a9+dTCXpUc
2aoJk6Zp9a5Sopaovbh/kEL+Gs1/7t/0u24P61tfvVbJ++rlKVunh67/Fz3T41l95+sPamlJi8rW
jdT1X79LPXrdo6//5lUVNFed/bz8Zl5OAAAAELVvma2yzXP01He/qv97Pku13nptXrBUz929QC0h
Sz6PVyF368mAPB6/bOc+b0uLmhrrVdfQLK+3VQ21tWryBBRqKtTyxZPVJW2P6uL3Rc3f+kGfGmpq
VFPfrGA4orDzPjzNTWpqalSLL3SmCYJe53FVqq5rks+yFaw9pIyMEfrFoOU6WdNE1BK1F7uwLCss
O9CsDf3+VV+bsFtV24fp317dqoC/VfnTH9NvU3Zp+7Bf69WtTfK31mrG/ddqyrGWs573T5MP8lIC
AACAqH07UZu7UC/89Fr98PYHNWXjce3csEYD/7JUpSUF2rpkjSoCHpUe2atl83ap4sQxrZ6aqinO
GJM0WfPmT9eUsSOUtXiDamuLNWfqCH3nzpc1adwoTZ+/QZWNdSrMW63U8UkakzpP24/WqsZ5HyvS
xip91iytOVAb+yz8tTqat1DJY4Zr2PhpWrvjgI7vWaY/P36Pftw9VXllLUQtUXspfG/CajqxUy/9
5JvKOtagmvwM/esDKco7uEcLh92qH47eqvyMLnogZaX279+qsXd9R8l7W8563qzCNl5IAAAAELVv
WUilu7Zpeq++Gpc2Qw/cPUqLlq7QyFcWa/+mtcp49hUd9TZqx8Lleunu+Tq4aYEG3fNLDVmwUCn9
7tH/3fWgFs+bqNSe92jxvsNaOHmQfnnvKG1YOlVju92rQVNmafJL92jwgtWakTJBXZ+apd0bF6j/
nT/XwGV7VdXkc1/tyr3O++t9m4avydW6qRPU84HntS4/T9MmD9Ezk7ep4R3sp0vUopO/MRG11RRq
2oB79INBm2U5v0rCoRblLUnToOEj9OrD/6gHso4q1FKqJWmjNHzESD31ies087j3nOcBAAAARO3b
itrtrymrzxDtPrZTcwbfp3ueGahXByzWwW0bNK3HYB1ta9T2lcvV889O1DqPnek8tsBXowP71it1
cYFaS3K1dkZ/Ze/arw3Lp+nlucWy6o5p7cLxeuiFQXr1t/+kx1/tpz5P91HfZ6dq60bnffR23od1
5nMoXL9Kmc+9qgJ/VA2HN2hx0guanZuv9Sunqd+C0nf0lRG16NRfG7a/XsuG3qNP/N8w7Sk4qKLK
ZoV8jSo4cFzHD+xQ6mN3aX6JV77GUzpwvEAHdszXn77zgo62nPO8qhZxqCgAAAAQtW8najdq+ktD
nHht0a4lKfr3m/5Lt/1lqY7teE1pf3pBS7atUfL4ofr1X5bokBO17mM9jTp6KEdZi4+puShXqzOc
qM07qAVzJujXfeZp58rZmjS6lwZOnqaMZ+7SnC37VFxWppO1DSpOvI9A4nMI6+SOJUp/9l5lvbZb
r00fr6TuT2tb4RGtW5Wp/gsLiVqi9mIXlr9hr575t+/qu79/TF3u+74eHr9eNUeW6u7v3KnH7/uB
BmXvc75vAR1ZOkDfufMR3feDHyp7b9XrnvdIMqu1AAAAIGrfzt/ip/fv0fKkDJUGJW/1MWWnjdRz
E3LUWFOg7NFP64c//lf98vF7nPu2qmR/XuyxvhaVFu3Xyo3lajt5SNuXpGr14WLlLp6gR269S7/8
r9+o6/CVqmiq1paZw/WHn/2Xur74gobNzz3zPjqcpSfUVqlN04fq9//6r/rDXX9U5uZi575y5e1Y
qqmby4laovZS/hmzZIXPvcsS3y0AAAAQtZ3wWjhfc8R+myf3cV4z2fZZr2gkEnbuivzVV/6tPY6o
JWoBAAAAELWXOaIWAAAAAFFL1BK1RC0AAAAAovbSexWikbDbSaad3srj3U2HQ+GL5sCtRC0AAAAA
ovYKjdpwsFWVZQe1c/c+HTh4SKV1Hr1R2tpOWwW8Aec1C6mlsUbFBdV6a2eUjThdZsn3Ds4/e1lG
bfRNAvbcS6IWAAAAAFH75ppLdmhin9/q33/zgH5/5626b+Bc1Vm2fK1Nqq6qVkOzR1YooPLDh7R2
3iZV1JUrL2ezZk3bLn84JG9rg6qra9TsCboruKGgVy0tTWqoq1OrNyg72KAjh3Zp4bpjam7zKehv
U11NteqbvQq/Ry/nJRW15y6Hm0ll7jOhaq4nlswT4UrUAgAAACBq3yRqi3K1JnOgFhS06uCCmRr2
y3u161SN9r+2UGOHj1HanJXKKyjS8vFDdPePnlBKZoYmps5U9rL9qjpZqJXT0zR6zGjNW7Vd1Q01
Kshbo/T0qcoc59y3aItOlO7T+KHP6YdPDdPyDTnav3WexoxK0uxVeWp6j9Lsktv8OBGyiesmXAOB
gBurZti23f52ohYAAAAAUXt+LcV5Wpj0oobOX6e5E8ar+9PJKq6rV9HendqyfoHGjn5Bf5m/W4e2
rtakYdN1sOiwpiZn6q7bJmhB+mTd87NRWrdsmlJeflKZm/ZowcShuuWecVo1baLG3H2vlhwu1bY1
czQibZMK967TjNFPqOeUtSoqPanm92iL5Etr8+N40HYcZWVl2rZtW3vMJh7D5scAAAAAiNo311q2
R6mvPKr/+kNvTZq6RIer2uSrLlNOdqqG9uqqbk/focHLjqvswGEtTV2jlnCjctes1CuPjFZGcn99
/T/+pCH9+uiVvq8qe/1WbVgzVX0Xlai1JFdrp/fXvEOndPjgTk1bdFwhT402zhyhR2/7ndLmb1RN
4Ao8T60J147DBGpOTo4efPBBWZblPsZEbOLtwWDQDVsTtenp6UQtAAAAAKK2A3fz46kDtagkGL8n
pJI1CzTy9juUvma1sjOGq9/CIyrbvUNTXx6tnKJibV+5Wv0en6A5i1L1+1fmKP94scqLT6qxrlAb
Vmeo77wC9/2uznCi9ugp7du8QgP7zFbB6TpVVZRqbXaKRjzzBy0p8V95UdvY0KCqqip3eDwe9766
ujo9+sgj8vv97fvVmvvMY6qrq90xatQoVmoBAAAAELXnaCs/qG2LJmntCV/7q9JcfljpQ57XT+5+
UM/36qOZO8pVX7RD45/5o/7YdZo2bN6uqcmvqez4Zo3seb/++44u6v3HwcopKNKubYuUvPbEmfdb
1qCiDfP0zM/u1iMjZmjK+J763m+7qc/Q+Sp/b5r20olaM4GyZ83SoEGD1L9/f3eTY3NfZWWlHnv0
UfmcqDXBauJ2woQJ7uOGDBmisWPH6vbbb9ecOXOIWgAAAABE7Vt5bczunqHQOfdFnfsir3tc2DK7
fb75Kx1xXmPzVPfxZtfR9/BzvaSi9sCBA9q8ebM7ysvL3U2OS0pK3M2PzYqs2eTY3Ldr1y73MVu2
bNGOHTvUvXt3ZWdnE7UAAAAAiNrLzCV5oKjEeWhN2Pbp00e33Xabhg4dqtra2rPenjiY1OTJk9mn
FgAAAABRS9ReWGYl1py+xxz8yVxvaGhQbm6uu4Kbl5enlpYWN2ITB4jyxzdJTkpKUkZGBlELAAAA
4LKPWtsKytPaJst8HWbRL/H1xjf9vbBfRUQh5/Pz+oJv+nlEwiEF/V7ncX55W1tlRS+TqDWTKHHU
48Q5aRMTK/E2E7WJ6DVxa26npKRo2rRpRC0AAACAyztqo5bKDx/Q4qxVKm9tVkNliWr8Efcr9TY1
6FRBmdou5JcRblPJoX1auWS/rDd5mLemVAd2rNK67Xu1ceECHWgMXR5R684v818XOkSt7VwmQjbS
Ye9kM+HM/rWcpxYAAADAlRK1Ec8pvbYkW92H56i2YLOWTn5Ws46ZM8eEdPpwvlakz1Op11bQ51FL
ixO99U3yWe6rINvyq6muTnWNrQqGndcjFFBLQ51q6xvlDdqKhp3neVvV3Nys5hZ/bKXVHAAq4FFD
Xa0aW7wKO69RyPKpsb5ODU1tspxm83taVFsTe7sdqtfW2Uv18v3L1Oa8P19bo2pr69Tqs9z3F3Y+
ZqsT38W5KzR/ci9N35KndQsna+yykvOu7F512U5Q82LGQ5eoBQAAAHAlRG1b+R6tnDlE6XkNZ84V
W2CiNqzasiJtX/maSiorlLdunlKnT9XYMVO0ZEe5/L4mFe1Zq1SnnUZPnqec41WqOXVQC9OTNHJs
mpZvPKrm2lPavXKqktOma96K/TJrp2FfvY7tWKAxI8cpa/ku1XoaVZC3XJPGj1Fa9lodP12t/RsW
asyw0Uqds0qHq6uUs3yVBj6/TKdOFmrljFSNGj1aC9buVJ2nTWVHdmjKpCQNfqWHBvR4UsuOlmv7
4iV69U9L5IkStUQtAAAAgMs6apsKdmplal8tdkL27KgNqXjTWmU8+4pynHCcMPBR3TVsnhOQU/S7
u0dp5+41mtz7Xg1ZuFZZEyfqySenq/B0sXZu2aYFSRPU/bZXlGee9+rD+u2AFSqubHJfu5aSHZo1
uotezFiv4tITOpK7Qem9uip1wz4dO7RX+QUVKt63U9teW6RxY7qr56JcN2oHPJWueZMn6YFbxmj9
sqma0Leb0la8pqnJfXXviCVamjpYz/z+Xq0ordWhJauUfF+SSiyilqgFAAAAcFlHbc3BzZo7/Fkn
ar2vi9rS7a9p+ktDlHMoV2umDtSiEr9z3zbnvv5asX6WXvntP6lL31fUq+tL6v1kqnYc2KXJY4bp
kfue0m23DVGe+7wB7vMSQp4abc4aoYd+eYdS56/VjtVrlPlMXxX4zblpw2qrLNPO2Wka0uNxPfXk
bzR0yW43avs9Nl5pY/vpG//5jAb27amXX35Fk2fM0bK0PlpQ6FXT8S1aMaW3FhY2qei1TZr2YpIK
AkQtUQsAAADgso7alhInZDMHaM5hj/P552rJhF4au2K/SosLlbdmTXvUxmK3xYnazc59A7V20zJl
PHOX5m0/qLKT5SovzteCWUm64+X5Wp+ZreF3DnOj9kwkx4StgOqqyrVx3mSNfPr3GuuEadrTv9P0
zfk6dOyg1k+brpG336GM9Ws1O3OEBs7LVc6KFer/5HhlzZ+se/ov0KHiMp06UaGKwp1aNKmXBszd
oQ3zkzTi2d9oWUGFds1frH73p6rSJmqJWgAAAACXddT6qw9q6Yzhenn2MbVUHVXW0D/pe9/4hR66
6xENTV6qZePStb/ooLYtmqS1J9p0On+3e19BfZU2zxiq+3/yPXV54XkNmrFBuYuz9NRP7teDXZ5X
78Ezdaj9eb72j+epOq6s5J763m+76aVBc1VUdVrL0l/V17/+df3qwSeUtWar0oc8r5/c/aCe79VH
s7Yd0f4d25Q6caNKj76mYT0f0I9+00V9Hh+m3eU12r84Vff+6Ef6+h136K7H/6TNx45p9YJpemHk
VgVF1BK1AAAAAC7rqJXdpPVLluuRLvPUEH37r0gkEnY6KnLmtjm6ceSvPMucoca015kYUyR85nnm
7ZFQ6PzPtcypWXXWx7Tjt5tKdmrBtIFK3dtw3o9P1AIAAAAgai+XqHW+qrbaWhXuO6z60KX+HXK+
BzWVOpZ/RA22iFqiFgAAAMDlH7VXHqIWAAAAAFFL1BK1RC0AAAAAohZELVELAAAAgKgFUUvUAgAA
ACBqiVqiFgAAAABRS9QStUQtAAAAAKIWRC1RCwAAAICoBVELAAAAgKglaolaohYAAAAAUQuilqgF
AAAAQNSCqCVqAQAAABC1RC1RCwAAAODKiNpwe9RGO0ZtMlFL1L7HoWoiNdphQiWuR865bbxh1Nqx
qDUT1fwXGAAAAABXctRG3aCNhm0naiOynPuCzmUgHFJLiRO1Kamq3bEv1hnxFkk0CYjat81MHsuy
3NVWE6xupDr3mesh23Ynlu1cJmI2EAi4lykpKZo6dWosdK2Q+Y8szqR1JqMTuO5/hYmKwWAwGAwG
g8FgXGHDrMra8aiVHVI4GlLQyVy/c9sftpyoLdGRZCdqt+11WyMcttujlrAlat8RE7MmVBPxmtjE
OBgMurfNMJPL3E481lx2XKkNOJM1FHZC2N28ICLbiVonbRkMBoPBYDAYDMYVNEzQuquy5nbUuRVx
bjlR667aWs4I2WoucqJ2bJrqtua3R20kHCFqidp3sXlAfNNiE6pmmInU1tam2tpa+f1+N3ATjzGB
G3Di1qzsDhgwQJkZme6qrGU5oRuxnbC1nAnpvI8og8FgMBgMBoPBuOKGG6ZOWzgRG45aTisEYmFr
gtbj9IInoPKjh7V5TJKq8w60d4h5nrkkaInad7xS2zFaPR6P5s+bp1GjRmndunVu2CZWbM1myZYT
ubt27dK3vvUtDejfX21NTbIDTvyaAA4EnMtA7JLBYDAYDAaDwWBcccP2J5rA7w7LbYSggm0BFVaU
q//E4br/17/QlhXLFAwGYp0RDrev1IKofUdR23EiHT16VC+//LKmT5+uxx9/XIWFhW7wms2PzeXp
06f1s5/9TB+46gP62o03asnkdBVu3aVjG7fruHN5fHOOjm/LZTAYDAaDwWAwGFfYKNiSq+KNuSra
vFPHduzQ0Z3bdXjXLh3dsVv5m3I0ZNQIffprX9Knrvk7PfHYQzpRVtp+PJ/ElqMgat+2qqoqnThx
QmVlZWpqapI/EHA3MfZ6vVq5cqUbsWZynTx50n3coUOH9Jvf3KGrr75aP/3eDzSt12At7jdOSwem
aOmgZC0ZkKQlg1IYDAaDwWAwGAzGFTaW9U/R6j7JWvlqkhYNG6cFo8Zq3ugkLRg6UfMHTNLQv7ys
H3//+/rWF7+o0c//RTUVFe2LbIlNkEHUvu0jH6elpalXr1564YUX3M2NzURqbGzUgQMH1Nra6q7Q
mn1shw4dqh49eqhfv37685//rH/553/WzGnTY+/HbL7MP/7xj3/84x//+Mc//vHvyv5nuiAcPydt
+xlrnWE71wNRBbx+5axZrZQnntTpbbvcjkgELZsfE7XvWH19vSoqKlRdXe1GbF1dnbtCu2/fPi1Z
skSlpaXu5DIHjjKPMyu3TU70jh41StOmT3cnrs+2FIzaspwRcmaxGVb8NoPBYDAYDAaDwbgyhukA
cz5av9sDQSdu/U5LBBUOWor4Qor4Q2opLdOhyVNVs+tg7EBRJmrjmx5zoCii9l0fAdmMY8eOqVu3
burdu7cefPBBd5Pjcx9jIjcpKUnp8VP6+MK2e9huyx2KjyiDwWAwGAwGg8G4goZpAp/TAl7n0pzu
MxqxFI6EFHLCNWRZskOWmguLdWD0JNVs2dsetYmg5ZQ+RO07PlBUpMPO2Wb53+xba1ZwzX61iceY
0/iYt5lLczs5OVmZmZmxt9tmGwOp4xYG7bcZDAaDwWAwGAzGFTMi0diCmMz+sXbIuR1SMGIr4ERu
MBxSc5ETtWMmqmbr3vZT+iSClqglat/VSm3Hy3Pflti23Vw38Wtujxs3TlPiK7VELYPBYDAYDAaD
wUgMd49aE6hhW+FoRCG3KWIB21JcokPjU1W7fZ8JjLO2CCVoidr3ZXPkc+9PRO348ePPRC1HKQMA
AACgM+tcUSdmTdja5mBQ5g3m4FF2RC0lpTqUPMWJ2vz2qAVR26mxS9QCAAAAeMdRW+xEbVI6UUvU
ErUAAAAAiFoQtUQtAAAAAKIWRC0AAAAAELVELVELAAAAgKgFUUvUAgAAACBqQdQStQAAAACIWqKW
qAUAAABA1BK1RC1RCwAAAICoBVFL1AIAAAAgakHUErUAAAAAiFqilqgFAAAAQNSCqCVqAQAAABC1
IGqJWgAAAABELVFL1AIAAAAgaolaopaoBQAAAEDUgqglagEAAAAQtSBqiVoAAAAARC1RS9QCAAAA
IGpB1BK1AAAAAIhaELVELQAAAACilqglagEAAAAQtUQtUXtBApaoBQAAAEDUErWXZMx2DNXEfedG
bXp6OlELAAAAgKglai8cE6i2bbfHqrne2NioY8eOqaamxg1Wc5+ZbOa6eZy5JGoBAAAAELVE7QVn
gjUYDMrj8bhRW1lZqenTp6tXr17q2bOn6urq2sM28VgTtsnJyZo6dSpRCwAAAICoJWovHBOzTU1N
7uqs3+9XRUWFDh486I6uT3RVQUGBLMvSkSNHdODAAe3bt0+HDx9Wnz59lJWVRdQCAAAAIGqJ2gs0
4ZwJtGLFCqWlpWnSpEnas2dP+2bGw4YNczcxNqHr8/k0fPhw9XZC1sRsv3799POf/1zZ2dlELQAA
AACilqi9cFG7atUqZWRkuEcy3r9/vxux9fX17njxxRfdVVnDbHJsOcNsfmw2Qx43bpz7PKIWAAAA
AFFL1F7wuE0Mc3CoOXPmaMKECXr66ad14sSJ9tXbsDMpOaUPAAAAAKKWqL1oJA4CZfabNddNsJr9
aTMzM3X40KGzHmOYxxG1AAAAAIhaovaiYkK14/loE8Pcb0YiXIlaAAAAAEQtUXvxTLoOIWtWYxOr
su4+tE7AmuuJsDWPIWoBAAAAELVE7UXD3Vc2HqXnrtAm3pa4bS7ZpxYAAAAAUUvUXnRh23HF1p1z
8dXZSHw/WzMMohYAAAAAUUvUXjqTssMkY6UWAAAAAFFL1F7SgUvUAgAAACBqiVqiFgAAAABRS9QS
tUQtAAAAAKIWRC1RCwAAAICoBVELAAAAgKglaolaohYAAAAAUQuilqgFAAAAQNSCqCVqAQAAABC1
RO3Z33J/U708IecbaXt1srhYJSUNsiLnPCwSVJXztuI3GiUlaglGiFoAAAAARC06O2otrer5pJaU
22rdP0n/8bnr9aVreyi3IXLWtIj4DqrLl7+sL7/B+MpNN2n6kVaiFgAAAABRi86O2mYN/7uvaUFZ
gVLv/LR6bzimbcNv06DtTec8zlZLY6Ma46OutloVFRWqrKpWvXPbF+ykCUrUAgAAACBqidoz/Jr/
5Cf0D//zeX35piGqidjK6f+/Gr77/CuvVlut9m5dqUXLl2vlsvU6WFIvq5PmAVELAAAAgKglajvw
KvupOzRsziaVNoadb2hAe1asVanvPBMkElLe5If0uS/fpF937aoHbrpJX/z7p7W3hX1qAQAAABC1
6PSoDWjWL6/So6nr3tKBnyLheo389re16FQwHrlBLe/2bQ3e1UTUAgAAACBq0dlRG9SCW9/6gZ8i
4UZN+N8fKC2nQDW19ao+VaCZT39XY3I5UBQAAAAAohadHrWSt7le9fUdR4O8wfNFZURFKwfqKzd8
SU/9uZe6/vaLuvHmh7SnsZMmKFELAAAAgKglas+IqLH0oA4e7DgOqdYXOe/j2+prVVV6WK+tWaO1
2/aoytd5QUnUAgAAACBqidoOfJr9wFf0la+YcZNuuvF6/cNHPqqJB7xvPEEircp+9gEtLvNfmAlK
1AIAAAAgaonaszhBGHaH8332ndLI7/+Lphe+cbRGwx5l/fpD+mPaWzuwFFELAAAAgKjF+xi1zje1
qrg9UIsKjyrz/ms0JLflPFHr1cwffVZfuuHMgaVu+NIXlX6g5V2FasfrJlgT95nrifsTw7Ks9qhN
T08nagEAAAAQtVdu1PqU9fgNuuGGxLhRN3/1ae1pDL/h9IiEfVo3LlX5lfGDStXV6sDKdK0vfueb
I5tAjTgTyYSpbdvuSqy5bi4DgcBZ95uRiNpx48YRtQAAAACI2is7aqWWxlpVVZxSeXm5Tp6qked8
fRjxqjR/g57+0D8rbeM+Hdy3Twf271bK/Z8878ruW43asDMSwZq4PHXqlNasWaO2trb2FdpgMOiG
rolcs1I7depUohYAAAAAUXslR63lqdW+rSu1aPlyrVy2XgdL6mVFXz81Iq0H1fWmL+sz13xK1914
k266yYyb9dWv9TjPyu5bk1iBNbHqBq4TqCZkJ06cqP/+7//WoUOH3Mf5fD55vd72kZycrOnTpxO1
AAAAAIjaKzdqI9qb9rA+e8NX9OuuXfWAE6pf/PuntbfljQ/8FI00a9ErY3XUG9v3NTHezTxoaWlx
N2Wuq6tzw9W8v9WrV2vWrFl6+eWXtXPnTneirVu3TkuWLHGHefsTTzyhGTNmELUAAAAAiNorN2qb
NOKb39TCU8F4tAa1vNu3NXhX03mfYXkaVHzkyFnnta3xvumBXeAAABRdSURBVLOjH5sJlJ2drcGD
B6t///7avn27G7lPP/20G7NPPvmkNm7c6Ibu5MmTNWrUKI0cOVIpKSm68847NXv2bKIWAAAAAFF7
5UZtiyb8+D+VmlOgmtp6VZ8q0Mynv6sxua1vPEEiIeUlPalrv3Sju/mxOb/tzV/9mqYcaH3HUbt3
716tX7dOa9eu1enTp92jMD/++OPq2aOHvukEd1paWvtjE5eJyOWUPgAAAACI2is6aiPKn/qoPv7J
v1eXP/VQ199+UTfe/JD2NJ7n0XaDxn36E5p5pLE9Jt9tUHY8XY8ZgWDQPSCUWQW+5ZZblJSU5Eas
uc98rMSBosaOHUvUAgAAACBqr+yo9Smry3V69MVX1af/cE3IXqGjNW3ON/48EyQS0KJuP9BfsnLa
z21bXFKilmDkHX+y5iBRJlLN0Y3dU/k4183EMpsh79m7V8ePH3ffbobR8Ty1RC0AAAAAovaKjlqp
pfKIFqYP1k033qDP/ufP1WvkNBWc70BRYZ/m3fdlXX/dF/S5z31On//CF/Xlm27S9COt7/iTNUFq
QjUaP1dt4ra5TKzeJkLWTDoTwUQtAAAAAKKWqHXZAY8aqk+o7PAmjXv8Gl37hS8pOb/lvFOkubJQ
m1bO1Yzs2ZqbvUg79hWrJfDOP1kTqImVWBOsJlDNfWYz48R5a83bEuFK1AIAAAAgaonaRFLq+Oo0
dbv9s7ruhi/rly+M0urdBfKdpxHNgaJ2pz2sz1x3g27t0kX3Os/53Ce7aV/rO9/82F2B7XA9doqg
2Iqs+zE7TLQoK7UAAAAAiFqi9gyv1o97RaPnblBRVZNamlvcfVkD59mpNhKu18hvf1uL3sYpgN7T
CUrUAgAAACBqidqO3/LmoteUOmaYBr7UT8MGj9Sr3ftoXUngPFHbqJQff18ZeSWqb2hUXWWJsp/5
N43ObSFqAQAAABC16Oyo9SvjVx/V7waO1EOfukYDZmToF5+5RpOO+s8TlREVrujvHijqyed66onf
fE7X3/iAdjd20gQlagEAAAAQtUTtGS0a892fK9eKaOfApzW/qFJ5Q+7SsJzm1z80YqmlxedMkKia
yw9rw+rVWr0lR8crW9RZSUnUAgAAACBqidoObK3683Uae9Cjyo399YXP3q4ff+F6ZRf4Xjc1Aic3
qN+oVfJ1uC/iL9TovskqszpnIhC1AAAAAIhaotYV8rbIG3K+3d4anaxslD/k1/Gc1Xpt98nXrbxG
I2Hlj/+5/jtl31n3R8KtmnrbJzRyn4eoBQAAAEDUovOi9ujs/pp9tM29XrZ+qlYX+s8/MZyozR39
W/VZX6WOB0aOhnza2v8WDc1rJmoBAAAAELXovKjNHfRTDdjZ6H7bdw78qfpuazzvN9U9QNS8x/SZ
f++trQUnVFldreqKMhXmzNH/fepzmva6zZWJWgAAAABELd7HqM0ffae6ZefqxIkSzX/h5+o+O08n
SgpUUFioxmDk9ZMjUqmZXa7XdV/8vH58xx26438+q89fd4O+MniNfJ01QYlaAAAAAEQtUWsULOit
66+/Xl9yxvUdxg1fvlFp+ec572zUVk1JvrZsyVHOzp06crKxcycoUQsAAACAqCVqE+xgUF5nBDsM
ny+oi7URiVoAAAAARC1Re+lOUKIWAAAAAFFL1BK1AAAAAIhaopaoJWoBAAAAELUgaolaAAAAAEQt
iFoAAAAARC1RS9QStQAAAACIWhC1RC0AAAAAohZELVELAAAAgKglai+5iCVqAQAAABC1RO0lF7O2
bbsBm5hkJmSJWgAAAABELVF70TPh6vP5FAwG3WA1EWtZVvvbiFoAAAAARC1Re9EyMdvS0qLW1lY3
YE3IJlZtTdwStQAAAACIWqL24puA8Um1bds2jR07VtOmTXPj1gRtIBBwN0n2+/3ubRO16enpRC0A
AAAAopaovTgkNjV+/vnn1aNHDy1evFjNzc3u/WbV1lw3kWsuk5KSiFoAAAAARC1Re2GZQK2pqXFH
W1ubG6h9+/ZVz549tW/fPndzY6/X667ampBNTk7WpEmTdNddd2nWrFlELQAAAACilqi9MMyqrAnU
5557Ts8++6zWr1/vbmJ89OhRTZ06VY8//riOHz/uhu2SJUuUlZWl2dnZmjt3rrp06eJeErUAAAAA
iFqi9oKpq6vT6dOndfLkSXfT4lOnTmnNmjWqrKzUU089pdzc3NjkjE84M0wMp6WlcaAoAAAAAEQt
UXuBJ905sWoi1xwkqmvXrho2bJi7L23inLXmqMjmVD/m9rhx44haAAAAAEQtUXthmU2LTbCaSxOs
CWal1sSrGeZ+M9nMdRO2Jn4nTJjg7mdL1AIAAAAgaonaCyZxxGMTrOby3EBNrOCa+zlPLQAAAACi
lqi9+CfieSYXUQsAAACAqCVqL+nYNZsqE7UAAAAAiFqilqgFAAAAQNSCqCVqAQAAABC1IGqJWgAA
AABELVFL1AIAAAAgaolaopaoBQAAAEDUgqglagEAAAAQtSBqiVoAAAAARC1RS9QCAAAAIGqJWqKW
qAUAAABA1IKoJWoBAAAAELUgagEAAAAQtUQtUUvUAgAAACBqQdQStQAAAACIWhC1RC0AAAAAopao
JWoBAAAAELVELVFL1AIAAAAgakHUErUAAAAAiFoQtQAAAACIWqKWqO30UH2z+81llKgFAAAAQNQS
tRcjE6humDqXZpjbZmIlrpthO9EajU84ohYAAAAAUUvUXlRMlIY7hKtt2264Ju6LxO8ziFoAAAAA
RC1Re9FFrTsBTcA6E8+Eq4nYxLCc24m3E7UAAAAAiFqi9uKbfPEJZYK1ra1NTU1NsizLjVoTrYnN
lIlaAAAAAEQtUXvRSOw3a2LVTKjGxkZNmzZNffv21ZEjR9y3mbhNvN1cmoglagEAAAAQtURt506w
+ISJxPeTdQ8IFd+fNrEqO3/+fC1cuFBbt2xRTU1Ne/Am9rFNbJKclJSkDKIWAAAAAFFL1HZm1CY2
JzbMqmxBQYEKCwtVXl6uYDCo/v37a/To0ZoxY4aam5vbY7akpETHjx93H19UVOSu5JoVXaIWAAAA
AFFL1HZK0CYOAGXi1YToxo0b9cwzz+i5555TcnKyKioq9MADD2jVqlXavn27jh496j7X4/FowIAB
6t69u1544QX16NFDP/nJTzR79myiFgAAAABRS9R2TtSa+EwErbk0mxx72toUCATc4D18+LC6devm
rtrm5uZqz5497nPNY83bzeO9Xq97aTY/njlzJlELAAAAgKglajtH+36x55yyx0hcN/vTPv/88+5B
oMwRkBMrvImjI5sANu/H3ac2I4OoBQAAAEDUErWdG7aJkI12mEQdr3eM1MT9Hc9ha94+btw4jn4M
AAAAgKglai+ySfgmkyqxast5agEAAAAQtUTtJRe2RC0AAAAAopaovaRjl6gFAAAAQNQStUQtAAAA
AKKWqCVqiVoAAAAARC2IWqIWAAAAAFELohYAAAAAUUvUErVELQAAAACiFkQtUQsAAACAqAVRS9QC
AAAAIGqJWqIWAAAAAFFL1BK1RC0AAAAAohZELVELAAAAgKgFUQsAAACAqCVqiVqiFgAAAABRC6KW
qAUAAABA1IKoJWoBAAAAELVELVELAAAAgKglaolaohYAAAAAUQuilqgFAAAAQNSCqAUAAAAAopao
JWoBAAAAELUgaolaAAAAAEQtrtiofaPJRdQCAAAAIGqJWqIWAAAAAFFL1BK17wXbtt1hQtVMKMuy
VF9fr7q6OjU0NLhvM/ebt5t4TTw2KSlJmZmZRC0AAAAAopaovXACgYC8Xq8bsyZWc3Nzdffdd+v5
55/X/fffr7KyMvdx5u0maP1+v3tpojYjI4OoBQAAAEDUErUXjonVYDDoDrNpcX5+vhYuXKjKykp1
795dx48fd2O34+NMCKekpCg9PZ2oBQAAAEDUErUXaMI5EygvL09r1qzRihUr3IBN3L9nzx4NGTIk
tpLr82nTpk1atWqVO9avX69u3bopKyuLqAUAAABA1BK1Fy5qp0+frgEDBujll1/Wtm3b3PtMpM6c
OVPTpk1zH9fW1uYeGKpfv35u6I4aNUq33Xab5syZQ9QCAAAAIGqJ2osrdM1+syZ0i4uL2w8Q1fHt
5j6z6TH71AIAAAAgaonaCyoRre6IRNz7fD6f1q1b5+5H657CJ34qH/MYszmyOVDU2LFjOaUPAAAA
AKKWqL34mEiNdgjZxOl+OE8tAAAA/n97d/gjxVkHcDwkvigx9YXhhTamf4GamFrfaEx8Z0z6Vhq1
0UhCIq0v24CamJYX0lbAVoRCgYMmhJI2attgDF6obSxYkNaqjRTOBs/KQXuUo/Rud2d25uc8szvb
vaYm4p1mSD4fMrd7s7y6mUzmu88zMyBqRW3rpWhNdzlunmE7HraiFgAAELWittWacE3X1qb3TdiO
fyZqAQAAUStqWylFazMym4I1Ra3pxwAAgKgVtdfHjvhvdi5RCwAAiFpRe13HrqgFAABEragVtQAA
gKgVtaJW1AIAAKIWUStqAQAAUYuoBQAARK2oFbWiFgAAELWIWlELAACIWkStqAUAAEStqBW1AACA
qBW1olbUAgAAohZRK2oBAABRi6gFAABEragVtaIWAAAQtYhaUQsAAIhaRK2oBQAARK2oFbUAAICo
FbWiVtQCAACiFlEragEAAFGLqAUAABC1orY1Urh+UNT2ej1Rex0eWYr6OFK+d6QBAID/Q9RmqSFS
M1RRW+T9uFxF7SsP7YyLLwyj9gO6A1F7TVKQ5nleh2oTrGldp9MZrW/WvT9qd+/eLWrbflCpDh55
J4uF6gCykGXRz6pt2s0XhW05+ql2AQBYStBW4Vr9Sz/rkdnqJQXtlWrNO2UeeT+Lt1+bilNbdsbM
sVN1XxTDlqjfC1xR+1/teGk6QBWv6bUJ3BSu7777bv0+rUu/p2nH6fdut1vvbNu2bYuJiQlR23JF
dTBJIZulLy3SNu5lHxy1aRTX1A8AAJYYtVVBVD3br6M2tW2aejxX9OPNbD56eScunTkbJ3+6K954
8VR9/tkMoo0PpCFqrzF6ilHMpnBNATs5ORlbt26NEydOjNYvLCzUn83Pz9e/p89NP74+tm/6IuIv
r74aM+dn6sjNfQMGAMD/4twz0lTjfh22TdSml061/mpRNUVvPs798eU4fP8DMf3Sy4NrbtNA2ljY
ilpRe81SkKadpxmJPXbsWNx5552xa9euWLduXZw9e7besVLUpqBNSxrF3b59u+nHLVdPF6+262+e
/23cesstsfbba+KfF2YiS9t8/Ppaxw0AAJYpartV0PaaqO3HYApy1RsL/TxenzoT3//uuvjKrZ+N
Xx84EPlwFmjqieaGtKJW1F6zFKhzc3P1kq6jPX78eGzYsCGee+65uO++++qoTTtYmmr88MMP19OO
d+zYEatXr46DBw+K2hYHbVqmL5yPz3/5S/GhFSviIzfeGPdv+0k9LaSfji71lOP66DN6CwAAS4na
TvWzl941UZun62bLuPzOXOzY80isWvXR+PANN8RXb7stzpz+6+gyyGawTdSK2mvb6YY3fEojs2vX
ro0jR47E9N+n63VPP/107Nu3L2ZmZuqoPXToUD3deO/evbF///6466674qmnnhK1LY/aq52F2Lnv
0fjcxz4et3/hi/GHV1+Jy0UWWZEP/2PE2OwQAABYQtRGdKsTzCyGcZoyoQrasl9Et9eN4yePx+3f
uD0+9elPxs+2PRRzc5dH563jC6L2mpw/fz7OnTsXU1NTcfXq1fjV4cPx4IMPxKVLl2L9+vVx8uTJ
RTvX+Guaiky71dc0dLpx5N4tcfiHm+tvz2b684M7y5XDks3rY034agIAgKUoB6eW1Xnl8Bq35vk+
xeCpHL08i9Ovn4nJ54/G3NW5RX2BqF3azjcWqhcuXIiNGzfGmjVrYtOmTXHlypV6WvJCtaQbRTWv
KWjTK+3WLfLIq+30xi9eiJd+tKd++PXFYj7yYmx4Nqvitxzcbh0AAJYjbsd/SUGbRmuLZopxNM+y
FbSidhlkw0f4NI/vSdKI7fT0dB2zzU2i0h10m7nuaTpyc2Mp2i2vorboZXFu4kj86Qc7Iq8OIRfT
SG3a1tWBpb7OoarZhTJNFQEAgCXWbDMyO3pb1ks9+zM9iSMvIq/OQ/spdP3FRO2y7HfDqcV1sKbb
aA/f10FURWvz3NrmrmTNa1pnpLb9+kVWRWseMzsn48z3Hq2jdjZfiCLvp+IVtQAALG/U9gfLYCpy
ur423aS0Ctvq3LNM55/F8HPXvona5VIMn1laDJ8R1dxxrBmNrT97X/iWw/9feN7pdbB9s3qk9h8T
k/Hne/fU267T7w62Y/HeNbW5a2oBAFiOqF00UluOrrEtxz4bzD325xK18J8cV1LUZnmc/eWzcXzL
nsHKrFdfP5svOvCUgxtHAQAAotafgLZF7dTPj8bvNw+ituz26qnGo6gtRS0AACBqaXPUPnk0Xvzx
e1E7mAYyFrWlqAUAAEQtLY3avz1RRe2Dewa3VO/06qBdfEW0qAUAAEQtbY3aJ5+NE5snhlGbLYra
wXX6zZAtAAAgaqFlUVtPP94yMRqpTXe0bqJ2ELiiFgAAELW0MmqzOP3M0fjd1t31FONioRN5eiRT
DDp28CixMjz+GgAAELW0Sq/fizzrxdQzk/HCI/uqyC0in1+IrChHN4oStQAAgKilfcoqXMt+XLj4
Rmxa/bV49O4N0e12I6+WbjmM2hC1AACAqKV1PVslalnEW2/Pxh3f+WasWrEiPnPzzfH4E4/X6ztp
xHb4fwtRCwAAiFraF7VlvDn7Vnz9W3fEypUr4xM33RQHDh6on9yTrqmVsAAAgKil9WE7Ozsbd99z
T+x/7LF6fb/fj6Io/IEAAABRS7uleE1LnmWjyE1RCwAAIGq5LjQjs3me10s2DFwAAABRCwAAgKgF
AAAAUQsAAABL8C8dzlZHaex9ZwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Skærmbillede 2015-08-19 kl. 11.09.31.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2015-12-23 13:05:39 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of AT III vs placebo or no intervention on number of bleeding events. The Diversity (D-square) is 0%, the control event proportion is 13.2% and the required information size is estimated for an anticipated relative risk increase of 20% with a type 1 and 2 error risk of 5% and 20% respectively. The cumulative Z-curve is breaking through the trial sequential monitoring boundary for harm suggesting, even though the required information size has not been reached, that AT III increases the number of bleeding events. The TSA-adjusted meta-analysis yields a RR of 1.85 (95% CI 1.35 to 1.85).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA04AAAH5CAYAAAC28G5lAACAAElEQVR42uzdd3zUdaLv//vH795z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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-08-27 19:54:43 +0100" MODIFIED_BY="Jane Cracknell">
<APPENDIX ID="APP-01" MODIFIED="2015-08-27 19:54:43 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2008-01-14 13:56:55 +0000" MODIFIED_BY="Karen Hovhannisyan">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-08-27 16:30:36 +0100" MODIFIED_BY="Mikkel Allingstrup">
<TABLE COLS="2" ROWS="7">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>The Cochrane Central Register of<BR/>Controlled Trials (CENTRAL)</P>
</TD>
<TD>
<P>#1 MeSH descriptor: (Antithrombin III) explode all trees<BR/>#2 (antithrombin III or AT III):ti,ab<BR/>#3 #1 or #2<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>CINAHL (EBSCO host)</P>
</TD>
<TD>
<P>S1 TI ( antithrombin*) OR AB ( antithrombin*)<BR/>S2 (random* or ((controlled or clinical) N3 trial*) or placebo* or multicenter or prospective*) or ((blind* or mask*) and (single or double or triple or treble))<BR/>S3 S1 and S2</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD>
<P>1. Antithrombins/ or AT?III.mp. or antithrombin*.mp.<BR/>2. ((randomised controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) not (animals not (humans and animals)).sh.<BR/>3. 1 and 2 ()<BR/>(()))<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE (Ovid SP)</P>
</TD>
<TD>
<P>1. antithrombin/ or exp antithrombin III/ or (AT?III or antithrombin*).ti,ab.<BR/>2. (randomized-controlled-trial/ or randomization/ or controlled-trial/ or multicenter-trial/ or phase-3-clinical-trial/ or phase-4-clinical-trial/ or double-blind-procedure/ or single-blind-procedure/ or (random* or cross?over* or multicenter* or factorial* or placebo* or volunteer*).mp. or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).ti,ab. or (latin adj square).mp.) not (animals not (humans and animals)).sh.<BR/>3. 1 and 2<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Science Citation Index EXPANDED</P>
</TD>
<TD>
<P>#1 TS=(antithrombin* or AT?III)<BR/>#2 TS=(random* or ((controlled or clinical) SAME trial*) or placebo* or multicenter or prospective) or TS=((blind* or mask*) SAME (single or double or triple or treble))<BR/>#3 #1 and #2<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Latin American Caribbean Health Sciences Literature (LILACS</P>
</TD>
<TD>
<P>"antithrombin$" or "AT III"<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="AFF_z1403241137508671148788714740679_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="z1403241137508671148788714740679"><ADDRESS><DEPARTMENT>Department of Paediatric and Obstetric Anaesthesia</DEPARTMENT><ORGANISATION>Rigshospitalet, Copenhagen University Hospital</ORGANISATION><CITY>Copenhagen</CITY><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>